1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47
row_id,oMIM_ID,oMIM_ID__via_disease_name,omim_number_prefix,omim_number,omim_title_preferred,omim_title_alternative,omim_title_included,disease_name,disease_comments,gene_affected__orig,gene_affected__csv,enzyme_or_protein_detected,enzyme_or_protein_detected__sha256,uniprotids_and_or_ecnumbers_gene_product__orig,ec_number__csv,uniprot_ID__csv,regimen_name,regimen_comments,drug_IDs__orig,drug_ID2,drug_ID2__sha256,drug_ID__ORed__csv,drugbank_ID__ORed__csv,chEBI_ID__ORed__csv,wHOCC_ID__ORed__csv,drug_ID__ANDed__csv,drugbank_ID__ANDed__csv,chEBI_ID__ANDed__csv,wHOCC_ID__ANDed__csv,study_type_evidence_codes__orig,study_type_evidence_code__csv,mutation_improved_by_treatment__csv,mutation_not_improved_by_treatment__csv,regimen_mechanism_of_action_ontology_category__csv,regimen_mechanism_of_action_abbreviation__csv,phenotype_improved_by_treatment__csv,phenotype_ID__csv,phenotype_improved_by_treatment_comments,treatment_manuscript_reference__csv,gene_id__csv,gene_symbol__csv,iembase_id__csv,uniprotkb_id__csv,ko_id__csv,ec_number__csv,XML/RDF
1,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Hydrocortisone,DB00741,DB00741,d55f242360bccc5155198cd6643f9c51065254fd32e5c26b3016071ac1965000,DB00741,DB00741,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Abnormal plasma aldosterone,HP:0040085,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
2,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Hydrocortisone,DB00741,DB00741,d55f242360bccc5155198cd6643f9c51065254fd32e5c26b3016071ac1965000,DB00741,DB00741,,,,,,,,,,,,,Abnormality of potassium homeostasis,HP:0011042,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
3,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Hydrocortisone,DB00741,DB00741,d55f242360bccc5155198cd6643f9c51065254fd32e5c26b3016071ac1965000,DB00741,DB00741,,,,,,,,,,,,,Abnormal circulating renin,HP:0040084,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
4,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Hydrocortisone,DB00741,DB00741,d55f242360bccc5155198cd6643f9c51065254fd32e5c26b3016071ac1965000,DB00741,DB00741,,,,,,,,,,,,,Hypertension,HP:0000822,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
5,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Dexamethasone,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Abnormal plasma aldosterone,HP:0040085,,"https://www.ncbi.nlm.nih.gov/pubmed/18458702#,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
6,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Dexamethasone,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,,,,,,,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
7,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Dexamethasone,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,,,,,,,Abnormal circulating renin,HP:0040084,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
8,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Dexamethasone,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,,,,,,,Hypertension,HP:0000822,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
9,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Dexamethasone,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,,,,,,,Bone massÂ loss,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
10,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Testosterone,DB00624,DB00624,3793204739c40d15db77aca642ada0e03f6080957e1778a784fca03f3f024e72,DB00624,DB00624,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Puberty and gonadal disorders,HP:0008373,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,https://www.ncbi.nlm.nih.gov/pubmed/18458702",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
11,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,"Estrogen replacement (                                                             
Estradiol)",DB00783,DB00783,102bf3a48f5629450533d490b6f3cdafd4acafc04910d4d17440e7aa962a1c8d,DB00783,DB00783,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Puberty and gonadal disorders,HP:0008373,,"https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
12,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Cyclic medroxyprogesterone,DB00603,DB00603,a234730cb907c7cbc30f1d06491247dca9bcee6c19ee863a6a46f31a1859ca56,DB00603,DB00603,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Puberty and gonadal disorders,HP:0008373,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
13,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Cyclic medroxyprogesterone,DB00603,DB00603,a234730cb907c7cbc30f1d06491247dca9bcee6c19ee863a6a46f31a1859ca56,DB00603,DB00603,,,,,,,,,,,,,Amenorrhea,HP:0000141,,"https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
14,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Pioglitazone,DB01132,DB01132,b480a29fbdfeb3ae6ee3a43c7963906cce5e34d9d28da69bf7c49540c1f2f6b6,DB01132,DB01132,,,,,,,ECO:0007121 /ECO:0000352,"ECO:0007121,ECO:0000352",,,symptomatic treatment procedure,C,Insulin resistance,HP:0000855,,"https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php?lng=EN&data_id=38680&ClinicalTrialName=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&title=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&search=ResearchTrials_ClinicalTrials_Simple,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
15,202110,,Number Sign,202110,"ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 17-ALPHA-HYDROXYLASE DEFICIENCY",ADRENAL HYPERPLASIA V;; 17-ALPHA-HYDROXYLASE DEFICIENCY,"17,20-LYASE DEFICIENCY, ISOLATED, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED COMPLETE, INCLUDED;; 17-ALPHA-HYDROXYLASE/17,20-LYASE DEFICIENCY, COMBINED PARTIAL, INCLUDED",17-alpha-hydroxylase deficiency,,CYP17A1,CYP17A1,Steroid 17-alpha-hydroxylase,9497338c2a0adfaee2e0644776336ab7b28f991d25f35e39bb28a26352b0b5f2,1.14.14.19,1.14.14.19,,,Pioglitazone,DB01132,DB01132,b480a29fbdfeb3ae6ee3a43c7963906cce5e34d9d28da69bf7c49540c1f2f6b6,DB01132,DB01132,,,,,,,,,,,,,Hypertension,HP:0000822,,"https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php?lng=EN&data_id=38680&ClinicalTrialName=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&title=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&search=ResearchTrials_ClinicalTrials_Simple,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710",1586,CYP17A1,125,P05093,K00512,1.14.14.19; 1.14.14.32,
16,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,Cognitive impairment,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/22391998,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
17,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,HP:0040144,,"https://www.ncbi.nlm.nih.gov/pubmed/24321868,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
18,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,Poor motor coordination,HP:0002275,,"https://www.ncbi.nlm.nih.gov/pubmed/24321868,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
19,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147Â +DB00583,DB03147 + DB00583,cc2f33a879e103dd3848216c9039e96ce31dfea6304e5d20e28ce728b423addf,,,,,"DB03147,DB00583","DB03147,DB00583",,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein+functional complementation of a genetically defective protein,A+B,defected  L-2-HGDH enzyme activity,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
20,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147Â +DB00583,DB03147 + DB00583,cc2f33a879e103dd3848216c9039e96ce31dfea6304e5d20e28ce728b423addf,,,,,"DB03147,DB00583","DB03147,DB00583",,,,,,,,,L-2-hydroxyglutaric aciduria,HP:0040144,,"https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
21,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147Â +DB00583,DB03147 + DB00583,cc2f33a879e103dd3848216c9039e96ce31dfea6304e5d20e28ce728b423addf,,,,,"DB03147,DB00583","DB03147,DB00583",,,,,,,,,Leukodystrophy,HP:0002415,,"https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
22,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147Â +DB00583,DB03147 + DB00583,cc2f33a879e103dd3848216c9039e96ce31dfea6304e5d20e28ce728b423addf,,,,,"DB03147,DB00583","DB03147,DB00583",,,,,,,,,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
23,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,Flavin adenine dinucleotide + levocarnitine chloride.,DB03147Â +DB00583,DB03147 + DB00583,cc2f33a879e103dd3848216c9039e96ce31dfea6304e5d20e28ce728b423addf,,,,,"DB03147,DB00583","DB03147,DB00583",,,,,,,,,Neurological impairment,HP:0000707,,"https://n.neurology.org/content/70/13/1051,https://www.ncbi.nlm.nih.gov/pubmed/22391998,https://clinicaltrials.gov/ct2/show/NCT00151710",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
24,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,FAD+Riboflavin,DB03147+DB00140,DB03147 + DB00140,4b5bf2ddcc7a779a722942c2cd15bf316ab54c01c6bdfed05011f301fa318a51,,,,,"DB03147,DB00140","DB03147,DB00140",,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein+functional complementation of a genetically defective protein,A+B,Neurological impairment,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/26208971,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
25,236792,,Number Sign,236792,L-2-HYDROXYGLUTARIC ACIDURIA; L2HGA,L-2-HYDROXYGLUTARIC ACIDEMIA,,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,468038a36d8507af7ed2af46c427a9f8148abe6c1bd6ecfd0a017f920a44920f,1.1.99.2,1.1.99.2,,,FAD+Riboflavin,DB03147+DB00140,DB03147 + DB00140,4b5bf2ddcc7a779a722942c2cd15bf316ab54c01c6bdfed05011f301fa318a51,,,,,"DB03147,DB00140","DB03147,DB00140",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/26208971,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",79944,L2HGDH,165,Q9H9P8,K00109,1.1.99.2,
26,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Status epilepticus,,,"https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",5428,POLG,411,P54098,K02332,2.7.7.7,
27,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",5428,POLG,411,P54098,K02332,2.7.7.7,
28,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",5428,POLG,411,P54098,K02332,2.7.7.7,
29,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",5428,POLG,411,P54098,K02332,2.7.7.7,
30,203700,,Number Sign,203700,MITOCHONDRIAL DNA DEPLETION SYNDROME 4A (ALPERS TYPE); MTDPS4A,"ALPERS DIFFUSE DEGENERATION OF CEREBRAL GRAY MATTER WITH HEPATIC CIRRHOSIS;; ALPERS PROGRESSIVE INFANTILE POLIODYSTROPHY;; ALPERS SYNDROME;; ALPERS-HUTTENLOCHER SYNDROME;; NEURONAL DEGENERATION OF CHILDHOOD WITH LIVER DISEASE, PROGRESSIVE; PNDC",,ALPERS SYNDROME,,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,,Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",5428,POLG,411,P54098,K02332,2.7.7.7,
31,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,Citrate treatment,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/24687295,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",6576,SLC25A1,924,P53007,K15100,"""""",
32,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,Citrate treatment,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,,,,,,,D-2-hydroxyglutaric aciduria,HP:0012321,,"https://www.ncbi.nlm.nih.gov/pubmed/24687295,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",6576,SLC25A1,924,P53007,K15100,"""""",
33,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,Citrate treatment,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,HP:0040144,,"https://www.ncbi.nlm.nih.gov/pubmed/24687295,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",6576,SLC25A1,924,P53007,K15100,"""""",
34,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,Citrate treatment,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,,,,,,,low urinary excretion of TCA cycle intermediates malate and succinate,,,"https://www.ncbi.nlm.nih.gov/pubmed/24687295,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",6576,SLC25A1,924,P53007,K15100,"""""",
35,615182,,Number Sign,615182,COMBINED D-2- AND L-2-HYDROXYGLUTARIC ACIDURIA; D2L2AD,,,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,SLC25A1,"Tricarboxylate transport protein, mitochondrial",7d71be247d965d4845e4ec4427fe2373dc032d82fc4e9996f29e739a3466474a,P53007,,P53007,,Citrate treatment,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,,,,,,,Hypocitraturia,HP:0012405,,"https://www.ncbi.nlm.nih.gov/pubmed/24687295,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",6576,SLC25A1,924,P53007,K15100,"""""",
36,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,Benzhexol,DB00376,DB00376,9bd438fb7ce723e5b6b6831690d700f1ff2b5deea66023810bd5ce522026558d,DB00376,DB00376,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,tremor,HP:0001337,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
37,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,Benzhexol,DB00376,DB00376,9bd438fb7ce723e5b6b6831690d700f1ff2b5deea66023810bd5ce522026558d,DB00376,DB00376,,,,,,,,,,,,,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
38,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,Vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,seizures,HP:0001250,,"http://www.medlink.com/scripts/mpdf/print_friendly.php?title=2-methyl-3-hydroxybutyryl-coa_dehydrogenase_deficiency&action=download&channel=public_content&entryid=19985,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
39,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/30013934,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
40,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,carbidopa,DB00190,DB00190,d7f94bdb31c5da398b696aaf74c3323db02ff60744e3df281da951d492901f6b,DB00190,DB00190,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,tremor,HP:0001337,,"https://www.ncbi.nlm.nih.gov/pubmed/30013934,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
41,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,cefoperazone sodium,DB01329,DB01329,69098c55654437667604f916e5d7dd4edfd33469799a94712a877f90391da29b,DB01329,DB01329,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal inflammatory response,HP:0012647,,"https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
42,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,tazobactam sodium,DB01606,DB01606,bc8be247387bc1fdd57acef1e85b75b700eebfb8304ff98db9adb3ba61cb9b01,DB01606,DB01606,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal inflammatory response,HP:0012647,,"https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
43,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,B vitamins,A11E,A11E,23b189823901b6887852acbb767754b52eacc2cd6ed20ecb156d30dc907e711f,A11E,,,A11E,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormality of the nervous system,HP:0000707,,"https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
44,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,creatine phosphate sodium,DB13191,DB13191,8c5d446d48c0426cf1e66e63a0d9c479682d29dcaf4e6354cf7b4b54b71a3b7a,DB13191,DB13191,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormality of cardiovascular system physiology,HP:0011025,,"https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
45,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,,Carbamazepine,DB00564,DB00564,d7432f727b8e4d8a7e02cf9e041ae6a05684d37d649a8d66c2081dea81a7aebc,DB00564,DB00564,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22132097,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
46,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day),Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal muscle physiology,HP:0011804,,"https://www.ncbi.nlm.nih.gov/pubmed/22132097,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
47,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day),Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/22132097,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
48,300438,,Number Sign,300438,HSD10 MITOCHONDRIAL DISEASE; HSD10MD,"HSD17B10 DEFICIENCY;; 17-BETA-HYDROXYSTEROID DEHYDROGENASE X DEFICIENCY;; 3-HYDROXYACYL-CoA DEHYDROGENASE II DEFICIENCY;; 2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY;; MHBD DEFICIENCY;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 10; MRXS10;; CHORIOATHETOSIS WITH MENTAL RETARDATION AND ABNORMAL BEHAVIOR; CAMR;; MENTAL RETARDATION WITH CHORIOATHETOSIS AND ABNORMAL BEHAVIOR",,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,4256ddeda3c6231d89c2edfeafddd8062a3697b24c32a5656f371dc53fb96cb2,1.1.1.178,"1.1.1.35,1.1.1.51,1.1.1.178",,The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day),Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/22132097,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",3028,HSD17B10,64,Q99714,K08683,1.1.1.35; 1.1.1.51; 1.1.1.178,
49,610006,610006,Number Sign,610006,2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,2-METHYLBUTYRYL GLYCINURIA;; SHORT/BRANCHED-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY; SBCADD,,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSB,ACADSB,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,00c7809543aa8a8bfefd5f2daf283c2a80b3dc1de6b593d6cbc7ea68f7478b31,1.1.1.178,1.1.1.178,,The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day),L-Carnitine+ low-protein diet,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+dietary exclusion,C+B,Abnormality of muscle physiology,HP:0011804,,"https://www.ncbi.nlm.nih.gov/pubmed/12837870,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",36,ACADSB,63,P45954,K09478,1.3.8.5,
50,610006,610006,Number Sign,610006,2-METHYLBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,2-METHYLBUTYRYL GLYCINURIA;; SHORT/BRANCHED-CHAIN ACYL-CoA DEHYDROGENASE DEFICIENCY; SBCADD,,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSB,ACADSB,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,00c7809543aa8a8bfefd5f2daf283c2a80b3dc1de6b593d6cbc7ea68f7478b31,1.1.1.178,1.1.1.178,,The drug was accompained by mild protein restriction (1.5â2.0 g/kg/day),L-Carnitine+ low-protein diet,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Elevated serum toxic intermediates in isoleucine pathway,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pubmed/12837870,https://www.ncbi.nlm.nih.gov/pubmed/11102558,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025",36,ACADSB,63,P45954,K09478,1.3.8.5,
51,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",Biotin,DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,ECO:0000352,ECO:0000352,MCCA-R385S(heterozygote mutation),MCCB-(IVS16Ã¾1G>A)/ MCCB-missense mutation E99Q Homozygous mutation,activity modification of a genetically defective protein,B,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
52,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",Biotin,DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,,,"""heterozygote missense mutation, MCCA-R385S""",,,,Organic aciduria,HP:0001992,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
53,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",Biotin,DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,,,,,,,EEG abnormality,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
54,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",Biotin,DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,,,,,,,Hypsarrhythmia,HP:0002521,,"https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
55,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
56,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,,,,,,,Increased 3-hydroxyisovaleric acid excretion,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
57,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,,,,,,,Increased 3-methylcrotonylglycine excretion,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
58,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,,,,,,,abnormal Biotinidase activity in plasma,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
59,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,,,,,,,EEG abnormality,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/16773504,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
60,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",L-Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Abnormality of muscle physiology,HP:0011804,,"https://www.ncbi.nlm.nih.gov/pubmed/10485305,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
61,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",L-Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,secondary carnitine deficiency,HP:0003234*,,"https://www.ncbi.nlm.nih.gov/pubmed/8831079,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
62,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",L-Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,elevated serum toxic intermediates (,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pubmed/8831079,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
63,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Glycine,DB00145,DB00145,79f350e4081104f76a71ae9acfb363437413faff62ebdace99bac99264773df5,DB00145,DB00145,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,defected excertion of 3- MCG,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
64,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Glycine,DB00145,DB00145,79f350e4081104f76a71ae9acfb363437413faff62ebdace99bac99264773df5,DB00145,DB00145,,,,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,HP:0001939 *,,"https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
65,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Glycine +L-Carnitine,DB00145Â +DB00583,DB00145 + DB00583,3b944267403c33e88c1ec7983b17d0d2af8877b8be5653fb334888feee30467e,,,,,"DB00145,DB00583","DB00145,DB00583",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,B+B,Acute metabolic crisis ( Metabolism abnormality)*,HP:0001939 *,,"https://link.springer.com/article/10.1007/BF00710419,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
66,210200,,Number Sign,210200,3-METHYLCROTONYL-CoA CARBOXYLASE 1 DEFICIENCY; MCC1D,MCCD TYPE 1;; MCC1 DEFICIENCY;; 3-METHYLCROTONYLGLYCINURIA I;; METHYLCROTONYLGLYCINURIA TYPE I,,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,"MCCC1,MCCC2",3 Methylcrotonyl-CoA carboxylase,413649a2dbe1f1c6f6b959a233c8ffc0617c0c46b3978421604c36e23e6ece93,6.4.1.4,6.4.1.4,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Glycine +L-Carnitine,DB00145Â +DB00583,DB00145 + DB00583,3b944267403c33e88c1ec7983b17d0d2af8877b8be5653fb334888feee30467e,,,,,"DB00145,DB00583","DB00145,DB00583",,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,HP:0001939 *,,"https://link.springer.com/article/10.1007/BF00710419,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","56922,64087","MCCC1,MCCC2",1284,"Q96RQ3,Q9HCC0","K01968,K01969","6.4.1.4,6.4.1.4",
67,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,secondary carnitine deficiency,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
68,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,high  short chain acyl-carnitine metabolite level,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
69,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Muscle weakness,HP:0001324,,"https://link.springer.com/article/10.1023%2FA%3A1024031714659?LI=true,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
70,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",vitamin E supplements,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Abnormality of peripheral nerves,HP:0045010,,"https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
71,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",vitamin E supplements,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Neuropathy,HP:0009830,,"https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
72,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Myalgia,HP:0003326,,"https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
73,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Abnormal cardiac function,HP:0011025,,"https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
74,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Fatigue,HP:0011025,,"https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
75,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Fatigue,HP:0011025,,"https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.sciencedirect.com/science/article/pii/088789949400109F,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
76,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,Impaired nerve conduction,HP:0040129,,"https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.sciencedirect.com/science/article/pii/088789949400109F,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
77,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,Defected mucle plasma membrane,,,"https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.sciencedirect.com/science/article/pii/088789949400109F,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
78,231530,,Number Sign,231530,3-HYDROXYACYL-CoA DEHYDROGENASE DEFICIENCY,"HADH DEFICIENCY;; SCHAD DEFICIENCY, FORMERLY",,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,HADH,3-hydroxylacyl-CoA dehydrogenase,69d5d2e0f7aa7bad5fd0500f6388339748c9ef0c2dffa3afcfe453d173280bbc,1.1.1.35,1.1.1.35,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,Defected neuronal plasma membrane,,,"https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.sciencedirect.com/science/article/pii/088789949400109F,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3033,HADH,236,Q16836,K00022,1.1.1.35,
79,236795,236795,Percent,236795,3-HYDROXYISOBUTYRIC ACIDURIA,,,3-Hydroxyisobutyric aciduria,,ALDH6A1,ALDH6A1,3-hydroxyisobutyrate dehydrogenase,96a7c136253464a3a84f7709f116ef98d6a3e4b4a291cec9a46a1d22484f4a89,1.1.1.31,1.1.1.31,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,acidemia,HP:0001941,,"http://eknygos.lsmuni.lt/springer/365/81-92.pdf,https://www.sciencedirect.com/science/article/pii/088789949400109F,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4329,ALDH6A1,,Q02252,K00140,1.2.1.18; 1.2.1.27,
80,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122/,https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",549,AUH,58,Q13825,K05607,4.2.1.18; 4.2.1.56,
81,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Abnormality of movement,HP:0100022,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122/,https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",549,AUH,58,Q13825,K05607,4.2.1.18; 4.2.1.56,
82,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Metabolic Decompensation,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pubmed/11400757/,https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",549,AUH,58,Q13825,K05607,4.2.1.18; 4.2.1.56,
83,250950,,Number Sign,250950,"3-METHYLGLUTACONIC ACIDURIA, TYPE I; MGCA1","MGA, TYPE I; MGA1;; 3-METHYLGLUTACONYL-CoA HYDRATASE DEFICIENCY;; 3-MG-CoA-HYDRATASE DEFICIENCY",,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH,AUH,Methylglutaconyl-CoA hydratase,3dd1a04e0e2d7d5790db7f2130c5d157c834a731b67c26e7aaa48bdb8dd7899c,4.2.1.18,4.2.1.18,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Delayed Growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/11400757/,https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new,https://www.jci.org/articles/view/11948,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",549,AUH,58,Q13825,K05607,4.2.1.18; 4.2.1.56,
84,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Sapropterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,metabolite replacement,B,Behavioral abnormality,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
85,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Sapropterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,Personality disorder,HP:0012075,,"https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
86,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Sapropterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
87,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",Antisense morpholino oligonucleotides (AMOs),NA,,,,,,,,,,,ECO:0001565,ECO:0001565,"""c.84â322A>T, c.163 + 695_163 + 751del57, or c.164â712A>T""",,direct complementation of a genetically defective protein,A,pseudoexon activation,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/21542064,https://www.ncbi.nlm.nih.gov/pubmed/22832064,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
88,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,ECO:0000352,ECO:0000352,,,metabolite replacement+metabolite replacement+metabolite replacement,B+B+B,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
89,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,,,,,,,Abnormality of neurotransmitter metabolism,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
90,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,,,,,,,Neurological abnormality,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
91,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,,,,,,,Neurodevelopmental abnormality,HP:0012759,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
92,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,,,,,,,Intellectual disability,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
93,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",BH4+L-Dopa+5HTP,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,,,,,,,Delayed CNS mylinaton,HP:0002188,"The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879","https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
94,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879,Oxitriptan,DB02959,DB02959,baa3bf62cec194a8ef32b70a5765a4cbe13178b318b13495a3454c144baceb47,DB02959,DB02959,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Abnormality of neurotransmitter metabolism,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
95,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879,Oxitriptan,DB02959,DB02959,baa3bf62cec194a8ef32b70a5765a4cbe13178b318b13495a3454c144baceb47,DB02959,DB02959,,,,,,,,,,,,,Abnormality in serotonin turnover (Abnormality of circulating hormone level),HP:0003117,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
96,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRDâplus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of lâdopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",levodopa (L-dopa),DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Abnormality of neurotransmitter metabolism,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
97,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRDâplus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of lâdopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",levodopa (L-dopa),DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Paroxysmal movements,HP:0007166,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
98,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRDâplus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of lâdopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",levodopa (L-dopa),DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Movement disorder,HP:0100022,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
99,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, lâdopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",carbidopa,DB00190,DB00190,d7f94bdb31c5da398b696aaf74c3323db02ff60744e3df281da951d492901f6b,DB00190,DB00190,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Abnormality of neurotransmitter metabolism,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
100,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",pramipexole + L- dopa,DB00413+DB01235,DB00413 + DB01235,7595e126d2990dac6112bbf564594e94ac729fdf3635748cc9c255c7e0df00ae,,,,,"DB00413,DB01235","DB00413,DB01235",,,ECO:0007121,ECO:0007121,,,functional complementation of a defective protein by stimulation+metabolite replacement,B+B,Movement Disability,HP:0100022,,"https://www.ncbi.nlm.nih.gov/pubmed/19704083,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
101,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",pramipexole + L- dopa,DB00413+DB01235,DB00413 + DB01235,7595e126d2990dac6112bbf564594e94ac729fdf3635748cc9c255c7e0df00ae,,,,,"DB00413,DB01235","DB00413,DB01235",,,,,,,,,High prolactin level,HP:0000870,,"https://www.ncbi.nlm.nih.gov/pubmed/19704083,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
102,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",pramipexole + L- dopa,DB00413+DB01235,DB00413 + DB01235,7595e126d2990dac6112bbf564594e94ac729fdf3635748cc9c255c7e0df00ae,,,,,"DB00413,DB01235","DB00413,DB01235",,,,,,,,,Behavioural Disability,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/19704083,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
103,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",pramipexole + L- dopa,DB00413+DB01235,DB00413 + DB01235,7595e126d2990dac6112bbf564594e94ac729fdf3635748cc9c255c7e0df00ae,,,,,"DB00413,DB01235","DB00413,DB01235",,,,,,,,,Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/19704083,https://www.ncbi.nlm.nih.gov/pubmed/16601879,https://www.ncbi.nlm.nih.gov/pubmed/23690520?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
104,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",selective monoamine oxidase (MAO) B inhibitor,DB01247,DB01247,f9b43a00b76b73233eb21ecbe37b0b4ea50b8b79310d1c2d90628c6f5473068a,DB01247,DB01247,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Low dopamine level,HP:0012656,,"https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf,https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
105,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,direct complementation of a genetically defective protein by gene therapy,A,Low tetrahydrobiopterin level,HP:0040210,,"https://www.ncbi.nlm.nih.gov/pubmed/8864759,https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
106,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",Retrovirus-mediated gene transfer of 6-pyruvoyl-tetrahydropterin synthase,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/8864759,https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
107,261640,,Number Sign,261640,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, A; HPABH4A","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTS DEFICIENCY;; 6-PYRUVOYL-TETRAHYDROPTERIN SYNTHASE DEFICIENCY;; PTS DEFICIENCY","HYPERPHENYLALANINEMIA, BH4-DEFICIENT, DUE TO PARTIAL PTS DEFICIENCY, INCLUDED",6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,PTPS,6-pyruvoyl-tetrahydropterin synthase,70f65c228e2af993ebe6f1cad2e303645e11ec96046ca87f6e4cb02d78bd2bac,4.2.3.12,4.2.3.12,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",folinic acid,DB03256,DB03256,5b369f795c2a3fc8642011ec55ddb3ad8ed440324021c98b9058def8fc45af9f,DB03256,DB03256,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Abnormal serum folate,HP:0040087,,"https://www.ncbi.nlm.nih.gov/pubmed/8864759,https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf","""""","""""",4,"""""","""""","""""",
108,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,metabolite replacement,B,Elevated Phe level in blood,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/8433887/,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
109,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,Neurological abnormality,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/8433887/,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
110,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4+L-dopa+5-hydroxytryptophan,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,ECO:0000352,ECO:0000352,,,metabolite replacement+metabolite replacement+metabolite replacement,B+B+B,Elevated blood phenylalanine concentration,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
111,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4+L-dopa+5-hydroxytryptophan,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,,,,,,,Abnormality of neurotransmitter metabolism,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
112,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4+L-dopa+5-hydroxytryptophan,DB00360+DB01235+DB02959,DB00360 + DB01235 + DB02959,042db1ac0f7eb035c3d2d6db45b6b76e355d0cefb577ead3c46acbe96e6b8db2,,,,,"DB00360,DB01235,DB02959","DB00360,DB01235,DB02959",,,,,,,,,Neurological abnormality,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
113,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,DB00360 + DB01235 + DB02959 + DB03256,19db2fce0e879d3ee2f4f7d58588f280ddd7cfc17d9c0d4fbb52645399aa8f57,,,,,"DB00360,DB01235,DB02959,DB03256","DB00360,DB01235,DB02959,DB03256",,,ECO:0000352,ECO:0000352,,,metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein,B+B+B+B,Developmental delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
114,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,DB00360 + DB01235 + DB02959 + DB03256,19db2fce0e879d3ee2f4f7d58588f280ddd7cfc17d9c0d4fbb52645399aa8f57,,,,,"DB00360,DB01235,DB02959,DB03256","DB00360,DB01235,DB02959,DB03256",,,,,,,,,Delayed receptive language,HP:0010863,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
115,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,DB00360 + DB01235 + DB02959 + DB03256,19db2fce0e879d3ee2f4f7d58588f280ddd7cfc17d9c0d4fbb52645399aa8f57,,,,,"DB00360,DB01235,DB02959,DB03256","DB00360,DB01235,DB02959,DB03256",,,,,,,,,Neurological impairment,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
116,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,DB00360+DB01235+DB02959+DB03256,DB00360 + DB01235 + DB02959 + DB03256,19db2fce0e879d3ee2f4f7d58588f280ddd7cfc17d9c0d4fbb52645399aa8f57,,,,,"DB00360,DB01235,DB02959,DB03256","DB00360,DB01235,DB02959,DB03256",,,,,,,,,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
117,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",folinic acid,DB03256,DB03256,5b369f795c2a3fc8642011ec55ddb3ad8ed440324021c98b9058def8fc45af9f,DB03256,DB03256,,,,,,,ECO:0000352,ECO:0000352,,,compensatory complementation of a genetically defective protein,B,Progressive basal ganglia calcification,HP:0002135,,"https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
118,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",folinic acid,DB03256,DB03256,5b369f795c2a3fc8642011ec55ddb3ad8ed440324021c98b9058def8fc45af9f,DB03256,DB03256,,,,,,,,,,,,,Subcortical calcification,HP:0007346,,"https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
119,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",folinic acid,DB03256,DB03256,5b369f795c2a3fc8642011ec55ddb3ad8ed440324021c98b9058def8fc45af9f,DB03256,DB03256,,,,,,,,,,,,,Seizure,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
120,261630,261630,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,QDPR,Dihydropteridine reductase,4cc97ee49232084a27d86693a0a3b481e0302f5b4017b9dc47519070e8fd8d01,1.5.1.34,1.5.1.34,,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",folinic acid,DB03256,DB03256,5b369f795c2a3fc8642011ec55ddb3ad8ed440324021c98b9058def8fc45af9f,DB03256,DB03256,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/23138986,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5860,QDPR,5,P09417,K00357,1.5.1.34,
121,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,"The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038",MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",vitamin E therapy,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,nervous system abnormalities,HP:0002011,,"https://www.ncbi.nlm.nih.gov/pubmed/30358967,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
122,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",vitamin E therapy,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,neurologic dysfunction,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/30358967,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
123,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",vitamin E therapy,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Retinopathy,HP:0000488,,"https://www.ncbi.nlm.nih.gov/pubmed/3954973/,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
124,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",medium-chain fatty acid supplements,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Growth impairment,HP:0008897,,"https://www.ncbi.nlm.nih.gov/pubmed/3954973/,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
125,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",Vitamin K,CHEBI:28384,CHEBI:28384,ecb601251a789dcf3deca6380d185812b577fddd0923e2054edf04a013beef8f,CHEBI:28384,,CHEBI_28384,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,HP:0002630,,"https://www.ncbi.nlm.nih.gov/pubmed/26396722,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
126,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",Vitamin D,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,HP:0002630,,"https://www.ncbi.nlm.nih.gov/pubmed/26396722,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
127,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",vitamin A+ Vitamin E,DB00162+DB00163,DB00162 + DB00163,b7a5951749df631da8a605be5ac85c241780c063c39a44e0c5dc768908f0c1e4,,,,,"DB00162,DB00163","DB00162,DB00163",,,ECO:0000352,ECO:0000352,,,metabolite replacement+metabolite replacement,B+B,Retinal degeneration,HP:0000546,,"https://www.ncbi.nlm.nih.gov/pubmed/11767031,https://www.ncbi.nlm.nih.gov/pubmed/30731125,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
128,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",vitamin A+ Vitamin E,DB00162+DB00163,DB00162 + DB00163,b7a5951749df631da8a605be5ac85c241780c063c39a44e0c5dc768908f0c1e4,,,,,"DB00162,DB00163","DB00162,DB00163",,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/14749227,https://www.ncbi.nlm.nih.gov/pubmed/30731125,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
129,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K,DB13959+DB00162+DB11094+DB00163+CHEBI:28384,DB13959 + DB00162 + DB11094 + DB00163 + CHEBI:28384,c642fea6ddbc185bb2eb49ab478df353841ffddc084150ddba0a6f4df2f17523,,,,,"DB13959,DB00162,DB11094,DB00163,CHEBI:28384","DB13959,DB00162,DB11094,DB00163",CHEBI_28384,,ECO:0000352,ECO:0000352,,,metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement,B+B+B+B+B,Neurological abnormalities,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/30731125,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
130,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K,DB13959+DB00162+DB11094+DB00163+CHEBI:28384,DB13959 + DB00162 + DB11094 + DB00163 + CHEBI:28384,c642fea6ddbc185bb2eb49ab478df353841ffddc084150ddba0a6f4df2f17523,,,,,"DB13959,DB00162,DB11094,DB00163,CHEBI:28384","DB13959,DB00162,DB11094,DB00163",CHEBI_28384,,,,,,,,Disease progression (Progressive),HP:0003676,,"https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/30731125,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
131,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",Progesteron,DB00396,DB00396,443360a06525a0b3f190045706807cee5cf695a7a3bd5cd542dd2d9d76fdcf4c,DB00396,DB00396,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Female infertility,HP:0008222,,"https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/30731125,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
132,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",Vitamin B12+iron,DB00115+DB01592,DB00115 + DB01592,42f42dfa1280bac5c92e5c3a432ac2ea405fd34ce350d7ef4c3b47fd3e022f07,,,,,"DB00115,DB01592","DB00115,DB01592",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,C+C,Anemia,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/30731125,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
133,200100,,Number Sign,200100,ABETALIPOPROTEINEMIA; ABL,ACANTHOCYTOSIS;; BASSEN-KORNZWEIG SYNDROME;; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN DEFICIENCY;; MTP DEFICIENCY,,Abetalipoproteinemia,,MTTP,MTTP,microsomal triglyceride transfer protein,06d7b68bc01e7ffdedc58b069fc70ecd54a7a0b2b0855732f83bb14c6aa04111,P55157,,P55157,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",levothyroxine,DB00451,DB00451,55499b3bcef6fb6f5029a1d7616498410a2edcee934df2555522c03ff686047b,DB00451,DB00451,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,subclinical hypothyroidism,HP:0000821,,"https://www.ncbi.nlm.nih.gov/pubmed/26396722,https://www.ncbi.nlm.nih.gov/pubmed/17132287/,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",4547,MTTP,371,P55157,K14463,"""""",
134,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CP,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",Deferasirox,DB01609,DB01609,ece99e5185fe01b151ec6d8a32883b6ba773b80b7652158782d72699831f7b57,DB01609,DB01609,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,high serum ferritin concentration,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1356,CP,872,P00450,K13624,1.16.3.1,
135,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CP,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",Deferasirox,DB01609,DB01609,ece99e5185fe01b151ec6d8a32883b6ba773b80b7652158782d72699831f7b57,DB01609,DB01609,,,,,,,,,,,,,high brain and liver iron stores,HP:0003281*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1356,CP,872,P00450,K13624,1.16.3.1,
136,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CP,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",vitamin E+ Zinc,DB00163Â +DB01593,DB00163 + DB01593,978c4fc248d12906503cf88dc8e31cc73b4a29fc630db814476e7ec27ca34bcd,,,,,"DB00163,DB01593","DB00163,DB01593",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,tissue damage,NA,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1356,CP,872,P00450,K13624,1.16.3.1,
137,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CP,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",vitamin E+ Zinc,DB00163Â +DB01593,DB00163 + DB01593,978c4fc248d12906503cf88dc8e31cc73b4a29fc630db814476e7ec27ca34bcd,,,,,"DB00163,DB01593","DB00163,DB01593",,,,,,,,,Liver dysfunction,HP:0001410,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1356,CP,872,P00450,K13624,1.16.3.1,
138,604290,604290,Number Sign,604290,ACERULOPLASMINEMIA,,"HYPOCERULOPLASMINEMIA, INCLUDED;; CERULOPLASMIN DEFICIENCY, INCLUDED;; HEMOSIDEROSIS, SYSTEMIC, DUE TO ACERULOPLASMINEMIA, INCLUDED",Aceruloplasminemia,,CP,CP,Ferroxidase,b7c1f37f7601b3c8ba03cd65da2f868ce234c5a61d87811371436b12fa73cf1f,1.16.3.1,1.16.3.1,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",vitamin E+ Zinc,DB00163Â +DB01593,DB00163 + DB01593,978c4fc248d12906503cf88dc8e31cc73b4a29fc630db814476e7ec27ca34bcd,,,,,"DB00163,DB01593","DB00163,DB01593",,,,,,,,,pancreatic dysfunction,HP:0001738,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1356,CP,872,P00450,K13624,1.16.3.1,
139,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",L-Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,fasting ketogenesis,"HP:0001946,HP:0025212",,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1384,CRAT,671,P43155,"""""",2.3.1.7,
140,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",L-Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,cardiac dysfunction,HP:0011025,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1384,CRAT,671,P43155,"""""",2.3.1.7,
141,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",L-Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Delayed growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1384,CRAT,671,P43155,"""""",2.3.1.7,
142,606175,,NULL,606175,CARNITINE ACETYLTRANSFERASE DEFICIENCY,,,Acetyl-carnitine deficiency,,CRAT,CRAT,Carnitine acetyltransferase,d81add243802582836b8a0363b628a72e6f0f15013d9206f38db3ff1f258e8ac,2.3.1.7,2.3.1.7,,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",L-Carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,cognitive impairment,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",1384,CRAT,671,P43155,"""""",2.3.1.7,
143,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",zinc,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,skin inflammation,HP:0011123,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
144,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",zinc,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,,,,,,,Alopecia,HP:0001596,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
145,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",zinc,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,,,,,,,Agitation,HP:0000713,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
146,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",zinc,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,,,,,,,irritability,HP:0000737,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
147,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",zinc,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,,,,,,,diarrhea,HP:0002014,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
148,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",zinc,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,,,,,,,emotional disturbances,HP:0000712,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
149,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",Zinc+ linoleic acid,DB01593+DB14104,DB01593 + DB14104,b8bd26246c91a48785bb0cad4932c0b92154691812754cc3e082b9db68408b7e,,,,,"DB01593,DB14104","DB01593,DB14104",,,ECO:0000352,ECO:0000352,,,metabolite replacement+symptomatic treatment procedure,B+C,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
150,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Diiodoquinoline,DB09115,DB09115,b40e358518c02414cf504cb64c2212cb23371f763a623218585a1f0d8675ceea,DB09115,DB09115,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Acrodermatitis (Dermatitis)*,HP:0011123,,"https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
151,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Diiodoquinoline,DB09115,DB09115,b40e358518c02414cf504cb64c2212cb23371f763a623218585a1f0d8675ceea,DB09115,DB09115,,,,,,,,,,,,,Diarrhea,HP:0002014,,"https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
152,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Diiodoquinoline,DB09115,DB09115,b40e358518c02414cf504cb64c2212cb23371f763a623218585a1f0d8675ceea,DB09115,DB09115,,,,,,,,,,,,,Alopecia,HP:0001596,,"https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
153,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Diiodoquinoline,DB09115,DB09115,b40e358518c02414cf504cb64c2212cb23371f763a623218585a1f0d8675ceea,DB09115,DB09115,,,,,,,,,,,,,Perioral dermatitis,HP:0040181,,"https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
154,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Clioquinol,DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Dermatitis,HP:0011123,,"https://www.ncbi.nlm.nih.gov/pubmed/375935,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
155,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Clioquinol,DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/375935,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
156,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",Clioquinol,DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/375935,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
157,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",Zn-DTSM (zinc ionophore),DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,ECO:0001565/ ECO:0005542,"ECO:0001565,ECO:0005542",,,functional complementation of a genetically defective protein,B,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30669644,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
158,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",Zn-DTSM (zinc ionophore),DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30669644,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
159,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",Zn-DTSM (zinc ionophore),DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30669644,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
160,201100,,Number Sign,201100,"ACRODERMATITIS ENTEROPATHICA, ZINC-DEFICIENCY TYPE; AEZ",,,Acrodermatitis enteropathica,,SLC39A4,SLC39A4,zinc/iron-regulated transporter-like protein,44ebb2e113186f4ed945ac2600c2c4b86d92e12611d2fd87d446cc0d4619d38c,Q6P5W5,,Q6P5W5,"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",Zn-DTSM (zinc ionophore),DB04815,DB04815,2234e44d9ba66f86df25457d7f8e678c67decee47a6298c77c535322560542aa,DB04815,DB04815,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30669644,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",55630,SLC39A4,202,Q6P5W5,K14710,"""""",
161,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Glucose,DB09341,DB09341,4b19e06833e9a2137a0550330975c20e3933eaf5df506a0444738008c59e5b4c,DB09341,DB09341,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*,HP:0010472,,"https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
162,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Glucose,DB09341,DB09341,4b19e06833e9a2137a0550330975c20e3933eaf5df506a0444738008c59e5b4c,DB09341,DB09341,,,,,,,,,,,,,"""(abdominal pain, nausea, vomiting)""","HP:0002027, HP:0002017",,"https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
163,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Glucose,DB09341,DB09341,4b19e06833e9a2137a0550330975c20e3933eaf5df506a0444738008c59e5b4c,DB09341,DB09341,,,,,,,,,,,,,Mild attack,HP:0012825,,"https://www.ncbi.nlm.nih.gov/pubmed/23605132/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.ncbi.nlm.nih.gov/pubmed/1275520,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
164,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Panhematin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,ECO:0000352/ECO:0007121,"ECO:0000352,ECO:0007121",,,metabolite replacement,B,pain,HP:0012531,,"https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
165,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Panhematin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,,,,,,,hypertension,HP:0000822,,"https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
166,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Panhematin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,,,,,,,tachycardia,HP:0001649,,"https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
167,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Panhematin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,,,,,,,abnormal mental status,HP:0100543,,"https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
168,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",Panhematin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,,,,,,,Acute attack,HP:0011009,,"https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
169,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",rh-HMBS,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,,Accumulated  plasma porphobilinogen,,,"https://www.ncbi.nlm.nih.gov/pubmed/17375984/,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
170,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",rh-HMBS,NA,,,,,,,,,,,,,,,,,Accumulated  urine porphobilinogen,HP:0012217,,"https://www.ncbi.nlm.nih.gov/pubmed/17375984/,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
171,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",rhPBGD,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein,,Eevated porphyrin precursors porphobilinogen,HP:0012217,,"https://www.ncbi.nlm.nih.gov/pubmed/15208740/,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
172,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",rAAV8-mediated gene therapy expressing murine HMB-synthase,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,Hepatic metabolic abnormalities ( Metabolism abnormality)*,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/19861948,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
173,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patientsâ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",rAAV8-mediated gene therapy expressing murine HMB-synthase,NA,,,,,,,,,,,,,,,,,Abnormal neuromotor function,HP:0002333,,"https://www.ncbi.nlm.nih.gov/pubmed/19861948,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
174,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",AAV2/5-PBGD,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,,Low PBGD expression in liver,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24933563,https://www.ncbi.nlm.nih.gov/pubmed/24933563,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
175,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",Givosiran,DB15066,DB15066,9bfca3e88334c93147c5e387577dc411e8df04f6d2a04ed918733e5fd2e23359,DB15066,DB15066,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,functional complementation of a defective protein by inhibition,,Abnormal circulating porphyrin concentration,HP:0010472,,"https://www.ncbi.nlm.nih.gov/pubmed/30766957,https://www.ncbi.nlm.nih.gov/pubmed/30726693,https://www.ncbi.nlm.nih.gov/pubmed/24821812,https://clinicaltrials.gov/ct2/show/NCT02452372,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
176,176000,,Number Sign,176000,"PORPHYRIA, ACUTE INTERMITTENT; AIP","PORPHYRIA, SWEDISH TYPE;; PORPHOBILINOGEN DEAMINASE DEFICIENCY;; PBGD DEFICIENCY;; UROPORPHYRINOGEN SYNTHASE DEFICIENCY;; UPS DEFICIENCY","PORPHYRIA, ACUTE INTERMITTENT, NONERYTHROID VARIANT, INCLUDED;; PORPHYRIA, CHESTER TYPE, INCLUDED; PORC, INCLUDED",Acute intermittent porphyria,,HMBS,HMBS,Hydroxymethylbilane synthase.,15afe7c54db9c3c3a7778e3791f61e01055ebba4f71f23d202e822fff0a7f558,2.5.1.61,2.5.1.61,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",Givosiran,DB15066,DB15066,9bfca3e88334c93147c5e387577dc411e8df04f6d2a04ed918733e5fd2e23359,DB15066,DB15066,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30766957,https://www.ncbi.nlm.nih.gov/pubmed/30726693,https://www.ncbi.nlm.nih.gov/pubmed/24821812,https://clinicaltrials.gov/ct2/show/NCT02452372,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3145,HMBS,112,P08397,K01749,2.5.1.61,
177,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,urolithiasis,HP:0000787,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
178,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,crystalline nephropathy,HP:0000112,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
179,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Hematuria,HP:0000790,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
180,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Dysuria,HP:0100518,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
181,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Recurrent urinary tract infections,HP:0000010,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
182,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Chronic kidney disease,HP:0012622,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
183,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,"https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
184,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Kidney stones,,,"https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
185,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,urolithiasis,HP:0000787,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
186,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,,,,,,,crystalline nephropathy,HP:0000112,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
187,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,,,,,,,Hematuria,HP:0000790,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
188,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,,,,,,,Dysuria,HP:0100518,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
189,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,,,,,,,Recurrent urinary tract infections,HP:0000010,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
190,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,,,,,,,Chronic kidney disease,HP:0012622,,"https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
191,614723,,Number Sign,614723,ADENINE PHOSPHORIBOSYLTRANSFERASE DEFICIENCY; APRTD,"APRT DEFICIENCY;; UROLITHIASIS, 2,8-DIHYDROXYADENINE;; UROLITHIASIS, DHA;; NEPHROLITHIASIS, DHA",,Adenine phosphoribosyltransferase deficiency,,APRT,APRT,Adenine phosphoribosyltransferase,81cebdc43a840fe98ffb65841abf1f640527cbb60e30b2678ddecf38993e9dff,2.4.2.7,2.4.2.7,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",febuxostat,DB04854,DB04854,c82f6213750b4349bfe0ecb0567bdc61f329e5a4aecbdf49d13529b6413fa593,DB04854,DB04854,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,"https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",353,APRT,,P07741,K00759,2.4.2.7,
192,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,ECO:0000352,ECO:0000352,,,direct complementation of a genetically defective protein,A,lymphopenia,HP:0001888,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
193,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,hepatosplenomegaly,HP:0001433,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
194,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,Elevated liver enzyme levels,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
195,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,Low weight,HP:0004325,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
196,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,Abnormal eosinophil counts,HP:0001879,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
197,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,Hemolysis,HP:0001878,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
198,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,Thyroid antibodies (autoimmunity)*,HP:0002960,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
199,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,Abnormal immune function,HP:0010978,,"https://adisinsight.springer.com/trials/700243447,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
200,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),DB14712,DB14712,e32a5d64cd740911147e38433e8a7ad978c6d21082c88e5d5c7b1e58c30c9c95,DB14712,DB14712,,,,,,,,,,,,,dermatitis,HP:0011123,,"https://adisinsight.springer.com/trials/700243447,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
201,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061,DB00061,2f450320e31095cfc1ba28f1f21db9f9b8373e5d71125f0b9e0656e9b73d0938,DB00061,DB00061,,,,,,,ECO:0000352,ECO:0000352,,,direct complementation of a genetically defective protein,A,Abnormal immune function,HP:0010978,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
202,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061,DB00061,2f450320e31095cfc1ba28f1f21db9f9b8373e5d71125f0b9e0656e9b73d0938,DB00061,DB00061,,,,,,,,,,,,,Recurrent infection,HP:0002719,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
203,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061,DB00061,2f450320e31095cfc1ba28f1f21db9f9b8373e5d71125f0b9e0656e9b73d0938,DB00061,DB00061,,,,,,,,,,,,,"""Frequent, severe infections""",HP:0002719,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
204,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061,DB00061,2f450320e31095cfc1ba28f1f21db9f9b8373e5d71125f0b9e0656e9b73d0938,DB00061,DB00061,,,,,,,,,,,,,Abnormal lymphocyte counts,HP:0040088,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
205,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061,DB00061,2f450320e31095cfc1ba28f1f21db9f9b8373e5d71125f0b9e0656e9b73d0938,DB00061,DB00061,,,,,,,,,,,,,Abnormal number of b cells,HP:0010975,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
206,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",Pegademase bovine ((PEG-ADA)),DB00061,DB00061,2f450320e31095cfc1ba28f1f21db9f9b8373e5d71125f0b9e0656e9b73d0938,DB00061,DB00061,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
207,102700,,Number Sign,102700,"SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY","SCID DUE TO ADA DEFICIENCY;; ADA-SCID;; SCID DUE TO ADA DEFICIENCY, EARLY-ONSET","SCID DUE TO ADA DEFICIENCY, DELAYED ONSET, INCLUDED;; SCID DUE TO ADA DEFICIENCY, LATE-ONSET, INCLUDED;; ADENOSINE DEAMINASE DEFICIENCY, PARTIAL, INCLUDED;; PARTIAL ADA DEFICIENCY, INCLUDED",Adenosine deaminase deficiency,,ADA,ADA,Adenosine deaminase,32a006c409e5a6d2d4bf8f9485f3efa9e1e8f6a9c9757b8717a41d993cee0e7a,3.5.4.4,3.5.4.4,,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,Immune Globulin Human,DB00028,DB00028,b4a020967fdfce429d858a0849d50d3228b8294a28110560a624ebc67aa6811e,DB00028,DB00028,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Recurrent infection,HP:0002719,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",100,ADA,142,"""""","""""","""""",
208,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,D- Ribose,DB02053,DB02053,eabda4f8b44a13a741f0afd53711a1dcc4bdbe6cff37bf638ddb81e693d39610,DB02053,DB02053,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Exercise-induced muscle fatigue,HP:0009020,,"https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",270,AMPD1,,P23109,K01490,3.5.4.6,
209,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,D- Ribose,DB02053,DB02053,eabda4f8b44a13a741f0afd53711a1dcc4bdbe6cff37bf638ddb81e693d39610,DB02053,DB02053,,,,,,,,,,,,,Exercise-induced myalgia,HP:0003738,,"https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",270,AMPD1,,P23109,K01490,3.5.4.6,
210,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,D- Ribose,DB02053,DB02053,eabda4f8b44a13a741f0afd53711a1dcc4bdbe6cff37bf638ddb81e693d39610,DB02053,DB02053,,,,,,,,,,,,,Limb muscle weakness,HP:0003690,,"https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",270,AMPD1,,P23109,K01490,3.5.4.6,
211,615511,,Number Sign,615511,MYOPATHY DUE TO MYOADENYLATE DEAMINASE DEFICIENCY; MMDD,"ADENOSINE MONOPHOSPHATE DEAMINASE-1 DEFICIENCY, MYOPATHY DUE TO;; AMPD1 DEFICIENCY;; MYOADENYLATE DEAMINASE DEFICIENCY, MYOPATHY DUE TO",,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMPD1,AMP deaminase,dbce8a439e487c325f6af16fecd8bc274bc88840919370f5a7c6f652708054fd,3.5.4.6,3.5.4.6,,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,D- Ribose,DB02053,DB02053,eabda4f8b44a13a741f0afd53711a1dcc4bdbe6cff37bf638ddb81e693d39610,DB02053,DB02053,,,,,,,,,,,,,Muscle cramps,HP:0003394,,"https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://clinicaltrials.gov/ct2/show/NCT01420627,https://www.ncbi.nlm.nih.gov/pubmed/29241594,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",270,AMPD1,,P23109,K01490,3.5.4.6,
212,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,"It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732",Lorenzo's oil(Terminated),DB12528,DB12528,ff0f6cb97866beeedb0199181a2fbc05ccd6ae32f2efa71c269742fa5e0a326f,DB12528,DB12528,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Disease progression,HP:0003678,,"https://clinicaltrials.gov/ct2/show/NCT00545597,https://www.ncbi.nlm.nih.gov/pubmed/16009761,https://www.ncbi.nlm.nih.gov/pubmed/7666063,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
213,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,"It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732",Lorenzo's oil(Terminated),DB12528,DB12528,ff0f6cb97866beeedb0199181a2fbc05ccd6ae32f2efa71c269742fa5e0a326f,DB12528,DB12528,,,,,,,,,,,,,Abnormal elevated level of VLCFA in plasma,HP:0003455,,"https://clinicaltrials.gov/ct2/show/NCT00545597,https://www.ncbi.nlm.nih.gov/pubmed/16009761,https://www.ncbi.nlm.nih.gov/pubmed/7666063,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
214,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,"It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732",Lenti-D geneÂ therapy(advanced self-inactivating lentiviral vector TYF-ABCD1),DB12528,DB12528,ff0f6cb97866beeedb0199181a2fbc05ccd6ae32f2efa71c269742fa5e0a326f,DB12528,DB12528,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,Functional disability(Constitutional symptom)*,HP:0025142,,"https://clinicaltrials.gov/ct2/show/NCT03727555?cond=Adrenoleukodystrophy&rank=4,https://www.myelin.org/tag/lenti-d/,https://www.ncbi.nlm.nih.gov/pubmed/28976817,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
215,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/,Sobetirome (NV1205),DB07425,DB07425,fa24e3f98b6f364249dcdf28690475c06594501bb1e056954ecd570ce03b01c9,DB07425,DB07425,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,functional complementatoin of a defective protein by stimulation,B,Elevated long chain fatty acids,HP:0003455,,"https://www.ncbi.nlm.nih.gov/pubmed/28200172,https://clinicaltrials.gov/ct2/show/NCT03196765?cond=Adrenoleukodystrophy&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/28976817,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
216,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/,Lovastatin,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,ECO:0000352/ECO:0001565/ECO:0007121,"ECO:0000352,ECO:0001565,ECO:0007121",,,functional complementatoin of a defective protein,C,High plasma level of very-long-chain fatty acids,HP:0003455,,"https://www.ncbi.nlm.nih.gov/pubmed/16949688,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/20089986,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
217,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/,Lovastatin,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,,,,,,,High plasma levels of hexacosanoic acid,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/20089986,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
218,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",interferon beta + thalidomide,DB00060+DB01041,DB00060 + DB01041,c793f24520a844a8b9ad79caa145585b6ebe90fdfd3570f13ca2b6dc711d6cb2,,,,,"DB00060,DB01041","DB00060,DB01041",,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure+symptomatic treatment procedure,C+C,NO revealed clinical benefit,,,"https://clinicaltrials.gov/ct2/show/NCT00004450?cond=Adrenoleukodystrophy&rank=20,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
219,300100,,Number Sign,300100,ADRENOLEUKODYSTROPHY; ALD,ADDISON DISEASE AND CEREBRAL SCLEROSIS;; SIEMERLING-CREUTZFELDT DISEASE;; BRONZE SCHILDER DISEASE;; MELANODERMIC LEUKODYSTROPHY,"ADRENOMYELONEUROPATHY, INCLUDED; AMN, INCLUDED",Adrenomyeloneuropathy,,ABCD1,ABCD1,adrenoleukodystrophy protein,529eaa94756f07a3044b91134a3b7822addc6f93402ca6b4180d726441a20aae,3.5.4.6,3.5.4.6,,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",interferon beta + thalidomide,DB00060+DB01041,DB00060 + DB01041,c793f24520a844a8b9ad79caa145585b6ebe90fdfd3570f13ca2b6dc711d6cb2,,,,,"DB00060,DB01041","DB00060,DB01041",,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT00004450?cond=Adrenoleukodystrophy&rank=20,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",215,ABCD1,280,P33897,K05675,7.6.2.4,
220,263570,,Number Sign,263570,"POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN","POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD",,Adult polyglucosan body disease,,GBE1,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",5b41d85459c61a12b5041efa34df0ee9705a1652c1d8bfa54a7bae32d18c959e,3.2.1.196,3.2.1.196,,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,muscle pain,HP:0003326,,"https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",2632,GBE1,,Q04446,K00700,2.4.1.18,
221,263570,,Number Sign,263570,"POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN","POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD",,Adult polyglucosan body disease,,GBE1,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",5b41d85459c61a12b5041efa34df0ee9705a1652c1d8bfa54a7bae32d18c959e,3.2.1.196,3.2.1.196,,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,defective heart function,HP:0011025,,"https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",2632,GBE1,,Q04446,K00700,2.4.1.18,
222,263570,,Number Sign,263570,"POLYGLUCOSAN BODY NEUROPATHY, ADULT FORM; APBN","POLYGLUCOSAN BODY DISEASE, ADULT FORM; APBD",,Adult polyglucosan body disease,,GBE1,GBE1,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",5b41d85459c61a12b5041efa34df0ee9705a1652c1d8bfa54a7bae32d18c959e,3.2.1.196,3.2.1.196,,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Lack of energy,HP:0012378,,"https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",2632,GBE1,,Q04446,K00700,2.4.1.18,
223,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,Medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of genetically defective protein,B,High blood ammonia level,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/29651749,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/26427088,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
224,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,Medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Relapse of hyperammonemic encephalopathy,HP:0001298*,,"https://www.ncbi.nlm.nih.gov/pubmed/29651749,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/26427088,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
225,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,Medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,High plasma citrulline levels,HP:0011966,,"https://www.ncbi.nlm.nih.gov/pubmed/29651749,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/26427088,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
226,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,Medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,low plasma glutamine levels,HP:0010903,,"https://www.ncbi.nlm.nih.gov/pubmed/29651749,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/26427088,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
227,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,L-Arginine,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of genetically defective protein,B,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
228,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,L-Arginine,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
229,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,L-Arginine,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,,,,,,,Encephalopathy,HP:0001298,,"https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
230,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,Pyruvic acid,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
231,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,anorexia,HP:0002039,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
232,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,,,,,,,lethargy,HP:0001254,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
233,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,,,,,,,fatigue,HP:0012378,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
234,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,,,,,,,Poor growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
235,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,,,,,,,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
236,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,,,,,,,Elevated plasma citrulline level,HP:0011966,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
237,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,,,,,,,Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*,HP:0004337*,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
238,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,L-Arginine+Pyruvic acid,DB00125+DB00119,DB00125 + DB00119,8f12fd90c936e0bb43f7591b3ad375a4b08a10c1d3ee18f648e4bb6994a08734,,,,,"DB00125,DB00119","DB00125,DB00119",,,,,,,,,Elevated serum pancreatic secretory trypsin inhibitor,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
239,603471,,Number Sign,603471,"CITRULLINEMIA, TYPE II, ADULT-ONSET; CTLN2",CITRIN DEFICIENCY,,adult-onset typeÂ IIÂ citrullinemia,,SLC25A13,SLC25A13,citrin ( protein),9f7d70a827ac9232032d70e7720f3a6e2ad25d5534c3ba453680176ef7dcf351,Q9UJS0,,Q9UJS0,"According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956",D-mannitol,DB00742,DB00742,6901ce517b0e556bdf0e1512436665e7cacf116fb1a39fbd50503cf07b13f38d,DB00742,DB00742,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Brain oedema,HP:0002181,,"https://www.ncbi.nlm.nih.gov/pubmed/16449956,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",10165,SLC25A13,18,"""""","""""","""""",
240,612953,,Number Sign,612953,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14","DYSTONIA-PARKINSONISM, ADULT-ONSET",,Adult-onset dystonia-parkinsonism,,PLA2G6,PLA2G6,Phospholipase A(2),02f5ac6177812aaaa701b880f4919006662bf03727daa1d08e827b15844dd3c8,3.1.1.4,3.1.1.4,,It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,Pergolide,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/24613933,https://www.ncbi.nlm.nih.gov/books/NBK1181/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,https://www.ncbi.nlm.nih.gov/pubmed/15670720/,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",8398,PLA2G6,,O60733,K16343,3.1.1.4,
241,612953,,Number Sign,612953,"PARKINSON DISEASE 14, AUTOSOMAL RECESSIVE; PARK14","DYSTONIA-PARKINSONISM, ADULT-ONSET",,Adult-onset dystonia-parkinsonism,,PLA2G6,PLA2G6,Phospholipase A(2),02f5ac6177812aaaa701b880f4919006662bf03727daa1d08e827b15844dd3c8,3.1.1.4,3.1.1.4,,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",L- dopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/25660576/,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",8398,PLA2G6,,O60733,K16343,3.1.1.4,
242,615395,,Number Sign,615395,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16,,,Combined oxidative phosphorylation deficiencyÂ 16,,MRPL44,MRPL44,MITOCHONDRIAL RIBOSOMAL PROTEIN L44,a7b6822329646a27ebeff35ed519d80b78777b54ba5a01db37bb12b716c034f5,Q9H9J2,,Q9H9J2,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",creatine,DB00148,DB00148,ca6ae4a8ad76e426ecc26363a6d502ab7a26604d4642cf9e63dd1aa11d40af8d,DB00148,DB00148,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Low physical capacity (Constitutional symptom)*,HP:0025142,,"https://www.ncbi.nlm.nih.gov/pubmed/25797485,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",65080,MRPL44,961,Q9H9J2,K17425,3.1.26.-,
243,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0007121,ECO:0007121,,,metabolite replacement,B,Hepatic Biochemical abnormalities (Laboratory abnormality)*,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
244,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Histologic abnormalities in liver (Abnormal test result)*,HP:0500014,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
245,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,progression of the disease (Rapidly progressive)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
246,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Bile flow defect,HP:0001396,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
247,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,synthesisÂ of atypicalÂ bileÂ acids,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
248,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,production of toxic intermediates,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
249,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,HP:0002630*,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
250,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of genetically defective protein,B,Abnormal liver function tests,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
251,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Pruritus,HP:0000989,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
252,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Abnormal urinary steroids levels(Abnormality of urine hormone level)*,HP:0012029,,"https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
253,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",ursodeoxycholic acid,DB01586,DB01586,6c6cbaf6a1e3ee3787e164056f1e99191eaecb0970fe79065bc15239e6327655,DB01586,DB01586,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Abnormal liver function tests,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/7915305,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
254,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",Glycocholic Acid,DB02691,DB02691,03e89641534d0243274641dac3fb206495468eca87b614a8ecaafafcf4a5128f,DB02691,DB02691,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
255,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",Glycocholic Acid,DB02691,DB02691,03e89641534d0243274641dac3fb206495468eca87b614a8ecaafafcf4a5128f,DB02691,DB02691,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,HP:0002630*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
256,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,DB00162 + DB11094 + DB01022 + DB00163 + DB01586 + DB06777,027f257b129714df32be1a781a1235287ee1ddb1c47e1c41ff0c0230a74fcd92,,,,,"DB00162,DB11094,DB01022,DB00163,DB01586,DB06777","DB00162,DB11094,DB01022,DB00163,DB01586,DB06777",,,ECO:0000352,ECO:0000352,,,metabolite replacement+metabolite replacement+metabolite replacement+metabolite replacement+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,B+B+B+B+B+B,fat soluble vitamin malabsorption(Fat malabsorption)*,HP:0002630*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
257,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,DB00162 + DB11094 + DB01022 + DB00163 + DB01586 + DB06777,027f257b129714df32be1a781a1235287ee1ddb1c47e1c41ff0c0230a74fcd92,,,,,"DB00162,DB11094,DB01022,DB00163,DB01586,DB06777","DB00162,DB11094,DB01022,DB00163,DB01586,DB06777",,,,,,,,,Abnormal gait,HP:0001288,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
258,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,5f8259927169c5186da89eadd670c7f0c2407ea05b9e3d538f8a2eb9bbaa67b0,Q9H2F3,1.1.1.181,Q9H2F3,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",Vitamin A+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,DB00162 + DB11094 + DB01022 + DB00163 + DB01586 + DB06777,027f257b129714df32be1a781a1235287ee1ddb1c47e1c41ff0c0230a74fcd92,,,,,"DB00162,DB11094,DB01022,DB00163,DB01586,DB06777","DB00162,DB11094,DB01022,DB00163,DB01586,DB06777",,,,,,,,,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
259,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,biochemical abnormalities,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
260,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Histologic abnormalities in liver(Abnormal test result)*,HP:0500014,,"https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
261,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
262,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Bile flow defect,HP:0001396,,"https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
263,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,synthesisÂ of atypicalÂ bileÂ acids,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
264,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,production of bile acid toxic intermediates,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
265,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,fat soluble vitamin malabsorption (Fat malabsorption)*,HP:0002630*,,"https://www.ncbi.nlm.nih.gov/pubmed/8225213,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
266,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid + cholic acid,DB06777+DB02659,DB06777 + DB02659,4b51d9e44cfc71b19079d3987372457b3fb9ea53f896e511555bff899c675665,,,,,"DB06777,DB02659","DB06777,DB02659",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+metabolite replacement,,Abnormal liver function tests,,,"https://www.ncbi.nlm.nih.gov/pubmed/8707100,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
267,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid + cholic acid,DB06777+DB02659,DB06777 + DB02659,4b51d9e44cfc71b19079d3987372457b3fb9ea53f896e511555bff899c675665,,,,,"DB06777,DB02659","DB06777,DB02659",,,,,,,,,Liver biopsy abnormalities,,,"https://www.ncbi.nlm.nih.gov/pubmed/8707100,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
268,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid + cholic acid,DB06777+DB02659,DB06777 + DB02659,4b51d9e44cfc71b19079d3987372457b3fb9ea53f896e511555bff899c675665,,,,,"DB06777,DB02659","DB06777,DB02659",,,,,,,,,Abnormal bilirubin level,,,"https://www.ncbi.nlm.nih.gov/pubmed/8707100,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
269,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Abnormal liver function,,,"https://www.ncbi.nlm.nih.gov/pubmed/28697823,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
270,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Hepatomegaly,,,"https://www.ncbi.nlm.nih.gov/pubmed/28697823,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
271,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,92dbee30233a9d77726798279fb5e9d78679e3019c7e8d2bb1e57efaedd43271,1.3.1.3,1.3.1.3,EC,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",Chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28697823,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",6718,AKR1D1,,P51857,K00251,1.3.1.3,
272,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",Nitisinone,DB00348,DB00348,7c4b6db2c231de3544f887bbcf87476369137c671b51bdd2b20726e7f9d81df4,DB00348,DB00348,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a defective protein by inhibition,B,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://clinicaltrials.gov/ct2/show/NCT00107783?cond=Alkaptonuria&rank=4,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
273,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",Nitisinone,DB00348,DB00348,7c4b6db2c231de3544f887bbcf87476369137c671b51bdd2b20726e7f9d81df4,DB00348,DB00348,,,,,,,,,,,,,ochronosis,HP:0030764,,"https://www.ncbi.nlm.nih.gov/pubmed/26891864,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
274,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",Nitisinone,DB00348,DB00348,7c4b6db2c231de3544f887bbcf87476369137c671b51bdd2b20726e7f9d81df4,DB00348,DB00348,,,,,,,,,,,,,High circulating HGA (homogentisic acid)level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/26891864,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
275,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",Nitisinone,DB00348,DB00348,7c4b6db2c231de3544f887bbcf87476369137c671b51bdd2b20726e7f9d81df4,DB00348,DB00348,,,,,,,,,,,,,Joint disesae,HP:0001367,,"https://www.ncbi.nlm.nih.gov/pubmed/26891864,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
276,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",N-ACETYL-CYSTEINE,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,apoptosis induced in chondrocytes,NA,,"https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alkaptonuria,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
277,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",ASCORBIC ACID,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal chondrocyte growth,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/9718357/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
278,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",ASCORBIC ACID,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
279,203500,,Number Sign,203500,ALKAPTONURIA; AKU,HOMOGENTISIC ACID OXIDASE DEFICIENCY,,Alkaptonuria,,HGD,HGD,"Homogentisate 1,2-dioxygenase.",436ddd7b687be448a04c12af9daa867ca21ba382774bc2604aa6e473c1166bfc,1.13.11.5,1.13.11.5,,"Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",ASCORBIC ACID,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,,,,,,,abnormality of proteoglycan metabolism,HP:0004355,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",3081,HGD,23,Q93099,K00451,1.13.11.5,
280,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",ARC-AAT,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,activity modification of a genetically defective protein,A,,,,"https://clinicaltrials.gov/ct2/show/NCT02363946?cond=Alpha-1+antitrypsin+deficiency&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23527792,https://clinicaltrials.gov/ct2/show/NCT02900183,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5265,SERPINA1,,P01009,K03984,"""""",
281,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Recombinant alpha 1-antitrypsin (rAAT),DB05481,DB05481,03d5b47c3fbfa1dc8708cfe9a116f75eab13122951fd3cb99b8f661fa25cdc6b,DB05481,DB05481,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Progressive emphysema,HP:0002097,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://clinicaltrials.gov/ct2/show/NCT02900183,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5265,SERPINA1,,P01009,K03984,"""""",
282,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Recombinant alpha 1-antitrypsin (rAAT),DB05481,DB05481,03d5b47c3fbfa1dc8708cfe9a116f75eab13122951fd3cb99b8f661fa25cdc6b,DB05481,DB05481,,,,,,,,,,,,,Decreased lung function,HP:0005952,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://clinicaltrials.gov/ct2/show/NCT02900183,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5265,SERPINA1,,P01009,K03984,"""""",
283,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Recombinant alpha 1-antitrypsin (rAAT),DB05481,DB05481,03d5b47c3fbfa1dc8708cfe9a116f75eab13122951fd3cb99b8f661fa25cdc6b,DB05481,DB05481,,,,,,,,,,,,,Recurrent infection,HP:0002719,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://clinicaltrials.gov/ct2/show/NCT02900183,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5265,SERPINA1,,P01009,K03984,"""""",
284,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Retinoic acid,DB00755,DB00755,aced4bf08f024cfece6353b780698ceda3a4e6cf5c19c9ba8abd6f07f5a61ec2,DB00755,DB00755,,,,,,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,,Alveoli damage ( interstitial pulmonary abnormality)*,HP:0006530,,"https://www.ncbi.nlm.nih.gov/pubmed/22282548/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://clinicaltrials.gov/ct2/show/NCT02900183,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5265,SERPINA1,,P01009,K03984,"""""",
285,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Beta2-agonists +corticosteroids + anti-cholinergics,DB00755,DB00755,aced4bf08f024cfece6353b780698ceda3a4e6cf5c19c9ba8abd6f07f5a61ec2,DB00755,DB00755,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Difficulty breathing,HP:0002098,,"https://www.ncbi.nlm.nih.gov/pubmed/22282548/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://clinicaltrials.gov/ct2/show/NCT02900183,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5265,SERPINA1,,P01009,K03984,"""""",
286,613490,,Number Sign,613490,ALPHA-1-ANTITRYPSIN DEFICIENCY; A1ATD,,,Alpha-1 antitrypsin deficiency,,SERPINA1,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),29b43300018df9d4913e321e0b1ddf4441335c742391236c6eafe886a129aa98,P01009,,P01009,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Beta2-agonists +corticosteroids + anti-cholinergics,DB00755,DB00755,aced4bf08f024cfece6353b780698ceda3a4e6cf5c19c9ba8abd6f07f5a61ec2,DB00755,DB00755,,,,,,,,,,,,,Lung inflammation (Abnormality of respiratory system),HP:0002086,,"https://www.ncbi.nlm.nih.gov/pubmed/22282548/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,https://clinicaltrials.gov/ct2/show/NCT02900183,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf",5265,SERPINA1,,P01009,K03984,"""""",
287,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Lamazym(rhLAMAN),DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Reduced pulmonary function,HP:0005952,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
288,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Lamazym(rhLAMAN),DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,,,,,,,Low FVC%,HP:0030878*,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
289,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Lamazym(rhLAMAN),DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,,,,,,,High NFL (neurofilament light signature ) in CSF,NA,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
290,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Lamazym(rhLAMAN),DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,,,,,,,Elevated GFAP(Glial fibrillary acidic protein) level in CSF,NA,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
291,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Lamazym(rhLAMAN),DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,,,,,,,Elevated Tau-p level in CSF,NA,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
292,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Lamazym(rhLAMAN),DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,,,,,,,High CSF MAN2-oligosaccharides,,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
293,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",Lamazym(rhLAMAN),DB12374,DB12374,526135296ba6f7d8202027c1dc2c80e89990d77fcf51f3155038ba24596efe13,DB12374,DB12374,,,,,,,,,,,,,cognitive deficits,HP:0100543,,"https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
294,609458,,Asterisk,609458,"MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1","MANNOSIDASE, ALPHA B, LYSOSOMAL; MANB;; LAMAN",,Alpha-mannosidosis,,MAN2B1,MAN2B1,Alpha-mannosidase,5415876b22e934a38dcf1309c8d0701ef3451aa98dbfef59bf95a77ef8170c48,3.2.1.24,3.2.1.24,,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",AAV1vector expressing Î±-Mannosidase,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Neurological abnormalities,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Effective+gene+therapy+for+an+inherited+CNS+disease+in+a+large+animal+mode,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",4125,MAN2B1,,O00754,K12311,3.2.1.24,
295,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,Glycerol phenylbutyrate,DB08909,DB08909,2586da7dbf2d6a945d5981b8b8b7394f72544f04b5a969e4b658667ef0e87e30,DB08909,DB08909,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,low quality of life(Constitutional symptom )*,HP:0025142*,,"https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
296,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,AEB1102(Pegzilarginase) â Co-ArgI-PEG modified human Arginase I,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Elevated blood arginine levels( Abnorality in arginie metabolism)*,HP:0010909*,,"https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
297,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,AEB1102(Pegzilarginase) â Co-ArgI-PEG modified human Arginase I,NA,,,,,,,,,,,,,,,,,Unstable neurological function (Abnormality of the nervous system)*,HP:0000707*,,"https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
298,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,AEB1102(Pegzilarginase) â Co-ArgI-PEG modified human Arginase I,NA,,,,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
299,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,sodium benzoate,DB03793,DB03793,6fac18cc5e193e26705b1cafd1139dbfac2e66ab9c2727b72d3a14280ac4dfd7,DB03793,DB03793,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/11148549,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
300,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,sodium phenylbutyrate,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/11148549,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
301,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,AAV-based gene therapy,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,neurotoxicity,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25474440,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.ncbi.nlm.nih.gov/pubmed/23388701,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
302,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,AAV-based gene therapy,NA,,,,,,,,,,,,,,,,,neurological abnormalities,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/25474440,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.ncbi.nlm.nih.gov/pubmed/23388701,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
303,207800,,Number Sign,207800,ARGININEMIA,ARGINASE DEFICIENCY;; HYPERARGININEMIA;; ARG1 DEFICIENCY,,Arginase deficiency,,ARG1,ARG1,Arginase,3179c90b5495ecf918f1e6d235c8e4d20b6c25f6eb3949673a4780eafcad4357,3.5.3.1,3.5.3.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,AAV-based gene therapy,NA,,,,,,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/25474440,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.ncbi.nlm.nih.gov/pubmed/23388701,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",383,ARG1,16,P05089,K01476,3.5.3.1,
304,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Nitric oxide supplement,DB00435,DB00435,fff3b5808e32492e0effa63b6f7e40ba6b70e06ff3422142c737416e0b4aecbd,DB00435,DB00435,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,B,hypertension,HP:0000822,,"https://www.ncbi.nlm.nih.gov/pubmed/22541557,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
305,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Nitric oxide supplement,DB00435,DB00435,fff3b5808e32492e0effa63b6f7e40ba6b70e06ff3422142c737416e0b4aecbd,DB00435,DB00435,,,,,,,,,,,,,absence of flow-mediated dilatation of brachial artery,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22541557,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
306,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Nitric oxide supplement,DB00435,DB00435,fff3b5808e32492e0effa63b6f7e40ba6b70e06ff3422142c737416e0b4aecbd,DB00435,DB00435,,,,,,,,,,,,,endothelial dysfunction,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22541557,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
307,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Nitric oxide supplement,DB00435,DB00435,fff3b5808e32492e0effa63b6f7e40ba6b70e06ff3422142c737416e0b4aecbd,DB00435,DB00435,,,,,,,,,,,,,Cardiac hypertrophy,,,"https://www.ncbi.nlm.nih.gov/pubmed/22541557,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
308,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Nitric oxide supplement,DB00435,DB00435,fff3b5808e32492e0effa63b6f7e40ba6b70e06ff3422142c737416e0b4aecbd,DB00435,DB00435,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/22541557,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
309,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Nitric oxide supplement,DB00435,DB00435,fff3b5808e32492e0effa63b6f7e40ba6b70e06ff3422142c737416e0b4aecbd,DB00435,DB00435,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/22541557,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
310,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Sodium citrate,DB09154,DB09154,7dfb3c751c48770217688e4602f154f80add9e9a472388e4dd0bad634fbbddb3,DB09154,DB09154,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal renal nitrogen elimination,HP:0004364,,"https://www.ncbi.nlm.nih.gov/pubmed/8582405,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
311,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,keto-analogues of essential amino acids,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,seizure,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/668730,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
312,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,keto-analogues of essential amino acids,NA,,,,,,,,,,,,,,,,,High blood ammonia levels,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/668730,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
313,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,keto-analogues of essential amino acids,NA,,,,,,,,,,,,,,,,,Defective argininosuccinic acid excretion,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/668730,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
314,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Sodium Phenylbutyrate +Arginin,DB06819+DB00125,DB06819 + DB00125,861d80de6bb5c57448657264b826026526cff1506651818b5ddd2b8e8f42cc64,,,,,"DB06819,DB00125","DB06819,DB00125",,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,Hyperammonemia,HP:0001987,,"https://clinicaltrials.gov/ct2/show/NCT00345605,https://www.ncbi.nlm.nih.gov/pubmed/8582405,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
315,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Arginine,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,abnormal hepatic function tests,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
316,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Arginine,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,,,,,,,Low plasma arginine levels,HP:0005961,,"https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
317,207900,207900,Number Sign,207900,ARGININOSUCCINIC ACIDURIA,ARGININOSUCCINASE DEFICIENCY;; ARGININOSUCCINATE LYASE DEFICIENCY;; ASL DEFICIENCY;; ARGININOSUCCINIC ACID LYASE DEFICIENCY,,Argininosuccinic aciduria,,ASL,ASL,argininosuccinate lyase,03de523af1c71e4e6bec6e278675323fbad2b933e3ebba363937b2d9bece6d7f,4.3.2.1,4.3.2.1,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Arginine,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,,,,,,,Acute hyperammonemia,HP:0008281,,"https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",435,ASL,15,P04424,K01755,4.3.2.1,
318,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,AAV2-hAADC ( Gene therapy),NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,motor malperformance,HP:0002275,,"https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
319,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,AAV2-hAADC ( Gene therapy),NA,,,,,,,,,,,,,,,,,increased dopamine and serotonin levelsÂ (neurotransmitter levels),HP:0012654,,"https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
320,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,hypokinesia,HP:0002375,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
321,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,axial hypotonia,HP:0008936,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
322,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,limb hypertonia,HP:0002509,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
323,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
324,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,choreoathetosis,HP:0001266,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
325,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,Poor head control,HP:0002421,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
326,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,Oculogyric crises,HP:0010553,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
327,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,Abnormalitilty in voluntary movements(Abnormality of movement)*,HP:0100022*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
328,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Bromocriptine,DB01200,DB01200,2923707a7e9927cac72b12b0078fffbb8d3dcad860ac6552a148726467a79040,DB01200,DB01200,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
329,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,boost residual AADC activity with a cofactor excess,NA,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
330,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,Pyrodixal 5 phosphate,DB00114,DB00114,8aa8f0a051e57b66fec0638a7c38161ad76887734ba9bd3111cd00f3841f9b13,DB00114,DB00114,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,boost residual AADC activity with a cofactor excess,,,"https://www.ncbi.nlm.nih.gov/pubmed/25001633/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
331,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,pramipexole,DB12890,DB12890,022ba1c7d581193e172fe00ac4dea61869759509db4846292bf8fd1689f3ef9e,DB12890,DB12890,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hypotonia,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
332,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,pramipexole,DB12890,DB12890,022ba1c7d581193e172fe00ac4dea61869759509db4846292bf8fd1689f3ef9e,DB12890,DB12890,,,,,,,,,,,,,Oculogyric crisis,HP:0010553,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
333,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,pramipexole,DB12890,DB12890,022ba1c7d581193e172fe00ac4dea61869759509db4846292bf8fd1689f3ef9e,DB12890,DB12890,,,,,,,,,,,,,Poor head control,HP:0002421,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
334,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,pramipexole,DB12890,DB12890,022ba1c7d581193e172fe00ac4dea61869759509db4846292bf8fd1689f3ef9e,DB12890,DB12890,,,,,,,,,,,,,Voluntary movement abnormalities(Abnormality of movement)*,HP:0100022*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
335,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,pramipexole,DB12890,DB12890,022ba1c7d581193e172fe00ac4dea61869759509db4846292bf8fd1689f3ef9e,DB12890,DB12890,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
336,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Rotigotine,DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hypotonia,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
337,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Rotigotine,DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,,,,,,,Oculogyric crisis,HP:0010553,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
338,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Rotigotine,DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,,,,,,,Poor head control,HP:0002421,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
339,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Rotigotine,DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,HP:0100022*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
340,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Rotigotine,DB05271,DB05271,4846424056f4fd7b7d2eaffcb6c815c969bf64faa39e2cc44d2f4edd1da14d26,DB05271,DB05271,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
341,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Pergolide,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hypotonia,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
342,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Pergolide,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,,,,,,,Oculogyric crisis,HP:0010553,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
343,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Pergolide,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,,,,,,,Poor head control,HP:0002421,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
344,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Pergolide,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,HP:0100022*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
345,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Pergolide,DB01186,DB01186,c2d34c02f2f18dd7427d2e3a1de30bdec5fae84df1776e05d1a8aade69885b62,DB01186,DB01186,,,,,,,,,,,,,Autonomic dysfunction,HP:0002459,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
346,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,cerebral folate depletion,HP:0012446,,"https://www.ncbi.nlm.nih.gov/pubmed/25001633/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
347,608643,608643,Number Sign,608643,AROMATIC L-AMINO ACID DECARBOXYLASE DEFICIENCY,AADC DEFICIENCY;; DOPA DECARBOXYLASE DEFICIENCY;; DDC DEFICIENCY,,Aromatic L-amino acid decarboxylase deficiency,,DDC,DDC,Aromatic-L-amino-acid decarboxylase,0db57f556c1cc841eb25c2408b3e4ed3f9f6c245c21ac7272c6f8cb610e8378a,4.1.1.28,4.1.1.28,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",Pargyline,DB01626,DB01626,d111c3960f6beafd424461e2aa35d0bca282e8427b5c5a16b077bc71ade82e7f,DB01626,DB01626,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hypotonia,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",1644,DDC,100,P20711,K01593,4.1.1.28,
348,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,low levels of purines,HP:0004369,,"https://www.sciencedirect.com/science/article/pii/S0002929707613470,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",5631,PRPS1,,P60891,K00948,2.7.6.1,
349,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Progression of retinal degeneration ( Rapidly Progressive)*,HP:0003678*,,"https://www.sciencedirect.com/science/article/pii/S0002929707613470,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",5631,PRPS1,,P60891,K00948,2.7.6.1,
350,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Ataxia Progression(Rapid progression),HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",5631,PRPS1,,P60891,K00948,2.7.6.1,
351,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Recurrent infection,HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",5631,PRPS1,,P60891,K00948,2.7.6.1,
352,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,frequent hospital admission,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",5631,PRPS1,,P60891,K00948,2.7.6.1,
353,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Hearing impairment progression(Rapid progression)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",5631,PRPS1,,P60891,K00948,2.7.6.1,
354,301835,,Number Sign,301835,ARTS SYNDROME; ARTS,"MENTAL RETARDATION, X-LINKED, SYNDROMIC, ARTS TYPE; MRXSARTS;; ATAXIA, FATAL X-LINKED, WITH DEAFNESS AND LOSS OF VISION;; MENTAL RETARDATION, X-LINKED, SYNDROMIC 18; MRXS18",,Arts Syndrome,,PRPS1,PRPS1,Ribose-phosphate diphosphokinase,64052e2b4e891cad16a784be5ddc9cf7c41a6d41870968dab8c17f094d9b1303,2.7.6.1,2.7.6.1,,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Noctornal difficulty breathing,HP:0002098,,"https://www.ncbi.nlm.nih.gov/pubmed/23190330,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",5631,PRPS1,,P60891,K00948,2.7.6.1,
355,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,"As by 2016 Banning et al. mentioned ""Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years",AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. ""This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. "" It posses the ability to cross the BBB. ""Our data show for the first time that Amlexanox might provide a valid therapy for AGU."" https://www.ncbi.nlm.nih.gov/pubmed/29247835",Amlexanox,DB01025,DB01025,80f15884cb03a9796fc7107d6ffcf92d0754edc547a1c163cd778ad25649d5e5,DB01025,DB01025,,,,,,,ECO:0001565,ECO:0001565,Ser72Pro/Trp168X,,activity modification of a genetically defective protein,A,Low AGA activity,NA,,"https://www.semanticscholar.org/topic/amlexanox/510418,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
356,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",betaine,DB06756,DB06756,a8f65864591a4e53f7884308c647c506d5d939fadb78576e1a1f21a5c6e4a5af,DB06756,DB06756,,,,,,,ECO:0001565,ECO:0001565,T122K,,activity modification of a genetically defective protein,A,Low AGA activity,NA,,"https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
357,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",betaine,DB06756,DB06756,a8f65864591a4e53f7884308c647c506d5d939fadb78576e1a1f21a5c6e4a5af,DB06756,DB06756,,,,,,,,,,,,,Unstable AGA enzyme,NA,,"https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
358,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",betaine,DB06756,DB06756,a8f65864591a4e53f7884308c647c506d5d939fadb78576e1a1f21a5c6e4a5af,DB06756,DB06756,,,,,,,,,,,,,Misfolded AGA,NA,,"https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
359,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",betaine,DB06756,DB06756,a8f65864591a4e53f7884308c647c506d5d939fadb78576e1a1f21a5c6e4a5af,DB06756,DB06756,,,,,,,,,,,,,Abnormal AGA processing,NA,,"https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
360,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",Glycine,DB00145,DB00145,79f350e4081104f76a71ae9acfb363437413faff62ebdace99bac99264773df5,DB00145,DB00145,,,,,,,,,,,activity modification of a genetically defective protein,A,Low AGA activity,NA,,"https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pubmed/23601642,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/29247835,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
361,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",Recombinant human Aspartylglucosamidase,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein,A,pathology in many somatic tissues,HP:0000924*,,"https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
362,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",Recombinant human Aspartylglucosamidase,NA,,,,,,,,,,,,,,,,,accumulating substance aspartylglucosamine from ( Metaboic abnormality)*,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
363,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",Recombinant human Aspartylglucosamidase,NA,,,,,,,,,,,,,,,,,High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*,HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
364,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",Recombinant human Aspartylglucosamidase,NA,,,,,,,,,,,,,,,,,High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*),HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
365,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",Gene therapy (wild-type Ad-AGA),NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Low expression of AGA enzyme,,,"https://www.ncbi.nlm.nih.gov/pubmed/9930336/,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
366,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",Gene therapy (wild-type Ad-AGA),NA,,,,,,,,,,,,,,,,,Liver lysosomal storage abnormality,,,"https://www.ncbi.nlm.nih.gov/pubmed/9930336/,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
367,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",Gene therapy (wild-type Ad-AGA),NA,,,,,,,,,,,,,,,,,Brain lysosomal storage disease,,,"https://www.ncbi.nlm.nih.gov/pubmed/9930336/,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
368,208400,,Number Sign,208400,ASPARTYLGLUCOSAMINURIA; AGU,GLYCOSYLASPARAGINASE DEFICIENCY;; ASPARTYLGLUCOSAMINIDASE DEFICIENCY;; AGA DEFICIENCY;; GLYCOASPARAGINASE;; ASPARTYLGLYCOSAMINURIA,,Aspartylglycosaminuria,,AGA,AGA,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,48346613ae4cd9d4b3a9332a205dc0cbe8d1cfded543921c4c057234bfae6390,3.5.1.26,3.5.1.26,,"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",Gene therapy (wild-type Ad-AGA),NA,,,,,,,,,,,,,,,,,ipsilateral brain neuronal storage abnormalities,,,"https://www.ncbi.nlm.nih.gov/pubmed/16518877/,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",175,AGA,258,P20933,K01444,3.5.1.26,
369,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPA,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20301419,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7274,TTPA,658,P49638,"""""","""""",
370,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPA,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Abnormal vitamin E level(Vitamin E deficiency)*,HP:0100513*,,"https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20301419,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7274,TTPA,658,P49638,"""""","""""",
371,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPA,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Ataxia,HP:0001251,,"https://www.ncbi.nlm.nih.gov/pubmed/9931538,https://www.ncbi.nlm.nih.gov/pubmed/11554913,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7274,TTPA,658,P49638,"""""","""""",
372,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPA,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Neurological abnormalitis,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/11554913,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7274,TTPA,658,P49638,"""""","""""",
373,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPA,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",RRR-Î±-tocopherol,DB14002,DB14002,92900224055cbadcf6c80003489a230f3c28a1ecaf594d0dc3a0c5fe40be77c6,DB14002,DB14002,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*,HP:0030390*,,"https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7274,TTPA,658,P49638,"""""","""""",
374,277460,,Number Sign,277460,"VITAMIN E, FAMILIAL ISOLATED DEFICIENCY OF; VED","ATAXIA, FRIEDREICH-LIKE, WITH SELECTIVE VITAMIN E DEFICIENCY; AVED;; FRIEDREICH-LIKE ATAXIA",,Ataxia with vitamin E deficiency,,TTPA,TTPA,Î±-tocopherol transfer protein,ea831cf64e2dac6b249ca8cbb1d4359b1793a4f00c174def6fa1d6ab4fdbedde,P49638,,P49638,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",RRR-Î±-tocopherol,DB14002,DB14002,92900224055cbadcf6c80003489a230f3c28a1ecaf594d0dc3a0c5fe40be77c6,DB14002,DB14002,,,,,,,,,,,,,Abnormal H50 (The erythrocyte resistance to oxidative stress),NA,,"https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7274,TTPA,658,P49638,"""""","""""",
375,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",myo-inositol,DB13178,DB13178,ced8fe513f10e1fefbed4496ffa213252995e3da39b86b760f3efded57a1716f,DB13178,DB13178,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,neurological malfunction,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
376,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",myo-inositol,DB13178,DB13178,ced8fe513f10e1fefbed4496ffa213252995e3da39b86b760f3efded57a1716f,DB13178,DB13178,,,,,,,,,,,,,immune dysfunctions,HP:0002715,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
377,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Alpha lipoic acid,DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Neuronal death,HP:0002529,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
378,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Alpha lipoic acid,DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
379,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",nicotinamide,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal levels of urine total alkanes,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
380,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",nicotinamide,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
381,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Alpha-lipoic acid + nicotinamide,DB00166+DB02701,DB00166 + DB02701,06ec7c35b99dd3cb38e5758cbbd01898caead5f074f39ed2013492b0e6df3155,,,,,"DB00166,DB02701","DB00166,DB02701",,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Abnormal serum fast ORAC(oxygen reduced absorbance capacity),NA,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
382,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Alpha-lipoic acid + nicotinamide,DB00166+DB02701,DB00166 + DB02701,06ec7c35b99dd3cb38e5758cbbd01898caead5f074f39ed2013492b0e6df3155,,,,,"DB00166,DB02701","DB00166,DB02701",,,,,,,,,Abnormal lymphocyte counts,HP:0040088,,"https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
383,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Immunoglobulin replacement therap,DB00028,DB00028,b4a020967fdfce429d858a0849d50d3228b8294a28110560a624ebc67aa6811e,DB00028,DB00028,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Recurrent infection,HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/28318010,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
384,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",amantadine,DB00915,DB00915,20a06e9c70955f962a379c58cd1083f8a64e47e4e58c850cbe9ca05656efd7d5,DB00915,DB00915,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Ataxia,HP:0001251,,"https://www.ncbi.nlm.nih.gov/pubmed/22550086/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
385,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",amantadine,DB00915,DB00915,20a06e9c70955f962a379c58cd1083f8a64e47e4e58c850cbe9ca05656efd7d5,DB00915,DB00915,,,,,,,,,,,,,involuntary movements,HP:0004305,,"https://www.ncbi.nlm.nih.gov/pubmed/22550086/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
386,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",amantadine,DB00915,DB00915,20a06e9c70955f962a379c58cd1083f8a64e47e4e58c850cbe9ca05656efd7d5,DB00915,DB00915,,,,,,,,,,,,,parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/22550086/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
387,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",clonazepam,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,myoclonuic Jerk,HP:0001336,,"https://www.ncbi.nlm.nih.gov/pubmed/26232052/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
388,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",clonazepam,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,,,,,,,Poor fine motor skills,HP:0007010,,"https://www.ncbi.nlm.nih.gov/pubmed/26232052/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
389,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",clonazepam,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,,,,,,,Voice tremor,HP:0012477,,"https://www.ncbi.nlm.nih.gov/pubmed/26232052/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
390,208900,,Number Sign,208900,ATAXIA-TELANGIECTASIA; AT,AT1;; LOUIS-BAR SYNDROME,"AT, COMPLEMENTATION GROUP A, INCLUDED; ATA, INCLUDED;; AT, COMPLEMENTATION GROUP C, INCLUDED; ATC, INCLUDED;; AT, COMPLEMENTATION GROUP D, INCLUDED; ATD, INCLUDED;; AT, COMPLEMENTATION GROUP E, INCLUDED; ATE, INCLUDED;; ATAXIA-TELANGIECTASIA VARIANT, INCLUDED",Ataxia Telangectesia,,ATM,ATM,ATM serine/threonine kinase,32d29fd50ab5651ce3431401bd114c137ea8f3263b4dd3edd52a6abb960f4c2b,2.7.11.21,2.7.11.21,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",clonazepam,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,,,,,,,Poor intelligibility,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/26232052/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",472,ATM,,Q13315,K04728,2.7.11.1,
391,208920,,Number Sign,208920,"ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH","ATAXIA-OCULOMOTOR APRAXIA SYNDROME; AOA;; ATAXIA-OCULOMOTOR APRAXIA 1; AOA1;; ATAXIA-TELANGIECTASIA-LIKE SYNDROME;; CEREBELLAR ATAXIA, EARLY-ONSET, WITH HYPOALBUMINEMIA; EOCA-HA","ATAXIA, ADULT-ONSET, WITH OCULOMOTOR APRAXIA, INCLUDED",Ataxia-oculomotor apraxia type 1,,APTX,APTX,Aprataxin,ff454d93c31ed6f6d09999cd7b6d59974b0256a21cbad59406de89b358f45b15,3.1.12.2,3.1.12.2,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",CoQ10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,lack of strenght,HP:0003750,,"https://www.ncbi.nlm.nih.gov/pubmed/28277561,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",54840,APTX,,Q7Z2E3,K10863,3.1.11.7; 3.1.12.2,
392,208920,,Number Sign,208920,"ATAXIA, EARLY-ONSET, WITH OCULOMOTOR APRAXIA AND HYPOALBUMINEMIA; EAOH","ATAXIA-OCULOMOTOR APRAXIA SYNDROME; AOA;; ATAXIA-OCULOMOTOR APRAXIA 1; AOA1;; ATAXIA-TELANGIECTASIA-LIKE SYNDROME;; CEREBELLAR ATAXIA, EARLY-ONSET, WITH HYPOALBUMINEMIA; EOCA-HA","ATAXIA, ADULT-ONSET, WITH OCULOMOTOR APRAXIA, INCLUDED",Ataxia-oculomotor apraxia type 1,,APTX,APTX,Aprataxin,ff454d93c31ed6f6d09999cd7b6d59974b0256a21cbad59406de89b358f45b15,3.1.12.2,3.1.12.2,,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",CoQ10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/28277561,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/27906067,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",54840,APTX,,Q7Z2E3,K10863,3.1.11.7; 3.1.12.2,
393,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TF,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Human apotransferrin,CHEBI:2786,CHEBI:2786,e70c6b5799bf1f6b401efc912a9b7d33a0088c1a818b232bc81928673fc6a533,CHEBI:2786,,CHEBI_2786,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,hypochromic anemia,HP:0001931,,"https://clinicaltrials.gov/ct2/show/NCT01797055?cond=Atransferrinemia&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/8317485,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7018,TF,206,P02787,K14736,"""""",
394,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TF,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",Deferoxamine,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,hypochromic anemia,HP:0001931,,"https://www.ncbi.nlm.nih.gov/pubmed/8187613,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/8317485,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7018,TF,206,P02787,K14736,"""""",
395,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TF,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,"Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. ""Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrinâbound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280",Ferrous sulfate,DB13257,DB13257,a8ed5c403d6017336ca159660834c6338855cddd0b2d2bbad95e3670d7a93bcf,DB13257,DB13257,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Decreased hemoglobin,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/28895280,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/8317485,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7018,TF,206,P02787,K14736,"""""",
396,209300,209300,Number Sign,209300,ATRANSFERRINEMIA,"HYPOTRANSFERRINEMIA, FAMILIAL","TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 1, INCLUDED; TFQTL1, INCLUDED",Atransferrinemia,,TF,TF,transferrin,6b4dddf6c6d25b3e7ebafc7de848065f8afb2260ca749b8d86c9a0d481cdc0fd,P02787,,P02787,"Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. ""Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrinâbound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280",Ferrous sulfate,DB13257,DB13257,a8ed5c403d6017336ca159660834c6338855cddd0b2d2bbad95e3670d7a93bcf,DB13257,DB13257,,,,,,,,,,,,,High ferritin level,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pubmed/28895280,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/17586848,https://www.ncbi.nlm.nih.gov/pubmed/15300460,https://www.ncbi.nlm.nih.gov/pubmed/8317485,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/",7018,TF,206,P02787,K14736,"""""",
397,162350,,Number Sign,162350,"CEROID LIPOFUSCINOSIS, NEURONAL, 4B, AUTOSOMAL DOMINANT; CLN4B","KUFS DISEASE, AUTOSOMAL DOMINANT;; CEROID LIPOFUSCINOSIS, NEURONAL, PARRY TYPE",,Autosomal dominant neuronal ceroid lipofuscinosis 4B,,DNAJC5,DNAJC5,DnaJ homolog subfamily C member 5(cysteine string PROTEIN),2330e114db5b1f7d3e1e424c05947a90eb56cc4bdf430d6885d98ca253788a18,Q9H3Z4,,Q9H3Z4,"Symptomatic treatment can be successful in mitigating the manifestations of NCL. Seizures, sleep-related problems, malnutrition, gastroesophageal reflux, pneumonia, sialorrhea, hyperactivity and behavior problems, psychosis, anxiety, spasticity, Parkinsonian symptoms, and dystonia can be palliated. https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management",No treatment is available in DDIEM,,,,,,,,,,,,,,,,symptomatic treatment procedure,C,,,,,80331,DNAJC5,309,Q9H3Z4,K09525,"""""",
398,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,Cystagon,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,progression of neurodegeneration,HP:0002344,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
399,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,DB06151 + DB00847,73f604cfaf3993a0200b6dad4a2b89b2bebda7797c491467b08d1a8f943e296d,,,,,"DB06151,DB00847","DB06151,DB00847",,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,granular osmiophilic deposits (GROD),HP:0003657,,"https://www.ncbi.nlm.nih.gov/pubmed/24997880,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
400,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,DB06151 + DB00847,73f604cfaf3993a0200b6dad4a2b89b2bebda7797c491467b08d1a8f943e296d,,,,,"DB06151,DB00847","DB06151,DB00847",,,,,,,,,irritability,HP:0000737,,"https://www.ncbi.nlm.nih.gov/pubmed/24997880,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
401,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,DB06151 + DB00847,73f604cfaf3993a0200b6dad4a2b89b2bebda7797c491467b08d1a8f943e296d,,,,,"DB06151,DB00847","DB06151,DB00847",,,,,,,,,Defected alertness,HP:0004372,,"https://www.ncbi.nlm.nih.gov/pubmed/24997880,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
402,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",N-Acetylcysteine+cysteamine bitartrate,DB06151+DB00847,DB06151 + DB00847,73f604cfaf3993a0200b6dad4a2b89b2bebda7797c491467b08d1a8f943e296d,,,,,"DB06151,DB00847","DB06151,DB00847",,,,,,,,,Isoelectric electroencephalogram,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/24997880,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
403,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",Î´-tocopherol (DT),DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,B,cognitive deficits,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
404,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",hydroxypropyl-Î²-cyclodextrin (HPBCD),NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,B,brain atrophy,HP:0012444,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
405,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,Î´-tocopherol (DT) + hydroxypropyl-Î²-cyclodextrin (HPBCD),DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,B,Lipid accumulation( Abnorality in lipid meabolism)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
406,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,Î´-tocopherol (DT) + hydroxypropyl-Î²-cyclodextrin (HPBCD),DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,,,,,,,Lysosomal enlargment (Abnormality of lysosomal metabolism)*,HP:0004356*,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
407,256730,,Number Sign,256730,"CEROID LIPOFUSCINOSIS, NEURONAL, 1; CLN1","CEROID LIPOFUSCINOSIS, NEURONAL, 1, VARIABLE AGE AT ONSET","NEURONAL CEROID LIPOFUSCINOSIS, INFANTILE, INCLUDED; INCL, INCLUDED;; SANTAVUORI DISEASE, INCLUDED;; SANTAVUORI-HALTIA DISEASE, INCLUDED",InfantileÂ Neuronal Ceroid Lipofuscinosis,,PPT1,PPT1,PALMITOYL-PROTEIN THIOESTERASE,2684427c2d88b0c89c54a57e025a54227a0e5fa09f1e0a5f8c7b6716331f851e,3.1.2.22,3.1.2.22,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,Recombinant human palmitoyl-protein thioesterase 1 ( PPT1),NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,direct complementation of a genetically defective protein,A,Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*,HP:0004356*,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13",5538,PPT1,305,P50897,K01074,3.1.2.22,
408,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,Mycophenolate mofetil,DB00688,DB00688,c4034355ca9cb7c4b5e332b5578e3df223e6dd710880dbeffbd730080f3abbed,DB00688,DB00688,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,symptomatic treatment procedure,C,The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated,,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://clinicaltrials.gov/ct2/show/results/NCT01399047?cond=neuronal+ceroid+lipofuscinosis&rank=1&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/29923092",1201,CLN3,307,Q13286,K12389,"""""",
409,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,carbenoxolone,DB02329,DB02329,de2101a8c9f2a03505d41ef6199bdbc99ab73ca91ac891d0a0d03f1af1e0d247,DB02329,DB02329,,,,,,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,C,Blood-brain barrier (BBB) impairment,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://www.ncbi.nlm.nih.gov/pubmed/29660499,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/29923092",1201,CLN3,307,Q13286,K12389,"""""",
410,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,carbenoxolone,DB02329,DB02329,de2101a8c9f2a03505d41ef6199bdbc99ab73ca91ac891d0a0d03f1af1e0d247,DB02329,DB02329,,,,,,,,,,,,,Low cell autofluorescence,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://www.ncbi.nlm.nih.gov/pubmed/29660499,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/29923092",1201,CLN3,307,Q13286,K12389,"""""",
411,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,carbenoxolone,DB02329,DB02329,de2101a8c9f2a03505d41ef6199bdbc99ab73ca91ac891d0a0d03f1af1e0d247,DB02329,DB02329,,,,,,,,,,,,,membrane fluidity alterations,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://www.ncbi.nlm.nih.gov/pubmed/29660499,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/29923092",1201,CLN3,307,Q13286,K12389,"""""",
412,204200,,Number Sign,204200,"CEROID LIPOFUSCINOSIS, NEURONAL, 3; CLN3","NEURONAL CEROID LIPOFUSCINOSIS, JUVENILE; JNCL;; BATTEN DISEASE;; VOGT-SPIELMEYER DISEASE;; SPIELMEYER-SJOGREN DISEASE",,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,CLN3,battenin,06971bd7f18fb3d85e152dc7309b6ba87ee9d7914ed5cfbc8146611b0c0a8c1e,Q13286,,Q13286,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,carbenoxolone,DB02329,DB02329,de2101a8c9f2a03505d41ef6199bdbc99ab73ca91ac891d0a0d03f1af1e0d247,DB02329,DB02329,,,,,,,,,,,,,extended G1 interval,HP:0011018,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://www.ncbi.nlm.nih.gov/pubmed/29660499,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/29923092",1201,CLN3,307,Q13286,K12389,"""""",
413,601780,,Number Sign,601780,"CEROID LIPOFUSCINOSIS, NEURONAL, 6; CLN6","CEROID LIPOFUSCINOSIS, NEURONAL, 6, VARIABLE AGE AT ONSET;; NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, VARIANT; vLINCL;; CEROID LIPOFUSCINOSIS, NEURONAL, 6 (Kufs type);; CEROID LIPOFUSCINOSIS, NEURONAL, 4A, AUTOSOMAL RECESSIVE, FORMERLY; CLN4A, FORMERLY",,Late infantile neuronal ceroid lipofuscinoses CLN6,,CLN6,CLN6,"CLN6, transmembrane ER protein",2772bfaf86ea57a692429f41141a8131888aee9c0d0c0d9de629f38a2f979710,id,,"NO,Human,id",A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,scAVV9.CB.CLN6,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,,,,"https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://www.ncbi.nlm.nih.gov/pubmed/31331814,https://clinicaltrials.gov/ct2/show/NCT01399047?cond=Batten+Disease&rank=7,https://clinicaltrials.gov/ct2/show/NCT02725580?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=14",54982,CLN6,311,Q9NWW5,K12359,"""""",
414,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,functional complementation of a genetically defective protein,B,neurologic deficits,HP:0000707,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
415,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
416,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,brain atrophy,HP:0012444,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
417,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,loss of ambulation,HP:0002540,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
418,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
419,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
420,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
421,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
422,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
423,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,cerliponase alfa,DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
424,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,AAVrh.10CUhCLN2,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://clinicaltrials.gov/ct2/show/NCT01161576?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=8,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
425,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,AAV2CUhCLN2,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,,,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://clinicaltrials.gov/ct2/show/NCT00151216?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=9,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720",1200,TPP1,306,O14773,K01279,3.4.14.9,
426,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,Î´-tocopherol (DT),DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,B,cognitive deficits,HP:0100543,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",1200,TPP1,306,O14773,K01279,3.4.14.9,
427,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,hydroxypropyl-Î²-cyclodextrin (HPBCD),NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,B,brain atrophy,HP:0012444,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",1200,TPP1,306,O14773,K01279,3.4.14.9,
428,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,BMN 190 (cerliponase alfa),DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,ECO:0001565/ECO:0007121,"ECO:0001565,ECO:0007121",,,direct complementation of a genetically defective protein,A,neurological disease,HP:0000707,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",1200,TPP1,306,O14773,K01279,3.4.14.9,
429,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,BMN 190 (cerliponase alfa),DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,neurologic deficits,HP:0000707,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",1200,TPP1,306,O14773,K01279,3.4.14.9,
430,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,BMN 190 (cerliponase alfa),DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",1200,TPP1,306,O14773,K01279,3.4.14.9,
431,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,BMN 190 (cerliponase alfa),DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,brain atrophy,HP:0012444,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",1200,TPP1,306,O14773,K01279,3.4.14.9,
432,204500,,Number Sign,204500,"CEROID LIPOFUSCINOSIS, NEURONAL, 2; CLN2","CEROID LIPOFUSCINOSIS, NEURONAL, 2, VARIABLE AGE AT ONSET;; JANSKY-BIELSCHOWSKY DISEASE","NEURONAL CEROID LIPOFUSCINOSIS, LATE INFANTILE, INCLUDED; LINCL, INCLUDED",Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TPP1,TRIPEPTIDYL PEPTIDASE I,6d4f4913efadab5f28c488dcf63d8236e5846ea3254105a0c6eb9b269f190d05,3.4.14.9,3.4.14.9,EC,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,BMN 190 (cerliponase alfa),DB13173,DB13173,37d39e89520059aa2d86df0a2b2f74de073437d61caf68148e4af1b9291ec7a4,DB13173,DB13173,,,,,,,,,,,,,loss of ambulation,HP:0002540,,"https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",1200,TPP1,306,O14773,K01279,3.4.14.9,
433,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0007121,ECO:0007121,comp. htz c.[895C > T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24],,functional complementation of a genetically defective protein,B,tremor,HP:0001298,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
434,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,Drawing inabiliity,MP:0004144,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
435,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,Myoclonus,HP:0002180,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
436,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
437,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,Hetero c.[1541AâG] + [1750_1752 delACC],,,,exercise intolerance,HP:0012211,,"https://www.ncbi.nlm.nih.gov/pubmed/18319074,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
438,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15326254/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
439,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,hyperlactatemia,HP:0003128,,"https://www.ncbi.nlm.nih.gov/pubmed/15326254/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
440,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,Homozygous deletion (c.504del_CT),,,,Speech problem,HP:0002167,,"https://www.ncbi.nlm.nih.gov/pubmed/26818466,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
441,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,Gait abnormality,HP:0001288,,"https://www.ncbi.nlm.nih.gov/pubmed/26818466,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
442,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,Neurological abormalities,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/26818466,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
443,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs),,,,Fatigue,HP:0012378,,"https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
444,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,High ataxia score ( Ataxia)*,HP:0001251*,,"https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
445,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A,,,,Myoclonic abnormalities(Myoclouns)*,HP:0001336*,,"https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
446,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,ataxic gait,HP:0002066,,"https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
447,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,A combination therapy of Î´-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,CoQ10(ubiquinone),DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,dysarthric speech,HP:0001260,,"https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
448,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,"Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873",idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0000352,ECO:0000352,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15326254/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
449,612016,,Number Sign,612016,"COENZYME Q10 DEFICIENCY, PRIMARY, 4; COQ10D4","SPINOCEREBELLAR ATAXIA, AUTOSOMAL RECESSIVE 9; SCAR9",,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,ADCK3,"Atypical kinase COQ8A, mitochondrial",b164917daabfaaa14835606818d8815066d1b9dcaddba6755d95c9cba0efe319,1.3.5.1,1.3.5.1,,"Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873",Sodium Valproate,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,,,,,symptomatic treatment procedure,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",,"""""","""""","""""",
450,607091,,Number Sign,607091,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IId; CDG2D",CDG IId; CDGIId,,B4GALT1-CDG (CDG-IId),,GALT1,GALT1,"beta-1,4-galactosyl transferase.",c4dcaf42b8042b735f0768ac89f9085c112da2f2028922247817bedd4576c4b4,2.4.1.274,2.4.1.274,,Drug name: Treatment is under trial.,galactose supplementation,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,ECO:0007121,ECO:0007121,,,dietary supplementation,C,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24164873,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/","""""","""""",338,"""""","""""","""""",
451,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,Drug name: Treatment is under trial.,mannose supply,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Metabolism abnormality,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",4351,MPI,322,P34949,K01809,5.3.1.8,
452,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,Drug name: Treatment is under trial.,mannose supply,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,,,,,,,hypoproteinemia,MP:0005567,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",4351,MPI,322,P34949,K01809,5.3.1.8,
453,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,Drug name: Treatment is under trial.,mannose supply,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,,,,,,,blood coagulation,HP:0001928,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",4351,MPI,322,P34949,K01809,5.3.1.8,
454,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,Drug name: Treatment is under trial.,mannose supply,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,,,,,,,protein-losing enteropathy,HP:0002243,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",4351,MPI,322,P34949,K01809,5.3.1.8,
455,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,Drug name: Treatment is under trial.,mannose supply,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,,,,,,,hypoglycaemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/10484808,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",4351,MPI,322,P34949,K01809,5.3.1.8,
456,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,Drug name: Treatment is under trial.,mannose supply,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,,,,,,,Hypoglycosylation of serum glycoproteins,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/9525984,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",4351,MPI,322,P34949,K01809,5.3.1.8,
457,602579,,Number Sign,602579,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ib; CDG1B","CDG Ib; CDGIb;; CDG, GASTROINTESTINAL TYPE;; MANNOSEPHOSPHATE ISOMERASE DEFICIENCY;; MPI DEFICIENCY;; PROTEIN-LOSING ENTEROPATHY-HEPATIC FIBROSIS SYNDROME;; SAGUENAY-LAC SAINT-JEAN SYNDROME;; SLSJ SYNDROME",,CDG-Ib,,MPI,MPI,Mannose-6-phosphate isomerase,10cf7ab6c2da7136df8436243af9121d46d1712237ebcca026b95d2d8e43c15e,5.3.1.8,5.3.1.8,,Drug name: Treatment is under trial.,mannose supply,DB12907,DB12907,e993efe735865234afad94125d683dcc2687d7e52ccfce879df4c6993cd236d6,DB12907,DB12907,,,,,,,,,,,,,urinary tract infection,HP:0000010,,"https://www.ncbi.nlm.nih.gov/pubmed/9525984,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",4351,MPI,322,P34949,K01809,5.3.1.8,
458,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,Drug name: Treatment is under trial.,D- Galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Abnormal aPTT level,HP:0003645,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",5236,PGM1,600,P36871,K01835,5.4.2.2,
459,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,Drug name: Treatment is under trial.,D- Galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,Abnormal AST level (Abnormal liver enzymes)*,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",5236,PGM1,600,P36871,K01835,5.4.2.2,
460,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,Drug name: Treatment is under trial.,D- Galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,Abnormal ALT level(Abnormal liver enzymes)*,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",5236,PGM1,600,P36871,K01835,5.4.2.2,
461,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,Drug name: Treatment is under trial.,D- Galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,Abnormal Antithrombin-III levels,HP:0001976,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",5236,PGM1,600,P36871,K01835,5.4.2.2,
462,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,Drug name: Treatment is under trial.,D- Galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/",5236,PGM1,600,P36871,K01835,5.4.2.2,
463,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,Drug name: Treatment is under trial.,fucose therapy,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,B,Abnormal Golgi located fucosylation,NA,,"http://www.jbc.org/content/282/14/10762.long#ref-14,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/,""espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II), correction of the delayed psychomotor development was expected to be more difficult to achieve. However, the patient showed significant psychomotor improvement while on fucose therapy.""",55343,SLC35C1,341,Q96A29,K15279,"""""",
464,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,Drug name: Treatment is under trial.,fucose therapy,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,,,,,,,Abnormal fucosylation state of glycoconjugates.,NA,,"http://www.jbc.org/content/282/14/10762.long#ref-14,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/,""espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II), correction of the delayed psychomotor development was expected to be more difficult to achieve. However, the patient showed significant psychomotor improvement while on fucose therapy.""",55343,SLC35C1,341,Q96A29,K15279,"""""",
465,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,Drug name: Treatment is under trial.,fucose therapy,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,ECO:0005542,ECO:0005542,,,,,Abnormal selectin ligand function,NA,,"http://www.bloodjournal.org/content/94/12/3976.abstract?ijkey=201ceaaf5f2f21a180c7df639f863d067551bca5&keytype2=tf_ipsecsha,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/,""espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II), correction of the delayed psychomotor development was expected to be more difficult to achieve. However, the patient showed significant psychomotor improvement while on fucose therapy.""",55343,SLC35C1,341,Q96A29,K15279,"""""",
466,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,CDG IIc,,SLC35C1,SLC35C1,GDP-fucose transporter 1,d3ba8d85d6c54473d36c90f417d49369c01888ba70b472a84d4199f64a68d0e7,Q96A29,,Q96A29,Drug name: Treatment is under trial.,fucose therapy,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,ECO:0005542,ECO:0005542,,,,,Neutropenia,HP:0001875,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/,""espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II), correction of the delayed psychomotor development was expected to be more difficult to achieve. However, the patient showed significant psychomotor improvement while on fucose therapy.""",55343,SLC35C1,341,Q96A29,K15279,"""""",
467,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPL,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,Drug name: Treatment is under trial.,Asfotase Alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,ECO:0000352,ECO:0000352,,,direct complementation of a genetically defective protein,A,Abnormal developmental milestones,HP:0012759,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",249,ALPL,,P05186,K01077,3.1.3.1,
468,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPL,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,Drug name: Treatment is under trial.,Asfotase Alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,deteriorating pulmonary function,HP:0005952,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",249,ALPL,,P05186,K01077,3.1.3.1,
469,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPL,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,Drug name: Treatment is under trial.,Asfotase Alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,Decreased physical function,HP:0025142,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",249,ALPL,,P05186,K01077,3.1.3.1,
470,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPL,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,Drug name: Treatment is under trial.,Asfotase Alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,failure-to-thrive,HP:0001508,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",249,ALPL,,P05186,K01077,3.1.3.1,
471,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPL,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,Drug name: Treatment is under trial.,Asfotase Alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,Dental Defects,HP:0000164,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124/,https://www.ncbi.nlm.nih.gov/pubmed/12756558,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",249,ALPL,,P05186,K01077,3.1.3.1,
472,241510,,Number Sign,241510,"HYPOPHOSPHATASIA, CHILDHOOD",,,Childhood hypophosphatasia,,ALPL,ALPL,Alkaline phosphatase,14d10348163df0fd27c06985a7080db59fd74855d810516f810be81a0e845709,3.1.3.1,3.1.3.1,,Drug name: Treatment is under trial.,pyridoxal,DB00147,DB00147,e4e9653857187889e123957c2167ebd6d98261a31e548707bc2e1bd7002fda38,DB00147,DB00147,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,epilepsy,HP:0001250,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",249,ALPL,,P05186,K01077,3.1.3.1,
473,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Accumulation of toxic metabolites in cholesterol biosynthetic pathway,HP:0001939*,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
474,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,,,,,,,ichthyosiform erythematous plaques,HP:0008064,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
475,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,,,,,,,waxy scaling plaques,HP:0040189*,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
476,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,,,,,,,inflammation,MP:0001845,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
477,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,,,,,,,skin thickening,HP:0100725,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
478,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,lovastatin+cholesterol,DB00227+DB04540,DB00227 + DB04540,aea53ff37491f6c9dd3f41d1b8f8a80053b307fce2d3823a311fa5693405e27a,,,,,"DB00227,DB04540","DB00227,DB04540",,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Cutaneous abnormalities,MP:00011911,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
479,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,lovastatin+cholesterol,DB00227+DB04540,DB00227 + DB04540,aea53ff37491f6c9dd3f41d1b8f8a80053b307fce2d3823a311fa5693405e27a,,,,,"DB00227,DB04540","DB00227,DB04540",,,,,,,,,Ichthyosiform erythroderma,HP:0007431,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
480,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,ketoconazole,DB01026,DB01026,b60b0b8ef6aa34242467e4ddc87ad1d2845091eb8c05f056e84054c684c4717b,DB01026,DB01026,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Cutaneous abnormalities,MP:0001191,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
481,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin+cholesterol,DB00641+ DB04540,DB00641 + DB04540,8cbeef646e619c0e120573e94fe77cd369f9062f39b3204c7f68115dcf3335d7,,,,,"DB00641,DB04540","DB00641,DB04540",,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Ichthyosiform erythroderma,HP:0007431,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
482,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin+cholesterol,DB00641+ DB04540,DB00641 + DB04540,8cbeef646e619c0e120573e94fe77cd369f9062f39b3204c7f68115dcf3335d7,,,,,"DB00641,DB04540","DB00641,DB04540",,,,,,,,,Itchy skin,HP:0000989,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
483,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin+cholesterol,DB00641+ DB04540,DB00641 + DB04540,8cbeef646e619c0e120573e94fe77cd369f9062f39b3204c7f68115dcf3335d7,,,,,"DB00641,DB04540","DB00641,DB04540",,,,,,,,,Scaling Skin,HP:0040189,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
484,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin+cholesterol,DB00641+ DB04540,DB00641 + DB04540,8cbeef646e619c0e120573e94fe77cd369f9062f39b3204c7f68115dcf3335d7,,,,,"DB00641,DB04540","DB00641,DB04540",,,,,,,,,Erythema,HP:0010783,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
485,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin+cholesterol,DB00641+ DB04540,DB00641 + DB04540,8cbeef646e619c0e120573e94fe77cd369f9062f39b3204c7f68115dcf3335d7,,,,,"DB00641,DB04540","DB00641,DB04540",,,,,,,,,Verruciform plaques(verruciform xanthomas)*,HP:0031517*,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29341259,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
486,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,simvastatin+cholesterol,DB00641+ DB04540,DB00641 + DB04540,8cbeef646e619c0e120573e94fe77cd369f9062f39b3204c7f68115dcf3335d7,,,,,"DB00641,DB04540","DB00641,DB04540",,,,,,,,,VXâlike lesions,NA,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29341259,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
487,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,Retinoids,CHEBI:26537,CHEBI:26537,75cede199dcabebdeb1685d362d37882b001179a89276267737877c5557ba548,CHEBI:26537,,CHEBI_26537,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Scaling Skin,HP:0040189,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29392821,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
488,308050,,Number Sign,308050,CONGENITAL HEMIDYSPLASIA WITH ICHTHYOSIFORM ERYTHRODERMA AND LIMB DEFECTS,"CHILD SYNDROME;; ICHTHYOSIFORM ERYTHRODERMA, UNILATERAL, WITH IPSILATERAL MALFORMATIONS, ESPECIALLY ABSENCE DEFORMITY OF LIMBS",,CHILD syndrome,,NSDHL,NSDHL,NAD(P) dependent steroid dehydrogenase-like,d23cc0db734d1a227ee43dfa0d61a9e210786ac1560d580226b92a5b3a54e5fd,Q3US15*,,Q3US15*,Drug name: Treatment is under trial.,Glycolic acid+lovastatin+cholesterol,DB03085+DB00227+DB04540,DB03085 + DB00227 + DB04540,256d4592b76615e3a3522ef56a90d4b2aaa1f417ee97a69498fb6e6308adcb46,,,,,"DB03085,DB00227,DB04540","DB03085,DB00227,DB04540",,,ECO:0000352,ECO:0000352,,,,,verruciform xanthomas,HP:0031517,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29392821,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",50814,NSDHL,194,Q15738,K07748,1.1.1.170,
489,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients +acitretin,A06AA+DB00459,A06AA + DB00459,76b6658f54e21ca91f015e90842cefadb24fef650daafec59aad714d4a94acae,,,,,"A06AA,DB00459",DB00459,,A06AA,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Ichthyosis,HP:0008064,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/?term=Acitretin%E2%80%90Responsive+Ichthyosis+in+ChanarinâDorfman+Syndrome+with+a+Novel+Mutation+in+the+ABHD5%2FCGI%E2%80%9058+Gene,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
490,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients +acitretin,A06AA+DB00459,A06AA + DB00459,76b6658f54e21ca91f015e90842cefadb24fef650daafec59aad714d4a94acae,,,,,"A06AA,DB00459",DB00459,,A06AA,,,,,,,Erythroderma,HP:0001019,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
491,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients +acitretin,A06AA+DB00459,A06AA + DB00459,76b6658f54e21ca91f015e90842cefadb24fef650daafec59aad714d4a94acae,,,,,"A06AA,DB00459",DB00459,,A06AA,,,,,,,Diffuse scaling(Skin Scaling)*,HP:0040189*,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
492,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients +acitretin,A06AA+DB00459,A06AA + DB00459,76b6658f54e21ca91f015e90842cefadb24fef650daafec59aad714d4a94acae,,,,,"A06AA,DB00459",DB00459,,A06AA,,,,,,,Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*,HP:0007479*,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
493,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients +acitretin,A06AA+DB00459,A06AA + DB00459,76b6658f54e21ca91f015e90842cefadb24fef650daafec59aad714d4a94acae,,,,,"A06AA,DB00459",DB00459,,A06AA,,,,,,,Erythema,HP:0010783,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28979034,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
494,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients +acitretin,A06AA+DB00459,A06AA + DB00459,76b6658f54e21ca91f015e90842cefadb24fef650daafec59aad714d4a94acae,,,,,"A06AA,DB00459",DB00459,,A06AA,,,,,,,Scaling,HP:0040189,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28979034,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
495,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients,A06AA,A06AA,b64fe70b67eafd88c09ed6cf397a9a5aa41284ea532408db8746b7f4d1da793b,A06AA,,,A06AA,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,erythema,HP:0010783,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
496,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients,A06AA,A06AA,b64fe70b67eafd88c09ed6cf397a9a5aa41284ea532408db8746b7f4d1da793b,A06AA,,,A06AA,,,,,,,,,,,Ichthyosis,HP:0008064,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28636073,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
497,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients,A06AA,A06AA,b64fe70b67eafd88c09ed6cf397a9a5aa41284ea532408db8746b7f4d1da793b,A06AA,,,A06AA,,,,,,,,,,,Pruritis,HP:0000989,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28636073,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
498,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Emollients,A06AA,A06AA,b64fe70b67eafd88c09ed6cf397a9a5aa41284ea532408db8746b7f4d1da793b,A06AA,,,A06AA,,,,,,,,,,,scaling,HP:0040189,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28636073,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
499,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,Ursodeoxycholic acid,DB01586,DB01586,6c6cbaf6a1e3ee3787e164056f1e99191eaecb0970fe79065bc15239e6327655,DB01586,DB01586,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,steatohepatitis,HP:0001397,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
500,275630,,Number Sign,275630,CHANARIN-DORFMAN SYNDROME; CDS,NEUTRAL LIPID STORAGE DISEASE WITH ICHTHYOSIS; NLSDI;; TRIGLYCERIDE STORAGE DISEASE WITH IMPAIRED LONG-CHAIN FATTY ACID OXIDATION;; ICHTHYOTIC NEUTRAL LIPID STORAGE DISEASE;; DORFMAN-CHANARIN SYNDROME; DCS;; CHANARIN-DORFMAN DISEASE;; ICHTHYOSIFORM ERYTHRODERMA WITH LEUKOCYTE VACUOLATION,,Chanarin-Dorfman syndrome,,ABHD5,ABHD5,adipose triglyceride lipase (ATGL),b41754823841a15114f766c9e5018a5344377f2ccd4c6ad3b7f9607c1da14681,3.1.1.3,3.1.1.3,,Drug name: Treatment is under trial.,vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,steatohepatitis,HP:0001397,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,""ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number,Â NCT00744042.).""",51099,ABHD5,753,Q8WTS1,K13699,2.3.1.51,
501,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,neurological dysfunctions,HP:0000707,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/25424010,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
502,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,cataracts,HP:0000518,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/25424010,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
503,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,chronic diarrhoea,MP:0001665,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/25424010,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
504,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Elevated serum cholesterol,HP:0003124,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
505,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,EEG abnormalities,HP:0002353,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28980151,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
506,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,abnormal gait,HP:0001288,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
507,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Xanthoma,HP:0001114,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
508,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Incoordination,HP:0002311,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
509,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Movement disorder,HP:0100022,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
510,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Cognitive impairment,HP:0100543,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/31115677,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
511,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Abnormal nerve conduction velocity,HP:0040129,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
512,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,seizure,HP:0001250,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/29260356,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
513,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,Pravastatin+Chenodeoxycholic acid,DB00175Â +DB06777,DB00175 + DB06777,ef7556428ecc5938f1746ab2dd2af6ac8df5a65b33a401b952877d9c257c4e65,,,,,"DB00175,DB06777","DB00175,DB06777",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+metabolite replacement,B+B,Xanthoma,HP:0001114,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/7964884,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
514,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,Pravastatin+Chenodeoxycholic acid,DB00175Â +DB06777,DB00175 + DB06777,ef7556428ecc5938f1746ab2dd2af6ac8df5a65b33a401b952877d9c257c4e65,,,,,"DB00175,DB06777","DB00175,DB06777",,,,,,,,,Elevated serum cholesterol,HP:0003124,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/7964884,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
515,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,Pravastatin+Chenodeoxycholic acid,DB00175Â +DB06777,DB00175 + DB06777,ef7556428ecc5938f1746ab2dd2af6ac8df5a65b33a401b952877d9c257c4e65,,,,,"DB00175,DB06777","DB00175,DB06777",,,,,,,,,Disease progression,,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/7964884,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
516,213700,,Number Sign,213700,CEREBROTENDINOUS XANTHOMATOSIS; CTX,CEREBRAL CHOLESTERINOSIS,,Cerebrotendinous xanthomatosis,,CYP27A1,CYP27A1,Cholestanetriol 26-monooxygenase,3328f3c68c694be94343c8e9f9257a96269c162913461a79ff95f722c2c991c2,1.14.15.15,1.14.15.15,,Drug name: Treatment is under trial.,coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,muscle weakness,HP:0001324,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/20301583,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1593,CYP27A1,183,Q02318,K00488,1.14.15.15,
517,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,FOLR1,FOLR1,Folate receptor alpha,fa9795212e8a989c55c4de3574c5b43b124e273a023f2ed8866563ecd092d22e,P15328,,P15328,Drug name: Treatment is under trial.,folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,Impaired social interaction,HP:0000735,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/20301583,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",2348,FOLR1,71,P15328,K13649,"""""",
518,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,FOLR1,FOLR1,Folate receptor alpha,fa9795212e8a989c55c4de3574c5b43b124e273a023f2ed8866563ecd092d22e,P15328,,P15328,Drug name: Treatment is under trial.,folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,Movement disorder,HP:0100022,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/20301583,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",2348,FOLR1,71,P15328,K13649,"""""",
519,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,MTHFR,MTHFR,Methylenetetrahydrofolate reductase,5cdc84624c0d5fbb1bccfcb035fc3b340e211d42b2ec1e4989945c9105ac5667,1.5.1.20,1.5.1.20,,Drug name: Treatment is under trial.,folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,seizure,HP:0001250,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671/,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",4524,MTHFR,71,P42898,K00297,1.5.1.20,
520,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,MTHFR,MTHFR,Methylenetetrahydrofolate reductase,5cdc84624c0d5fbb1bccfcb035fc3b340e211d42b2ec1e4989945c9105ac5667,1.5.1.20,1.5.1.20,,Drug name: Treatment is under trial.,folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,Myoclonic seizures,HP:0002123,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/22734130,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",4524,MTHFR,71,P42898,K00297,1.5.1.20,
521,613068,,Number Sign,613068,NEURODEGENERATION DUE TO CEREBRAL FOLATE TRANSPORT DEFICIENCY,,,Cerebral folate deficiency,,MTHFR,MTHFR,Methylenetetrahydrofolate reductase,5cdc84624c0d5fbb1bccfcb035fc3b340e211d42b2ec1e4989945c9105ac5667,1.5.1.20,1.5.1.20,,Drug name: Treatment is under trial.,folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,astatic seizures,HP:0010819,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/22734130,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",4524,MTHFR,71,P42898,K00297,1.5.1.20,
522,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Drug name: Treatment is under trial.,Desmopressin,DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,polyuria,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://clinicaltrials.gov/ct2/show/NCT01280188?cond=Central+diabetes+insipidus&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
523,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Drug name: Treatment is under trial.,Vasopressin,DB00067,DB00067,e9fc4af7bd908224aefe167a2729421282bcbc25ae28d9836f3fb71ea8e4f799,DB00067,DB00067,,,,,,,,,,,direct complementation of a genetically defective protein,A,polydipsia,MP:0001426,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://academic.oup.com/jcem/article/98/10/3958/2833930,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
524,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Drug name: Treatment is under trial.,Vasopressin,DB00067,DB00067,e9fc4af7bd908224aefe167a2729421282bcbc25ae28d9836f3fb71ea8e4f799,DB00067,DB00067,,,,,,,,,,,,,thirst,HP:0001959,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://academic.oup.com/jcem/article/98/10/3958/2833930,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
525,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Drug name: Treatment is under trial.,chlorpropamide,DB00672,DB00672,1b02186f4830609aa0bcaa3357749eab2002066fff689e8c09ab10999fd61209,DB00672,DB00672,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Polyurea,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999/,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
526,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,Chlorpropamide + carbamazepine,DB00672+DB00564,DB00672 + DB00564,5f627ab82a019d8d70f1356bfdde1f0c27621081b1f295a1fac632661a08104c,,,,,"DB00672,DB00564","DB00672,DB00564",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,chlorpropamide-induced hypoglycaemia (Hypoglycemia)*,HP:0001943*,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/1220254,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
527,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,Chlorpropamide + carbamazepine,DB00672+DB00564,DB00672 + DB00564,5f627ab82a019d8d70f1356bfdde1f0c27621081b1f295a1fac632661a08104c,,,,,"DB00672,DB00564","DB00672,DB00564",,,,,,,,,Polyuria,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/1220254,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
528,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,chlorpropamide+Hydrochlorothiazide,DB00672+DB00999,DB00672 + DB00999,d8e42848b73e0dfb5b2d04e2a21327383f3d381a26b44714c75300e58f81cd96,,,,,"DB00672,DB00999","DB00672,DB00999",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Ployuria,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/1220254,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
529,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,chlorpropamide+Hydrochlorothiazide,DB00672+DB00999,DB00672 + DB00999,d8e42848b73e0dfb5b2d04e2a21327383f3d381a26b44714c75300e58f81cd96,,,,,"DB00672,DB00999","DB00672,DB00999",,,,,,,,,,,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/1220254,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
530,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,chlorpropamide+Hydrochlorothiazide,DB00672+DB00999,DB00672 + DB00999,d8e42848b73e0dfb5b2d04e2a21327383f3d381a26b44714c75300e58f81cd96,,,,,"DB00672,DB00999","DB00672,DB00999",,,,,,,,,,,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/1220254,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
531,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Pitressin tannate in oil,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,direct complementation of a genetically defective protein,A,Ployuria,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/3940717,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
532,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Clofibrate,DB00636,DB00636,4f4a0caa17de4a7c7581c0cd32e83b6af5948953cf19f3d8f3d787f30c592aa9,DB00636,DB00636,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Ployuria,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/23884783,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
533,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Clofibrate,DB00636,DB00636,4f4a0caa17de4a7c7581c0cd32e83b6af5948953cf19f3d8f3d787f30c592aa9,DB00636,DB00636,,,,,,,,,,,,,Hyposthenuria,HP:0003158,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/23884783,https://www.ncbi.nlm.nih.gov/pubmed/1316120,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
534,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Indapamide,DB00808,DB00808,a63d31f207a29b8421e497c08b97b156d768c7caeebc62299eca3b05e749e92e,DB00808,DB00808,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,High serum osmolality,NA,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
535,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Indapamide,DB00808,DB00808,a63d31f207a29b8421e497c08b97b156d768c7caeebc62299eca3b05e749e92e,DB00808,DB00808,,,,,,,,,,,,,Ployuria,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
536,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Indapamide,DB00808,DB00808,a63d31f207a29b8421e497c08b97b156d768c7caeebc62299eca3b05e749e92e,DB00808,DB00808,,,,,,,,,,,,,Reduced urinary osmolality,HP:0003158,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
537,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",dDAVP (1-Desamino-8-D Arginine Vasopressin),DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,ECO:0000352,ECO:0000352,,,direct complementation of a genetically defective protein,A,Increased urine output,HP:0000103,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/626447,https://www.ncbi.nlm.nih.gov/pubmed/12016800,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
538,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",dDAVP (1-Desamino-8-D Arginine Vasopressin),DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,,,,,,,,,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/626447,https://www.ncbi.nlm.nih.gov/pubmed/12016800,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
539,125700,,Number Sign,125700,"DIABETES INSIPIDUS, NEUROHYPOPHYSEAL","DIABETES INSIPIDUS, PRIMARY CENTRAL; CDI;; DIABETES INSIPIDUS, CRANIAL TYPE",,Central diabetes insipidus,,AVP,AVP,Hormone ( Arginine vasopressin),08a06d3a2f0a2cb198c545aa2df44ad1a6784cb3d5d60b30aa3bbf26f0d0e4f0,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",dDAVP (1-Desamino-8-D Arginine Vasopressin),DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,,,,,,,,,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/626447,https://www.ncbi.nlm.nih.gov/pubmed/12016800,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",551,AVP,,P01185,K05242,"""""",
540,212138,,Number Sign,212138,CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD,CACT DEFICIENCY,,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,SLC25A20,carnitine-acylcarnitine translocase,704439c99e4b5b33a95fb32259a710d6e2fe0acd9dfb2d37bf3ecc1161610c90,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,developmental delay,HP:0001263,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/25614308,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",788,SLC25A20,229,O43772,K15109,"""""",
541,212138,,Number Sign,212138,CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD,CACT DEFICIENCY,,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,SLC25A20,carnitine-acylcarnitine translocase,704439c99e4b5b33a95fb32259a710d6e2fe0acd9dfb2d37bf3ecc1161610c90,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hypocarnitinemia,HP:0003234,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/25614308,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",788,SLC25A20,229,O43772,K15109,"""""",
542,212138,,Number Sign,212138,CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD,CACT DEFICIENCY,,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,SLC25A20,carnitine-acylcarnitine translocase,704439c99e4b5b33a95fb32259a710d6e2fe0acd9dfb2d37bf3ecc1161610c90,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",carnitine+Medium-chain triglycerides,DB00583+DB13959,DB00583 + DB13959,1d4a10d6511c1f6ad09987ce23c5794155035e543338dfc7f03b20dc35bc273e,,,,,"DB00583,DB13959","DB00583,DB13959",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,B+B,developmental delay,HP:0001263,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/17508264,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",788,SLC25A20,229,O43772,K15109,"""""",
543,212138,,Number Sign,212138,CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD,CACT DEFICIENCY,,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,SLC25A20,carnitine-acylcarnitine translocase,704439c99e4b5b33a95fb32259a710d6e2fe0acd9dfb2d37bf3ecc1161610c90,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",carnitine+Medium-chain triglycerides,DB00583+DB13959,DB00583 + DB13959,1d4a10d6511c1f6ad09987ce23c5794155035e543338dfc7f03b20dc35bc273e,,,,,"DB00583,DB13959","DB00583,DB13959",,,,,,,,,Hypocarnitinemia,HP:0003234,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/17508264,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",788,SLC25A20,229,O43772,K15109,"""""",
544,212138,,Number Sign,212138,CARNITINE-ACYLCARNITINE TRANSLOCASE DEFICIENCY; CACTD,CACT DEFICIENCY,,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,SLC25A20,carnitine-acylcarnitine translocase,704439c99e4b5b33a95fb32259a710d6e2fe0acd9dfb2d37bf3ecc1161610c90,1.5.1.20,1.5.1.20,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",carnitine+Medium-chain triglycerides,DB00583+DB13959,DB00583 + DB13959,1d4a10d6511c1f6ad09987ce23c5794155035e543338dfc7f03b20dc35bc273e,,,,,"DB00583,DB13959","DB00583,DB13959",,,,,,,,,High plasma long-chain acylcarnitines,HP:0045045,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/17508264,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",788,SLC25A20,229,O43772,K15109,"""""",
545,601987,,Asterisk,601987,"CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B","CPT IB;; CPT I, MUSCLE;; MCCPT1; MCPT1;; KIAA1670",,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1B,CPT1B,"carnitine O-palmitoyltransferase 1, muscle isoform",bc205fb2ae3c455e166c24e1b4a9407dada6712431ab5bc61e38cf0159829dda,2.3.1.21,2.3.1.21,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,neurological damage,HP:0000707,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1375,CPT1B,,Q92523,K19523,2.3.1.21,
546,601987,,Asterisk,601987,"CARNITINE PALMITOYLTRANSFERASE I, MUSCLE; CPT1B","CPT IB;; CPT I, MUSCLE;; MCCPT1; MCPT1;; KIAA1670",,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1B,CPT1B,"carnitine O-palmitoyltransferase 1, muscle isoform",bc205fb2ae3c455e166c24e1b4a9407dada6712431ab5bc61e38cf0159829dda,2.3.1.21,2.3.1.21,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,hypoglycemia,HP:0001943,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle,https://www.ncbi.nlm.nih.gov/pubmed/19452263/,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1375,CPT1B,,Q92523,K19523,2.3.1.21,
547,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,muscle pain,HP:0003326,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/18645163,https://www.ncbi.nlm.nih.gov/pubmed/18645163,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1374,CPT1A,228,P50416,K08765,2.3.1.21,
548,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,rhabdomyolysis,HP:0003201,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/18645163,PMC2676979,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1374,CPT1A,228,P50416,K08765,2.3.1.21,
549,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,abnormal SF-36 physical composite scores,NA,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/18645163,PMC2676979,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1374,CPT1A,228,P50416,K08765,2.3.1.21,
550,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,B,Hypoglycemia,HP:0001943,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/15669684,PMC2676979,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1374,CPT1A,228,P50416,K08765,2.3.1.21,
551,255120,,Number Sign,255120,CARNITINE PALMITOYLTRANSFERASE I DEFICIENCY,"CARNITINE PALMITOYLTRANSFERASE IA DEFICIENCY;; CPT I DEFICIENCY;; CPT DEFICIENCY, HEPATIC, TYPE I",,Carnitine palmitoyl transferase 1 deficiency,,CPT1A,CPT1A,carnitine palmitoyltransferase 1A,dd30dd20b396430063d12ed9a1b0590e7acc9805212f0649b9075bce70791deb,2.3.1.21,2.3.1.21,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,Low growth rate (Abnormal growth)*,HP:0001507*,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/15669684,PMC2676979,https://www.ncbi.nlm.nih.gov/pubmed/28590052,https://www.ncbi.nlm.nih.gov/pubmed/30804055,https://www.ncbi.nlm.nih.gov/pubmed/15131757,https://www.ncbi.nlm.nih.gov/pubmed/26153518",1374,CPT1A,228,P50416,K08765,2.3.1.21,
552,237300,,Number Sign,237300,"CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO",CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY;; CPS I DEFICIENCY,,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,CPS1,Carbamoyl-phosphate synthase (ammonia,43bee49c22a4780972cfc810e2906c1eab1d745a53217442164ffda21d7ed362,6.3.4.16,6.3.4.16,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",N-Carbamylglutamate,DB06775,DB06775,4232311e92dd47c3fa1cd15c2af2c63ef49708a80c82e3cc943e86fc4cfdfaf2,DB06775,DB06775,,,,,,,ECO:0001565/ECO:0000352,"ECO:0001565,ECO:0000352",,,activity modification of a genetically defective protein,A,Hyperammonemia,HP:0001987,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/28281899,https://www.ncbi.nlm.nih.gov/pubmed/31392111,https://www.ncbi.nlm.nih.gov/pubmed/23649895/,https://www.ncbi.nlm.nih.gov/pubmed/14213380/,https://www.ncbi.nlm.nih.gov/pubmed/13992367/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1373,CPS1,11,P31327,K01948,6.3.4.16,
553,237300,,Number Sign,237300,"CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO",CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY;; CPS I DEFICIENCY,,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,CPS1,Carbamoyl-phosphate synthase (ammonia,43bee49c22a4780972cfc810e2906c1eab1d745a53217442164ffda21d7ed362,6.3.4.16,6.3.4.16,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",N-acetyl-l-glutamate,DB04075,DB04075,bf808123779c3bb0479cf5a2353df9114c277f7c8fb112b3984c6296307d02dd,DB04075,DB04075,,,,,,,ECO:0001565,ECO:0001565,,,activity modification of a genetically defective protein,A,Acidemia,HP:0001941,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/23649895,https://www.ncbi.nlm.nih.gov/pubmed/31392111,https://www.ncbi.nlm.nih.gov/pubmed/23649895/,https://www.ncbi.nlm.nih.gov/pubmed/14213380/,https://www.ncbi.nlm.nih.gov/pubmed/13992367/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1373,CPS1,11,P31327,K01948,6.3.4.16,
554,237300,,Number Sign,237300,"CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY, HYPERAMMONEMIA DUE TO",CARBAMOYL PHOSPHATE SYNTHETASE I DEFICIENCY;; CPS I DEFICIENCY,,Carbamoyl phosphate synthetase 1 deficiency,,CPS1,CPS1,Carbamoyl-phosphate synthase (ammonia,43bee49c22a4780972cfc810e2906c1eab1d745a53217442164ffda21d7ed362,6.3.4.16,6.3.4.16,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Gene Therapy ??,NA,,,,,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,direct complementation of a genetically defective protein by gene therapy,A,Hyperammonemia,HP:0001987,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.semanticscholar.org/paper/Cell-and-Gene-Therapy-for-Carbamoyl-Phosphate-1-Zhang-Li/2099b4f31e1fe5e8825f03deff088f7702694f02,https://www.ncbi.nlm.nih.gov/pubmed/31392111,https://www.ncbi.nlm.nih.gov/pubmed/23649895/,https://www.ncbi.nlm.nih.gov/pubmed/14213380/,https://www.ncbi.nlm.nih.gov/pubmed/13992367/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1373,CPS1,11,P31327,K01948,6.3.4.16,
555,253260,253260,Number Sign,253260,BIOTINIDASE DEFICIENCY,"BTD DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET;; MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET",,Biotinidase deficiency,,BTD,BTD,biotinidase,81e45d122ea656fa1777d4e26832ebcc30138d00c2615f2269280944117d4854,3.5.1.12,3.5.1.12,,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin,DB00121,DB00121,b5b26a79186f8718a7915269a4e5cfa4db68f19b568110d985aaf521a31dd44b,DB00121,DB00121,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,seizure,HP:0001250,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://clinicaltrials.gov/ct2/show/NCT03269045,https://www.ncbi.nlm.nih.gov/pubmed/28649539,https://www.ncbi.nlm.nih.gov/pubmed/26577040,https://www.ncbi.nlm.nih.gov/pubmed/25638506/,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",686,BTD,93,P43251,K01435,3.5.1.12,
556,253260,253260,Number Sign,253260,BIOTINIDASE DEFICIENCY,"BTD DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET;; MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET",,Biotinidase deficiency,,BTD,BTD,biotinidase,81e45d122ea656fa1777d4e26832ebcc30138d00c2615f2269280944117d4854,3.5.1.12,3.5.1.12,,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",baclofen,DB00181,DB00181,283d4a5ab576ae808a0995e16fe21d81a8a4de4f3d61614edd1975a48037e4c1,DB00181,DB00181,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,dystonia,HP:0001332,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://emedicine.medscape.com/article/942055-treatment,https://www.ncbi.nlm.nih.gov/pubmed/28649539,https://www.ncbi.nlm.nih.gov/pubmed/26577040,https://www.ncbi.nlm.nih.gov/pubmed/25638506/,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",686,BTD,93,P43251,K01435,3.5.1.12,
557,253260,253260,Number Sign,253260,BIOTINIDASE DEFICIENCY,"BTD DEFICIENCY;; MULTIPLE CARBOXYLASE DEFICIENCY, LATE-ONSET;; MULTIPLE CARBOXYLASE DEFICIENCY, JUVENILE-ONSET",,Biotinidase deficiency,,BTD,BTD,biotinidase,81e45d122ea656fa1777d4e26832ebcc30138d00c2615f2269280944117d4854,3.5.1.12,3.5.1.12,,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",baclofen,DB00181,DB00181,283d4a5ab576ae808a0995e16fe21d81a8a4de4f3d61614edd1975a48037e4c1,DB00181,DB00181,,,,,,,,,,,,,Spasticity,HP:0001257,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://emedicine.medscape.com/article/942055-treatment,https://www.ncbi.nlm.nih.gov/pubmed/28649539,https://www.ncbi.nlm.nih.gov/pubmed/26577040,https://www.ncbi.nlm.nih.gov/pubmed/25638506/,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",686,BTD,93,P43251,K01435,3.5.1.12,
558,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin+thiamine,DB00121+DB00152,DB00121 + DB00152,ee89609cf589646cdcedb69ae230a47466d23b223fdcb8f62c10902c7842a067,,,,,"DB00121,DB00152","DB00121,DB00152",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,B+B,seizures,HP:0001250,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/26577040,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",80704,SLC19A3,,Q9BZV2,K14610,"""""",
559,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin+thiamine,DB00121+DB00152,DB00121 + DB00152,ee89609cf589646cdcedb69ae230a47466d23b223fdcb8f62c10902c7842a067,,,,,"DB00121,DB00152","DB00121,DB00152",,,,,,,,C,encephalopathy,HP:0001298,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",80704,SLC19A3,,Q9BZV2,K14610,"""""",
560,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin+thiamine,DB00121+DB00152,DB00121 + DB00152,ee89609cf589646cdcedb69ae230a47466d23b223fdcb8f62c10902c7842a067,,,,,"DB00121,DB00152","DB00121,DB00152",,,,,,,,,signal abnormality of the cortex,HP:0030178,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",80704,SLC19A3,,Q9BZV2,K14610,"""""",
561,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin+thiamine,DB00121+DB00152,DB00121 + DB00152,ee89609cf589646cdcedb69ae230a47466d23b223fdcb8f62c10902c7842a067,,,,,"DB00121,DB00152","DB00121,DB00152",,,,,,,,,Abnormal movement,HP:0100022,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",80704,SLC19A3,,Q9BZV2,K14610,"""""",
562,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin+thiamine,DB00121+DB00152,DB00121 + DB00152,ee89609cf589646cdcedb69ae230a47466d23b223fdcb8f62c10902c7842a067,,,,,"DB00121,DB00152","DB00121,DB00152",,,,,,,,,Dystonia,HP:0001332,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",80704,SLC19A3,,Q9BZV2,K14610,"""""",
563,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Biotin+thiamine,DB00121+DB00152,DB00121 + DB00152,ee89609cf589646cdcedb69ae230a47466d23b223fdcb8f62c10902c7842a067,,,,,"DB00121,DB00152","DB00121,DB00152",,,,,,,,,Abnormal reflexes,HP:0001347,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",80704,SLC19A3,,Q9BZV2,K14610,"""""",
564,607483,,Number Sign,607483,THIAMINE METABOLISM DYSFUNCTION SYNDROME 2 (BIOTIN- OR THIAMINE-RESPONSIVE TYPE); THMD2,"BASAL GANGLIA DISEASE, BIOTIN-RESPONSIVE; BBGD;; BTBGD;; ENCEPHALOPATHY, THIAMINE-RESPONSIVE",,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3,SLC19A3,thiamine transporter,6d7871fe33c1ea8c1cfd8fc938699fa3a6a145523017136635c03b5b78fd1236,available,,"not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",L-dopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,dystonia,HP:0001332,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.ncbi.nlm.nih.gov/pubmed/24260777,Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",80704,SLC19A3,,Q9BZV2,K14610,"""""",
565,203750,,Number Sign,203750,ALPHA-METHYLACETOACETIC ACIDURIA,2-METHYL-3-HYDROXYBUTYRIC ACIDEMIA;; BETA-KETOTHIOLASE DEFICIENCY;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY;; MAT DEFICIENCY;; T2 DEFICIENCY;; 3-OXOTHIOLASE DEFICIENCY;; 3-KETOTHIOLASE DEFICIENCY;; 3-KTD DEFICIENCY,,Beta ketothiolase deficiency,,ACAT1,ACAT1,Acetyl-CoA C-acetyltransferase.,7e7d0f2df5f7722bd26e7b77cb3a94b23e09dc21b571e98210f707fa7a679cf0,2.3.1.9,2.3.1.9,,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",glucose,DB09341,DB09341,4b19e06833e9a2137a0550330975c20e3933eaf5df506a0444738008c59e5b4c,DB09341,DB09341,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Ketosis,HP:0001946,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x,Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",38,ACAT1,65,P24752,K00626,2.3.1.9,
566,203750,,Number Sign,203750,ALPHA-METHYLACETOACETIC ACIDURIA,2-METHYL-3-HYDROXYBUTYRIC ACIDEMIA;; BETA-KETOTHIOLASE DEFICIENCY;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY;; MAT DEFICIENCY;; T2 DEFICIENCY;; 3-OXOTHIOLASE DEFICIENCY;; 3-KETOTHIOLASE DEFICIENCY;; 3-KTD DEFICIENCY,,Beta ketothiolase deficiency,,ACAT1,ACAT1,Acetyl-CoA C-acetyltransferase.,7e7d0f2df5f7722bd26e7b77cb3a94b23e09dc21b571e98210f707fa7a679cf0,2.3.1.9,2.3.1.9,,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Organic aciduria,HP:0001992,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.sciencedirect.com/science/article/pii/S1110863016300763,Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",38,ACAT1,65,P24752,K00626,2.3.1.9,
567,203750,,Number Sign,203750,ALPHA-METHYLACETOACETIC ACIDURIA,2-METHYL-3-HYDROXYBUTYRIC ACIDEMIA;; BETA-KETOTHIOLASE DEFICIENCY;; MITOCHONDRIAL ACETOACETYL-CoA THIOLASE DEFICIENCY;; MAT DEFICIENCY;; T2 DEFICIENCY;; 3-OXOTHIOLASE DEFICIENCY;; 3-KETOTHIOLASE DEFICIENCY;; 3-KTD DEFICIENCY,,Beta ketothiolase deficiency,,ACAT1,ACAT1,Acetyl-CoA C-acetyltransferase.,7e7d0f2df5f7722bd26e7b77cb3a94b23e09dc21b571e98210f707fa7a679cf0,2.3.1.9,2.3.1.9,,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Bicitra,DB09154,DB09154,7dfb3c751c48770217688e4602f154f80add9e9a472388e4dd0bad634fbbddb3,DB09154,DB09154,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Acidosis,HP:0001941,,"http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/24218524,http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency,Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",38,ACAT1,65,P24752,K00626,2.3.1.9,
568,601678,,Number Sign,601678,"BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 1, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 1",,Bartter Syndrome 1,,SLC12A1,SLC12A1,Solute carrier family 12 member 1,775dd7d771cc2a594646f83918a87e7e3b5e7a31a7a98dfb8f901e34ee180714,Q13621,,Q13621,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",spironolactone+potassium+ACE-inhibitor,DB00421+DB14500+C09A,DB00421 + DB14500 + C09A,2c1de8c0d712f2c71cdce34819cb42813e8b5c5d01001db2b81dffd21f5761b8,,,,,"DB00421,DB14500,C09A","DB00421,DB14500",,C09A,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,electrolyte disturbances,HP:0003111,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6557,SLC12A1,,Q13621,K14425,"""""",
569,601678,,Number Sign,601678,"BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 1, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 1",,Bartter Syndrome 1,,SLC12A1,SLC12A1,Solute carrier family 12 member 1,775dd7d771cc2a594646f83918a87e7e3b5e7a31a7a98dfb8f901e34ee180714,Q13621,,Q13621,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Acetazolamide,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,EC:0007121,EC:0007121,,,symptomatic treatment procedure,,Metabolic alkalosis,HP:0200114,,"https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6557,SLC12A1,,Q13621,K14425,"""""",
570,601678,,Number Sign,601678,"BARTTER SYNDROME, TYPE 1, ANTENATAL; BARTS1","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 1, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 1",,Bartter Syndrome 1,,SLC12A1,SLC12A1,Solute carrier family 12 member 1,775dd7d771cc2a594646f83918a87e7e3b5e7a31a7a98dfb8f901e34ee180714,Q13621,,Q13621,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Acetazolamide,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,,,,,,,Hypokalemia Metabolic Alkalosis,HP:0002900,,"https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6557,SLC12A1,,Q13621,K14425,"""""",
571,241200,,Number Sign,241200,"BARTTER SYNDROME, TYPE 2, ANTENATAL; BARTS2","HYPOKALEMIC ALKALOSIS WITH HYPERCALCIURIA 2, ANTENATAL;; HYPERPROSTAGLANDIN E SYNDROME 2",,Bartter Syndrome 2,,KCNJ1,KCNJ1,ATP-sensitive inward rectifier potassium channel 1,7874457d65b7a0e39ed008d10aa44e47f4fb3cf2b60362a5281b740a6e1d42d7,P48048,,P48048,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Acetazolamide,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,,,,,,,hypomagnesemia,HP:0002917,,"https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3758,KCNJ1,,P48048,K04995,"""""",
572,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Tanespimycin,DB05134,DB05134,c3a87a16ebbe8207b0e248cb1bbab1fd703e09631da95cb765dbc631832c92d6,DB05134,DB05134,,,,,,,ECO:0005542,ECO:0005542,,,activity modification of a genetically defective protein,B,Low plasma membrane expression of R8Lin kidney,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
573,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Tanespimycin,DB05134,DB05134,c3a87a16ebbe8207b0e248cb1bbab1fd703e09631da95cb765dbc631832c92d6,DB05134,DB05134,,,,,,,,,,,,,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
574,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Tanespimycin,DB05134,DB05134,c3a87a16ebbe8207b0e248cb1bbab1fd703e09631da95cb765dbc631832c92d6,DB05134,DB05134,,,,,,,,,,,,,Metabolic alkalosis,HP:0200114,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
575,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Tanespimycin,DB05134,DB05134,c3a87a16ebbe8207b0e248cb1bbab1fd703e09631da95cb765dbc631832c92d6,DB05134,DB05134,,,,,,,,,,,,,Sensorineural hearing impairment,HP:0000407,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
576,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Tanespimycin,DB05134,DB05134,c3a87a16ebbe8207b0e248cb1bbab1fd703e09631da95cb765dbc631832c92d6,DB05134,DB05134,,,,,,,,,,,,,ER-associated degradation of R8L,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
577,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Tanespimycin,DB05134,DB05134,c3a87a16ebbe8207b0e248cb1bbab1fd703e09631da95cb765dbc631832c92d6,DB05134,DB05134,,,,,,,,,,,,,Mislocalization of R8L,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
578,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Potassium Chloride,DB00761,DB00761,67f1e0b55afe5c60ce17dcb742c8ee747c1e0593a6d968a63548f2028bdaab68,DB00761,DB00761,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/books/NBK442019/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
579,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Naproxen,DB00788,DB00788,83b9e912cfdff5b2c454f7f49e4d6604ea83bb3382d2fc30730719b92d2b3d28,DB00788,DB00788,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hypokalemia,HP:0002900,,"https://www.nejm.org/doi/full/10.1056/NEJM197807132990214,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
580,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Niflumic acid,DB04552,DB04552,5713f2b6a75cfae35e3aa40027d972812579f1da3c3e790f8d66dda705bb2029,DB04552,DB04552,,,,,,,ECO:0001565,ECO:0001565,L155/ G345/ A349,G167A / F213A,functional complementation of a genetically defective protein,B,Abnormal ClC-Ka function,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/20649569/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
581,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Niflumic acid,DB04552,DB04552,5713f2b6a75cfae35e3aa40027d972812579f1da3c3e790f8d66dda705bb2029,DB04552,DB04552,,,,,,,,,"""L155A, G345S and A349E""",,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20649569/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
582,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Niflumic acid,DB04552,DB04552,5713f2b6a75cfae35e3aa40027d972812579f1da3c3e790f8d66dda705bb2029,DB04552,DB04552,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20649569/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
583,602522,,Number Sign,602522,"BARTTER SYNDROME, TYPE 4A, NEONATAL, WITH SENSORINEURAL DEAFNESS; BARTS4A","BARTTER SYNDROME, NEONATAL, WITH SENSORINEURAL DEAFNESS; BSND","SENSORINEURAL DEAFNESS WITH MILD RENAL DYSFUNCTION, INCLUDED",Bartter Syndrome 4,,BSND,BSND,barttin,c51e21619430c7b36b2b6776745500701e22c21f81919a428bda1cbcaae6e4f7,Q8WZ55,,Q8WZ55,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Niflumic acid,DB04552,DB04552,5713f2b6a75cfae35e3aa40027d972812579f1da3c3e790f8d66dda705bb2029,DB04552,DB04552,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20649569/,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",7809,BSND,,Q8WZ55,K19331,"""""",
584,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",POTASSIUM-SPARING AGENTS,C03D,C03D,2149b82adae974abae88f3e4f4af9dc52149787611ba4b9ef4ee0e21e49f385e,C03D,,,C03D,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Deleterious prognosis,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
585,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",POTASSIUM-SPARING AGENTS,C03D,C03D,2149b82adae974abae88f3e4f4af9dc52149787611ba4b9ef4ee0e21e49f385e,C03D,,,C03D,,,,,,,,,,,Decreased life expectancy,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
586,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",POTASSIUM-SPARING AGENTS,C03D,C03D,2149b82adae974abae88f3e4f4af9dc52149787611ba4b9ef4ee0e21e49f385e,C03D,,,C03D,,,,,,,,,,,Salt wasting,HP:0000127,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
587,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",POTASSIUM-SPARING AGENTS,C03D,C03D,2149b82adae974abae88f3e4f4af9dc52149787611ba4b9ef4ee0e21e49f385e,C03D,,,C03D,,,,,,,,,,,Growth retardation,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/24218524,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
588,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Deleterious prognosis,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
589,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,,Decreased life expectancy (Mortality)*,HP:0040006*,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
590,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,,Salt wasting,HP:0000127,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
591,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Growth hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
592,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Growth hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,,,,,,,Decreased serum IGFâ1,HP:0030353,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
593,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Growth hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,,,,,,,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
594,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Potassium,DB14500,DB14500,e125cfa968fc61758afee8060f8f001728433f4e42edde1b8995f33e02470fe8,DB14500,DB14500,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
595,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hypomagnesemia,HP:0002917,,"https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
596,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Sodium,DB09395,DB09395,a2e90a7e24334a5ed20abf64752128f167cc038382ad998c3b313a690ed639d0,DB09395,DB09395,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hyponatremia,HP:0002902,,"https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
597,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Aminoglycoside (Geneticin),DB04263,DB04263,cd2dbb29480b68e7de99d5788d9ff351b31bfb1079109d60285c8ed6195afa7b,DB04263,DB04263,,,,,,,ECO:0001565,ECO:0001565,W610X,,direct complementation of a genetically defective protein,A,Defected ClC-Kb expression,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/23772144?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
598,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Potassium+IndomethacinÂ±Spironolactone,DB14500+DB00328+ DB00421,DB14500 + DB00328 + DB00421,74018c025b92f10cc55009de38eb9e0ce8552cf86ae4a3142d4755fb71953df2,,,,,"DB14500,DB00328,DB00421","DB14500,DB00328,DB00421",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/28288174,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
599,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Nonsteroidal anti-inflammatory drugs,M01AX,M01AX,1d07c4e8d775e1b7a83076b8032adfa28e035bca5f842078d3bf8b2ea7e2f329,M01AX,,,M01AX,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Elevated prostaglandin E2,HP:0003566,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473/,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
600,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Nonsteroidal anti-inflammatory drugs,M01AX,M01AX,1d07c4e8d775e1b7a83076b8032adfa28e035bca5f842078d3bf8b2ea7e2f329,M01AX,,,M01AX,,,,,,,,,,,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473/,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
601,607364,607364,Number Sign,607364,"BARTTER SYNDROME, TYPE 3; BARTS3","BARTTER SYNDROME, CLASSIC","BARTTER SYNDROME, TYPE 3, WITH HYPOCALCIURIA, INCLUDED","BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,CLCNKB,Chloride channel protein ClC-Kb,1a55321bc009fb783079d74ea2d61b93beb8f5d1ebbd47e2438619aeea07cb1c,P51801,,P51801,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Nonsteroidal anti-inflammatory drugs,M01AX,M01AX,1d07c4e8d775e1b7a83076b8032adfa28e035bca5f842078d3bf8b2ea7e2f329,M01AX,,,M01AX,,,,,,,,,,,High calcium excretion in urine,HP:0002150,,"https://www.ncbi.nlm.nih.gov/pubmed/24189473/,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",1188,CLCNKB,,P51801,K05018,"""""",
602,300971,300971,Number Sign,300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5","Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084",MAGED2,MAGED2,Melanoma-associated antigen D2,b00da096e8725d8e2fe515eee3945d5e88ccec5481d88723a0c03654cb906c2f,Q9UNF1,,Q9UNF1,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Electrolytes,B05BB01,B05BB01,6f47b13d3c6f83aad8615713775b60e6109d75b86612e998d531873f4a032bf0,B05BB01,,,B05BB01,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Renal salt wasting,HP:0000127,,"https://www.ncbi.nlm.nih.gov/pubmed/27120771,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",10916,MAGED2,,Q9UNF1,"""""","""""",
603,300971,300971,Number Sign,300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,MAGED2,MAGED2,Melanoma-associated antigen D2,b00da096e8725d8e2fe515eee3945d5e88ccec5481d88723a0c03654cb906c2f,Q9UNF1,,Q9UNF1,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/27120771,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",10916,MAGED2,,Q9UNF1,"""""","""""",
604,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Elamipretide,DB11981,DB11981,93106ebba74b42431139bfb7235cd31d8452a8ca11f25d519d7a7e064b452ff8,DB11981,DB11981,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,oxidative stress,HP:0025464,,"https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome/,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Elamipretide+in+Barth+syndrome&rank=1,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
605,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Elamipretide,DB11981,DB11981,93106ebba74b42431139bfb7235cd31d8452a8ca11f25d519d7a7e064b452ff8,DB11981,DB11981,,,,,,,,,,,,,abnormal energy production in damaged mitochondria,HP:0003287,,"https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Elamipretide+in+Barth+syndrome&rank=1,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
606,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Elamipretide,DB11981,DB11981,93106ebba74b42431139bfb7235cd31d8452a8ca11f25d519d7a7e064b452ff8,DB11981,DB11981,,,,,,,,,,,,,Fatigue,HP:0012378,,"https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Elamipretide+in+Barth+syndrome&rank=1,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,https://www.ncbi.nlm.nih.gov/pubmed/24260777,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
607,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Granulocyte colony stimulating factor (GâCSF),DB00020,DB00020,b30e8917a9527780729c37174f10d6b3473ada85a8039e302e35ce90cd12fc78,DB00020,DB00020,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Neutropenia,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/15098233/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
608,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Granulocyte colony stimulating factor (GâCSF),DB00020,DB00020,b30e8917a9527780729c37174f10d6b3473ada85a8039e302e35ce90cd12fc78,DB00020,DB00020,,,,,,,,,,,,,Recurrent infection,HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
609,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin,DB00390,DB00390,f2bdf23583ba341ca8bdca42235e68f59c1808a47ae96e50a7735ba79978f392,DB00390,DB00390,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Low ejection fraction,HP:0012664,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
610,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin,DB00390,DB00390,f2bdf23583ba341ca8bdca42235e68f59c1808a47ae96e50a7735ba79978f392,DB00390,DB00390,,,,,,,,,,,,,Tricusped incompetence,HP:0005180,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
611,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin,DB00390,DB00390,f2bdf23583ba341ca8bdca42235e68f59c1808a47ae96e50a7735ba79978f392,DB00390,DB00390,,,,,,,,,,,,,Mitral incomptence,HP:0001653,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
612,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Pantothenic acid,DB01783,DB01783,43fb69bae0b7ae694a898670b637106c177f00de5646c04efb8f091279e1a415,DB01783,DB01783,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Low myocardial function,HP:0001638,,"https://www.ncbi.nlm.nih.gov/pubmed/7833193,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
613,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Pantothenic acid,DB01783,DB01783,43fb69bae0b7ae694a898670b637106c177f00de5646c04efb8f091279e1a415,DB01783,DB01783,,,,,,,,,,,,,T wave abnormalities,HP:0005135,,"https://www.ncbi.nlm.nih.gov/pubmed/7833193,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
614,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Pantothenic acid,DB01783,DB01783,43fb69bae0b7ae694a898670b637106c177f00de5646c04efb8f091279e1a415,DB01783,DB01783,,,,,,,,,,,,,Delayed Growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/7833193,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
615,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Pantothenic acid,DB01783,DB01783,43fb69bae0b7ae694a898670b637106c177f00de5646c04efb8f091279e1a415,DB01783,DB01783,,,,,,,,,,,,,hypocholesterolaemia,HP:0003146,,"https://www.ncbi.nlm.nih.gov/pubmed/7833193,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
616,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Pantothenic acid,DB01783,DB01783,43fb69bae0b7ae694a898670b637106c177f00de5646c04efb8f091279e1a415,DB01783,DB01783,,,,,,,,,,,,,hyperuricaemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/7833193,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
617,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Pantothenic acid,DB01783,DB01783,43fb69bae0b7ae694a898670b637106c177f00de5646c04efb8f091279e1a415,DB01783,DB01783,,,,,,,,,,,,,Neutropenia,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/7833193,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
618,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics,C09A/C09CA/C07/C03,C09A / C09CA / C07 / C03,67ec8dbfcc290dba514a279b4dc29f123750523946fc607fb885132a4a49ca67,"C09A,C09CA,C07,C03",,,"C09A,C09CA,C07,C03",,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Heart failure,HP:0001635,,"https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
619,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics + anticoagulate,C09A/C09CA/C07/C04+B01A,C09A / C09CA / C07 / C04 + B01A,47112a2b783bbdf9bce71ba82cf2f0bf6749d691fbd8b49a4923f0837bd88ddd,"C09A,C09CA,C07,C04",,,"C09A,C09CA,C07,C04",B01A,,,B01A,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Atrial fibrillation,HP:0005110,,"https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
620,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,,Cardiac dysfunction,HP:0001635,,"https://www.ncbi.nlm.nih.gov/pubmed/29695963/,https://www.ncbi.nlm.nih.gov/pubmed/28279226/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
621,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,,,,,Exercise intolerance,HP:0003546,,"https://www.ncbi.nlm.nih.gov/pubmed/29695963/,https://www.ncbi.nlm.nih.gov/pubmed/28279226/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
622,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",AAV9-TAZ,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementatoin of a genetically defective protein by gene therapy,A,Abnormal cardiac protein (TAZ) expression,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30788385/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
623,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",AAV9-TAZ,NA,,,,,,,,,,,,,,,,,Mitochondrial dysfunction,HP:0003287,,"https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
624,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",AAV9-TAZ,NA,,,,,,,,,,,,,,,,,Mueculoskeletal dysfunction,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
625,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,DB00390 + DB00695 + DB01197,20f14a5e5022cd01e4bc9cf7a51ba165c2fa6f604d055796f4b70da9a1298d12,,,,,"DB00390,DB00695,DB01197","DB00390,DB00695,DB01197",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Cardiomegaly,HP:0001640,,"https://www.ncbi.nlm.nih.gov/pubmed/20981509,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
626,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,DB00390 + DB00695 + DB01197,20f14a5e5022cd01e4bc9cf7a51ba165c2fa6f604d055796f4b70da9a1298d12,,,,,"DB00390,DB00695,DB01197","DB00390,DB00695,DB01197",,,,,,,,,Reduced ejection fraction,HP:0012664,,"https://www.ncbi.nlm.nih.gov/pubmed/20981509,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
627,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,DB00390 + DB00695 + DB01197,20f14a5e5022cd01e4bc9cf7a51ba165c2fa6f604d055796f4b70da9a1298d12,,,,,"DB00390,DB00695,DB01197","DB00390,DB00695,DB01197",,,,,,,,,Developmetal delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/20981509,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
628,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,DB00390 + DB00695 + DB01197,20f14a5e5022cd01e4bc9cf7a51ba165c2fa6f604d055796f4b70da9a1298d12,,,,,"DB00390,DB00695,DB01197","DB00390,DB00695,DB01197",,,,,,,,,Abormal liver size,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/20981509,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
629,302060,,Number Sign,302060,BARTH SYNDROME; BTHS,"CARDIOSKELETAL MYOPATHY WITH NEUTROPENIA AND ABNORMAL MITOCHONDRIA;; 3-METHYLGLUTACONIC ACIDURIA, TYPE II; MGCA2;; MGA, TYPE II; MGA2",,Barth syndrome,,TAZ,TAZ,tafazzin ( Protein),f93f481b455a232bd049a706ab17dcaf1c6ad34213fe285325130f33829b98f6,available,,"Not,available","Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Digoxin+furosemide+captopril,DB00390+DB00695+DB01197,DB00390 + DB00695 + DB01197,20f14a5e5022cd01e4bc9cf7a51ba165c2fa6f604d055796f4b70da9a1298d12,,,,,"DB00390,DB00695,DB01197","DB00390,DB00695,DB01197",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20981509,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",6901,TAZ,59,Q16635,K13511,"""""",
630,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",sebelipase alfa,DB11563,DB11563,7f8acd9f0ac4b4b70eaf1b4b13e7e036b51fbf7b06de7c9dc6dde5634925bc5b,DB11563,DB11563,,,,,,,ECO:0000352/ECO:0005542,"ECO:0000352,ECO:0005542",,,direct complementation of a genetically defective protein,A,High plasma cholesterol level*,HP:0003107,,"https://www.ncbi.nlm.nih.gov/pubmed/29773783,https://www.ncbi.nlm.nih.gov/pubmed/27878737,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
631,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",sebelipase alfa,DB11563,DB11563,7f8acd9f0ac4b4b70eaf1b4b13e7e036b51fbf7b06de7c9dc6dde5634925bc5b,DB11563,DB11563,,,,,,,,,,,,,hypertriglycemia,HP:0002155,,"https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
632,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",sebelipase alfa,DB11563,DB11563,7f8acd9f0ac4b4b70eaf1b4b13e7e036b51fbf7b06de7c9dc6dde5634925bc5b,DB11563,DB11563,,,,,,,,,,,,,Abnormal liver function,HP:0002910,,"https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
633,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",sebelipase alfa,DB11563,DB11563,7f8acd9f0ac4b4b70eaf1b4b13e7e036b51fbf7b06de7c9dc6dde5634925bc5b,DB11563,DB11563,,,,,,,,,,,,,Dyslipidemia,HP:0003119,,"https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
634,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",sebelipase alfa,DB11563,DB11563,7f8acd9f0ac4b4b70eaf1b4b13e7e036b51fbf7b06de7c9dc6dde5634925bc5b,DB11563,DB11563,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
635,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",fenofibrate,DB01039,DB01039,c0680bf86f5f9a0f66f08227ddde5c81f378e716c676fab8f6fff972243710b5,DB01039,DB01039,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,B,Increased plasma triglycerides,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475/,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
636,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,"Supplementation with biotin slows the progression of BTD in symptomatic patients, but does not reverse nerve atrophy. Nonetheless, introduction of the treatment with biotin during presymptomatic stage of the disease prevents the onset of symptoms including optic atrophy and hearing loss",Simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Hyperlipidemia,HP:0003077,,"https://www.ncbi.nlm.nih.gov/pubmed/16848116,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
637,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Lovastatin,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Increased LDL cholesterol,HP:0003141,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
638,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Lovastatin,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,,,,,,,Increased plasma triglycerides,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
639,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Lovastatin,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,,,,,,,Increased total cholesterol,HP:0003124,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
640,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Lovastatin,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,,,,,,,Elevated urine mevalonate levels,NA,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,https://clinicaltrials.gov/ct2/show/NCT01371825,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
641,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Colestyramine+Simivastatin,DB01432+DB00641,DB01432 + DB00641,ee4abff46f2607086d159b62a84c245332bf66d6dd105ab45ba06d83ef7b39f1,,,,,"DB01432,DB00641","DB01432,DB00641",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,B,Dyslipidemia,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pubmed/1801793,https://www.sciencedirect.com/science/article/pii/S1521691810001101,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
642,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Colestyramine+Simivastatin,DB01432+DB00641,DB01432 + DB00641,ee4abff46f2607086d159b62a84c245332bf66d6dd105ab45ba06d83ef7b39f1,,,,,"DB01432,DB00641","DB01432,DB00641",,,,,,,,,Abnormal liver function,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/1801793,https://www.sciencedirect.com/science/article/pii/S1521691810001101,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
643,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Ezetimibe,DB00973,DB00973,b9d2e44fba7b06d6e260dde36ead2bf55342bc620edb747f762e8de0be3d01a5,DB00973,DB00973,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Dyslipidemia,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.sciencedirect.com/science/article/pii/S1521691810001101,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
644,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Ezetimibe,DB00973,DB00973,b9d2e44fba7b06d6e260dde36ead2bf55342bc620edb747f762e8de0be3d01a5,DB00973,DB00973,,,,,,,,,,,,,Abnormal liver function,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.sciencedirect.com/science/article/pii/S1521691810001101,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
645,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Ezetimibe,DB00973,DB00973,b9d2e44fba7b06d6e260dde36ead2bf55342bc620edb747f762e8de0be3d01a5,DB00973,DB00973,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.sciencedirect.com/science/article/pii/S1521691810001101,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
646,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Ezetimibe,DB00973,DB00973,b9d2e44fba7b06d6e260dde36ead2bf55342bc620edb747f762e8de0be3d01a5,DB00973,DB00973,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.sciencedirect.com/science/article/pii/S1521691810001101,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
647,278000,,Number Sign,278000,LYSOSOMAL ACID LIPASE DEFICIENCY,CHOLESTERYL ESTER STORAGE DISEASE; CESD;; LIPA DEFICIENCY;; LAL DEFICIENCY;; CHOLESTEROL ESTER HYDROLASE DEFICIENCY,"WOLMAN DISEASE, INCLUDED",Cholesteryl ester storage diseaseÂ (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA,LIPA,lysosomal acid lipase,1cb5beed8c47d96ad997cebace5d5bcc8c6c756535e675fe39f3846cbee466cf,P38571,,P38571,Treatment success with statins has been mixed.,Ezetimibe,DB00973,DB00973,b9d2e44fba7b06d6e260dde36ead2bf55342bc620edb747f762e8de0be3d01a5,DB00973,DB00973,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.sciencedirect.com/science/article/pii/S1521691810001101,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",3988,LIPA,302,P38571,K01052,3.1.1.13,
648,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.",Colchicine(COL),DB01394,DB01394,1993a504d61ce758a9a5be3048f2dc6a7dd5154ce9a2be3f3b79121e71e9ce07,DB01394,DB01394,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Arthritis,HP:0001369,,"https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
649,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.",Colchicine(COL),DB01394,DB01394,1993a504d61ce758a9a5be3048f2dc6a7dd5154ce9a2be3f3b79121e71e9ce07,DB01394,DB01394,,,,,,,,,,,,,Arthralgia,HP:0002829,,"https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://www.ncbi.nlm.nih.gov/pubmed/29374495,https://www.ncbi.nlm.nih.gov/pubmed/28804516,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
650,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,ECO:0000352/ECO:0007121,"ECO:0000352,ECO:0007121",,,symptomatic treatment procedure,C,Arthritis,HP:0001369,,"https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/27790033/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
651,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,naproxen sodium,DB00788,DB00788,83b9e912cfdff5b2c454f7f49e4d6604ea83bb3382d2fc30730719b92d2b3d28,DB00788,DB00788,,,,,,,,,,,symptomatic treatment procedure,C,Arthralgia,HP:0002829,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
652,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,naproxen sodium,DB00788,DB00788,83b9e912cfdff5b2c454f7f49e4d6604ea83bb3382d2fc30730719b92d2b3d28,DB00788,DB00788,,,,,,,,,,,,,Recurrent repisode of flares (Recurrent)*,HP:0025303,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,https://www.ncbi.nlm.nih.gov/pubmed/28220409,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
653,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",Anakinra/canakinuma,DB00026/DB06168,DB00026 / DB06168,8da5bac4d209298507ef0e3267481c0112e66a975848f515c7cfd8b1e52cc48b,"DB00026,DB06168","DB00026,DB06168",,,,,,,ECO:0007121/ ECO:0000352,"ECO:0007121,ECO:0000352",,,symptomatic treatment procedure,C,Recurrent repisode of flares (Recurrent)*,HP:0025303,,"https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pubmed/19289295,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
654,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",Anakinra/canakinuma,DB00026/DB06168,DB00026 / DB06168,8da5bac4d209298507ef0e3267481c0112e66a975848f515c7cfd8b1e52cc48b,"DB00026,DB06168","DB00026,DB06168",,,,,,,,,,,,,Arthritis,HP:0001369,,"https://www.ncbi.nlm.nih.gov/pubmed/23022422,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
655,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",Anakinra/canakinuma,DB00026/DB06168,DB00026 / DB06168,8da5bac4d209298507ef0e3267481c0112e66a975848f515c7cfd8b1e52cc48b,"DB00026,DB06168","DB00026,DB06168",,,,,,,,,,,,,Refractory Arthritis,HP:0031375,,"https://www.ncbi.nlm.nih.gov/pubmed/22658375,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
656,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",Anakinra/canakinuma,DB00026/DB06168,DB00026 / DB06168,8da5bac4d209298507ef0e3267481c0112e66a975848f515c7cfd8b1e52cc48b,"DB00026,DB06168","DB00026,DB06168",,,,,,,,,,,,,Synovitis,HP:0100769,,"https://www.ncbi.nlm.nih.gov/pubmed/22341584?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
657,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1Î² inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",rilonacept,DB06372,DB06372,333591c7ae0fc057cca9ea7dbb86a8f4cd537758e3df888c094e1f0a470a4c07,DB06372,DB06372,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Recurrent repisode of flares (Recurrent)*,HP:0025303,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
658,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",methotrexate,DB00563,DB00563,ad15fbb18adebcf2b1ad9bf875bb79f89bf8334ac3b7ee462dedaabaf303964b,DB00563,DB00563,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,swollen joint,HP:0001386,,"https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/,https://www.ncbi.nlm.nih.gov/pubmed/25315665,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
659,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",methotrexate,DB00563,DB00563,ad15fbb18adebcf2b1ad9bf875bb79f89bf8334ac3b7ee462dedaabaf303964b,DB00563,DB00563,,,,,,,,,,,,,Arthralgia,HP:0002829,,"https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/,https://www.ncbi.nlm.nih.gov/pubmed/25315665,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
660,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Hydroxychloroquine,DB01611,DB01611,f77095ab6907cedf6f841df612e5949c6a03afd4e8f75a8a4379e876c8c1130f,DB01611,DB01611,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,swollen joint,HP:0001386,,"https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
661,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Hydroxychloroquine,DB01611,DB01611,f77095ab6907cedf6f841df612e5949c6a03afd4e8f75a8a4379e876c8c1130f,DB01611,DB01611,,,,,,,,,,,,,Arthralgia,HP:0002829,,"https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
662,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Hydroxychloroquine,DB01611,DB01611,f77095ab6907cedf6f841df612e5949c6a03afd4e8f75a8a4379e876c8c1130f,DB01611,DB01611,,,,,,,,,,,,,Arthropathy,HP:0003040,,"https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
663,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Probenecid,DB01032,DB01032,2eaf2c7a70dc6dbae04804ddaf804322045de4d452b206ddf563c955877393ec,DB01032,DB01032,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,,Abnormality of phosphate homeostasis,HP:0100529,,"https://www.ncbi.nlm.nih.gov/pubmed/7520501,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
664,118600,,Number Sign,118600,CHONDROCALCINOSIS 2; CCAL2,"CHONDROCALCINOSIS, FAMILIAL ARTICULAR;; CALCIUM GOUT;; CALCIUM PYROPHOSPHATE ARTHROPATHY;; CALCIUM PYROPHOSPHATE DIHYDRATE DEPOSITION DISEASE; CPPDD",,Chondrocalcinosis 2,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Probenecid,DB01032,DB01032,2eaf2c7a70dc6dbae04804ddaf804322045de4d452b206ddf563c955877393ec,DB01032,DB01032,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/7520501,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
665,118610,118610,NULL,118610,CHONDROCALCINOSIS DUE TO APATITE CRYSTAL DEPOSITION,FAMILIAL APATITE DISEASE,,Chondrocalcinosis due to apatite crystal deposition,,ANKH,ANKH,Progressive ankylosis protein homolog,e012865ffce18864bf3cc634114c21f49542a2d9c7d53dfa300ea8cd744d2576,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",NSAIDs,DB00788,DB00788,83b9e912cfdff5b2c454f7f49e4d6604ea83bb3382d2fc30730719b92d2b3d28,DB00788,DB00788,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,acute arthritis,HP:0001369,,"https://www.ncbi.nlm.nih.gov/pubmed/17541659,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",56172,ANKH,,Q9HCJ1,K22734,"""""",
666,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,neurological abnormalities,HP:0012638,,"https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
667,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Alpha-tocopherol,DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,,,,,symptomatic treatment procedure,C,neurological abnormalities,HP:0012638,,"https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
668,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",Alpha-tocopherol,DB11251,DB11251,e7b0b222821210bd9463f7c1d84bc72ba826c60a57b98df742546afb8f27ba72,DB11251,DB11251,,,,,,,,,,,,,Abnormal Adipose tissue tocopherol level.,NA,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
669,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Tocofersolan,DB11635,DB11635,7608df18269ce24297436b4d5fd42d34fbc0c143fddc55d4b9d419f47d5cd202,DB11635,DB11635,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,No Studies were done on this drug.,,,"https://www.ncbi.nlm.nih.gov/pubmed/27520363,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
670,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Vitamin A+ Vitamin E,DB00162+DB00163,DB00162 + DB00163,b7a5951749df631da8a605be5ac85c241780c063c39a44e0c5dc768908f0c1e4,,,,,"DB00162,DB00163","DB00162,DB00163",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Minor visual abnormalities,HP:0000505,,"https://www.ncbi.nlm.nih.gov/pubmed/19285442/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
671,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Vitamin A+ Vitamin E,DB00162+DB00163,DB00162 + DB00163,b7a5951749df631da8a605be5ac85c241780c063c39a44e0c5dc768908f0c1e4,,,,,"DB00162,DB00163","DB00162,DB00163",,,,,,,,,Neurological abnormality,HP:0012638,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
672,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Vitamin A+ Vitamin E,DB00162+DB00163,DB00162 + DB00163,b7a5951749df631da8a605be5ac85c241780c063c39a44e0c5dc768908f0c1e4,,,,,"DB00162,DB00163","DB00162,DB00163",,,,,,,,,Muscular abnormality,HP:0012638,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
673,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",vitamin D,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,osteopenia,HP:0000938,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
674,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",vitamin D,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,,,,,,,Vitamin D insufficiency,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
675,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",vitamin K,DB01022,DB01022,053b7d961fb9916bcb2c1470e66df9490330721eaeb4caa1dfc3314164fb34ca,DB01022,DB01022,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Bleeding tendency,HP:0001892,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
676,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",vitamin K,DB01022,DB01022,053b7d961fb9916bcb2c1470e66df9490330721eaeb4caa1dfc3314164fb34ca,DB01022,DB01022,,,,,,,,,,,,,Vitamin K insufficiency,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
677,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,"Low weight,growth",HP:0004325,,"https://www.sciencedirect.com/science/article/pii/S0929693X16302044?via%3Dihub,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
678,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Diarrhea,HP:0002014,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
679,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",medium-chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Malnutrition,HP:0004395,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
680,246700,,Number Sign,246700,CHYLOMICRON RETENTION DISEASE; CMRD,ANDERSON DISEASE; ANDD;; LIPID TRANSPORT DEFECT OF INTESTINE;; HYPOBETALIPOPROTEINEMIA WITH ACCUMULATION OF APOLIPOPROTEIN B-LIKE PROTEIN IN INTESTINAL CELLS,,Chylomicron retention disease,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",fat emulsion,DB09422,DB09422,c5cc20af31e840d8cb75f3f1083525f9d9d5bcaa36e6dfa2a1bc66069d2a803c,DB09422,DB09422,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Fat malabsorption,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/2596948/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,https://www.ncbi.nlm.nih.gov/pubmed/30034506",51128,SAR1B,1083,Q9Y6B6,K07953,"""""",
681,215720,215720,NULL,215720,CITRULLINE TRANSPORT DEFECT,,,Citrulline transport defect,,SAR1B,SAR1B,Sar1bÂ protein,935da737bd476ee0165dff0e0c8270089eb2826d6661c004ec5f25ceef6a910c,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,51128,SAR1B,,Q9Y6B6,K07953,"""""",
682,611209,,Number Sign,611209,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIg; CDG2G",CDG IIg; CDGIIg;; CDGII/COG1 CEREBROCOSTOMANDIBULAR-LIKE SYNDROME,,COG1-CDG (CDG-IIg),,COG1,COG1,component of oligomeric golgi complex 1,3df5aa58aa53109ad9018723d40ec1cbd78cf5bcaacc8b5992db8463691f54e8,Q9HCJ1,,Q9HCJ1,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1749-6632.2010.05840.x,9382,COG1,344,Q8WTW3,K20288,"""""",
683,615395,,Number Sign,615395,COMBINED OXIDATIVE PHOSPHORYLATION DEFICIENCY 16; COXPD16,,,Combined oxidative phosphorylation deficiency 16,,MRPL44,MRPL44,mitochondrial ribosomal protein L44,0051cb8730a139212747dc7ecedfd46ad21198c07c5c7cdd9f7c8b5c577401d8,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",l-carnitineÂ +propranolol,DB00583+DB00571,DB00583 + DB00571,378f46f7743b389bc94209f52906555d449a160e4f81a4e80d0e03888546a542,,,,,"DB00583,DB00571","DB00583,DB00571",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,low physical capacity,HP:0012378,,"https://link.springer.com/article/10.1007%2Fs10048-015-0444-2,https://www.ncbi.nlm.nih.gov/pubmed/25797485",65080,MRPL44,961,Q9H9J2,K17425,3.1.26.-,
684,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Atypical bile acids,NA,,"https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1,https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
685,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Defected bile flow,HP:0001396,,"https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
686,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Cirrhosis,HP:0001394,,"https://www.ncbi.nlm.nih.gov/pubmed/30373615,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
687,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Pruritus,HP:0000989,,"https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
688,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Abnormal urinary steroid level,HP:0012030,,"https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
689,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,Ill-being (Constitutional symptoms)*,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
690,607765,,Number Sign,607765,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 1; CBAS1",3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 1",,HSD3B7,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,e1ad9b22451f559321b0851b9258304104a7ffbc4e1e1d7b50571c0be20373c6,Q9H9J2,,Q9H9J2,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Ursodeoxycholic acid,DB01586,DB01586,6c6cbaf6a1e3ee3787e164056f1e99191eaecb0970fe79065bc15239e6327655,DB01586,DB01586,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,,,,"https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",80270,HSD3B7,,Q9H2F3,K12408,1.1.1.-; 1.1.1.181,
691,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Liver biochemical abnormalitiesÂ (Laboratory abnormalities)*,HP:0001939,,"https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
692,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Histological abnormalitiesÂ (Abnormal test result)*,HP:0500014,,"https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
693,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
694,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Defected bile flow(Cholestasis)*,HP:0001396,,"https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
695,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,fat soluble vitamin malabsorption*,HP:0002630,,"https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
696,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,Atypical bile acid synthesis,NA,,"https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
697,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Cholic acid,DB02659,DB02659,3dff2d07a2f43a43fa23ae0777b1c4f9e2ef3822ba54288c35fd8ffff30db692,DB02659,DB02659,,,,,,,,,,,,,production of toxic bile acid metabolic intermediates,NA,,"https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
698,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",chenodeoxycholicÂ acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,abnormal liver function,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/28697823,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
699,235555,,Number Sign,235555,"BILE ACID SYNTHESIS DEFECT, CONGENITAL, 2; CBAS2",CHOLESTASIS WITH DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE DEFICIENCY,,"Congenital bile acid synthesis defect, type 2",,AKR1D1,AKR1D1,Aldo-keto reductase family 1 member D1,03923a77aa7fb50654c08e634370e5566e1d4320134b61bf35f44c398185bad9,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",chenodeoxycholicÂ acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,,,,,,,hepatomegaly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/28697823,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",6718,AKR1D1,,P51857,K00251,1.3.1.3,
700,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",interferon Î±-2a,DB00034,DB00034,6acbf91f3d728fdb4641adedec9508e8123689c18890640525e6a12ed5ef6454,DB00034,DB00034,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,low hemoglobin concentration,HP:0001931,,"https://www.ncbi.nlm.nih.gov/pubmed/16141353,https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",146059,CDAN1,,Q8IWY9,K19531,"""""",
701,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",interferon Î±-2a,DB00034,DB00034,6acbf91f3d728fdb4641adedec9508e8123689c18890640525e6a12ed5ef6454,DB00034,DB00034,,,,,,,,,,,,,Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*,HP:0011031*,,"https://www.ncbi.nlm.nih.gov/pubmed/16141353,https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",146059,CDAN1,,Q8IWY9,K19531,"""""",
702,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",deferoxamine,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,high plasma ferritin,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",146059,CDAN1,,Q8IWY9,K19531,"""""",
703,224120,,Number Sign,224120,"ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE Ia; CDAN1A","DYSERYTHROPOIETIC ANEMIA, CONGENITAL, TYPE Ia;; CDA Ia;; ANEMIA, CONGENITAL DYSERYTHROPOIETIC, TYPE I",,Congenital dyserythropoietic anemia type 1,,CDAN1,CDAN1,codanin 1,21600172c1bbe851aeb77061b6ffeb6f576be8ebd291374709ed44894e611c7f,1.3.1.3,1.3.1.3,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",deferiprone,DB08826,DB08826,ecac33e809e84cbd68c4ad875f2d52e72c6fc8367bdeabc70a344a6582d0858a,DB08826,DB08826,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Elevated serum ferritin concentrations,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pubmed/16141353,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",146059,CDAN1,,Q8IWY9,K19531,"""""",
704,220120,,Number Sign,220120,D-GLYCERIC ACIDURIA,D-GLYCERIC ACIDEMIA;; GLYCERATE KINASE DEFICIENCY,,D-glycericacidemia,,GLYCTK,GLYCTK,d-glycerateÂ kinase,bdf5b0f4fde0a1db11335b73d7193512c015dbca0a59c41e205517e262913975,2.7.1.31,2.7.1.31,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Sodium bicarbonate,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/26247153,http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652015005050021&lng=en&nrm=iso&tlng=en,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",132158,GLYCTK,,Q8IVS8,K11529,2.7.1.31,
705,261515,261515,Number Sign,261515,D-BIFUNCTIONAL PROTEIN DEFICIENCY,17-BETA-HYDROXYSTEROID DEHYDROGENASE IV DEFICIENCY;; DBP DEFICIENCY;; PEROXISOMAL BIFUNCTIONAL ENZYME DEFICIENCY;; PBFE DEFICIENCY,,D-bifunctional protein deficiency,"No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/",HSD17B4,HSD17B4,17Î²-hydroxysteroid dehydrogenase type 4,71ecb46f2ff29b43d552e82b83eecd08adbf8ed63bd14e093c300a4022496830,2.7.1.31,2.7.1.31,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",chenodeoxycholic acid+cholic acid,DB06777+DB02659,DB06777 + DB02659,4b51d9e44cfc71b19079d3987372457b3fb9ea53f896e511555bff899c675665,,,,,"DB06777,DB02659","DB06777,DB02659",,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,C,The study was terminated,,,"https://clinicaltrials.gov/ct2/show/NCT00004442?cond=D-bifunctional+protein+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",3295,HSD17B4,274,P51659,K12405,1.1.1.n12; 4.2.1.107; 4.2.1.119,
706,261515,261515,Number Sign,261515,D-BIFUNCTIONAL PROTEIN DEFICIENCY,17-BETA-HYDROXYSTEROID DEHYDROGENASE IV DEFICIENCY;; DBP DEFICIENCY;; PEROXISOMAL BIFUNCTIONAL ENZYME DEFICIENCY;; PBFE DEFICIENCY,,D-bifunctional protein deficiency,,HSD17B4,HSD17B4,17Î²-hydroxysteroid dehydrogenase type 4,71ecb46f2ff29b43d552e82b83eecd08adbf8ed63bd14e093c300a4022496830,2.7.1.31,2.7.1.31,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",cholic acid+ursodiol,DB02659Â +DB14555,DB02659 + DB14555,d90e7fd11b2e5d24821872fb692d884f540cf9eb1111c6df8e170f11f43c6d61,,,,,"DB02659,DB14555","DB02659,DB14555",,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,C,The study was terminated,,,"https://clinicaltrials.gov/ct2/show/NCT00004442?cond=D-bifunctional+protein+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",3295,HSD17B4,274,P51659,K12405,1.1.1.n12; 4.2.1.107; 4.2.1.119,
707,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",L- carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,DNA damage (Abnormality of DNA repair)*,HP:0003254*,,"https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,166,Q8N465,K18204,1.1.99.-,
708,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",L- carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,oxidative injury*,HP:0025463,,"https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,166,Q8N465,K18204,1.1.99.-,
709,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",L- carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Protein oxidation,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,166,Q8N465,K18204,1.1.99.-,
710,600721,,Number Sign,600721,D-2-HYDROXYGLUTARIC ACIDURIA 1; D2HGA1,D2HGA,,D-2-hydroxyglutaric aciduria,,D2HGDH,D2HGDH,D-2-hydroxyglutarate dehydrogenase,7892de2e37b623ceb9143f740970a7224c7fa633269e5544be4727905ce5c27c,2.7.1.31,2.7.1.31,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",L- carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,lipid peroxidation,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,166,Q8N465,K18204,1.1.99.-,
711,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",Valproic acid,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
712,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",carbamazepine,DB00593,DB00593,8f6c6cd8e7b651a924326a65216d6a6f55ed8cd6902c293f9a6f333d852da414,DB00593,DB00593,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
713,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",phenobarbital,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
714,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",phenytoin,DB00252,DB00252,7355ede4950f929c039e58163d1daf16e75b5ea0f0e2193086b6c3e613e23110,DB00252,DB00252,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
715,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",oxcarbazepine,DB00776,DB00776,6a44b1d0bede25feaed15b1c595afe0b465e2e906bd91165d2306e1d9da650cf,DB00776,DB00776,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
716,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
717,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",gabapentin,DB00996,DB00996,8c05f551ff6c46816ab7d5744ebfe36a01784a399e682aa2f8482ee68150a544,DB00996,DB00996,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
718,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",topiramate,DB00273,DB00273,46d06fb3beec9e56fac672d0347e5531cd01d3fdc69d2741b9289b4fe642bf70,DB00273,DB00273,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
719,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",zonisamide,DB00909,DB00909,18de586f793c8d7432d331c9afe6dfcf1fcb41f7152cad42ef308d101c3060c9,DB00909,DB00909,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
720,220110,,Number Sign,220110,MITOCHONDRIAL COMPLEX IV DEFICIENCY,CYTOCHROME c OXIDASE DEFICIENCY;; COX DEFICIENCY,,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,D2HGDH,cytochrome c oxidase assembly factor,ecf0c5966d414624f424f20a2f749e15960e309d7c9f8c2988cceca6fd3d4d74,1.9.3.1,1.9.3.1,,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",ethosuximide,DB00593,DB00593,8f6c6cd8e7b651a924326a65216d6a6f55ed8cd6902c293f9a6f333d852da414,DB00593,DB00593,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22149023,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",728294,D2HGDH,937,Q8N465,K18204,1.1.99.-,
721,219750,,Number Sign,219750,"CYSTINOSIS, ADULT NONNEPHROPATHIC","CYSTINOSIS, OCULAR NONNEPHROPATHIC;; CYSTINOSIS, BENIGN NONNEPHROPATHIC",,"Cystinosis, ocular nonnephropathic",,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,ECO:0005542/ECO:0007121,"ECO:0005542,ECO:0007121",,,functional complementation of a genetically defective protein,B,corneal crystals,HP:0000531,,"https://www.ncbi.nlm.nih.gov/pubmed/12370309/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12488257/,https://www.ncbi.nlm.nih.gov/pubmed/1929112/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
722,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,ECO:0000352/ECO:0005542,"ECO:0000352,ECO:0005542",,,functional complementation of a genetically defective protein,B,corneal crystals,HP:0000531,,"https://www.ncbi.nlm.nih.gov/pubmed/11001803,https://www.ncbi.nlm.nih.gov/pubmed/9758713,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
723,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,Photophobia,HP:0000613,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/9758713,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
724,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,Kidney disease progression ( Progressive disorder)*,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
725,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,development of extra-renal pathologies ( Progressive disorder)*,HP:0003678*,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
726,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,hypothyroidism,HP:0000821,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
727,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,Delayed growth,HP:0001510,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
728,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,cystine accumulation in muscle parenchyma,HP:0003358,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
729,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,shorter life expectancy,NA,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
730,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,Reduction of WBC cystine levels,NA,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
731,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,renal function declines,HP:0012622,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
732,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism),HP:0010918*,,"https://www.ncbi.nlm.nih.gov/pubmed/23416144,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
733,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",cysteamine,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,,,,,,,glomerular damage,HP:0000095*,,"https://www.ncbi.nlm.nih.gov/pubmed/23416144,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
734,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,polyuria,HP:0000103,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
735,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,,weight gain,HP:0004324,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
736,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,,proximal tubule salt lossesÂ (Proximal tubular defect),HP:0000114,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
737,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,indomethacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,,renal salt wasting,HP:0000127,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
738,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,Bicarbonate+potassium supplements,DB01390+DB01345,DB01390 + DB01345,8fe6f9a7e240a8467a633c2992e62e3ee42ae6ab67a7d5a310585f6687ae4db3,,,,,"DB01390,DB01345","DB01390,DB01345",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,acidosis,HP:0001941,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
739,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,neutral phosphate+Vitamin D,DB14502 orDB09449 +DB11094,DB14502 or DB09449 + DB11094,418faa3c57dfedc8d5e738a454d7f9610ff7779297d6a0981897e792402555f0,"DB14502,DB09449","DB14502,DB09449",,,DB11094,DB11094,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Phosphate imbalance (Abnormality of phosphate homeostasis),HP:0100529,,"https://www.ncbi.nlm.nih.gov/pubmed/27102039,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
740,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,Thiazide,DB01324,DB01324,220a0c5acbf784f3ffab6250232a8f228a59e8fdd431a6ae0acc2e73ec19d03b,DB01324,DB01324,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,low proximal tubular reabsorption of bicarbonates,HP:0004910*,,"https://www.ncbi.nlm.nih.gov/pubmed/27102039,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
741,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,growth hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,retarded growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
742,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,growth hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,,,,,,,low phosphate reabsorption,HP:0000117,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
743,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,Thyroxine,DB00451,DB00451,55499b3bcef6fb6f5029a1d7616498410a2edcee934df2555522c03ff686047b,DB00451,DB00451,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hypothyroidism,HP:0000821,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
744,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,ACE inhibitors,DB01348,DB01348,e1dec09af2974110d81151f593a251bbda4fdcfa89d6f9ac483ea8803a766e9e,DB01348,DB01348,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,glomerular proteinuria,HP:0000100,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
745,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,ACE inhibitors,DB01348,DB01348,e1dec09af2974110d81151f593a251bbda4fdcfa89d6f9ac483ea8803a766e9e,DB01348,DB01348,,,,,,,,,,,,,Albuminuria,HP:0012592,,"https://www.ncbi.nlm.nih.gov/pubmed/14690254/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
746,219800,,Number Sign,219800,"CYSTINOSIS, NEPHROPATHIC; CTNS","LYSOSOMAL CYSTINE TRANSPORT PROTEIN, DEFECT OF;; CYSTINOSIN, DEFECT OF","CYSTINOSIS, INFANTILE NEPHROPATHIC, INCLUDED;; CYSTINOSIS, ATYPICAL NEPHROPATHIC, INCLUDED",Cystinosis,,CTNS,CTNS,cystinosin,0ab61966f9986f972898fe0640a8e5255f06e6f8cb238e7a84a519383cefddb1,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,Testosterone,DB00624,DB00624,3793204739c40d15db77aca642ada0e03f6080957e1778a784fca03f3f024e72,DB00624,DB00624,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Low serum testosterone levels,HP:004017,,"https://www.ncbi.nlm.nih.gov/pubmed/19217094/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,https://www.ncbi.nlm.nih.gov/pubmed/19622360",1497,CTNS,525,O60931,K12386,"""""",
747,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2","Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,phenobarbital,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,high serum bilirubin level,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/23162302/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=27264814&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
748,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,orlistat,DB01083,DB01083,05274725c88e0413fd7da09c5773bce9703f303f4d41952d69a72d6aa00d3a92,DB01083,DB01083,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,high plasma level of unconjugated bilirubin concentration,HP:0008282,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
749,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,orlistat,DB01083,DB01083,05274725c88e0413fd7da09c5773bce9703f303f4d41952d69a72d6aa00d3a92,DB01083,DB01083,,,,,,,,,,,,,increased fecal fat excretion,HP:0002570,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
750,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,orlistat,DB01083,DB01083,05274725c88e0413fd7da09c5773bce9703f303f4d41952d69a72d6aa00d3a92,DB01083,DB01083,,,,,,,,,,,,,low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*,HP:0008282*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
751,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,AT342,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,High serum  bilirubin concentration,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://clinicaltrials.gov/ct2/show/NCT03223194?cond=Crigler+Najjar+syndrome&rank=3,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
752,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,GNT0003,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,High serum  bilirubin concentration,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://clinicaltrials.gov/ct2/show/NCT03466463?cond=Crigler+Najjar+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
753,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,hypericum extract,DB01323,DB01323,7299029353133dbaf5d6253ef3ae989f77790dd9f2eb93e893d60bfc552a4174,DB01323,DB01323,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
754,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,AAV-mediated gene therapy,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,Abnormal liver function,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
755,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,AAV-mediated gene therapy,NA,,,,,,,,,,,,,,,,,High serum  bilirubin concentration,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
756,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,AAV-mediated gene therapy,NA,,,,,,,,,,,,,,,,,Increased inflammatory response,HP:0012649,,"https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
757,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,AAV-mediated gene therapy,NA,,,,,,,,,,,,,,,,,Abnormality of metabolism,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
758,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,Chlofibrate,DB00636,DB00636,4f4a0caa17de4a7c7581c0cd32e83b6af5948953cf19f3d8f3d787f30c592aa9,DB00636,DB00636,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,,High serum  bilirubin concentration,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/7483726,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
759,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,Fenofibrate,DB01039,DB01039,c0680bf86f5f9a0f66f08227ddde5c81f378e716c676fab8f6fff972243710b5,DB01039,DB01039,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,,Drug wasn't effective (Insignificant effect),,,"https://www.ncbi.nlm.nih.gov/pubmed/16830281,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
760,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,Calcium,DB01373,DB01373,752f5e1d8a1808aa3274b10279d52abd2d2cb5fbd6901891efde70a9e3eb0a58,DB01373,DB01373,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Calcium makes phototherapy more efficient,,,"https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
761,606785,,Number Sign,606785,"CRIGLER-NAJJAR SYNDROME, TYPE II","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE II; HBLRCN2",,"Crigler Najjar syndrome, type 2",,UGT1A1,UGT1A1,UDP glucuronosyltransferase family 1 member A1,57300ee754bdf1162a0236e65c9ccea3c6941732e5275b7076aae86694b0952f,O60931,,O60931,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,Calcium,DB01373,DB01373,752f5e1d8a1808aa3274b10279d52abd2d2cb5fbd6901891efde70a9e3eb0a58,DB01373,DB01373,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
762,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,The drug is effective in conjuction with phototherapy,Tin-protoporphyrin,DB02285,DB02285,a3ce67a332f4f19482d5635c9d0a88ffbb869428c5cf4a370a9284554a66ea58,DB02285,DB02285,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,High serum bilirubin level,HP:0002904,,"https://www.nature.com/articles/pr1989488,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,http://pediatrics.aappublications.org/content/86/1/152,https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
763,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,"Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.",orlistat,DB01083,DB01083,05274725c88e0413fd7da09c5773bce9703f303f4d41952d69a72d6aa00d3a92,DB01083,DB01083,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,functional complementation of a genetically defective protein,B,high plasma level of unconjugated bilirubin concentration,HP:0008282,,"https://www.ncbi.nlm.nih.gov/pubmed/17957158,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
764,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,"Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.",AT342,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,Study was suspended based on Sponsor Decision.,HP:0002904,,"https://clinicaltrials.gov/ct2/show/NCT03223194,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
765,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,GNT0003,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,,Study is still recruiting,,,"https://clinicaltrials.gov/ct2/show/NCT03466463,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
766,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,Ad5/CMV/hUG-Br1,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Hyperbilirubinemia,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/9525311/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
767,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,Chimeric oligonucleotide(oligonucleotide-based gene therapy),NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,UDP-glucuronosyltransferase gene defect,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/10468611/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
768,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,Retrovirus,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/9457971/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
769,218800,,Number Sign,218800,"CRIGLER-NAJJAR SYNDROME, TYPE I","HYPERBILIRUBINEMIA, CRIGLER-NAJJAR TYPE I; HBLRCN1;; CRIGLER-NAJJAR SYNDROME",,"Crigler Najjar syndrome, type 1",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,Ad-hBUGT1,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,Hyperbilirubinemia,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/8900123/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,661,P22309,K00699,2.4.1.17,
770,608158,608158,Percent,608158,CoQ-RESPONSIVE OXPHOS DEFICIENCY,,,CoQ-responsive OXPHOS deficiency,,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",sodium benzoate,DB03793,DB03793,6fac18cc5e193e26705b1cafd1139dbfac2e66ab9c2727b72d3a14280ac4dfd7,DB03793,DB03793,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/12948744,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,,P22309,K00699,2.4.1.17,
771,608158,608158,Percent,608158,CoQ-RESPONSIVE OXPHOS DEFICIENCY,,,CoQ-responsive OXPHOS deficiency,,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",sodium phenylacetate,DB09269,DB09269,b4d195b67707744e24c0b704d907ac0beea0eca42d2d3f7f6360e3b5f86d036d,DB09269,DB09269,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/12948744,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,,P22309,K00699,2.4.1.17,
772,608158,608158,Percent,608158,CoQ-RESPONSIVE OXPHOS DEFICIENCY,,,CoQ-responsive OXPHOS deficiency,,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",CoQ,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Abnormal liver function,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/12948744,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,,P22309,K00699,2.4.1.17,
773,121270,121270,NULL,121270,"COPPER DEFICIENCY, FAMILIAL BENIGN",,,"Copper deficiency, familial benign",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",copper,DB09130,DB09130,5507c2652d23e5ac96b92e36d181679beb34dd7987e8c695ab1a85505fe86fa4,DB09130,DB09130,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,hypocupraemia,HP:0010836,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,,P22309,K00699,2.4.1.17,
774,121270,121270,NULL,121270,"COPPER DEFICIENCY, FAMILIAL BENIGN",,,"Copper deficiency, familial benign",,UGT1A1,UGT1A1,uridine diphosphateâglucuronyl transferase,db3c9e15e2771728af571d00eec31280c342c25547cdb048f513ccc516b2d5c8,O60931,,O60931,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",copper,DB09130,DB09130,5507c2652d23e5ac96b92e36d181679beb34dd7987e8c695ab1a85505fe86fa4,DB09130,DB09130,,,,,,,,,,,,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",54658,UGT1A1,,P22309,K00699,2.4.1.17,
775,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROS,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",bortezomib,DB00188,DB00188,a6a2133e216ab026d57f139fdb094f539926e74a46fd747087dc4a70e1f3b1a4,DB00188,DB00188,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,activity modification of a genetically defective protein,B,high porphyrin accumulation in circulating RBCs,HP:0012187,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/,https://www.ncbi.nlm.nih.gov/pubmed/24145442,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",7390,UROS,111,P10746,K01719,4.2.1.75,
776,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROS,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",bortezomib,DB00188,DB00188,a6a2133e216ab026d57f139fdb094f539926e74a46fd747087dc4a70e1f3b1a4,DB00188,DB00188,,,,,,,,,,,,,skin photosensitivity,HP:0000992,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/,https://www.ncbi.nlm.nih.gov/pubmed/24145442,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",7390,UROS,111,P10746,K01719,4.2.1.75,
777,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROS,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",bortezomib,DB00188,DB00188,a6a2133e216ab026d57f139fdb094f539926e74a46fd747087dc4a70e1f3b1a4,DB00188,DB00188,,,,,,,,,,,,,premature degradation of misfolded UROS mutants,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/28334762,https://www.ncbi.nlm.nih.gov/pubmed/24145442,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",7390,UROS,111,P10746,K01719,4.2.1.75,
778,263700,,Number Sign,263700,"PORPHYRIA, CONGENITAL ERYTHROPOIETIC; CEP",GUNTHER DISEASE;; UROPORPHYRINOGEN III SYNTHASE DEFICIENCY;; UROS DEFICIENCY,,Congenital erythropoietic porphyria,,UROS,UROS,uroporphyrinogen III synthase,302d7025ec275a50540559ef9553005227313264522ca82d8384e1f76d8dc4de,4.2.1.75,4.2.1.75,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",bortezomib,DB00188,DB00188,a6a2133e216ab026d57f139fdb094f539926e74a46fd747087dc4a70e1f3b1a4,DB00188,DB00188,,,,,,,,,,,,,abnormal porphyrin accumulation in urine,HP:0010473,,"https://www.ncbi.nlm.nih.gov/pubmed/28334762,https://www.ncbi.nlm.nih.gov/pubmed/24145442,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",7390,UROS,111,P10746,K01719,4.2.1.75,
779,610198,,Number Sign,610198,"3-METHYLGLUTACONIC ACIDURIA, TYPE V; MGCA5","CARDIOMYOPATHY, DILATED, WITH ATAXIA; DCMA;; MGA, TYPE V; MGA5",,"DCMA syndromeÂ (3-methylglutaconic aciduria, type V)",,DNAJC19,DNAJC19,DnaJ heat shock protein family (Hsp40) member C19,5d69fff92ceebbdfaa7868a0560025b09c62f8db0af410b4e7096aec3f5d6528,Q96DA6,,Q96DA6,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Angiotensin-converting enzyme (ACE) inhibitors+digoxin+furosemide,C09C+DB00390+DB00695,C09C + DB00390 + DB00695,90c0a3658738c46c75da5391ab80a802bdb6c8aa2d0dbeb83c445eefd868a16a,,,,,"C09C,DB00390,DB00695","DB00390,DB00695",,C09C,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Low ejection fraction,,,"https://www.ncbi.nlm.nih.gov/pubmed/27928778,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",131118,DNAJC19,1012,Q96DA6,K09539,"""""",
780,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Dextrothyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,Hepatomegaly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/280544,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5257,PHKB,1258,Q93100,K07190,"""""",
781,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Dextrothyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,Elevated hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/280544,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5257,PHKB,1258,Q93100,K07190,"""""",
782,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Dextrothyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/280544,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5257,PHKB,1258,Q93100,K07190,"""""",
783,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Dextrothyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,Mild asymptomatic hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/280544,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5257,PHKB,1258,Q93100,K07190,"""""",
784,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Complex Carbohydrates,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5257,PHKB,1258,Q93100,K07190,"""""",
785,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Complex Carbohydrates,NA,,,,,,,,,,,,,,,,,Short Stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5257,PHKB,1258,Q93100,K07190,"""""",
786,261750,261750,Number Sign,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,"GSD IXb;; GLYCOGENOSIS OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE;; PHOSPHORYLASE KINASE DEFICIENCY OF LIVER AND MUSCLE, AUTOSOMAL RECESSIVE",,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,PHKB,Phosphorylase b kinase regulatory subunit beta,7f51f50e1105a0548008d3fcba0d7f9b247dc6bb0379fe65d5d76bcb769f1263,Q93100,,Q93100,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Complex carbohydrates+Beneprotein+Low fats,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5257,PHKB,1258,Q93100,K07190,"""""",
787,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein+Low fats diet,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5256,PHKA2,492,P46019,K07190,"""""",
788,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5256,PHKA2,492,P46019,K07190,"""""",
789,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,,,,,,,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5256,PHKA2,492,P46019,K07190,"""""",
790,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5256,PHKA2,492,P46019,K07190,"""""",
791,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,,,,,,,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5256,PHKA2,492,P46019,K07190,"""""",
792,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein+CoCarbs(Complex carbohydrate),DB11599+NA+NA,DB11599 + NA + NA,264d5cf13c3538baad0ab6a3eec2426c75f9220a78fdf9231cfa721dac86dafc,,,,,"DB11599,NA,NA",DB11599,,"NA,NA",ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,"On this regimen, one patient had the enlevated liver enxymes stabilized while the other had mild improvement.","https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5256,PHKA2,492,P46019,K07190,"""""",
793,306000,,Number Sign,306000,GLYCOGEN STORAGE DISEASE IXa1; GSD9A1,"LIVER GLYCOGENOSIS, X-LINKED, TYPE I; XLG1;; GLYCOGEN STORAGE DISEASE VIII, FORMERLY;; GSD VIII, FORMERLY; GSD8, FORMERLY","GLYCOGEN STORAGE DISEASE IXa2, INCLUDED; GSD9A2, INCLUDED;; GSD IXa2, INCLUDED;; LIVER GLYCOGENOSIS, X-LINKED, TYPE II, INCLUDED; XLG2, INCLUDED",GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8Â ),,PHKA2,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",c3b1324e5b088a5d70bc6e883643389d741ee1ef18a06074a3659e5b13a3005a,P46019,,P46019,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",CoCarbs + HPro,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5256,PHKA2,492,P46019,K07190,"""""",
794,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated hepatic transaminases,HP:0002910,Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5261,PHKG2,1259,P15735,K00871,2.7.11.19,
795,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein,NA,,,,,,,,,,,,,,,,,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5261,PHKG2,1259,P15735,K00871,2.7.11.19,
796,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5261,PHKG2,1259,P15735,K00871,2.7.11.19,
797,613027,613027,Number Sign,613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,GSD IXc,,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",051d322750c392d2b675e76b2628f7605cc527c010b15ae2fbda6ef0a702045f,P15735,,P15735,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Uncooked cornstarch+ Beneprotein,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pubmed/12930917,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",5261,PHKG2,1259,P15735,K00871,2.7.11.19,
798,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver","GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Glycosade,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,dietary supplementation,B,Nocturnal Hypoglycemia(Hypoglycemia)*,HP:0001943*,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=Glycogen+Storage+Disease+Type+0&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",2998,GYS2,497,P54840,K00693,2.4.1.11,
799,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4â20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",Glycosade,NA,,,,,,,,,,,,,,,,,Poor sleep quality(Sleep disturbance)*,HP:0002360*,,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",2998,GYS2,497,P54840,K00693,2.4.1.11,
800,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,B,MorningHypoglycemia (Hypoglycemia)*,HP:0012051,,"https://www.ncbi.nlm.nih.gov/pubmed/12794686,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",2998,GYS2,497,P54840,K00693,2.4.1.11,
801,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,Ketosis,HP:0001946,,"https://www.ncbi.nlm.nih.gov/pubmed/12794686,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",2998,GYS2,497,P54840,K00693,2.4.1.11,
802,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12794686,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",2998,GYS2,497,P54840,K00693,2.4.1.11,
803,240600,,Number Sign,240600,"GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A",GSD 0a;; HYPOGLYCEMIA WITH DEFICIENCY OF GLYCOGEN SYNTHETASE IN THE LIVER;; LIVER GLYCOGEN SYNTHASE DEFICIENCY;; LIVER GLYCOGEN STORAGE DISEASE 0,,"Glycogen storage disease type 0, liver",,GYS2,GYS2,glycogen synthase 2,da858e1e4d1ad294486b7955dcfb2739119e3e58145e91f963b94b2a3877f577,2.4.1.11,2.4.1.11,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12794686,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,https://www.ncbi.nlm.nih.gov/pubmed/15726662,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",2998,GYS2,497,P54840,K00693,2.4.1.11,
804,611881,,Number Sign,611881,GLYCOGEN STORAGE DISEASE XII; GSD12,"GSD XII;; ALDOLASE A DEFICIENCY;; ALDOA DEFICIENCY;; ALDOLASE DEFICIENCY, RED CELL;; RED CELL ALDOLASE DEFICIENCY",,Glycogen storage disease type 12,,ALDOA,ALDOA,"aldolase, fructose-bisphosphate A",765e3f734fb51fe756a52b5fc92eb554299da15770d33cbf0de1d803bc460696,4.1.2.13,4.1.2.13,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,done,,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,226,ALDOA,500,P04075,K01623,4.1.2.13,
805,612932,,Number Sign,612932,GLYCOGEN STORAGE DISEASE XIII; GSD13,GSD XIII;; ENOLASE 3 DEFICIENCY;; ENOLASE-BETA DEFICIENCY,,Glycogen storage disease type 13,,ENO3,ENO3,enolase 3,b8821d4006d3d4ef72ac65052dd7252623400ecb5fc8291514ac714627f1a465,4.2.1.11,4.2.1.11,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,done,,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,2027,ENO3,501,P13929,K01689,4.2.1.11,
806,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",DTX401,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,"""The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level.""",done,,"https://clinicaltrials.gov/ct2/show/NCT03517085?cond=von+Gierke&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
807,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",FIV-hAAT-G6Pase,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Hypoglycemia,done,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
808,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Ad-mG6Pase,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Growth retardation,,,"https://www.ncbi.nlm.nih.gov/pubmed/10625614,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
809,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Ad-mG6Pase,NA,,,,,,,,,,,,,,,,,Hypoglycemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/10625614,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
810,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Ad-mG6Pase,NA,,,,,,,,,,,,,,,,,Hyperuricemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/10625614,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
811,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Ad-mG6Pase,NA,,,,,,,,,,,,,,,,,Hyperlipidemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/10625614,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
812,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Ad-mG6Pase,NA,,,,,,,,,,,,,,,,,Enlarged kidney,HP:0000105,,"https://www.ncbi.nlm.nih.gov/pubmed/10625614,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
813,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",Ad-mG6Pase,NA,,,,,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/10625614,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
814,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",AAV-cG6PGH,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Growth Failure,,,"https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/20163245",2538,G6PC,484,P35575,K01084,3.1.3.9,
815,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",AAV-cG6PGH,NA,,,,,,,,,,,,,,,,,Hyperlipidemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128",2538,G6PC,484,P35575,K01084,3.1.3.9,
816,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",AAV-cG6PGH,NA,,,,,,,,,,,,,,,,,Hypoglycemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128",2538,G6PC,484,P35575,K01084,3.1.3.9,
817,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",HDAd-G6Pase,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Hypoglycemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/17505475,https://www.ncbi.nlm.nih.gov/pubmed/17430128",2538,G6PC,484,P35575,K01084,3.1.3.9,
818,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Glycosade,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,dietary supplementation,B,Fasting hypoglycemia,HP:0003162,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
819,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Glycosade,NA,,,,,,,,,,,,,,,,,"Sleep disturbance,Poor sleep quality",HP:0002360,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
820,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Glycosade,NA,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
821,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",l-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0007764,ECO:0007764,,,symptomatic treatment procedure,C,mitochondrial dysfunction,HP:0003287,,"http://www.ncbi.nlm.nih.gov/pubmed/28317891?dopt=Abstract,https://www.nature.com/articles/srep44408,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
822,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Tempol,DB12449,DB12449,b6f511b8dda4a7374a265acd57094467915d8b79768f706f3fac644c5bf034a7,DB12449,DB12449,,,,,,,ECO:0005242,ECO:0005242,,,symptomatic treatment procedure,,Abnormal renal function,HP:0012211,,"https://www.ncbi.nlm.nih.gov/pubmed/20195241,https://www.nature.com/articles/srep44408,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
823,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Tempol,DB12449,DB12449,b6f511b8dda4a7374a265acd57094467915d8b79768f706f3fac644c5bf034a7,DB12449,DB12449,,,,,,,,,,,,,Renal disease progression( Progressive disorder)*,HP:0003676*,,"https://www.ncbi.nlm.nih.gov/pubmed/20195241,https://www.nature.com/articles/srep44408,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
824,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Tempol,DB12449,DB12449,b6f511b8dda4a7374a265acd57094467915d8b79768f706f3fac644c5bf034a7,DB12449,DB12449,,,,,,,,,,,,,Nephropathy,HP:0000112,,"https://www.ncbi.nlm.nih.gov/pubmed/20195241,https://www.nature.com/articles/srep44408,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
825,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",ACEâinhibitors,C09C,C09C,6a0d1e5e802ebca5d05eafd0cd73278083f54b5327d44c07713f56c8d198b9ae,C09C,,,C09C,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Glomerular hyperfilteration (Abnormal glomerular filtration rate),HP:0012212,,"https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
826,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Antioxidant + ACE inhibitors,DB12449+C09C,DB12449 + C09C,efbd842276f530133b1a9e0b5437448a7d861f01bd4344a83118634d4a160bfb,,,,,"DB12449,C09C",DB12449,,C09C,ECO:0007764,ECO:0007764,,,symptomatic treatment procedure,,Nephropathy,HP:0000112,,"https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
827,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Glucose,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
828,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Uncooked cornstarch,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,ECO:0000352,ECO:0000352,,,dietary supplementation,,Hypoglycemia,HP:0001943,,"https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
829,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",Allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,High plasma uric acid levels,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
830,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,Calcium+ vitamin D3,DB01373+DB00169,DB01373 + DB00169,6ce9cd0a5e5edd83421774b5d0464c1727779801a14fcec589dfa00a065b3f18,,,,,"DB01373,DB00169","DB01373,DB00169",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Osteoporosis,HP:0000939,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,"https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
831,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,medium chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hyperuricemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/20357432,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
832,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,medium chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/20357432,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
833,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,medium chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Growth failure,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/20357432,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
834,232200,,Number Sign,232200,GLYCOGEN STORAGE DISEASE Ia; GSD1A,GSD Ia;; GLYCOGEN STORAGE DISEASE I; GSD1;; VON GIERKE DISEASE;; HEPATORENAL FORM OF GLYCOGEN STORAGE DISEASE;; GLUCOSE-6-PHOSPHATASE DEFICIENCY;; HEPATORENAL GLYCOGENOSIS,,Glycogen storage disease type 1A,,G6PC,G6PC,Glucose 6-phophatase,31dd3a2251f68126ce03132c958b5ec5e5f856c30fb86c98d64aa3c8f7752be7,3.1.3.9,3.1.3.9,,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,medium chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20357432,https://www.semanticscholar.org/paper/Glycogen-storage-diseases%3A-Diagnosis%2C-treatment-and-Chen-Weinstein/439025d057229db1b3a117cb02b3c7e6f2bd3580,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2538,G6PC,484,P35575,K01084,3.1.3.9,
835,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382,Human granulocyte-colony-stimulating-factor,DB00099,DB00099,df8f4f7cffc198cc131ab66c85b0c27934125ec41a478c68ad5cf2e48ad87507,DB00099,DB00099,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Neutropenia,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956",2542,SLC37A4,485,O43826,K08171,"""""",
836,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382,Human granulocyte-colony-stimulating-factor,DB00099,DB00099,df8f4f7cffc198cc131ab66c85b0c27934125ec41a478c68ad5cf2e48ad87507,DB00099,DB00099,,,,,,,,,,,,,Recurrent bacterial infection,HP:0002718,,"https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.ncbi.nlm.nih.gov/pubmed/1719175,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956",2542,SLC37A4,485,O43826,K08171,"""""",
837,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382,Human granulocyte-colony-stimulating-factor,DB00099,DB00099,df8f4f7cffc198cc131ab66c85b0c27934125ec41a478c68ad5cf2e48ad87507,DB00099,DB00099,,,,,,,,,,,,,"""Frequent, severe infections""",HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.ncbi.nlm.nih.gov/pubmed/1719175,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956",2542,SLC37A4,485,O43826,K08171,"""""",
838,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",GâCSF + 5âaminosalicylic acid,DB00099+DB00244,DB00099 + DB00244,fbc15a36027247fdc87df3f319b1ce0c1ed359a9a52ca7d13fb7bc7356ab0c18,,,,,"DB00099,DB00244","DB00099,DB00244",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Neutropenia with IBD,HP:0001875+HP:0002037,,"https://www.ncbi.nlm.nih.gov/pubmed/12373585,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/19541498,https://www.ncbi.nlm.nih.gov/pubmed/19066956",2542,SLC37A4,485,O43826,K08171,"""""",
839,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",Adalimumab,DB00051,DB00051,d0469cb0448e5ccde0062db62c5408d9c353d0f5ae5f47d2d855c09470b45a6b,DB00051,DB00051,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,GSD-associated enterocolitis(enterocolitis),HP:0004387,,"https://www.ncbi.nlm.nih.gov/pubmed/18172743,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/19541498,https://www.ncbi.nlm.nih.gov/pubmed/19066956",2542,SLC37A4,485,O43826,K08171,"""""",
840,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",Glycosade,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,dietary supplementation,B,Fasting hypoglycemia,HP:0003162,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
841,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",Glycosade,NA,,,,,,,,,,,,,,,,,"Sleep disturbance,Poor sleep qaulity",HP:0002360,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
842,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",Glycosade,NA,,,,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
843,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",rAAV-GPE-G6PT,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,hyperlipidemia,HP:0003077,,"http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
844,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",rAAV-GPE-G6PT,NA,,,,,,,,,,,,,,,,,hypoglycemia,HP:0001943,,"http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
845,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",rAAV-GPE-G6PT,NA,,,,,,,,,,,,,,,,,hyperuricemia,HP:0002149,,"http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
846,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",rAAV-GPE-G6PT,NA,,,,,,,,,,,,,,,,,lactic acidemia,HP:0003128,,"http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
847,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",rAAV-GPE-G6PT,NA,,,,,,,,,,,,,,,,,age-related insulin resistance(Insulin resistance)*,HP:0000855*,,"http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
848,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",rAAV-GPE-G6PT,NA,,,,,,,,,,,,,,,,,obesity,HP:0001513,,"http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
849,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.",galactose+Uridine,DB11735+DB02745,DB11735 + DB02745,5f525431b12ec66e372ad1e76a90015d7b1bbf5e6e800c87d3557e2396b087a3,,,,,"DB11735,DB02745","DB11735,DB02745",,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Partial correction of neutrophil dysfunction,HP:0011990,"In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract","http://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
850,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.",vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,neutropenia,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/19066956,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
851,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.",vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,"""Frequent, severe infections""",HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/19066956,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
852,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",testosterone,DB00624,DB00624,3793204739c40d15db77aca642ada0e03f6080957e1778a784fca03f3f024e72,DB00624,DB00624,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,decreased male libido,HP:0040306,,"https://www.ncbi.nlm.nih.gov/pubmed/28160246,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
853,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",testosterone,DB00624,DB00624,3793204739c40d15db77aca642ada0e03f6080957e1778a784fca03f3f024e72,DB00624,DB00624,,,,,,,,,,,,,low physical activity,HP:0025142,,"https://www.ncbi.nlm.nih.gov/pubmed/28160246,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
854,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",testosterone,DB00624,DB00624,3793204739c40d15db77aca642ada0e03f6080957e1778a784fca03f3f024e72,DB00624,DB00624,,,,,,,,,,,,,decrease muscle strenght,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/28160246,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
855,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",medium chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,B,Hyperurecemia,done,,"https://www.ncbi.nlm.nih.gov/pubmed/20357432,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
856,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",medium chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Hypertriglyceridemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/20357432,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
857,232220,,Number Sign,232220,GLYCOGEN STORAGE DISEASE Ib; GSD1B,GSD Ib;; GLUCOSE-6-PHOSPHATE TRANSPORT DEFECT,,Glycogen storage disease type 1b,,SLC37A4,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),f88e1c4a50cafc52efc73f9bb96a929f1e1d7d66792edb88283351804957baa4,O43826,,O43826,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",medium chain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Growth failure,,,"https://www.ncbi.nlm.nih.gov/pubmed/20357432,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432",2542,SLC37A4,485,O43826,K08171,"""""",
858,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,C,linear growth velocity(Abnormality of body height)*,HP:0000002*,,"https://www.nature.com/articles/gim201069,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
859,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,hypoglycemic seizures,HP:0002173,,"https://www.nature.com/articles/gim201069,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
860,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,Enlarged size of the liver,HP:0002240,,"https://www.nature.com/articles/gim201069,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
861,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",calcium and vitamin D,DB01373 + DB11094,DB01373 + DB11094,7885d7e836e075132866496ac09834e338f19bebfe3771d77d34ec43420f0f84,,,,,"DB01373,DB11094","DB01373,DB11094",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Osteoporosis,HP:0000939,,"https://www.nature.com/articles/gim201069,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
862,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Glycosade,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,dietary supplementation,B,Fasting hypoglycemia,HP:0003162,,"https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
863,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type 3,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Glycosade,NA,,,,,,,,,,,,,,,,,Sleep disturbance,HP:0002360,,"https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
864,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Rapamycin,DB00877,DB00877,ea9e13320cce70f27ecdbf6e3632fdfe9e3bab5823bcc20abce8efd05a6a6961,DB00877,DB00877,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a defective protein by inhibition,B,high glycogen levels in muscles,HP:0009051,,"https://www.ncbi.nlm.nih.gov/pubmed/24509886,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
865,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Rapamycin,DB00877,DB00877,ea9e13320cce70f27ecdbf6e3632fdfe9e3bab5823bcc20abce8efd05a6a6961,DB00877,DB00877,,,,,,,,,,,,,liver fibrosis progression,HP:0001395,,"https://www.ncbi.nlm.nih.gov/pubmed/24509886,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
866,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",fructose,DB04173,DB04173,0f3d4d64e17c3caea0a67312f04920172569a615afacf6f1c21a6f4b824eb673,DB04173,DB04173,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,exercise intolerance,HP:0003546,,"https://www.ncbi.nlm.nih.gov/pubmed/25832663,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
867,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",high protein diet,NA,,,,,,,,,,,,,,,dietary regime modification,C,delayed growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
868,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",high protein diet,NA,,,,,,,,,,,,,,,,,myopathy,HP:0003198,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
869,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",high protein diet,NA,,,,,,,,,,,,,,,,,cardiomyopathy,HP:0001638,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
870,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary regime modification,C,abnormal blood levels of ketone bodies,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
871,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,,,,,,,Abnormal blood levels of  fatty acids,HP:0004359,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
872,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,,,,,,,high creatine kinase,HP:0003236,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
873,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,,,,,,,cardiomyopathy,HP:0001638,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
874,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,,,,,,,low energetic state of heart(Abnormality of cardiovascular system physiology)*,HP:0011025*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
875,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,,,,,,,low energetic state of skeletal muscle,HP:0011804,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
876,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,,,,,,,Increased creatine kinase activity,HP:0003236,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
877,232400,,Number Sign,232400,GLYCOGEN STORAGE DISEASE III; GSD3,"FORBES DISEASE;; CORI DISEASE;; LIMIT DEXTRINOSIS;; AMYLO-1,6-GLUCOSIDASE DEFICIENCY;; AGL DEFICIENCY;; GLYCOGEN DEBRANCHER DEFICIENCY;; GDE DEFICIENCY","GLYCOGEN STORAGE DISEASE IIIa, INCLUDED; GSD IIIa, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIb, INCLUDED; GSD IIIb, INCLUDED;; GLYCOGEN STORAGE DISEASE IIIc, INCLUDED; GSD IIIc, INCLUDED;; GLYCOGEN STORAGE DISEASE IIId, INCLUDED; GSD IIId, INCLUDED",Glycogen storage disease type IIIa,,AGL,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",7c676971a4606a69d45d6c5322d2c8e9f591adabadc21e7081cbce0b6164bd20,3.2.1.33,"2.4.1.25,3.2.1.33",,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Modified Atkins diet,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,https://www.ncbi.nlm.nih.gov/pubmed/17514432,https://www.ncbi.nlm.nih.gov/pubmed/24613482",178,AGL,487,P35573,K01196,2.4.1.25; 3.2.1.33,
878,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Sodium Valproate,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0007121/ECO:0001565,"ECO:0007121,ECO:0001565",,,functional complementation of a defective protein by stimulation,B,Difficulty walking,HP:0002355,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://clinicaltrials.gov/ct2/show/NCT03112889?cond=McArdle+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25762569",5837,PYGM,489,P11217,K00688,2.4.1.1,
879,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,abnormal fat metabolism,HP:0004359,,"https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25762569",5837,PYGM,489,P11217,K00688,2.4.1.1,
880,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,abnormal carbohydrate metabolism*,HP:0011013,,"https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25762569",5837,PYGM,489,P11217,K00688,2.4.1.1,
881,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",creatine,DB00148,DB00148,ca6ae4a8ad76e426ecc26363a6d502ab7a26604d4642cf9e63dd1aa11d40af8d,DB00148,DB00148,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,exercise intolerance,HP:0003546,,"https://www.ncbi.nlm.nih.gov/pubmed/25391139,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf",5837,PYGM,489,P11217,K00688,2.4.1.1,
882,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",sucrose,DB02772,DB02772,315878de726debaf51db4155574061556fa558a7791b78bbca31f9a90bfde016,DB02772,DB02772,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,exercise intolerance,HP:0003547,,"http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25391139,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5837,PYGM,489,P11217,K00688,2.4.1.1,
883,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",vitamin B6,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,insufficient anaerobic glycolysis of skeletal muscle,,,"https://www.ncbi.nlm.nih.gov/pubmed/22334182,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5837,PYGM,489,P11217,K00688,2.4.1.1,
884,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",vitamin B6,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,exercise intolerance,HP:0003546,,"https://www.ncbi.nlm.nih.gov/pubmed/22334182,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5837,PYGM,489,P11217,K00688,2.4.1.1,
885,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",vitamin B6,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,abnormal muscle phosphorylase activity,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22334182,https://www.ncbi.nlm.nih.gov/pubmed/17490880,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5837,PYGM,489,P11217,K00688,2.4.1.1,
886,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",ramipril,DB00178,DB00178,619aea6ef0e92c91d7d8591df28d34f3d7e8c3131e655d93aad7947ddf784744,DB00178,DB00178,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,disability(Functional motor problems)*,HP:0004302*,,"https://www.ncbi.nlm.nih.gov/pubmed/18098237,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5837,PYGM,489,P11217,K00688,2.4.1.1,
887,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",ramipril,DB00178,DB00178,619aea6ef0e92c91d7d8591df28d34f3d7e8c3131e655d93aad7947ddf784744,DB00178,DB00178,,,,,,,,,,,,,Abnormal exercise physiology,HP:0009020,,"https://www.ncbi.nlm.nih.gov/pubmed/18098237,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5837,PYGM,489,P11217,K00688,2.4.1.1,
888,232600,,Number Sign,232600,GLYCOGEN STORAGE DISEASE V; GSD5,GSD V;; MCARDLE DISEASE;; MYOPHOSPHORYLASE DEFICIENCY;; MUSCLE GLYCOGEN PHOSPHORYLASE DEFICIENCY;; PYGM DEFICIENCY,,Glycogen storage disease type 5,,PYGM,PYGM,"Glycogen phosphorylase, Muscle form",fc154e359d1905d51887d3cda840757e72ede52100f34313a22d65c11368326a,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",GENTAMICIN,DB04729,DB04729,d2bb23a9527e496109b0e1ea6cc9907f90b9339c059a5bd86c4a54d7ecc50c98,DB04729,DB04729,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,C,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5837,PYGM,489,P11217,K00688,2.4.1.1,
889,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch(Uncooked),DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,B,short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
890,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch(Uncooked),DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,Abnormal blood glucose concentration,HP:0011015,,"https://www.ncbi.nlm.nih.gov/pubmed/20301760,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
891,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch(Uncooked),DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,Low energy level(Tiredness)*,HP:0012378,,"https://www.ncbi.nlm.nih.gov/pubmed/20301760,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
892,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch(Uncooked),DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
893,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Cornstarch(Uncooked),DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,,,,,,,Elevated Hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
894,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Beneprotein,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,B,short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
895,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",Uncooked cornstarch+Beneprotein,DB11599+NA,DB11599 + NA,631142a30f225107ae5137a014892fafa6af4799a70625d1b3fb66acf3dcd481,,,,,"DB11599,NA",DB11599,,NA,ECO:0000352,ECO:0000352,,,dietary supplementation,,Elevated Hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
896,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",D-Thyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Hepatomeglay,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
897,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",D-Thyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,Elevated Hepatic transaminases,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
898,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",D-Thyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
899,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",D-Thyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,Increased erythrocyte glycogen content,HP:0001939,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
900,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",D-Thyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
901,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",D-Thyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
902,232700,,Number Sign,232700,GLYCOGEN STORAGE DISEASE VI; GSD6,GSD VI;; HERS DISEASE;; PHOSPHORYLASE DEFICIENCY GLYCOGEN-STORAGE DISEASE OF LIVER,,Glycogen storage disease type 6,,PYGL,PYGL,"Glycogen phosphorylase, liver form",38b82e568369d4c373efac568ce8d3a4f334c131de29e08359e49f8eba6b1e26,2.4.1.1,2.4.1.1,,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2â3 months after therapy is initiated.",D-Thyroxine,DB00509,DB00509,d61437040e732f364be8d2e0c27036b2ad3dfb979519cab18f723f757203bd84,DB00509,DB00509,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5836,PYGL,490,P06737,K00688,2.4.1.1,
903,232800,,Number Sign,232800,GLYCOGEN STORAGE DISEASE VII; GSD7,GSD VII;; MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY;; PFKM DEFICIENCY;; TARUI DISEASE,,Glycogen storage disease type 7,"The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272",PFKM,PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",09f803234edd9c4360e283983e38b2ef63ee950038d3eeac6b4833679a83e11b,2.7.1.11,2.7.1.11,,"A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,Trial is still in the Recruiting stage.,,,"https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5213,PFKM,491,P08237,K00850,2.7.1.11,
904,232800,,Number Sign,232800,GLYCOGEN STORAGE DISEASE VII; GSD7,GSD VII;; MUSCLE PHOSPHOFRUCTOKINASE DEFICIENCY;; PFKM DEFICIENCY;; TARUI DISEASE,,Glycogen storage disease type 7,,PFKM,PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",09f803234edd9c4360e283983e38b2ef63ee950038d3eeac6b4833679a83e11b,2.7.1.11,2.7.1.11,,"A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1",Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1,https://www.nature.com/articles/pr19842087,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5213,PFKM,491,P08237,K00850,2.7.1.11,
905,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,"Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.",GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Nicotinamide,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,B,Liver steatosis,HP:0001397,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",27232,GNMT,25,Q14749,K00552,2.1.1.20,
906,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,,GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Nicotinamide,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,,,,,,,Fatty liver,HP:0001397,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",27232,GNMT,25,Q14749,K00552,2.1.1.20,
907,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,,GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Nicotinamide,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,,,,,,,Liver fibrosis,HP:0001395,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",27232,GNMT,25,Q14749,K00552,2.1.1.20,
908,606664,606664,Number Sign,606664,GLYCINE N-METHYLTRANSFERASE DEFICIENCY,GNMT DEFICIENCY,,Glycine N-methyltransferase deficiency,,GNMT,GNMT,glycine N-methyltransferase,25830e0355611228c9e7bcdfd5af88223047cf83cd640cc67545b183d09f7673,2.1.1.20,2.1.1.20,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Nicotinamide,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,,,,,,,DNA hypermethylation,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",27232,GNMT,25,Q14749,K00552,2.1.1.20,
909,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,OTZÂ (L-2-oxothiazoline-4-carboxylic acid,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,metabolite replacement,B,low intracellular cysteine*,HP:0010918,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2678,GGT1,214,P19440,K18592,3.4.19.13; 2.3.2.2; 3.4.19.14,
910,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,OTZÂ (L-2-oxothiazoline-4-carboxylic acid,NA,,,,,,,,,,,,,,,,,behavioral abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2678,GGT1,214,P19440,K18592,3.4.19.13; 2.3.2.2; 3.4.19.14,
911,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,OTZÂ (L-2-oxothiazoline-4-carboxylic acid,NA,,,,,,,,,,,,,,,,,GSH deficiency,HP:0003343,,"https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2678,GGT1,214,P19440,K18592,3.4.19.13; 2.3.2.2; 3.4.19.14,
912,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0005542,ECO:0005542,,,metabolite replacement,B,Delayed growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/20868666,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2678,GGT1,214,P19440,K18592,3.4.19.13; 2.3.2.2; 3.4.19.14,
913,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,Cataract,HP:0000518,,"https://www.ncbi.nlm.nih.gov/pubmed/11095909,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/20868666,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2678,GGT1,214,P19440,K18592,3.4.19.13; 2.3.2.2; 3.4.19.14,
914,231950,231950,Number Sign,231950,GLUTATHIONURIA,GAMMA-GLUTAMYLTRANSPEPTIDASE DEFICIENCY;; GGT DEFICIENCY;; GTG DEFICIENCY;; GAMMA-GLUTAMYLTRANSFERASE DEFICIENCY,,Glutathionuria,,GGT1,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,de1899d82d8b02887a2b085979ee0a23f0dc5c733d4c263154b6846773bbdd97,2.3.2.2,"3.4.19.13,2.3.2.2",,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,low reproductive capacity (infertility),HP:0000144,,"https://www.ncbi.nlm.nih.gov/pubmed/11089562,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/20868666,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2678,GGT1,214,P19440,K18592,3.4.19.13; 2.3.2.2; 3.4.19.14,
915,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,ascorbic acid,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/8301428/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
916,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Ascorbate + N-acetylcysteine,DB00126+DB06151,DB00126 + DB06151,91c2381c97f0b05c7f238d2769f7c96c9ac8c3d0f9b258ead7f86a09688a9e23,,,,,"DB00126,DB06151","DB00126,DB06151",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,High erythrocyte turnover(Abnormality of erythrocytes)*,HP:0001877*,,"https://www.ncbi.nlm.nih.gov/pubmed/8301428/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
917,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Polycitra (citric acid +potassium citrate + sodium citrate)+vitamin C+vitamin E+selenium,DB11135,DB11135,22f5abc3eb662b8283f23aa7fa4f08c4926ae913337d99d99f4d250de779d6fa,DB11135,DB11135,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,C,oxidative stress,HP:0025464,,"http://www.ncbi.nlm.nih.gov/pubmed/26984560?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
918,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,alpha-tocopherol,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,abnormal microtubule assembly,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
919,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,alpha-tocopherol,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Short erythrocyte survival (Abnormality of erythrocytes)*,HP:0001877*,,"https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
920,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,alpha-tocopherol,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,abnormal polymorphonuclear leukocyte function,HP:0001874,,"https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
921,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,alpha-tocopherol,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Neutropenia,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
922,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,alpha-tocopherol,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Susceptibility to Bacterial infection,HP:0002718,,"https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
923,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,alpha-tocopherol,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,retinal dystrophy,HP:0000556,,"https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
924,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,alpha-tocopherol,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,CNS damage progression,HP:0007367,,"https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
925,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin E+vitamin B1+ cobalamin,DB00583+DB00163+DB00152+DB14098+DB01390,DB00583 + DB00163 + DB00152 + DB14098 + DB01390,b1d3dacceb6ae2c16a9d8eb6e987d5ba702ea95658a905f29847e3ed88694343,,,,,"DB00583,DB00163,DB00152,DB14098,DB01390","DB00583,DB00163,DB00152,DB14098,DB01390",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hypersomnia,HP:0100786,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
926,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin E+vitamin B1+ cobalamin,DB00583+DB00163+DB00152+DB14098+DB01390,DB00583 + DB00163 + DB00152 + DB14098 + DB01390,b1d3dacceb6ae2c16a9d8eb6e987d5ba702ea95658a905f29847e3ed88694343,,,,,"DB00583,DB00163,DB00152,DB14098,DB01390","DB00583,DB00163,DB00152,DB14098,DB01390",,,,,,,,,Jaundice,HP:0000952,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
927,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin E+vitamin B1+ cobalamin,DB00583+DB00163+DB00152+DB14098+DB01390,DB00583 + DB00163 + DB00152 + DB14098 + DB01390,b1d3dacceb6ae2c16a9d8eb6e987d5ba702ea95658a905f29847e3ed88694343,,,,,"DB00583,DB00163,DB00152,DB14098,DB01390","DB00583,DB00163,DB00152,DB14098,DB01390",,,,,,,,,Carnitine deficiency,HP:0003234,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
928,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin E+vitamin B1+ cobalamin,DB00583+DB00163+DB00152+DB14098+DB01390,DB00583 + DB00163 + DB00152 + DB14098 + DB01390,b1d3dacceb6ae2c16a9d8eb6e987d5ba702ea95658a905f29847e3ed88694343,,,,,"DB00583,DB00163,DB00152,DB14098,DB01390","DB00583,DB00163,DB00152,DB14098,DB01390",,,,,,,,,Hypotonia,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
929,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin B1+B2+ B12+ C+E + sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,DB00583 + DB00163 + DB00152 + DB00140 + DB01390 + DB00126 + DB00115,d45ec54952c5d410109fb89d77997c093924fd1033baf758b19082f4d37fa234,,,,,"DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115","DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
930,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin B1+B2+ B12+ C+E + sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,DB00583 + DB00163 + DB00152 + DB00140 + DB01390 + DB00126 + DB00115,d45ec54952c5d410109fb89d77997c093924fd1033baf758b19082f4d37fa234,,,,,"DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115","DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115",,,,,,,,,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
931,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin B1+B2+ B12+ C+E + sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,DB00583 + DB00163 + DB00152 + DB00140 + DB01390 + DB00126 + DB00115,d45ec54952c5d410109fb89d77997c093924fd1033baf758b19082f4d37fa234,,,,,"DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115","DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115",,,,,,,,,Elevated urine 5-oxoproline,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
932,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+vitamin B1+B2+ B12+ C+E + sodium bicarbonate,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,DB00583 + DB00163 + DB00152 + DB00140 + DB01390 + DB00126 + DB00115,d45ec54952c5d410109fb89d77997c093924fd1033baf758b19082f4d37fa234,,,,,"DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115","DB00583,DB00163,DB00152,DB00140,DB01390,DB00126,DB00115",,,,,,,,,Decreased blood free carnitine,HP:0008315,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
933,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+ vitamin B1+B12+C + E,DB00583+DB00152+DB00115+DB00126+DB00163,DB00583 + DB00152 + DB00115 + DB00126 + DB00163,7af2822648ad36b2c767c0d15c33dbbcba7fb1ca2e5489bb0ffe1cafc4a3ff71,,,,,"DB00583,DB00152,DB00115,DB00126,DB00163","DB00583,DB00152,DB00115,DB00126,DB00163",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Elevated urine 5-oxoproline,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
934,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,L-carnitine+ vitamin B1+B12+C + E,DB00583+DB00152+DB00115+DB00126+DB00163,DB00583 + DB00152 + DB00115 + DB00126 + DB00163,7af2822648ad36b2c767c0d15c33dbbcba7fb1ca2e5489bb0ffe1cafc4a3ff71,,,,,"DB00583,DB00152,DB00115,DB00126,DB00163","DB00583,DB00152,DB00115,DB00126,DB00163",,,,,,,,,Decreased blood free carnitine,HP:0008315,,"https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7375069,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
935,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,Sodium Bicarbonate,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/26669244/,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
936,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,high-anion gap acidosis,HP:0001941*,,"http://www.ncbi.nlm.nih.gov/pubmed/26669244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26669244/,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
937,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,dorzolamide+acetazolamide,DB00869+DB00819,DB00869 + DB00819,14e2a66435960bede166016ae6e1ce9f44d2690cef9ea823f277327bd00e8ebd,,,,,"DB00869,DB00819","DB00869,DB00819",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,cystoid macular edema,HP:0011505,,"https://www.ncbi.nlm.nih.gov/pubmed/29395598?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26669244/,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
938,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GSS,GSS,glutathione synthetase,324fbad42f6ad0a336413cd8beb3b48d644600f0ad740a65261afa72a54010fd,6.3.2.3,6.3.2.3,,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,erythropoietin + iron+folic acid + vitamin B12,DB00016+DB01592+DB00158+DB00165,DB00016 + DB01592 + DB00158 + DB00165,ad6578000018db642a0813987755950ddab640bc3d430dc13ba5dbdc4a801fd9,,,,,"DB00016,DB01592,DB00158,DB00165","DB00016,DB01592,DB00158,DB00165",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,anaemia,HP:0001903,,"http://www.ncbi.nlm.nih.gov/pubmed/16435214?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16435214,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2937,GSS,512,P48637,K21456,6.3.2.3,
939,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,"It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622",GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",CarnitineÂ +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,DB00583+DB00130+DB09393,DB00583 + DB00130 + DB09393,5e34832864f55a7696367285109a61f410973bc9bcb2dbcef9ae5e007ffa15f5,,,,,"DB00583,DB00130,DB09393","DB00583,DB00130,DB09393",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+dietary supplementation,C,Brain damage,HP:0001298,Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622,"https://www.ncbi.nlm.nih.gov/pubmed/23326493,https://www.ncbi.nlm.nih.gov/pubmed/16435214,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
940,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",CarnitineÂ +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,DB00583+DB00130+DB09393,DB00583 + DB00130 + DB09393,5e34832864f55a7696367285109a61f410973bc9bcb2dbcef9ae5e007ffa15f5,,,,,"DB00583,DB00130,DB09393","DB00583,DB00130,DB09393",,,,,,,,,Cerebral palsy,HP:0100021,"Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918","https://www.ncbi.nlm.nih.gov/pubmed/10630918,https://www.ncbi.nlm.nih.gov/pubmed/16435214,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
941,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",CarnitineÂ +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,DB00583+DB00130+DB09393,DB00583 + DB00130 + DB09393,5e34832864f55a7696367285109a61f410973bc9bcb2dbcef9ae5e007ffa15f5,,,,,"DB00583,DB00130,DB09393","DB00583,DB00130,DB09393",,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234*,,"https://www.ncbi.nlm.nih.gov/pubmed/10630918,https://www.ncbi.nlm.nih.gov/pubmed/16435214,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
942,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",Carnitine+ Riboflavin+baclofen,DB00583+DB00130+DB00181,DB00583 + DB00130 + DB00181,8a6405f06d478a0cea25afe7f348f802b7e36fc3daaea682cc4eb559884563c7,,,,,"DB00583,DB00130,DB00181","DB00583,DB00130,DB00181",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,C,Disease progression,HP:0003676,,"https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/19019309,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
943,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",Carnitine+ Riboflavin+baclofen,DB00583+DB00130+DB00181,DB00583 + DB00130 + DB00181,8a6405f06d478a0cea25afe7f348f802b7e36fc3daaea682cc4eb559884563c7,,,,,"DB00583,DB00130,DB00181","DB00583,DB00130,DB00181",,,,,,,,C,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234*,,"https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
944,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",Carnitine+ Riboflavin+baclofen,DB00583+DB00130+DB00181,DB00583 + DB00130 + DB00181,8a6405f06d478a0cea25afe7f348f802b7e36fc3daaea682cc4eb559884563c7,,,,,"DB00583,DB00130,DB00181","DB00583,DB00130,DB00181",,,,,,,,,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
945,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",Carnitine+Thioridazine Hcl+Chloral hydrate+Baclofen,DB00583+DB00679+DB01563+DB00181,DB00583 + DB00679 + DB01563 + DB00181,4947ffaad4434bb054eaf943aa57514279f0f12f0b88eae9dfb97f4c70f4de2d,,,,,"DB00583,DB00679,DB01563,DB00181","DB00583,DB00679,DB01563,DB00181",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+symptomatic treatment procedure+symptomatic treatment procedure+functional complementation of a genetically defective protein,,Dystonia,HP:0001332,The phenotype has been reported in association to treatment with baclofen as,"https://www.ncbi.nlm.nih.gov/pubmed/8881997,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
946,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",chlorpromazine,DB00477,DB00477,d1a2c04a61c91aef138ad149b3c95e590cd1e66b7a2acc6f7a94893e6f27bf37,DB00477,DB00477,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hyperpyrexia in case of acute encephalopathic crises(Fever)*,HP:0001945*,,"https://www.ncbi.nlm.nih.gov/pubmed/10222465,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
947,231670,,Number Sign,231670,GLUTARIC ACIDEMIA I; GA1,GLUTARIC ACIDURIA I;; GA I;; GLUTARYL-CoA DEHYDROGENASE DEFICIENCY,,Glutaric acidemia type I,,GCDH,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",51c088393046ffb51324c960adadd168686e01dbfaa10290e89dd2ecc733c58a,1.3.8.6,1.3.8.6,,The combination was accompanied by Low L-lysine diet,Carnitine+Riboflavin+L-Arginine+clofibrate,DB00583+DB00130+DB00125+DB00636,DB00583 + DB00130 + DB00125 + DB00636,6e753d9c6e6ec14adce3ed1cefc7b2c92268534825d6744ff2da524b8af76f73,,,,,"DB00583,DB00130,DB00125,DB00636","DB00583,DB00130,DB00125,DB00636",,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein+symptomatic treatment procedure,B,Glutaric acidemia,HP:0003530,Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787,"https://www.ncbi.nlm.nih.gov/pubmed/20923787,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17397529,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2639,GCDH,163,Q92947,K00252,1.3.8.6,
948,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Carnitine+ riboflavin,DB00583+DB00140,DB00583 + DB00140,650f11b7e6f4777f00adca00b7917adc93c6bc3fa59a316e4ef42c82577b9fdc,,,,,"DB00583,DB00140","DB00583,DB00140",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+activity modification of a genetically defective protein,B,High serum creatine kinase,HP:0003236,,"https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
949,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Carnitine+ riboflavin,DB00583+DB00140,DB00583 + DB00140,650f11b7e6f4777f00adca00b7917adc93c6bc3fa59a316e4ef42c82577b9fdc,,,,,"DB00583,DB00140","DB00583,DB00140",,,,,,,,,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
950,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Carnitine+ riboflavin,DB00583+DB00140,DB00583 + DB00140,650f11b7e6f4777f00adca00b7917adc93c6bc3fa59a316e4ef42c82577b9fdc,,,,,"DB00583,DB00140","DB00583,DB00140",,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234,,"https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
951,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Carnitine+ riboflavin+Coenzyme Q,DB00583+DB00140+DB09270,DB00583 + DB00140 + DB09270,11206d52bacc0dd8486f1255d886b9b83ba197524527d61fedff15baddf2c298,,,,,"DB00583,DB00140,DB09270","DB00583,DB00140,DB09270",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,A,Dysphagia,HP:0002015,,"https://www.ncbi.nlm.nih.gov/pubmed/26236614,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
952,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Carnitine+ riboflavin+Coenzyme Q,DB00583+DB00140+DB09270,DB00583 + DB00140 + DB09270,11206d52bacc0dd8486f1255d886b9b83ba197524527d61fedff15baddf2c298,,,,,"DB00583,DB00140,DB09270","DB00583,DB00140,DB09270",,,,,,,,,Difficulty walking,HP:0002355,,"https://www.ncbi.nlm.nih.gov/pubmed/26236614,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
953,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Carnitine+ riboflavin+Coenzyme Q,DB00583+DB00140+DB09270,DB00583 + DB00140 + DB09270,11206d52bacc0dd8486f1255d886b9b83ba197524527d61fedff15baddf2c298,,,,,"DB00583,DB00140,DB09270","DB00583,DB00140,DB09270",,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,HP:0003234,,"https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
954,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Glycine+Riboflavin+Carnitine,DB00145+DB00140+DB00583,DB00145 + DB00140 + DB00583,7cfddedaefee3e74fea3c0426b9903e35e4cec0da84039dee7b8c5e4b0246848,,,,,"DB00145,DB00140,DB00583","DB00145,DB00140,DB00583",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+activity modification of a genetically defective protein+functional complementation of a genetically defective protein,C,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/3229565,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
955,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,"sodium-d,l-3-hydroxybutyrate",CHEBI:113373,CHEBI:113373,f9013acf5797722338d82172bac7001402845cead1ecb2bb15b3f83682b5a7df,CHEBI:113373,,CHEBI_113373,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,progressive leukodystrophy,HP:0002415,,"https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
956,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,"sodium-d,l-3-hydroxybutyrate",CHEBI:113373,CHEBI:113373,f9013acf5797722338d82172bac7001402845cead1ecb2bb15b3f83682b5a7df,CHEBI:113373,,CHEBI_113373,,,,,,,,,,,,paralysis,HP:0003470,,"https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
957,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,"sodium-d,l-3-hydroxybutyrate",CHEBI:113373,CHEBI:113373,f9013acf5797722338d82172bac7001402845cead1ecb2bb15b3f83682b5a7df,CHEBI:113373,,CHEBI_113373,,,,,,,,,,,,cardiomyopathy,HP:0001638,,"https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
958,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,"sodium-d,l-3-hydroxybutyrate",CHEBI:113373,CHEBI:113373,f9013acf5797722338d82172bac7001402845cead1ecb2bb15b3f83682b5a7df,CHEBI:113373,,CHEBI_113373,,,,,,,,,,,,Impaired myocardial contractility,HP:0006670,,"https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
959,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/10581232,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
960,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/10581232,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
961,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/10581232,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
962,231680,,Number Sign,231680,MULTIPLE ACYL-CoA DEHYDROGENASE DEFICIENCY; MADD,GLUTARIC ACIDEMIA II; GA2;; GLUTARIC ACIDURIA II;; GA II;; ETHYLMALONIC-ADIPICACIDURIA; EMA,"GLUTARIC ACIDEMIA IIA, INCLUDED; GA2A, INCLUDED;; ETFA DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIB, INCLUDED; GA2B, INCLUDED;; ETFB DEFICIENCY, INCLUDED;; GLUTARIC ACIDEMIA IIC, INCLUDED; GA2C, INCLUDED;; ETFDH DEFICIENCY, INCLUDED",Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",720847620872901d20c20bc91e4ade99d3bae1c4bd0c4fe55c85a5d20c47ec6a,1.3.8.6,1.3.8.6,,Synergism inmproves results,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/10581232,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","2108,2109,2110","ETFA,ETFB,ETFDH",1257,"P13804,P38117,Q16134","K03522,K03521,K00311",",,1.5.5.1",
963,231690,,Number Sign,231690,GLUTARIC ACIDURIA III; GA3,GA III;; GLUTARYL-CoA OXIDASE DEFICIENCY,,Glutaric acidemia type III,,SUGCT,SUGCT,succinate-hydroxymethylglutarate coA-transferase,b512eaa65cbec4557828616db1d43cbeebf11345ee9adbb652f36253a132a201,2.8.3.13,2.8.3.13,,Synergism inmproves results,Metronidazole,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:00007121,ECO:00007121,,,functional complementation of a genetically defective protein,C,Cyclic vomiting (Vomiting)*,HP:0002013,,"https://www.ncbi.nlm.nih.gov/pubmed/28766179,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",79783,SUGCT,537,Q9HAC7,K18703,2.8.3.13,
964,231690,,Number Sign,231690,GLUTARIC ACIDURIA III; GA3,GA III;; GLUTARYL-CoA OXIDASE DEFICIENCY,,Glutaric acidemia type III,,SUGCT,SUGCT,succinate-hydroxymethylglutarate coA-transferase,b512eaa65cbec4557828616db1d43cbeebf11345ee9adbb652f36253a132a201,2.8.3.13,2.8.3.13,,Synergism inmproves results,Metronidazole,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,Bacterial glutric acid production,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/28766179,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16368216,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",79783,SUGCT,537,Q9HAC7,K18703,2.8.3.13,
965,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,l-glutamine,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,ECO:0007121,ECO:0007121,,,metabolite replacement,B,Abnormal plasma glutamine levels,HP:0010903,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
966,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,l-glutamine,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,,,,,,,Low CSF glutamine level,HP:0030980*,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
967,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,l-glutamine,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,,,,,,,unalertness,HP:0002329,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
968,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,l-glutamine,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,,,,,,,Lack of emotional expressions,HP:0030213,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
969,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,l-glutamine,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,,,,,,,Abnormal EEG results,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
970,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,l-glutamine,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,,,,,,,Low brain glutamine concentration,HP:0030980,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
971,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,l-glutamine,DB00130,DB00130,2816bbdb169c65882b8e3650a7bd4d7b8a6b30146cdc868c833ef962c0d925ff,DB00130,DB00130,,,,,,,,,,,,,Secondary NAD+ deficiencyÂ in leucocytes,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
972,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,Nicotinamide,DB02701,DB02701,c788f4d1c5ce4838af3f1e83179ee0bf3494d911aad35df79a2d306348ff54b3,DB02701,DB02701,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,C,Secondary NAD+ deficiencyÂ in leucocytes,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
973,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,Vitamin C+Vitamin E+Selenium,DB00126+DB00163+DB11135,DB00126 + DB00163 + DB11135,7c5d88b35836a9a65be63f99853ea84fe5a45616d6739eeadba451f33f236dba,,,,,"DB00126,DB00163,DB11135","DB00126,DB00163,DB11135",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/26984560,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
974,266130,,Number Sign,266130,GLUTATHIONE SYNTHETASE DEFICIENCY; GSSD,5-OXOPROLINURIA;; PYROGLUTAMIC ACIDURIA,,Glutathione synthetase deficiency,,GLUL,GLUL,Glutamine synthetase,f4f22c4f6f6f4bd4dbc95f90cf39cd4096c9c6fae600390e7f89f7c14bf58273,6.3.1.2,6.3.1.2,,Synergism inmproves results,Citric acid+Sodium citrate+ Potassium citrate,DB04272+DB09154+DB09125,DB04272 + DB09154 + DB09125,41095ef54b60c995fc2f63a5a59b39de296c8ce3897cf9624b98a5d42e7e612b,,,,,"DB04272,DB09154,DB09125","DB04272,DB09154,DB09125",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/26984560,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2752,GLUL,512,P15104,K01915,6.3.1.2; 2.3.1.225,
975,229100,229100,Number Sign,229100,GLUTAMATE FORMIMINOTRANSFERASE DEFICIENCY,FORMIMINOTRANSFERASE DEFICIENCY;; FORMIMINOGLUTAMIC ACIDURIA;; FIGLU-URIA,,Glutamate formiminotransferase deficiency,The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726,FTCD,FTCD,formiminotransferase cyclodeaminase,fa3eaef7b61a25a93d5ae56c2f7a94a76809cfbe6c062feb39afaaa767a93501,6.3.1.2,6.3.1.2,,Synergism inmproves results,pyridoxine +folic acid,DB00165+DB00158,DB00165 + DB00158,3c0930810a383d269d2952caae6c609ecf08a455e5358398a34518d835c35883,,,,,"DB00165,DB00158","DB00165,DB00158",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+metabolite replacement,B,Megaloblastic anemia,HP:0001889,,"https://www.ncbi.nlm.nih.gov/pubmed/5301410,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",10841,FTCD,47,O95954,K13990,2.1.2.5; 4.3.1.4,
976,606824,,Number Sign,606824,GLUCOSE/GALACTOSE MALABSORPTION; GGM,MONOSACCHARIDE MALABSORPTION; GM,,Glucose-galactose malabsorption,Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187,SLC5A1,SLC5A1,sodium/glucose cotransporter protein called SGLT1,1c2c7c79d7ca7ca5975f200df167478430149d67daee923b3d8f9d2f685e274e,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,Fructose +Carbohydrate free formula,DB04173+NA,DB04173 + NA,74297897bb7f7cd844d4f386aa86f32aa76aba5460ac3c06bf6c896a5989f538,,,,,"DB04173,NA",DB04173,,NA,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Watery Diarrhea,HP:0002014,,"https://www.ncbi.nlm.nih.gov/pubmed/10404446,https://www.ncbi.nlm.nih.gov/pubmed/20486940,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/28283348,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6523,SLC5A1,482,P13866,K14158,"""""",
977,606824,,Number Sign,606824,GLUCOSE/GALACTOSE MALABSORPTION; GGM,MONOSACCHARIDE MALABSORPTION; GM,,Glucose-galactose malabsorption,,SLC5A1,SLC5A1,sodium/glucose cotransporter protein called SGLT1,1c2c7c79d7ca7ca5975f200df167478430149d67daee923b3d8f9d2f685e274e,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,Fructose +Carbohydrate free formula,DB04173+NA,DB04173 + NA,74297897bb7f7cd844d4f386aa86f32aa76aba5460ac3c06bf6c896a5989f538,,,,,"DB04173,NA",DB04173,,NA,,,,,,,Dehydration,HP:0001944,,"https://www.ncbi.nlm.nih.gov/pubmed/10404446,https://www.ncbi.nlm.nih.gov/pubmed/20486940,https://www.ncbi.nlm.nih.gov/pubmed/27775558,https://www.ncbi.nlm.nih.gov/pubmed/28283348,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6523,SLC5A1,482,P13866,K14158,"""""",
978,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,"The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitorsâfor example, topiramate, zonisamide, and acetazolamideâmay increase risk of nonâanion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract",SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,UX007 (triheptanoin),DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,symptomatic treatment procedure,C,seizures,HP:0001250,,"https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
979,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,UX007 (triheptanoin),DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,EEG with focal spike waves,HP:0011197,,"https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
980,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,UX007 (triheptanoin),DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Nonepileptic paroxysmal abnormalities,NA,,"https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
981,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,UX007 (triheptanoin),DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
982,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,UX007 (triheptanoin),DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,C,movement disorders,HP:0100022,,"https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
983,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,UX007 (triheptanoin),DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Dyskinesia,HP:0100660,,"https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/26982753,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
984,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,AAV-GLUT1,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Abnormal CSF glucose levels,HP:0031884,,"https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/29624790,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
985,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,AAV-GLUT1,NA,,,,,,,,,,,,,,,,,Abnormal motor function,HP:0004302,,"https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/29624790,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
986,606777,,Number Sign,606777,GLUT1 DEFICIENCY SYNDROME 1; GLUT1DS1,"GLUCOSE TRANSPORT DEFECT, BLOOD-BRAIN BARRIER","GLUT1 DEFICIENCY SYNDROME 1, AUTOSOMAL RECESSIVE, INCLUDED",Glucose transporter type 1 deficiency syndrome,,SLC2A1,SLC2A1,glucose transporter protein type 1 (GLUT1),0e7de367e413ba6ca566939d489e659213b581b1ca05cb9c934d9859a8fe26a3,6.3.1.2,6.3.1.2,,The enteric carbohydrateâfree formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,AAV-GLUT1,NA,,,,,,,,,,,,,,,,,Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia),HP:0007166,,"https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/29624790,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",6513,SLC2A1,480,P11166,K07299,"""""",
987,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,Rofecoxib,DB00533,DB00533,ff321d767684cde091e0c67da04440b914856f6f1938068a32dd01aa979fd9fe,DB00533,DB00533,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Refractory hypokalemia,HP:0002900*,,"https://www.ncbi.nlm.nih.gov/pubmed/12141411,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/29624790,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
988,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,Rofecoxib,DB00533,DB00533,ff321d767684cde091e0c67da04440b914856f6f1938068a32dd01aa979fd9fe,DB00533,DB00533,,,,,,,,,,,,,Abnormally reduced levels of aldosterone,HP:0004319,,"https://www.ncbi.nlm.nih.gov/pubmed/12141411,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/29624790,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
989,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,Rofecoxib,DB00533,DB00533,ff321d767684cde091e0c67da04440b914856f6f1938068a32dd01aa979fd9fe,DB00533,DB00533,,,,,,,,,,,,,Abnormal serum renin level,HP:0040084,,"https://www.ncbi.nlm.nih.gov/pubmed/12141411,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/29624790,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
990,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,Rofecoxib,DB00533,DB00533,ff321d767684cde091e0c67da04440b914856f6f1938068a32dd01aa979fd9fe,DB00533,DB00533,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12141411,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/29624790,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
991,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Indometacin/Amiloride/Eplerenone+Potassium,(DB00328/DB00594/DB00700)+DB00761,(DB00328 / DB00594 / DB00700) + DB00761,1a8db6aa750b8f1d42ae71169258db54bd12fd30097e42e497b586ce27512706,"(DB00328,DB00594,DB00700)",DB00594,,"(DB00328,DB00700)",DB00761,DB00761,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Refractory hypokalemia,HP:0002900*,,"https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://clinicaltrials.gov/ct2/show/NCT01146197?cond=Gitelman+syndrome&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
992,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Indometacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,developmental delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/25852896/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
993,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Indometacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,,high plasma RAAS activity,HP:0000847*,,"https://www.ncbi.nlm.nih.gov/pubmed/25852896/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
994,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Indometacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,C,Abnormally reduced levels of aldosterone,HP:0004319,,"https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
995,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Indometacin,DB00328,DB00328,57cf6e38642a75bdd719ef2a50df802a62f20a289c454e2de3a486d6851d9eae,DB00328,DB00328,,,,,,,,,,,,C,Abnormal serum renin level,HP:0040084,,"https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
996,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hypomagnesemia,HP:0002917,"In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications","https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
997,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,,,,,,,chondrocalcinosis,HP:0000934,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
998,263800,,Number Sign,263800,GITELMAN SYNDROME; GTLMNS,"HYPOMAGNESEMIA-HYPOKALEMIA, PRIMARY RENOTUBULAR, WITH HYPOCALCIURIA;; POTASSIUM AND MAGNESIUM DEPLETION",,Gitelman syndrome,,SLC12A3Â / CLCNKB,"SLC12A3,CLCNKB",sodium chloride co-transporter/ chloride channel called ClC-Kb,ce7e4c950b2037ba6ae280cadfa92d875b35f99e565c5f5fa82cc10cff361468,P51801,,P51801,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Potassium chloride,DB00761,DB00761,67f1e0b55afe5c60ce17dcb742c8ee747c1e0593a6d968a63548f2028bdaab68,DB00761,DB00761,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract","6559,1188","SLC12A3,CLCNKB",889,"P55017,P51801","K14426,K05018",",",
999,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Taliglucerase alfa,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Hepatomegaly,HP:0002240,,"https://clinicaltrials.gov/ct2/show/results/NCT01422187?cond=Gaucher+disease&draw=3&rank=23&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27839981,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1000,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Taliglucerase alfa,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,,,,,,,Splenomegaly,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1001,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Taliglucerase alfa,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,"https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1002,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Taliglucerase alfa,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,,,,,,,low mean hemoglobin concentration,HP:0025547,,"https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1003,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Taliglucerase alfa,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,,,,,,,low bone marrow fat fraction value,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/28131618,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1004,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",ImiglucÃ©rase (ISU302),DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,primary low heamoglobin level,HP:0001903*,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1005,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",ImiglucÃ©rase (ISU302),DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1006,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",ImiglucÃ©rase (ISU302),DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,,,,,,,splenomegaly,HP:0001744,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1007,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",ImiglucÃ©rase (ISU302),DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1008,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",ImiglucÃ©rase (ISU302),DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,,,,,,,high angiotensin- converting enzyme,HP:0000841,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1009,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",ImiglucÃ©rase (ISU302),DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,,,,,,,high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*,HP:0004356,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1010,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",ImiglucÃ©rase (ISU302),DB00053,DB00053,0de29df3eefe1e18f6bc4ab95403b95611b42d23dc1e9b0e53a120d51b51fb7f,DB00053,DB00053,,,,,,,,,,,,,"elevated Chemokine Ligand (CCL-18) Level [ng,mL]",NA,,"https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/30066229,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1011,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",prGCD,DB06667,DB06667,2db39cbe7a17725a986194cc7882a288be6c7ccce3fd5e43044bb70f8c3e2bb1,DB06667,DB06667,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Trial is no longer available,,,"https://clinicaltrials.gov/ct2/show/NCT00705939,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1012,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",prGCD,DB06667,DB06667,2db39cbe7a17725a986194cc7882a288be6c7ccce3fd5e43044bb70f8c3e2bb1,DB06667,DB06667,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT00705939,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1013,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Eliglustat tartrate,DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,Low mean hemoglobin level,HP:0001903,,"https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1014,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Eliglustat tartrate,DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,"https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1015,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Eliglustat tartrate,DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,"https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1016,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Eliglustat tartrate,DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,,,,,,,Splenomegaly,HP:0001744,,"https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1017,608013,,Number Sign,608013,"GAUCHER DISEASE, PERINATAL LETHAL","GAUCHER DISEASE, COLLODION TYPE",,Gaucher disease perinatal lethal,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Eliglustat tartrate,DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,,,,,,,Low lumbar spine bone mineral density(bnormality of bone mineral density)*,HP:0004348,,"https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1018,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Oxidative stress,HP:0025464,,"https://clinicaltrials.gov/ct2/show/NCT01427517,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1019,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,Low blood glutathione redox ratios,MP:0012604*,,"https://clinicaltrials.gov/ct2/show/NCT01427517,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1020,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,Inflammation,HP:0012649,,"https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1021,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,concentration of myo-inositol in brain,HP:0025460,,"https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1022,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",N-acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,concentration of TNF-alpha in plasma,HP:0011118*,,"https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1023,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Elelyso,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,ECO:0000352/ ECO:0007121,"ECO:0000352,ECO:0007121",,,direct complementation of a genetically defective protein,A,Hepatomegaly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1024,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Elelyso,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,,,,,,,Splenomegaly,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1025,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Elelyso,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,"https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1026,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Elelyso,DB08876,DB08876,76a8e9f137af5dd149c05d03ec9d46af4aee71a71da519d3b36ec727be887fa6,DB08876,DB08876,,,,,,,,,,,,,anaemia,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/23860343,https://www.ncbi.nlm.nih.gov/pubmed/27499018,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1027,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,changes in lumbar spine (LS),HP:0100712,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1028,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,abnormality in bone mineral density,HP:0004348,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1029,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,anaemia,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1030,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1031,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,hepatosplenomegaly,HP:0001433,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1032,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,growth faliure,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1033,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,avascular osteonecrosis,HP:0010885,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1034,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",Velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,Bone pain,HP:0002653,,"https://www.ncbi.nlm.nih.gov/pubmed/29503270,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1035,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The drug was used in a pilot study.,Ambroxol,DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,ECO:0007121,ECO:0007121,,,activity modification of a genetically defective protein,A,Anemia,done,,"https://clinicaltrials.gov/ct2/show/NCT01463215?cond=Gaucher+disease&draw=2&rank=17,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1036,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The drug was used in a pilot study.,Ambroxol,DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,,,,,,,Splenomegaly,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1037,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The drug was used in a pilot study.,Ambroxol,DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,,,,,,,Thrombocytpenia,HP:0001873,,"https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1038,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The drug was used in a pilot study.,Ambroxol,DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1039,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The drug was used in a pilot study.,Miglustat (NB-DNJ)(OGT 918),DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,functional complementation of a genetically defective protein,B,Splenomegly,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/11227045,https://www.ncbi.nlm.nih.gov/pubmed/12064906,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1040,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The drug was used in a pilot study.,Miglustat (NB-DNJ)(OGT 918),DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,,,,,,,hepatomegly,HP:0002240,,"https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/16199246,https://www.ncbi.nlm.nih.gov/pubmed/16285070,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1041,230800,,Number Sign,230800,"GAUCHER DISEASE, TYPE I","GD I;; GAUCHER DISEASE, NONCEREBRAL JUVENILE;; GLUCOCEREBROSIDASE DEFICIENCY;; ACID BETA-GLUCOSIDASE DEFICIENCY;; GBA DEFICIENCY",,Gaucher disease type 1,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The drug was used in a pilot study.,Miglustat (NB-DNJ)(OGT 918),DB06742,DB06742,c0bd8f3eedac6d80e4efa4fa830f2f6ed5bb9579d98f62f7c7cc3bd44e292496,DB06742,DB06742,,,,,,,,,,,,,High chitotriosidase level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://www.ncbi.nlm.nih.gov/pubmed/16199246,https://www.ncbi.nlm.nih.gov/pubmed/16285070,https://www.ncbi.nlm.nih.gov/pubmed/25801797,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,288,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1042,230900,,Number Sign,230900,"GAUCHER DISEASE, TYPE II","GD II;; GAUCHER DISEASE, ACUTE NEURONOPATHIC TYPE",,Gaucher disease type 2,"By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.",GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Glucocerebrosidase+ gadolinium-diethylenetriamine penta-acetic acid,DB06667,DB06667,2db39cbe7a17725a986194cc7882a288be6c7ccce3fd5e43044bb70f8c3e2bb1,DB06667,DB06667,,,,,,,ECO:0007121/ ECO:0000352,"ECO:0007121,ECO:0000352",,,direct complementation of a genetically defective protein+symptomatic treatment procedure,A,No result is  added,,,"https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://clinicaltrials.gov/ct2/show/NCT00244582?cond=Gaucher+disease+type+II&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1043,230900,,Number Sign,230900,"GAUCHER DISEASE, TYPE II","GD II;; GAUCHER DISEASE, ACUTE NEURONOPATHIC TYPE",,Gaucher disease type 2,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Glucocerebrosidase+ gadolinium-diethylenetriamine penta-acetic acid,DB06667,DB06667,2db39cbe7a17725a986194cc7882a288be6c7ccce3fd5e43044bb70f8c3e2bb1,DB06667,DB06667,,,,,,,,,,,,,,done,,"https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/23085429,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1044,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Miglustat (Substrate reduction therapy)+imiglucerase,DB00419+DB00053,DB00419 + DB00053,51bdf6bb3ec01460f1435d4730dae65a179de75a0147a4ffa717a8e1214c126a,,,,,"DB00419,DB00053","DB00419,DB00053",,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein+direct complementation of a genetically defective protein,B,neuropathy,HP:0009830,,"https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1045,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Miglustat (Substrate reduction therapy)+imiglucerase,DB00419+DB00053,DB00419 + DB00053,51bdf6bb3ec01460f1435d4730dae65a179de75a0147a4ffa717a8e1214c126a,,,,,"DB00419,DB00053","DB00419,DB00053",,,,,,,,,generalized tonic-clonic seizures,HP:0002069,,"https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1046,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Miglustat (Substrate reduction therapy)+imiglucerase,DB00419+DB00053,DB00419 + DB00053,51bdf6bb3ec01460f1435d4730dae65a179de75a0147a4ffa717a8e1214c126a,,,,,"DB00419,DB00053","DB00419,DB00053",,,,,,,,,speech impairment,HP:0002167,,"https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1047,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Eliglustat(Substrate reduction therapy),DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,ECO:0007121,ECO:0007121,CYP2D6,,functional complementation of a genetically defective protein,B,abnormal glucocerebroside level,HP:0003656,,"https://www.ncbi.nlm.nih.gov/pubmed/29680197,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1048,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Eliglustat(Substrate reduction therapy),DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,,,,,,,Hepatosplenomegaly,HP:0001433,,"https://www.ncbi.nlm.nih.gov/pubmed/28935503,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1049,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Eliglustat(Substrate reduction therapy),DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,"https://www.ncbi.nlm.nih.gov/pubmed/28935503,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1050,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,Eliglustat(Substrate reduction therapy),DB09039,DB09039,ff2ad0ec22ae6a78eb634eac48e022c8539c3644dbb784709cead074457ca435,DB09039,DB09039,,,,,,,,,,,,,low mean hemoglobin concentration,HP:0025547,,"https://www.ncbi.nlm.nih.gov/pubmed/28935503,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1051,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Decreased hemoglobin,HP:0001903,,"https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1052,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,thrombocytopenia,HP:0001873,,"https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1053,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,High spleen volume,HP:0001744,,"https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1054,231005,,Number Sign,231005,"GAUCHER DISEASE, TYPE IIIC",,,Gaucher disease type 3,,GBA,GBA,beta-glucocerebrosidase,8d9ca592f602e4d109f16f85c1c0b9127d76598cc9fe47768f609e5f8d61f7de,3.2.1.45,3.2.1.45,,The treatment was done via convection-enhanced delivery,velaglucerase alfa,DB06720,DB06720,82e87f060761e8f59210ba6f373ac414f3f3d2044ef3851127f8a97008b5c6c7,DB06720,DB06720,,,,,,,,,,,,,high liver volume,HP:0002240,,"https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",2629,GBA,,P04062,K01201,3.2.1.45; 2.4.1.-; 3.2.1.104,
1055,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,The treatment was done via convection-enhanced delivery,pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,Cystathioninuria,HP:0003153,,"http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",1491,CTH,28,P32929,K01758,4.4.1.1,
1056,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,The treatment was done via convection-enhanced delivery,pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,Tremor,HP:0001337,,"http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",1491,CTH,28,P32929,K01758,4.4.1.1,
1057,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,The treatment was done via convection-enhanced delivery,pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,Impaired fine motor skillls,HP:0007010,,"http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",1491,CTH,28,P32929,K01758,4.4.1.1,
1058,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,The treatment was done via convection-enhanced delivery,pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,EEG abnormality,HP:0002353,,"http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",1491,CTH,28,P32929,K01758,4.4.1.1,
1059,219500,,Number Sign,219500,CYSTATHIONINURIA,CYSTATHIONASE DEFICIENCY,,Gamma-cystathionase deficiency,,CTH,CTH,cystathionine gamma-lyase,3c389c47ca0b06b6f8293a8f838bc36abc935cfbc1c4bd71c46b11511f6c20f0,4.4.1.1,4.4.1.1,,The treatment was done via convection-enhanced delivery,pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,High total homocysteine level,HP:0010919,,"http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",1491,CTH,28,P32929,K01758,4.4.1.1,
1060,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,The treatment was done via convection-enhanced delivery,flumazenil,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,functional complementation of a defective protein by inhibition,C,unalertness,HP:0002329,,"http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1061,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,The treatment was done via convection-enhanced delivery,flumazenil,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,,,,,,,EEG abnormality,HP:0002353,,"http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1062,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,The treatment was done via convection-enhanced delivery,flumazenil,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,,,,,,,Functional motor deficit,HP:0004302,,"http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1063,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,The treatment was done via convection-enhanced delivery,flumazenil,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,,,,,,,excessive adventitious movements,HP:0100022*,,"http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1064,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,The treatment was done via convection-enhanced delivery,flumazenil,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,,,,,,,hypersomnolence,HP:0100786,,"http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1065,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,The treatment was done via convection-enhanced delivery,flumazenil,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,,,,,,,Oculomotor apraxia,HP:0000657,,"https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1066,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,The treatment was done via convection-enhanced delivery,flumazenil,DB01205,DB01205,476fd52785a51e9f71782387bf4da5d215f94061a46181c61e7c6dc63ac83ee3,DB01205,DB01205,,,,,,,,,,,,,Developmental delay,HP:0012758,,"https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1067,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",Phenobarbital/clonazepam/valproate/ midazolam,DB01174/DB01068/DB00313/DB00683,DB01174 / DB01068 / DB00313 / DB00683,5b3829335f50b39cc21a56f9e991ece77fabacec528a40c389b5e209b02047ff,"DB01174,DB01068,DB00313,DB00683","DB01174,DB01068,DB00313,DB00683",,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1068,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",rapamycin,DB00877,DB00877,ea9e13320cce70f27ecdbf6e3632fdfe9e3bab5823bcc20abce8efd05a6a6961,DB00877,DB00877,,,,,,,ECO:0007764/ECO:0005542,"ECO:0007764,ECO:0005542",,,symptomatic treatment procedure,C,elevated CSF GHB levels,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/24578415/,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1069,613163,,Number Sign,613163,GABA-TRANSAMINASE DEFICIENCY,,,Gamma aminobutyric acid transaminase deficiency,,ABAT,ABAT,GABA-transaminase,54e7073d5dca36ff12349c0203c91cbf93367768357a613d8809ff8566600b85,2.6.1.19,2.6.1.19,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",rapamycin,DB00877,DB00877,ea9e13320cce70f27ecdbf6e3632fdfe9e3bab5823bcc20abce8efd05a6a6961,DB00877,DB00877,,,,,,,,,,,,,oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/24578415/,https://www.ncbi.nlm.nih.gov/pubmed/29480352,https://www.ncbi.nlm.nih.gov/pubmed/5707897,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",18,ABAT,36,P80404,K13524,2.6.1.19; 2.6.1.22,
1070,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",rAAV-PPCR,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein,A,edematous,HP:0000969,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5476,CTSA,319,P10619,K13289,3.4.16.5,
1071,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",rAAV-PPCR,NA,,,,,,,,,,,,,,,,,infertility,HP:0000789,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5476,CTSA,319,P10619,K13289,3.4.16.5,
1072,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",rAAV-PPCR,NA,,,,,,,,,,,,,,,,,incoordination,HP:0002311,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5476,CTSA,319,P10619,K13289,3.4.16.5,
1073,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",rAAV-PPCR,NA,,,,,,,,,,,,,,,,,gait abnormality,HP:0001288,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5476,CTSA,319,P10619,K13289,3.4.16.5,
1074,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",rAAV-PPCR,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5476,CTSA,319,P10619,K13289,3.4.16.5,
1075,256540,,Number Sign,256540,GALACTOSIALIDOSIS; GSL,GOLDBERG SYNDROME;; NEURAMINIDASE DEFICIENCY WITH BETA-GALACTOSIDASE DEFICIENCY;; NEURAMINIDASE/BETA-GALACTOSIDASE EXPRESSION; NGBE;; LYSOSOMAL PROTECTIVE PROTEIN DEFICIENCY;; CATHEPSIN A DEFICIENCY;; PROTECTIVE PROTEIN/CATHEPSIN A DEFICIENCY;; PPCA DEFICIENCY,,Galactosialidosis,,CTSA,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/Î²-galactosidase/ neuraminidase,06c6f641b7aa09718e518fd70a5dfbb40c432af74c1f50a11a4fe57c3d739e87,3.4.16.5,3.4.16.5,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",N-octyl-4-epi-Î²-valienamine (NOEV),NA,,,,,,,,,,,ECO:0001565,ECO:0001565,SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all,,functional complementation of a defective protein by stimulation,B,"Low Î²-gal activity (Abnormal enzyme,coenzyme activity )*",,,"https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pubmed/26259553,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,https://www.ncbi.nlm.nih.gov/pubmed/29358012,https://www.ncbi.nlm.nih.gov/pubmed/7814809,https://www.ncbi.nlm.nih.gov/pubmed/15895716,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract",5476,CTSA,319,P10619,K13289,3.4.16.5,
1076,230200,230200,Number Sign,230200,GALACTOKINASE DEFICIENCY,GALK DEFICIENCY;; GALACTOSEMIA II,,Galactokinase deficiency,,GALK1,GALK1,galactokinase 1,edfaddb12a00796b20a59ed295aa2a16983295c3bcbc0e298f1254835fabf836,2.7.1.6,2.7.1.6,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,2584,GALK1,474,P51570,K00849,2.7.1.6,
1077,606812,,Number Sign,606812,FUMARASE DEFICIENCY; FMRD,FUMARIC ACIDURIA,,Fumarase deficiency,"The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812",FH,FH,"Fumarate hydratase, mitochondrial",40f9a301bd7696f1ff675b402e57eaf49d1189c6251954af0e2caa42c3b1a02d,4.2.1.2,4.2.1.2,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,2271,FH,174,P07954,K01679,4.2.1.2,
1078,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",antisense oligonucleotide (VMO AED cocktail),NA,,,,,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,activity modification of a genetically defective protein by transcriptional or translational modification,A,Abnormal fukutin mRNA expression,HP:0030098,,"https://www.nature.com/articles/nature10456,https://www.ncbi.nlm.nih.gov/pubmed/27421908",2218,FKTN,642,O75072,K19872,2.4.2.-,
1079,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",antisense oligonucleotide (VMO AED cocktail),NA,,,,,,,,,,,,,,,,,pathogenic exon trapping,NA,,"https://www.nature.com/articles/nature10456,https://www.ncbi.nlm.nih.gov/pubmed/27421908",2218,FKTN,642,O75072,K19872,2.4.2.-,
1080,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",AAV9-MCK-fukutin,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Imapired muscle function,HP:0011804,,"https://www.ncbi.nlm.nih.gov/pubmed/21102543,https://www.ncbi.nlm.nih.gov/pubmed/27421908",2218,FKTN,642,O75072,K19872,2.4.2.-,
1081,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",Corticosteroid,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/21726969,https://www.ncbi.nlm.nih.gov/pubmed/27421908",2218,FKTN,642,O75072,K19872,2.4.2.-,
1082,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",Corticosteroid,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,,,,,,,Muscle necrosis,HP:0003713,,"https://www.ncbi.nlm.nih.gov/pubmed/21726969,https://www.ncbi.nlm.nih.gov/pubmed/27421908",2218,FKTN,642,O75072,K19872,2.4.2.-,
1083,253800,,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,Fukuyama type muscular dystrophy,,FKTN,FKTN,fukutin,3886f7f2097999efb858f1f075f6e839e21338e9a09c7bc2dda75fc6d9e70404,O75072,,O75072,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",Corticosteroid,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,,,,,,,Muscle inflammation,HP:0100614,,"https://www.ncbi.nlm.nih.gov/pubmed/21726969,https://www.ncbi.nlm.nih.gov/pubmed/27421908",2218,FKTN,642,O75072,K19872,2.4.2.-,
1084,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein,A,High level of fucosyl-linked oligosaccharide accumulation,,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1085,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,Neuronal vacuolation,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1086,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,PyramidalÂ neuronÂ loss,HP:0002062*,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1087,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,Astrocytosis,MP:0003354,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1088,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,Microgliosis,HP:0100708,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1089,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,Purkinji cells apoptosis,MP:0000880,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1090,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,OligodendrocyteÂ loss,HP:0100709,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1091,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,Hypomyelination,MP:0013438,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1092,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,LysosomalÂ expansion inÂ neuronsÂ of deep cortex,HP:0004356*,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1093,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,AstrocytosisÂ inÂ cerebral cortex,HP:0002446,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1094,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1095,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",recombinant canine Î±-l-fucosidase enzyme,NA,,,,,,,,,,,,,,,,,Abnormal neurololgical function,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1096,230000,230000,Number Sign,230000,FUCOSIDOSIS,ALPHA-L-FUCOSIDASE DEFICIENCY,,Fucosidosis,,FUCA1,FUCA1,a-L-fucosidase,16dd91ed72008a535d316d655f9cf989f075aa3db104e58597e89615c73f9ad8,3.2.1.51,3.2.1.51,,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",Tocilizumab,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Arthritis,HP:0001369,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943/,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923",2517,FUCA1,259,P04066,K01206,3.2.1.51,
1097,229700,,Number Sign,229700,"FRUCTOSE-1,6-BISPHOSPHATASE DEFICIENCY; FBP1D",,,"Fructose-1,6-bisphosphatase deficiency","The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9",FBP1,FBP1,"Fructose-1,6-bisphosphatase 1",2af4dad1db9b1bf79da3b3893477a1067bd2b4cef5a98f748bcfc46cf56ebe08,3.1.3.11,3.1.3.11,,"Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains <7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193",Glucose,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/29203193,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",2203,FBP1,483,P09467,K03841,3.1.3.11,
1098,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,"Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146",LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,"Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains <7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193",statin,DB00175,DB00175,d31fa496b3e1f971be70434217e8047ef375f89af3b12e73b64c8cefb3ad1aa9,DB00175,DB00175,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein,B,decreased cholesterol absorption,MP:0002647,,"https://www.ncbi.nlm.nih.gov/pubmed/24636183,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",3931,LCAT,528,P04180,K00650,2.3.1.43,
1099,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,The drug was accomapined with fat-restricted diet,ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs),C09C,C09C,6a0d1e5e802ebca5d05eafd0cd73278083f54b5327d44c07713f56c8d198b9ae,C09C,,,C09C,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Abnormal lipoprotein profile,HP:0010979,,"https://www.ncbi.nlm.nih.gov/pubmed/23522979,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",3931,LCAT,528,P04180,K00650,2.3.1.43,
1100,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,The drug was accomapined with fat-restricted diet,ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs),C09C,C09C,6a0d1e5e802ebca5d05eafd0cd73278083f54b5327d44c07713f56c8d198b9ae,C09C,,,C09C,,,,,,,,,,,Abnormal renal function,HP:0012211,,"https://www.ncbi.nlm.nih.gov/pubmed/23522979,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",3931,LCAT,528,P04180,K00650,2.3.1.43,
1101,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,The drug was accomapined with fat-restricted diet,ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs),C09C,C09C,6a0d1e5e802ebca5d05eafd0cd73278083f54b5327d44c07713f56c8d198b9ae,C09C,,,C09C,,,,,,,,,,,Proteinuria,HP:0000093,,"https://www.ncbi.nlm.nih.gov/pubmed/23522979,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",3931,LCAT,528,P04180,K00650,2.3.1.43,
1102,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,The drug was accomapined with fat-restricted diet,ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs),C09C,C09C,6a0d1e5e802ebca5d05eafd0cd73278083f54b5327d44c07713f56c8d198b9ae,C09C,,,C09C,,,,,,,,,,,Low serum HDL-cholesterol,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/23522979,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",3931,LCAT,528,P04180,K00650,2.3.1.43,
1103,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,r LCAT,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein,,Abnormal lipoprotein profile,HP:0010979,,"https://www.ncbi.nlm.nih.gov/pubmed/20605907,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",3931,LCAT,528,P04180,K00650,2.3.1.43,
1104,136120,,Number Sign,136120,FISH-EYE DISEASE; FED,DYSLIPOPROTEINEMIC CORNEAL DYSTROPHY;; ALPHA-LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY;; ALPHA-LCAT DEFICIENCY;; LCATA DEFICIENCY,,Fish-eye disease,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,r LCAT,NA,,,,,,,,,,,,,,,,,Low HDL-C  level,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/20605907,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",3931,LCAT,528,P04180,K00650,2.3.1.43,
1105,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,baclofen/tizanidine/trihexyphenidyl/benzodiazepine/dantrolene,DB00182/DB00697/DB00376/DB12537/DB01219,DB00182 / DB00697 / DB00376 / DB12537 / DB01219,08c214003c71e6f8119bea13050b14b59459aea91999a3b551e7a598fca187cf,"DB00182,DB00697,DB00376,DB12537,DB01219","DB00182,DB00697,DB00376,DB12537,DB01219",,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/21735565,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",79152,FA2H,1054,Q7L5A8,K19703,1.14.18.-,
1106,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,baclofen/tizanidine/trihexyphenidyl/benzodiazepine/dantrolene,DB00182/DB00697/DB00376/DB12537/DB01219,DB00182 / DB00697 / DB00376 / DB12537 / DB01219,08c214003c71e6f8119bea13050b14b59459aea91999a3b551e7a598fca187cf,"DB00182,DB00697,DB00376,DB12537,DB01219","DB00182,DB00697,DB00376,DB12537,DB01219",,,,,,,,,,,,,spasticity,HP:0001257,,"https://www.ncbi.nlm.nih.gov/pubmed/21735565,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",79152,FA2H,1054,Q7L5A8,K19703,1.14.18.-,
1107,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,botulinum toxin,DB00083,DB00083,b9dc52dcd224285b94e12b074de67c2ffce6653f6761323b5a1e290921e09b72,DB00083,DB00083,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,abnormal muscular co-contraction,HP:0001257,,"https://www.ncbi.nlm.nih.gov/pubmed/21735565,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",79152,FA2H,1054,Q7L5A8,K19703,1.14.18.-,
1108,612319,,Number Sign,612319,"SPASTIC PARAPLEGIA 35, AUTOSOMAL RECESSIVE; SPG35","FATTY ACID HYDROXYLASE-ASSOCIATED NEURODEGENERATION; FAHN;; LEUKODYSTROPHY, DYSMYELINATING, AND SPASTIC PARAPARESIS WITH OR WITHOUT DYSTONIA",,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,FA2H,fatty acid 2-hydroxylase,ea5d691d77b400bd3e02706bd8330ae9adf8652c996984305edb83c668824619,2.3.1.43,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,Nimodipine,DB00393,DB00393,d0e57aca42d512727b33735654750b60e83b57417c7edc03c44bdd35e5855e0d,DB00393,DB00393,,,,,,,ECO:0000305/ECO:0001565,"ECO:0000305,ECO:0001565",,,activity modification of a genetically defective protein,,Abnormality of circulating enzyme level,HP:0011021,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/29390242",79152,FA2H,1054,Q7L5A8,K19703,1.14.18.-,
1109,616896,,Number Sign,616896,MITOCHONDRIAL DNA DEPLETION SYNDROME 14 (CARDIOENCEPHALOMYOPATHIC TYPE); MTDPS14,,,Fatal infantile encephalomyopathy,,OPA1,OPA1,mitochondrial dynamin like GTPase,8c185cea397cefe05a1e4fb116497d5b9d180d3ef5e3e1ec51170fac5455fd63,2.3.1.43,2.3.1.43,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,4976,OPA1,,O60313,K17079,3.6.5.5,
1110,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,direct complementation of a genetically defective protein,A,Delayed growth,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1111,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,High cermaide level,MP:0020582,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1112,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,High intracellular cermaid level,MP:0020582*,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1113,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,Abnormal spleen size,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1114,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,abnormal sphingosine level(Abnormality of lipid metabolism)*,MP:0009587,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1115,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,high plasma MCP-1,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1116,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,High macrophage infiltration into tissues(Abnormal inflammatory response)*,HP:0012647*,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1117,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1118,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,human recombinantÂ acidÂ ceramidase/human ACDase-encoding lentivector,NA,,,,,,,,,,,,,,,,,Joint inflammation,HP:0001369,,"https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1119,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,"The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.",Amitriptyline,DB00321,DB00321,e426629765e97e13340649966110e5d5221dff30c3b5497febb090ce8228e40c,DB00321,DB00321,,,,,,,ECO:0000305/ECO:0005542,"ECO:0000305,ECO:0005542",,,functional complementation of a defective protein by inhibition,,Abnormal pulmonary ceramide level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/18376404,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1120,228000,,Number Sign,228000,FARBER LIPOGRANULOMATOSIS; FRBRL,FARBER DISEASE;; CERAMIDASE DEFICIENCY;; ACID CERAMIDASE DEFICIENCY;; AC DEFICIENCY;; N-LAURYLSPHINGOSINE DEACYLASE DEFICIENCY,,Farber's disease,,ASAH1,ASAH1,acid ceramidase,2a6ef00a032cd482179c7fc050962759a14e4a6bcaa7c173a189379ab53e7a2c,3.5.1.23,3.5.1.23,,"The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.",Amitriptyline,DB00321,DB00321,e426629765e97e13340649966110e5d5221dff30c3b5497febb090ce8228e40c,DB00321,DB00321,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/18376404,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",427,ASAH1,1297,Q13510,K12348,3.5.1.23; 3.5.1.-,
1121,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Uncooked Cornstarch,DB11599,DB11599,a557e64c97f313612a77939824d0c110c0b508ee8765302ecf47a8b7b081dd2f,DB11599,DB11599,,,,,,,ECO:0000352,ECO:0000352,,,Dietary supplementation,C,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",6514,SLC2A2,481,P11168,K07593,"""""",
1122,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Vitamin D,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/24912437,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",6514,SLC2A2,481,P11168,K07593,"""""",
1123,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,phosphorus,DB14151,DB14151,be7969895fb0f5c6847d1e95ee9308f3a095a9e9395150489e03df8ba80a2af0,DB14151,DB14151,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Rickets,HP:0002748,,"https://www.ncbi.nlm.nih.gov/pubmed/24912437,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",6514,SLC2A2,481,P11168,K07593,"""""",
1124,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,bicarbonate,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Renal tubular acidosis,HP:0001947,,"https://www.ncbi.nlm.nih.gov/pubmed/24912437,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",6514,SLC2A2,481,P11168,K07593,"""""",
1125,227810,,Number Sign,227810,FANCONI-BICKEL SYNDROME; FBS,"HEPATORENAL GLYCOGENOSIS WITH RENAL FANCONI SYNDROME;; HEPATIC GLYCOGENOSIS WITH FANCONI NEPHROPATHY;; HEPATIC GLYCOGENOSIS WITH AMINO ACIDURIA AND GLUCOSURIA;; FANCONI SYNDROME WITH INTESTINAL MALABSORPTION AND GALACTOSE INTOLERANCE;; PSEUDO-PHLORIZIN DIABETES;; GLYCOGENOSIS, FANCONI TYPE;; GLYCOGEN STORAGE DISEASE XI",,Fanconi Bickel syndrome,,SLC2A2,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",7040e380382ccd0b2f90a8228979695d86a5bfd9fb55574230fd3ffb54d2d5a4,P11168,,P11168,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Insulin,DB00030,DB00030,cf26fce19e07aebb15d6d50e81eac479c8ce3fbd496c7010461f41ac5f463a3e,DB00030,DB00030,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Diabetes mellitus,HP:0000819,,"http://www.ncbi.nlm.nih.gov/pubmed/29116606?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/23456528,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",6514,SLC2A2,481,P11168,K07593,"""""",
1126,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,ISIS 703802 (AKCEA-ANGPTL3-LRx),NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,high fasting triglycerides,HP:0002155*,,"https://clinicaltrials.gov/ct2/show/NCT03514420?cond=Familial+partial+lipodystrophy+type+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/23456528,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1127,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Metreleptin(A-100),DB09046,DB09046,1a517f379389e13ad177a97ed71c30d24e12c060e8c593686602eb3ca271ad94,DB09046,DB09046,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,symptomatic treatment procedure,C,abnormal free fatty acid levels,HP:0040300,,"https://clinicaltrials.gov/ct2/show/NCT00025883?cond=Familial+partial+lipodystrophy+type+2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25734254,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1128,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Metreleptin(A-100),DB09046,DB09046,1a517f379389e13ad177a97ed71c30d24e12c060e8c593686602eb3ca271ad94,DB09046,DB09046,,,,,,,,,,,,,high facial soft tissue volume,HP:0000287,,"https://www.ncbi.nlm.nih.gov/pubmed/28993984,https://www.ncbi.nlm.nih.gov/pubmed/25734254,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1129,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Metreleptin(A-100),DB09046,DB09046,1a517f379389e13ad177a97ed71c30d24e12c060e8c593686602eb3ca271ad94,DB09046,DB09046,,,,,,,,,,,,,abnormal fasting glucose,MP:0013277,,"https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1130,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Metreleptin(A-100),DB09046,DB09046,1a517f379389e13ad177a97ed71c30d24e12c060e8c593686602eb3ca271ad94,DB09046,DB09046,,,,,,,,,,,,,high  HbA1c levels,HP:0040217,,"https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1131,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Albiglutide (glucagon-like peptide-1 receptor agonist),DB09043,DB09043,a9bfbb9ad22610a5e7b86d90e9c133de63a8f5e248549d5ac376ad129988f4f3,DB09043,DB09043,,,,,,,,,,,symptomatic treatment procedure,C,abnormal fasting glucose,MP:0013277,,"https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1132,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Albiglutide (glucagon-like peptide-1 receptor agonist),DB09043,DB09043,a9bfbb9ad22610a5e7b86d90e9c133de63a8f5e248549d5ac376ad129988f4f3,DB09043,DB09043,,,,,,,,,,,,,high  HbA1c levels,HP:0040217,,"https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1133,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,volanesorsen (IONIS-APOCIIIRx),NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Abnormal fasting triglycerides,HP:0002155*,,"https://clinicaltrials.gov/ct2/show/NCT02300233,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1134,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Obeticholic Acid,DB05990,DB05990,5ae68e2f089e8813114eb6689c739e28ef7eed31279def478f19c58e028193ca,DB05990,DB05990,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Hepatic steatosis,HP:0001397,,"https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1135,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Obeticholic Acid,DB05990,DB05990,5ae68e2f089e8813114eb6689c739e28ef7eed31279def478f19c58e028193ca,DB05990,DB05990,,,,,,,,,,,,,High liver triglyceride level(hyperlipidemia)*,HP:0003077*,,"https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1136,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Gemcabene,DB05123,DB05123,2b9e9729f24d96e3ec7a2062f7c7c0659acdf5f035650f7750c31728a7fba63c,DB05123,DB05123,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Hypertriglyceridemia,HP:0002155,,"https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1137,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,Gemcabene,DB05123,DB05123,2b9e9729f24d96e3ec7a2062f7c7c0659acdf5f035650f7750c31728a7fba63c,DB05123,DB05123,,,,,,,,,,,,,Hepatic steatosis,HP:0001397,,"https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1138,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,fibrates + omega-3 fatty acids (OMG-3),DB00636Â +DB11133,DB00636 + DB11133,c0d3e606bb58b12e43fe893c6646630d0a3cb9bfc9f8aa62e381b4398681311a,,,,,"DB00636,DB11133","DB00636,DB11133",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/27710244,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1139,151660,,Number Sign,151660,"LIPODYSTROPHY, FAMILIAL PARTIAL, TYPE 2; FPLD2","FPL2;; LIPODYSTROPHY, FAMILIAL PARTIAL, DUNNIGAN TYPE;; LIPODYSTROPHY, FAMILIAL, OF LIMBS AND LOWER TRUNK;; LIPODYSTROPHY, REVERSE PARTIAL;; LIPOATROPHIC DIABETES",,Familial partial lipodystrophy type 2,,LMNA,LMNA,lamins ( Lamins A and C),322ba597cb969bad8e5c67f07800e58652e9d4873e2cdb559d26dfcc89d02985,P02545,,P02545,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,fibrates + omega-3 fatty acids (OMG-3),DB00636Â +DB11133,DB00636 + DB11133,c0d3e606bb58b12e43fe893c6646630d0a3cb9bfc9f8aa62e381b4398681311a,,,,,"DB00636,DB11133","DB00636,DB11133",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/27710244,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",4000,LMNA,,P02545,K12641,"""""",
1140,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,anemia,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1141,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,Abnormal lecithin:cholesterol acyltransferase activity,MP:0011598,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1142,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,abnormal plasma lipids levels,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1143,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,low HDL level,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1144,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,low HDL-C level,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1145,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,Abnormal cholesterol efflux from cells,MP:0003193,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1146,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,dyslipidemia,MP:0003949,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1147,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,low APO A level,HP:0025201*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1148,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,Low Apo B protein level,HP:0025201*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1149,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,recombinant humanÂ LCAT (ACP-501),NA,,,,,,,,,,,,,,,,,proteinuria,HP:0000093,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1150,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,Captopril,DB01197,DB01197,3c8d1cdfa5d7eae0a7ed8072dc18cfc49bf2a7f83409f9c71cb7742bd0ea81be,DB01197,DB01197,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hypertension,HP:0000822,,"https://www.ncbi.nlm.nih.gov/pubmed/23391322,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1151,245900,,Number Sign,245900,LECITHIN:CHOLESTEROL ACYLTRANSFERASE DEFICIENCY,LCAT DEFICIENCY;; NORUM DISEASE,,Familial LCAT deficiency,,LCAT,LCAT,lecithin-cholesterol acyltransferase,03d1e288816a18ad221672b5d7957de3b2f4f6cb1c448ff4e04f2fec8d75ce5c,2.3.1.43,2.3.1.43,,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,Thiazide,DB01324,DB01324,220a0c5acbf784f3ffab6250232a8f228a59e8fdd431a6ae0acc2e73ec19d03b,DB01324,DB01324,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Oedema,HP:0000969,,"https://www.ncbi.nlm.nih.gov/pubmed/23391322,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",3931,LCAT,380,P04180,K00650,2.3.1.43,
1152,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,Probenecid,DB01032,DB01032,2eaf2c7a70dc6dbae04804ddaf804322045de4d452b206ddf563c955877393ec,DB01032,DB01032,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hyperurecemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/20301530,https://www.ncbi.nlm.nih.gov/pubmed/8842764,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",7369,UMOD,1405,P07911,K18274,"""""",
1153,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,Probenecid+Allopurinol,DB01032+DB00437,DB01032 + DB00437,086a1fa338dfeb1b1a0fa473ad50163f4b54bc57b80a2dcfab09c598787d3367,,,,,"DB01032,DB00437","DB01032,DB00437",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hyperurecemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/8842764,https://www.ncbi.nlm.nih.gov/pubmed/8842764,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",7369,UMOD,1405,P07911,K18274,"""""",
1154,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hyperurecemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/12205338,https://www.ncbi.nlm.nih.gov/pubmed/11068651,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",7369,UMOD,1405,P07911,K18274,"""""",
1155,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Mortality,HP:0040006,,"https://www.ncbi.nlm.nih.gov/pubmed/12205338,https://www.ncbi.nlm.nih.gov/pubmed/11068651,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",7369,UMOD,1405,P07911,K18274,"""""",
1156,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,Disaess progression(Progressive)*,HP:0003676,,"https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=20301530&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pubmed/11068651,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",7369,UMOD,1405,P07911,K18274,"""""",
1157,162000,,Number Sign,162000,"HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE, 1; HNFJ1","HYPERURICEMIC NEPHROPATHY, FAMILIAL JUVENILE; HNFJ;; FAMILIAL JUVENILE HYPERURICEMIC NEPHROPATHY; FJHN;; NEPHROPATHY, FAMILIAL, WITH GOUT;; GOUTY NEPHROPATHY, FAMILIAL JUVENILE",,Familial juvenile hyperuricaemic nephropathy,,UMOD,UMOD,uromodulin,dc909a2064be6959ae29d4095b30c83a4176484fc354a005f73778735796a7f5,P07911,,P07911,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Allopurinal+Benzbromarone,DB00437+DB12319,DB00437 + DB12319,2fc403f863cf86f34c01c21c9be2941ebdab5a370b373b3c229d513dd188b060,,,,,"DB00437,DB12319","DB00437,DB12319",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hyperurecemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/9678437,https://www.ncbi.nlm.nih.gov/pubmed/11068651,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/",7369,UMOD,1405,P07911,K18274,"""""",
1158,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,"In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511",CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,,Hypercalcemia,HP:0003072,,"https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/16882283/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",846,CASR,,P41180,K04612,"""""",
1159,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,,CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,,,,,,,Elevated circulating parathyroid hormone level,HP:0003165,,"https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",846,CASR,,P41180,K04612,"""""",
1160,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,,CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,,,,,,,Impaired renal uric acid clearance,HP:0004732,,"https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",846,CASR,,P41180,K04612,"""""",
1161,145980,,Number Sign,145980,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE I; HHC1","HHC; FHH;; FHH1;; FAMILIAL BENIGN HYPERCALCEMIA 1; FBH1;; HYPERCALCEMIA, FAMILIAL BENIGN","HYPOCALCIURIC HYPERCALCEMIA, ACQUIRED, INCLUDED",Familial hypocalciuric hypercalcemia type 1,,CASR,CASR,calcium-sensing receptor,b70bfc4b60e31acf71684b338e6726955e572fde0f0a3eef6714639f61ad84aa,P41180,,P41180,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,,,,,,,Polydipsia,HP:0001959,,"https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",846,CASR,,P41180,K04612,"""""",
1162,145981,,Number Sign,145981,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2","FAMILIAL BENIGN HYPERCALCEMIA, TYPE II; FBH2;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE II",,Familial hypocalciuric hypercalcemia type 2,,GNA11,GNA11,guanine nucleotide-binding proteinÂ (GÎ±11),46e2c268ba2563c9de64deab1ac7ef8ac2557ec540ff356ac866fa5bb398db23,P21278,,P21278,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,high serum ionized calcium concentrations,HP:0003072*,,"https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/28833550,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",2767,GNA11,,P29992,K04635,"""""",
1163,145981,,Number Sign,145981,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE II; HHC2","FAMILIAL BENIGN HYPERCALCEMIA, TYPE II; FBH2;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE II",,Familial hypocalciuric hypercalcemia type 2,,GNA11,GNA11,guanine nucleotide-binding proteinÂ (GÎ±11),46e2c268ba2563c9de64deab1ac7ef8ac2557ec540ff356ac866fa5bb398db23,P21278,,P21278,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,,,,,,,abnormal parathyroid hormone level,HP:0003165,,"https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/28833550,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",2767,GNA11,,P29992,K04635,"""""",
1164,600740,,Number Sign,600740,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3","FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III;; HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE",,Familial hypocalciuric hypercalcemia type 3,,AP2S1,AP2S1,adaptor protein-2Â Ï-subunit,a29d89184247eaee9299275976a750c03655cfaa5a65ffaf35be304b400766c9,P53680,,P53680,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,high serum ionized calcium concentrations,HP:0003072*,,"https://www.ncbi.nlm.nih.gov/pubmed/27050234/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",1175,AP2S1,,P53680,K11827,"""""",
1165,600740,,Number Sign,600740,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3","FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III;; HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE",,Familial hypocalciuric hypercalcemia type 3,,AP2S1,AP2S1,adaptor protein-2Â Ï-subunit,a29d89184247eaee9299275976a750c03655cfaa5a65ffaf35be304b400766c9,P53680,,P53680,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,,,,,,,abnormal parathyroid hormone level,HP:0003165,,"https://www.ncbi.nlm.nih.gov/pubmed/27050234/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",1175,AP2S1,,P53680,K11827,"""""",
1166,600740,,Number Sign,600740,"HYPOCALCIURIC HYPERCALCEMIA, FAMILIAL, TYPE III; HHC3","FAMILIAL BENIGN HYPERCALCEMIA, TYPE III; FBH3;; HYPERCALCEMIA, FAMILIAL BENIGN, TYPE III;; HYPERCALCEMIA, FAMILIAL BENIGN, OKLAHOMA TYPE",,Familial hypocalciuric hypercalcemia type 3,,AP2S1,AP2S1,adaptor protein-2Â Ï-subunit,a29d89184247eaee9299275976a750c03655cfaa5a65ffaf35be304b400766c9,P53680,,P53680,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Cinacalcet,DB01012,DB01012,346b1b0316c725a6dd4a95ed3aa92ebfd0824ba4db1675be92b1fe526ccaca48,DB01012,DB01012,,,,,,,,,,,,,low calcium urine excretion,HP:0003127,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",1175,AP2S1,,P53680,K11827,"""""",
1167,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Gemfibrozil+dietary fat restriction,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+Dietary exclusion,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/15251700/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1168,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Gemfibrozil+dietary fat restriction,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15251700/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1169,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",fenofibrateÂ +niacin+omegaâ3 fatty acids,DB01039,DB01039,c0680bf86f5f9a0f66f08227ddde5c81f378e716c676fab8f6fff972243710b5,DB01039,DB01039,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/24524914,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1170,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Omega 3 FA,DB11133,DB11133,80d39f88c7549395c1dc2db9c20c91b05054bf1e6f46c949c7e1d68d1696ed52,DB11133,DB11133,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/10925336?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1171,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Omega-3-acid ethyl esters,DB09539,DB09539,43846530f5398bc59b5473ab8ac39f3b9286a8b1c12fcbf0eefbbdbb61bc9778,DB09539,DB09539,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/16390715?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1172,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",Insulin,DB01306,DB01306,8474e51246a42aa71d5855f30fac998e2234fe6acb100b97d01961025ae4e99f,DB01306,DB01306,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by stimulation,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/25993639,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1173,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Heparin,DB01109,DB01109,09afac738c8d3dc21df8c9388d65391626ca69f4ae85f093a1534f4fe4a9767a,DB01109,DB01109,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/1800965,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1174,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Heparin,DB01109,DB01109,09afac738c8d3dc21df8c9388d65391626ca69f4ae85f093a1534f4fe4a9767a,DB01109,DB01109,,,,,,,,,,,,,Acute pancreatitis,HP:0001735,,"https://www.ncbi.nlm.nih.gov/pubmed/1800965,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1175,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Chenodeoxycholic acid,DB06777,DB06777,a8233bef8f08838987756a362dc06c83ee26b4406d333d90c914c7002af5193f,DB06777,DB06777,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a defective protein by inhibition,,Hypertriglyceridemia,HP:0002155,,"https://clinicaltrials.gov/ct2/show/NCT00465751?cond=Familial+hypertriglyceridemia&draw=3&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1176,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/23323877,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1177,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,,,,,,,High LDL level,HP:0003141,,"https://www.ncbi.nlm.nih.gov/pubmed/23323877,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1178,145750,145750,Number Sign,145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,APOA5,Apolipoprotein A-V,e451ad6363e72d1989bdfc94c48e6b10c474e4faefccb566f07e0a2afe5571c5,Q6Q788,,Q6Q788,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/23323877,https://www.ncbi.nlm.nih.gov/pubmed/12114919,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",116519,APOA5,,Q6Q788,K09025,"""""",
1179,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0007121,ECO:0007121,,,activity modification of a genetically defective protein,A,hypoalphalipoproteinemia,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622/,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1180,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,Low HDL cholesterol concentration,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1181,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,ECO:0005542,ECO:0005542,,,activity modification of a genetically defective protein,A,Low HDL cholesterol concentration,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1182,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Intravenous heparin 10,000 U per day is an effective, simple, and safe method of lowering the triglyceride level in hypertriglyceridemia-induced pancreatitis in pregnancy, However, the reduction of the triglyceride level by heparin is only temporary and long-term use may paradoxically result in an increase in the triglyceride level as a result of depletion of LPL. Heparin can be stopped once the triglyceride level falls below 11 mmol/L.https://www.ncbi.nlm.nih.gov/pubmed/12114919.  https://www.ncbi.nlm.nih.gov/pubmed/1800965",Pravastatin,DB00175,DB00175,d31fa496b3e1f971be70434217e8047ef375f89af3b12e73b64c8cefb3ad1aa9,DB00175,DB00175,,,,,,,ECO:0007121,ECO:0007121,R219K,,activity modification of a genetically defective protein,,Increased low-density lipoprotein cholesterol concentration,HP:0003141,,"https://www.ncbi.nlm.nih.gov/pubmed/24854628/,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1183,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",Atorvastatin/ Fenofibrate/ Niacin,DB00175,DB00175,d31fa496b3e1f971be70434217e8047ef375f89af3b12e73b64c8cefb3ad1aa9,DB00175,DB00175,,,,,,,ECO:0007121,ECO:0007121,,,activity modification of a genetically defective protein,A,hypoalphalipoproteinemia,HP:0003233,,"https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1184,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",Atorvastatin/ Fenofibrate/ Niacin,DB00175,DB00175,d31fa496b3e1f971be70434217e8047ef375f89af3b12e73b64c8cefb3ad1aa9,DB00175,DB00175,,,,,,,,,,,,A,Low HDL cholesterol concentration,HP:0003233,Niacin was the only effective drug to increase HDL cholesterol.,"https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.ncbi.nlm.nih.gov/pubmed/19770656?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28225998,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1185,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152","CER 001, a recombinant high-density lipoprotein (HDL)",NA,,,,,,,,,,,ECO:0007121/ECO:00055442/ECO:0001565,"ECO:0007121,ECO:00055442,ECO:0001565",,,functional complementation of a genetically defective protein,A,Decreased apolipoprotein AI level,HP:0031799,,"https://www.ncbi.nlm.nih.gov/pubmed/25561459/,https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1186,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152","CER 001, a recombinant high-density lipoprotein (HDL)",NA,,,,,,,,,,,,,,,,,Vasculitis,HP:0002633,,"https://www.ncbi.nlm.nih.gov/pubmed/25561459/,https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1187,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152","CER 001, a recombinant high-density lipoprotein (HDL)",NA,,,,,,,,,,,,,,,,,Decreased plasma HDL-c levels,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/25561459/,https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1188,604091,,Number Sign,604091,"HYPOALPHALIPOPROTEINEMIA, PRIMARY","HYPOALPHALIPOPROTEINEMIA, FAMILIAL; FHA;; HIGH DENSITY LIPOPROTEIN DEFICIENCY; HDLD;; FAMILIAL HDL DEFICIENCY; FHD;; HDL CHOLESTEROL, LOW SERUM; HDLC","HIGH DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 13, INCLUDED; HDLCQ13, INCLUDED",Familial HDL deficiencyÂ (Tangier Disease),,ABCA1,ABCA1,Phospholipid-transporting ATPase ABCA1,2f8d680b1eac750132567ae2a2bffce9a24f2c49c576b6d0e91931cc7cfed30c,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152","CER 001, a recombinant high-density lipoprotein (HDL)",NA,,,,,,,,,,,,,,,,,Arterial pluque,HP:0002621,,"https://www.ncbi.nlm.nih.gov/pubmed/25561459/,https://www.ncbi.nlm.nih.gov/pubmed/18993152,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/",19,ABCA1,379,O95477,K05641,7.6.2.1,
1189,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",Fabrazyme ( agalsidase beta) + pegunigalsidase alfa ( PRX-102),DB00103+DB14992,DB00103 + DB14992,16ab0df7443723a1529e1e3bf8212562d1e0aea955d04d7162c5c572f92718b5,,,,,"DB00103,DB14992","DB00103,DB14992",,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Abnormal kidney function,HP:0012211,,"https://www.ncbi.nlm.nih.gov/pubmed/25561459/,https://clinicaltrials.gov/ct2/show/study/NCT02795676?term=PRX-102&cond=Fabry+Disease&show_locs=Y#locn,https://www.ncbi.nlm.nih.gov/pubmed/25885911,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1190,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",REPLAGAL (Agalsidase Alfa),DB00103,DB00103,79dd432a3b190cdfcbbf5d9cd7daaf60890ec1bbd24bd6ab89acaf5926de95d4,DB00103,DB00103,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,cardiomegaly,HP:0001640,,"https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/25885911,https://www.ncbi.nlm.nih.gov/pubmed/25885911,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1191,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",REPLAGAL (Agalsidase Alfa),DB00103,DB00103,79dd432a3b190cdfcbbf5d9cd7daaf60890ec1bbd24bd6ab89acaf5926de95d4,DB00103,DB00103,,,,,,,,,,,,,low renal glomerular filtration rate,HP:0012213,,"https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/25885911,https://www.ncbi.nlm.nih.gov/pubmed/25885911,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1192,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"Drugs were used sequentially for 8 weeks, after 4 weeks washout. in the clinical trial. Atorvastatin or fenofibrate had little effect on HDL cholesterol; atorvastatin decreased the total cholesterol/HDL cholesterol ratio by 26%. Fenofibrate did not change HDL cholesterol levels and caused an increase in LDL cholesterol. Niacin was the only effective drug to increase HDL cholesterol. https://www.ncbi.nlm.nih.gov/pubmed/18993152",REPLAGAL (Agalsidase Alfa),DB00103,DB00103,79dd432a3b190cdfcbbf5d9cd7daaf60890ec1bbd24bd6ab89acaf5926de95d4,DB00103,DB00103,,,,,,,,,,,,,pain,HP:0012531,,"https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/25885911,https://www.ncbi.nlm.nih.gov/pubmed/25885911,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1193,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy",Pegunigalsidase alfa ( PRX-102),DB14992,DB14992,50d991db4093441f3f1a5a7a07784ed3ead8f312269521f22a8bb0cbca06ca5a,DB14992,DB14992,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Abnormal kidney function,HP:0012211,,"https://clinicaltrials.gov/ct2/show/NCT03180840?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01678898?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01769001?term=PRX-102&cond=Fabry+Disease,https://clinicaltrials.gov/ct2/show/NCT01981720?term=PRX-102&cond=Fabry+Disease,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1194,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"Given the favorable half-life of pegunigalsidase alfa and its low level of inhibition by pre-existing neutralizing antibodies, there is potential for pegunigalsidase alfa to attenuate and/or stabilize renal function in patients who continue to lose renal function while on currently-available enzyme replacement therapy",Lucerastat,DB14872,DB14872,d05ada8d18cc10f6637a3192a5248d3eaff13bc9e7b27e86982566097ef66bbe,DB14872,DB14872,,,,,,,ECO:0007121/ECO:0001565,"ECO:0007121,ECO:0001565",,,functional complementation of a defective protein by inhibition,,High Gb3(globotriaosylceramide) accumulation.,NA,,"https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2,https://clinicaltrials.gov/ct2/show/NCT03425539,https://clinicaltrials.gov/ct2/show/NCT03737214,https://www.ncbi.nlm.nih.gov/pubmed/28088251,https://www.ncbi.nlm.nih.gov/pubmed/29982630,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1195,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/",migalastat hydrochloride (AT1001),DB05018,DB05018,26263afdee071b23830adcf1925dfad451b65fba8859d901c4a85d66dd2edd33,DB05018,DB05018,,,,,,,ECO:0007121/ECO:0001565,"ECO:0007121,ECO:0001565","""p.D33G/p.L36W (n=2)/p.D55V/p.Q57L /p.G85D/p.R112H/G144V/p.I253T (n=4)/p.G258R (n=2) ,.A156T (n=3)                             p.P293T (n=2) /p.C174R                                                                                                           p.F295C                                                                  p.G183D (n=2)                                    p.L300P                                                                      p.M187I                                                                             p.R301Q   (n=3)                                                                           p.P205T (n=2)                                p.I317T                                                                  p.Y216C (n=3) /                             p.D322E (n=2)                                                    33p.L243F                                                                              p.G325R (n=2)/p.G373S / p.D244N/ p.R356W""","""E48K, R49P, S65I, I117S, G183V, G261D, G271S, S276G, R342Q (n=8), L414S""",activity modification of a genetically defective protein,A,High plasma lyso-globotriaosylsphingosine level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30875019,https://www.ncbi.nlm.nih.gov/pubmed/30765910,https://www.ncbi.nlm.nih.gov/pubmed/27509102/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1196,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/",migalastat hydrochloride (AT1001),DB05018,DB05018,26263afdee071b23830adcf1925dfad451b65fba8859d901c4a85d66dd2edd33,DB05018,DB05018,,,,,,,,,,,,,"High mean number of GL-3 inclusions,kidney interstitial capillary(KIC)",NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30875019,https://www.ncbi.nlm.nih.gov/pubmed/30765910,https://www.ncbi.nlm.nih.gov/pubmed/27509102/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1197,301500,301500,Number Sign,301500,FABRY DISEASE,ANGIOKERATOMA CORPORIS DIFFUSUM;; ANDERSON-FABRY DISEASE;; HEREDITARY DYSTOPIC LIPIDOSIS;; ALPHA-GALACTOSIDASE A DEFICIENCY;; GLA DEFICIENCY;; CERAMIDE TRIHEXOSIDASE DEFICIENCY,"FABRY DISEASE, CARDIAC VARIANT, INCLUDED",Fabry disease,,GLA,GLA,alpha-galactosidase A,ec207c1f05e8cbeca43d28f6303cec739583bb84aaeee385444d0d2ceda88f71,7.6.2.1,7.6.2.1,,"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/",migalastat hydrochloride (AT1001),DB05018,DB05018,26263afdee071b23830adcf1925dfad451b65fba8859d901c4a85d66dd2edd33,DB05018,DB05018,,,,,,,,,,,,,Left ventricular hypertrophy,HP:0001712,,"https://www.ncbi.nlm.nih.gov/pubmed/27834756/,https://www.nature.com/articles/s41436-019-0451-z,https://www.ncbi.nlm.nih.gov/pubmed/27509102/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",2717,GLA,296,P06280,K01189,3.2.1.22,
1198,612073,,Number Sign,612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5,"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITH OR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED",,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,SUCLA2,Succinyl-CoA synthetase ( beta subunit),4941f60c0707ae01849a2ae6f3fd896030f5051e3f2b38c70b4c97aff38e7613,7.6.2.1,7.6.2.1,,"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/",Carbamazepine,DB00564,DB00564,d7432f727b8e4d8a7e02cf9e041ae6a05684d37d649a8d66c2081dea81a7aebc,DB00564,DB00564,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/27834756/,https://www.nature.com/articles/s41436-019-0451-z,https://www.ncbi.nlm.nih.gov/books/NBK6803/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",8803,SUCLA2,503,Q9P2R7,K01900,6.2.1.5,
1199,612073,,Number Sign,612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5,"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITH OR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED",,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,SUCLA2,Succinyl-CoA synthetase ( beta subunit),4941f60c0707ae01849a2ae6f3fd896030f5051e3f2b38c70b4c97aff38e7613,7.6.2.1,7.6.2.1,,"The drug was more effective in some mutations than others, so if the results are analysed according to the mutation there is an advantage for migalastat.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370600/
 Miglustat stabilises specific mutant (amenable) forms of Î±-Gal to facilitate normal lysosomal trafficking. https://www.ncbi.nlm.nih.gov/pubmed/27834756/",Riboflavin and thiamine,DB00140+DB00152,DB00140 + DB00152,4d49b11c8b2e529a5a1ebcb0f7a6e5290c280dc5341e4383fb19a9729e6cf338,,,,,"DB00140,DB00152","DB00140,DB00152",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/19666145,https://www.nature.com/articles/s41436-019-0451-z,https://www.ncbi.nlm.nih.gov/books/NBK6803/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",8803,SUCLA2,503,Q9P2R7,K01900,6.2.1.5,
1200,612073,,Number Sign,612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5,"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITH OR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED",,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,SUCLA2,Succinyl-CoA synthetase ( beta subunit),4941f60c0707ae01849a2ae6f3fd896030f5051e3f2b38c70b4c97aff38e7613,7.6.2.1,7.6.2.1,,"The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.",L-DOPA,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal facial expression,HP:0005346,,"https://www.ncbi.nlm.nih.gov/pubmed/19666145,https://www.nature.com/articles/s41436-019-0451-z,https://www.ncbi.nlm.nih.gov/books/NBK6803/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",8803,SUCLA2,503,Q9P2R7,K01900,6.2.1.5,
1201,612073,,Number Sign,612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5,"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITH OR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED",,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,SUCLA2,Succinyl-CoA synthetase ( beta subunit),4941f60c0707ae01849a2ae6f3fd896030f5051e3f2b38c70b4c97aff38e7613,7.6.2.1,7.6.2.1,,"The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.",L-DOPA,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Functional motor deficit,HP:0004302,,"https://www.ncbi.nlm.nih.gov/pubmed/19666145,https://www.nature.com/articles/s41436-019-0451-z,https://www.ncbi.nlm.nih.gov/books/NBK6803/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",8803,SUCLA2,503,Q9P2R7,K01900,6.2.1.5,
1202,612073,,Number Sign,612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5 (ENCEPHALOMYOPATHIC WITH OR WITHOUT METHYLMALONIC ACIDURIA); MTDPS5,"MITOCHONDRIAL DNA DEPLETION SYNDROME, ENCEPHALOMYOPATHIC FORM, WITH OR WITHOUT METHYLMALONIC ACIDURIA, AUTOSOMAL RECESSIVE, SUCLA2-RELATED",,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,SUCLA2,Succinyl-CoA synthetase ( beta subunit),4941f60c0707ae01849a2ae6f3fd896030f5051e3f2b38c70b4c97aff38e7613,7.6.2.1,7.6.2.1,,"The drug has been used in two patients; in one patient it resulted in a tempoary improvment for 6 months, in the other it resulted in adverse effects and irritability with involuntary movements, and the treatment was discontinued.",L-DOPA,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/19666145,https://www.nature.com/articles/s41436-019-0451-z,https://www.ncbi.nlm.nih.gov/books/NBK6803/,https://clinicaltrials.gov/ct2/show/NCT00925301,https://clinicaltrials.gov/ct2/show/NCT01458119,https://www.ncbi.nlm.nih.gov/pubmed/30723321,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8",8803,SUCLA2,503,Q9P2R7,K01900,6.2.1.5,
1203,249900,,Number Sign,249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,METACHROMATIC LEUKODYSTROPHY DUE TO CEREBROSIDE SULFATASE ACTIVATOR DEFICIENCY;; SAPOSIN B DEFICIENCY,,Encephalopathy due to prosaposin deficiency,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,7.6.2.1,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,5660,PSAP,293,P07602,K12382,"""""",
1204,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,vitamin D,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,concommitant low vit D level,HP:0100512*,,https://www.ncbi.nlm.nih.gov/pubmed/24137761,2235,FECH,107,P22830,K01772,4.99.1.1,
1205,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,Afamelanotide (Scenesse),DB04931,DB04931,5f32666b0e51dace64dd70db686cc214256e5ad5ed3a5b06fb93bab008250600,DB04931,DB04931,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Erythema,HP:0010783,,"https://www.ncbi.nlm.nih.gov/pubmed/28003770,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1206,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,Afamelanotide (Scenesse),DB04931,DB04931,5f32666b0e51dace64dd70db686cc214256e5ad5ed3a5b06fb93bab008250600,DB04931,DB04931,,,,,,,,,,,,,Cutaneous photosensitivity,HP:0000992,,"https://www.ncbi.nlm.nih.gov/pubmed/28003770,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1207,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,corticosteroids,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Pain,HP:0012531,,"https://www.ncbi.nlm.nih.gov/pubmed/27139922,https://www.ncbi.nlm.nih.gov/pubmed/19744342,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1208,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,corticosteroids,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,,,,,,,Pruritus,HP:0000989,,"https://www.ncbi.nlm.nih.gov/pubmed/27139922,https://www.ncbi.nlm.nih.gov/pubmed/19744342,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/25402764,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1209,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,zinc,DB01593,DB01593,7a72322872c104b76d3c91aca064dfd8c45e3aee6b2644f3a1675d20072a2c72,DB01593,DB01593,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Increased ROS formation,HP:0025464,,"http://www.ncbi.nlm.nih.gov/pubmed/22092997?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19744342,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1210,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,"Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/",Î²-carotene,DB06755,DB06755,1655cf3e02a610000fa34728036de9e5ddeb4c6c0b23919f6affc0b796640c6b,DB06755,DB06755,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,intolerance to sunlight,HP:0000992,,"https://www.ncbi.nlm.nih.gov/pubmed/341955/,https://www.ncbi.nlm.nih.gov/pubmed/22791288,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1211,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,"Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/",Î²-carotene,DB06755,DB06755,1655cf3e02a610000fa34728036de9e5ddeb4c6c0b23919f6affc0b796640c6b,DB06755,DB06755,,,,,,,,,,,,,Pain in the skin,HP:0025280*,,"https://www.ncbi.nlm.nih.gov/pubmed/341955/,https://www.ncbi.nlm.nih.gov/pubmed/22791288,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1212,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,"Recent studies, however, have suggested inverse associations between carotenoids and lung cancer mainly in smokers.
https://www.ncbi.nlm.nih.gov/pubmed/18689373/ https://www.ncbi.nlm.nih.gov/pubmed/19254833/",Cholestyramine,DB01432,DB01432,99cdf2f21fcc72a3fb2865acd9480a160747f28c850655d0d48dcf1c14efa723,DB01432,DB01432,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal  protoporphyrin enterhepatic circulation,HP:0012187,,"https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1213,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,activated charcoal,DB09278,DB09278,26874a4e8222c12813c4874e858474e3b4f3412b4268348d8076fdbe71bc9706,DB09278,DB09278,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal liver function test,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1214,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,activated charcoal,DB09278,DB09278,26874a4e8222c12813c4874e858474e3b4f3412b4268348d8076fdbe71bc9706,DB09278,DB09278,,,,,,,,,,,,,Abdominal pain,HP:0002027,,"https://www.ncbi.nlm.nih.gov/pubmed/20375647,https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19656325/,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1215,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,activated charcoal,DB09278,DB09278,26874a4e8222c12813c4874e858474e3b4f3412b4268348d8076fdbe71bc9706,DB09278,DB09278,,,,,,,,,,,,,Photosenstivity,HP:0000992,,"https://www.ncbi.nlm.nih.gov/pubmed/20375647,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1216,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,activated charcoal,DB09278,DB09278,26874a4e8222c12813c4874e858474e3b4f3412b4268348d8076fdbe71bc9706,DB09278,DB09278,,,,,,,,,,,,,Pruritis,HP:0000989,,"https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1217,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,activated charcoal,DB09278,DB09278,26874a4e8222c12813c4874e858474e3b4f3412b4268348d8076fdbe71bc9706,DB09278,DB09278,,,,,,,,,,,,,Hepatotoxicity,,,"https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1218,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,activated charcoal,DB09278,DB09278,26874a4e8222c12813c4874e858474e3b4f3412b4268348d8076fdbe71bc9706,DB09278,DB09278,,,,,,,,,,,,,Fluid retention,HP:0000969,,"https://www.ncbi.nlm.nih.gov/pubmed/10189233?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1219,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,hemin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*,HP:0010472*,,"https://www.ncbi.nlm.nih.gov/pubmed/23016163,https://www.ncbi.nlm.nih.gov/pubmed/3335288?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/7758200?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1220,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,Some references are aganist activated charcoal as treatment for Erthropoietic Protoporphyria. https://www.ncbi.nlm.nih.gov/pubmed/8127352?dopt=Abstract,cysteine hydrochloride,DB00151,DB00151,f4a3b70861186a8191ed47b3b2c65115e5f04d82475df026af1be8f7d9fb8159,DB00151,DB00151,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,photosensitivity,HP:0000992,,"https://www.ncbi.nlm.nih.gov/pubmed/12535027,https://clinicaltrials.gov/ct2/show/NCT00004940,https://clinicaltrials.gov/ct2/show/NCT00004831,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1221,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,"The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332",Isoniazid,DB00951,DB00951,5135c377c53c781a3543872d45c849ab29cb39030e601326261c04d9b75871cc,DB00951,DB00951,,,,,,,ECO:0005542/ECO:0007121,"ECO:0005542,ECO:0007121",,,functional complementation of a defective protein by inhibition,C,Study was Terminated (Interim analysis demonstrated the treatment was not effective),,,"https://www.ncbi.nlm.nih.gov/pubmed/31395332,https://clinicaltrials.gov/ct2/show/NCT00004940,https://clinicaltrials.gov/ct2/show/NCT01550705,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1222,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic protoporphyria,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,"The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332",Iron,DB01592,DB01592,f3a10486a1ac3d6f8a96ed9a44748e3af2046be5171b04b2a9825d9e53243dc3,DB01592,DB01592,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,high erythrocyte protoporphyrin levels,HP:0012187,,"https://www.ncbi.nlm.nih.gov/pubmed/31395332,https://clinicaltrials.gov/ct2/show/NCT00004940,https://clinicaltrials.gov/ct2/show/NCT02979249?cond=Erythropoietic+protoporphyria&draw=1&rank=10,https://www.ncbi.nlm.nih.gov/pubmed/22092997,https://www.ncbi.nlm.nih.gov/pubmed/26979527,https://www.ncbi.nlm.nih.gov/pubmed/23884489/",2235,FECH,107,P22830,K01772,4.99.1.1,
1223,177000,,Number Sign,177000,"PROTOPORPHYRIA, ERYTHROPOIETIC, 1; EPP1","PROTOPORPHYRIA, ERYTHROPOIETIC; EPP;; ERYTHROHEPATIC PROTOPORPHYRIA;; HEME SYNTHETASE DEFICIENCY;; FERROCHELATASE DEFICIENCY",,Erythropoietic uroporphyria associated with myeloid malignancy,,FECH,FECH,ferrochelatase,650c354616598f13292e6527f97a5d48a710c34837185a5efb61dabb8e4cc348,7.6.2.1,7.6.2.1,,"The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,2235,FECH,107,P22830,K01772,4.99.1.1,
1224,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,"The drug resulted in significant reduction of  both plasma PPIX and hepatic PPIX in a murine animal model but no effect in humans during clinical trial. thus, These results demonstrate that while INH can lower PPIX in an animal model of EPP, the standard dose used to treat TB is insufficient to affect levels in humans. https://www.ncbi.nlm.nih.gov/pubmed/31395332",Acetylcysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0000352,ECO:0000352,,,"functional complementation of a genetically defective protein,functional complementation of a defective protein by inhibition",B,high Lactic acid,HP:0003648,,"https://www.ncbi.nlm.nih.gov/pubmed/16376514,https://www.ncbi.nlm.nih.gov/pubmed/27830356,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1225,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Drug used as an aternate therapy with (Metronidazole+Acetylcysteine),neomycin+Acetylcysteine,DB00994+DB06151,DB00994 + DB06151,ec161d3532d9d6500c4bb888269dd8ddb08cfaf6ca0d0794300577fcf835b7c4,,,,,"DB00994,DB06151","DB00994,DB06151",,,ECO:0000352,ECO:0000352,,,"functional complementation of a genetically defective protein,functional complementation of a defective protein by inhibition",B,abnormal thiosulfates level,HP:0011943,,"https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/27830356,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1226,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Drug used as an aternate therapy with (Metronidazole+Acetylcysteine),(Metronidazole+Acetylcysteine)+Dietary restricting sulfur containing amino acids treatment,DB00916+DB06151,DB00916 + DB06151,2df42ee44d86f264d07bc0a99252ed6deedd95307f9bed67dbb69b6eee7a6984,,,,,"DB00916,DB06151","DB00916,DB06151",,,ECO:0000352,ECO:0000352,,,"functional complementation of a genetically defective protein,functional complementation of a defective protein by inhibition",B,Hypotonia,MP:0004144,,"https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1227,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Drug used as an aternate therapy with (Metronidazole+Acetylcysteine),(Metronidazole+Acetylcysteine)+Dietary restricting sulfur containing amino acids treatment,DB00916+DB06151,DB00916 + DB06151,2df42ee44d86f264d07bc0a99252ed6deedd95307f9bed67dbb69b6eee7a6984,,,,,"DB00916,DB06151","DB00916,DB06151",,,,,,,,,diarrhea,HP:0002014,,"https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1228,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Drug used as an aternate therapy with (Metronidazole+Acetylcysteine),(Metronidazole+Acetylcysteine)+Dietary restricting sulfur containing amino acids treatment,DB00916+DB06151,DB00916 + DB06151,2df42ee44d86f264d07bc0a99252ed6deedd95307f9bed67dbb69b6eee7a6984,,,,,"DB00916,DB06151","DB00916,DB06151",,,,,,,,,high EMA levels,HP:0003219,,"https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1229,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,Drug used as an aternate therapy with (Metronidazole+Acetylcysteine),Ascorbic acid,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Decreased activity of cytochrome C oxidase in muscle tissue,HP:0003688,,"https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1230,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,carnitine+metronidazole,DB00583+DB00916,DB00583 + DB00916,0c924fab368d79b2956071f2cf88ab1afb975f8624a77bc8a90f562c87c8510c,,,,,"DB00583,DB00916","DB00583,DB00916",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+functional complementation of a genetically defective protein,C,,,,"https://www.ncbi.nlm.nih.gov/pubmed/26917598,https://www.ncbi.nlm.nih.gov/pubmed/20657580?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1231,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,Riboflavin and/or coenzyme Q10,DB00140+DB09270,DB00140 + DB09270,6b239a3dacee6c8204a0112191285e8d54f867e6785d9e0e429029a8a6d9a6e7,,,,,"DB00140,DB09270","DB00140,DB09270",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Functional motor deficit,HP:0004302,,"https://www.ncbi.nlm.nih.gov/pubmed/11916321,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1232,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,Riboflavin and/or coenzyme Q10,DB00140+DB09270,DB00140 + DB09270,6b239a3dacee6c8204a0112191285e8d54f867e6785d9e0e429029a8a6d9a6e7,,,,,"DB00140,DB09270","DB00140,DB09270",,,,,,,,,Cognitive impairment,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1233,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,Riboflavin and/or coenzyme Q10,DB00140+DB09270,DB00140 + DB09270,6b239a3dacee6c8204a0112191285e8d54f867e6785d9e0e429029a8a6d9a6e7,,,,,"DB00140,DB09270","DB00140,DB09270",,,,,,,,,Elevated plasma acylcarnitine levels,HP:0045045,,"https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1234,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,Riboflavin and/or coenzyme Q10,DB00140+DB09270,DB00140 + DB09270,6b239a3dacee6c8204a0112191285e8d54f867e6785d9e0e429029a8a6d9a6e7,,,,,"DB00140,DB09270","DB00140,DB09270",,,,,,,,,Chronic mucoid diarrhea,HP:0002028,,"https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1235,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,Riboflavin and/or coenzyme Q10,DB00140+DB09270,DB00140 + DB09270,6b239a3dacee6c8204a0112191285e8d54f867e6785d9e0e429029a8a6d9a6e7,,,,,"DB00140,DB09270","DB00140,DB09270",,,,,,,,,Petechiae,HP:0000967,,"https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1236,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,A drug regimen that was after liver transplataion surgery to maintain the achieved metabolic results.,Riboflavin and/or coenzyme Q10,DB00140+DB09270,DB00140 + DB09270,6b239a3dacee6c8204a0112191285e8d54f867e6785d9e0e429029a8a6d9a6e7,,,,,"DB00140,DB09270","DB00140,DB09270",,,,,,,,,Psychomotor retardation,HP:0025356,,"https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1237,602473,,Number Sign,602473,"ENCEPHALOPATHY, ETHYLMALONIC; EE",,,Ethylmalonic encephalopathy,,ETHE1,ETHE1,persulfide dioxygenase,adb8bd6fce0f456c5086ed3d84e47e81f4fc9c84a42ab4f50efa85c1b0193ea4,7.6.2.1,7.6.2.1,,"It significantly reduces the inhibitory effect of sulfide on cytochrome c oxidase, resulting in higher rates of respiration and sulfide oxidation in rat mitochondria.",Dehydroascorbic acid,DB08830,DB08830,88ed6287e37bb7402dc06d91a328dd906f0c6a3b47f91fa0dbb288a37d825341,DB08830,DB08830,,,,,,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,,Sulfide toxicity,NA,,"https://www.sciencedirect.com/science/article/pii/S0005272811001447#bb0230,https://www.ncbi.nlm.nih.gov/pubmed/17712735,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29526615",23474,ETHE1,172,O95571,K17725,1.13.11.18,
1238,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,DB01045 + DB01586,89b0c42ca78054fd1efde035da5c346f43caa1e22700dfa40843160f4633457a,,,,,"DB01045,DB01586","DB01045,DB01586",,,,,,,??? activity modification of a genetically defective protein,C,pruritus,HP:0000989,,"https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642",1244,ABCC2,554,Q92887,K05666,7.6.2.2,
1239,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,DB01045 + DB01586,89b0c42ca78054fd1efde035da5c346f43caa1e22700dfa40843160f4633457a,,,,,"DB01045,DB01586","DB01045,DB01586",,,,,,,,,hyperbilirunbinemia,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642",1244,ABCC2,554,Q92887,K05666,7.6.2.2,
1240,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,DB01045 + DB01586,89b0c42ca78054fd1efde035da5c346f43caa1e22700dfa40843160f4633457a,,,,,"DB01045,DB01586","DB01045,DB01586",,,,,,,,,elevated serum concentrations of bile acids,HP:0012202,,"https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642",1244,ABCC2,554,Q92887,K05666,7.6.2.2,
1241,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,DB01045 + DB01586,89b0c42ca78054fd1efde035da5c346f43caa1e22700dfa40843160f4633457a,,,,,"DB01045,DB01586","DB01045,DB01586",,,,,,,,,high serum alkaline phosphatase,HP:0003155,,"https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642",1244,ABCC2,554,Q92887,K05666,7.6.2.2,
1242,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,DB01045 + DB01586,89b0c42ca78054fd1efde035da5c346f43caa1e22700dfa40843160f4633457a,,,,,"DB01045,DB01586","DB01045,DB01586",,,,,,,,,hyperbilirunbinemia,HP:0002904,,"https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642",1244,ABCC2,554,Q92887,K05666,7.6.2.2,
1243,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,DB01045 + DB01586,89b0c42ca78054fd1efde035da5c346f43caa1e22700dfa40843160f4633457a,,,,,"DB01045,DB01586","DB01045,DB01586",,,,,,,,,elevated serum concentrations of bile acids,HP:0012202,,"https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642",1244,ABCC2,554,Q92887,K05666,7.6.2.2,
1244,237500,,Number Sign,237500,DUBIN-JOHNSON SYNDROME; DJS,"HYPERBILIRUBINEMIA, DUBIN-JOHNSON TYPE; HBLRDJ;; HYPERBILIRUBINEMIA II",,Dubin-JohnsonÂ syndrome,,ABCC2,ABCC2,MultidrugÂ resistanceÂ protein-2,4c7eb523527be4a3409a1250f2baf86d092f2817875e288cdc467279fb72a1c0,7.6.2.1,7.6.2.1,,"Rifampicin and ursodeoxycholic acid (UDCA) therapy have beneficial effects in chronic cholestatic diseases. These may result, in part, from the induction of MRP2 expression in the liver and kidney. However, neither an indication nor a general role for these agents in Dubin-Johnson syndrome has been defined.https://www.ncbi.nlm.nih.gov/pubmed/12012642
These drugs, in fact, should be used with caution in patients with Dubin-Johnson syndrome. Reporting on a patient with the disease who had a novel 974CâG nonsense mutation of the MRP2gene, Corpechot et al found a rise in conjugated bilirubinemia following the chronic administration of rifampicin, as well as a sharp increase in serum bile acid concentration following the concomitant chronic administration of rifampicin and UDCA. These adverse effects may result from an increased expression of MRP3at the basolateral membrane of hepatocytes as a direct consequence of drug induction.https://www.ncbi.nlm.nih.gov/pubmed/16952291 https://emedicine.medscape.com/article/173517-treatment",rifampicin+UDCA,DB01045+DB01586,DB01045 + DB01586,89b0c42ca78054fd1efde035da5c346f43caa1e22700dfa40843160f4633457a,,,,,"DB01045,DB01586","DB01045,DB01586",,,,,,,,,High biliary cholesterol saturation index,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16952291/,https://www.ncbi.nlm.nih.gov/pubmed/16083704/,https://www.ncbi.nlm.nih.gov/pubmed/26264947,https://www.ncbi.nlm.nih.gov/pubmed/12012642",1244,ABCC2,554,Q92887,K05666,7.6.2.2,
1245,608799,,Number Sign,608799,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Ie; CDG1E",CDG Ie; CDGIe,,DPM1-CDG (CDG-Ie),,DPM1,DPM1,dolichol-P-mannose synthase 1,b773b155ddcb516cf5362a5d343e120d248839d5cd0c5840d35c986824cf0202,7.6.2.1,7.6.2.1,,https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,8813,DPM1,336,O60762,K00721,2.4.1.83,
1246,615042,,Number Sign,615042,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Iu; CDG1U",CDG Iu; CDGIu,,DPM2-CDG,,DPM2,DPM2,dolichyl-phosphate mannosyltransferase subunit 2,4983bad482a07e1405069670c34280fef81663c6d4fef19ac3b60a2f38970216,7.6.2.1,7.6.2.1,,https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,8818,DPM2,604,O94777,K09658,"""""",
1247,612937,,Number Sign,612937,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15; MDDGC15","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, DPM3-RELATED;; CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io; CDG1O;; CDG Io; CDGIo;; CDG1(DPM3)",,DPM3-CDG (CDG-Io),,DPM3,DPM3,dolichyl-phosphate mannosyltransferase subunit 3,a3ad9b9f9a686daf48b067c277d740720c63b7647531cd4359702b364d210ca0,7.6.2.1,7.6.2.1,,https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,54344,DPM3,387,Q9P2X0,K09659,"""""",
1248,179850,,Number Sign,179850,DOWLING-DEGOS DISEASE 1; DDD1,DDD;; RETICULAR PIGMENT ANOMALY OF FLEXURES,,Dowling-Degos disease,,KRT5/POGLUT1,"KRT5,POGLUT1",keratin 5/protein O-glucosyltransferase,136e1b3e218315d92ce0e4910f8ec541cf01021bc68ea21440812274d36a1491,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,"3852,56983","KRT5,POGLUT1",,"P13647,Q8NBL1","K07605,K13667",",2.4.1.-; 2.4.2.26",
1249,223360,,Number Sign,223360,ORTHOSTATIC HYPOTENSION 1; ORTHYP1,"DOPAMINE BETA-HYDROXYLASE DEFICIENCY, CONGENITAL;; NOREPINEPHRINE DEFICIENCY;; NORADRENALINE DEFICIENCY",,Dopamine beta hydroxylase deficiency,,DBH,DBH,dopamine beta (Î²)-hydroxylase,c0d0848916a51126275a1226a107d62354d0cefe727b99c917dba88b8ae748d7,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",droxidopa,DB06262,DB06262,56df5a8da214638477d2d0a34f74a5a116d1462023085f75a22129bc0bf0e135,DB06262,DB06262,,,,,,,ECO:0007121,ECO:0007121,,,metabolite replacement,B,orthostatic hypotension,HP:0001278,,"https://www.ncbi.nlm.nih.gov/pubmed/20301647,https://www.sciencedirect.com/topics/medicine-and-dentistry/dopamine-beta-hydroxylase-deficiency,https://clinicaltrials.gov/ct2/show/NCT00889135?cond=Dopamine+beta+hydroxylase+deficiency&rank=10",1621,DBH,101,P09172,K00503,1.14.17.1,
1250,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",levedopa/carbidopa,DB01235/DB00190,DB01235 / DB00190,c949e7e804b192c3c884a2400ce759a9f8a172027d174e50fad63a9339f66036,"DB01235,DB00190","DB01235,DB00190",,,,,,,ECO:0007121,ECO:0007121,,,metabolite replacement,B,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/9886460/,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1251,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",levedopa/carbidopa,DB01235/DB00190,DB01235 / DB00190,c949e7e804b192c3c884a2400ce759a9f8a172027d174e50fad63a9339f66036,"DB01235,DB00190","DB01235,DB00190",,,,,,,,,,,,,Parkinsonism,,,"https://www.ncbi.nlm.nih.gov/pubmed/9886460/,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1252,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",levedopa/carbidopa,DB01235/DB00190,DB01235 / DB00190,c949e7e804b192c3c884a2400ce759a9f8a172027d174e50fad63a9339f66036,"DB01235,DB00190","DB01235,DB00190",,,,,,,,,,,,,Fatigue,,,"https://www.ncbi.nlm.nih.gov/pubmed/9886460/,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1253,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",levedopa/carbidopa,DB01235/DB00190,DB01235 / DB00190,c949e7e804b192c3c884a2400ce759a9f8a172027d174e50fad63a9339f66036,"DB01235,DB00190","DB01235,DB00190",,,,,,,,,,,,,Cerebellar dysfunction,,,"https://www.ncbi.nlm.nih.gov/pubmed/16908750,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1254,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",Serotonin reuptake inhibitors,N06AB,N06AB,84f0204520392556e8f705a5a8f3b7ee5f94591f77010dbac4f1a212f9f8ae55,N06AB,,,N06AB,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Depression,HP:0000716,,"https://www.ncbi.nlm.nih.gov/pubmed/16361586,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1255,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",Serotonin reuptake inhibitors,N06AB,N06AB,84f0204520392556e8f705a5a8f3b7ee5f94591f77010dbac4f1a212f9f8ae55,N06AB,,,N06AB,,,,,,,,,,,Obsessive-compulsive behavior,HP:0000722,,"https://www.ncbi.nlm.nih.gov/pubmed/16361586,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1256,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",Serotonin reuptake inhibitors,N06AB,N06AB,84f0204520392556e8f705a5a8f3b7ee5f94591f77010dbac4f1a212f9f8ae55,N06AB,,,N06AB,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/16361586,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1257,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",Serotonin reuptake inhibitors,N06AB,N06AB,84f0204520392556e8f705a5a8f3b7ee5f94591f77010dbac4f1a212f9f8ae55,N06AB,,,N06AB,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/16361586,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1258,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",Serotonin reuptake inhibitors,N06AB,N06AB,84f0204520392556e8f705a5a8f3b7ee5f94591f77010dbac4f1a212f9f8ae55,N06AB,,,N06AB,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/16361586,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1259,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",5âhydroxytryptophan,DB02959,DB02959,baa3bf62cec194a8ef32b70a5765a4cbe13178b318b13495a3454c144baceb47,DB02959,DB02959,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Depression,HP:0000716,,"https://www.ncbi.nlm.nih.gov/pubmed/16361586,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1260,128230,,Number Sign,128230,"DYSTONIA, DOPA-RESPONSIVE; DRD","DYSTONIA 5; DYT5;; DYSTONIA, PROGRESSIVE, WITH DIURNAL VARIATION;; DYSTONIA-PARKINSONISM WITH DIURNAL FLUCTUATION;; SEGAWA SYNDROME, AUTOSOMAL DOMINANT;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL DOMINANT;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL DOMINANT",,Dopa-responsive dystonia,,GCH1/TH/SPR,"GCH1,TH,SPR",GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,df1c08ccfdae3fbfefaeea8afca393f0cc6959b3902fe1724e15992195411f59,7.6.2.1,7.6.2.1,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",5âhydroxytryptophan,DB02959,DB02959,baa3bf62cec194a8ef32b70a5765a4cbe13178b318b13495a3454c144baceb47,DB02959,DB02959,,,,,,,,,,,,,Serotonin deficiency,HP:0003117*,,"https://www.ncbi.nlm.nih.gov/pubmed/16361586,https://www.ncbi.nlm.nih.gov/pubmed/11346370/,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887","2643,7054,6697","GCH1,TH,SPR",,"P30793,P07101,P35270","K01495,K00501,K00072","3.5.4.16,1.14.16.2,1.1.1.153",
1261,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",selegiline+L-dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1262,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",selegiline+L-dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,lack of eye contact,HP:0000817,,"https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1263,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",selegiline+L-dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,Delayed motor skills,HP:0002194,,"https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1264,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",selegiline+L-dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,Poor head control,HP:0002421,,"https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1265,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",selegiline+L-dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,Delayed mental development,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1266,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,"Topical retinoic acids, topical steroids, hydroquinone, tretinoin, and systemic retinoids have been used without success. https://www.ncbi.nlm.nih.gov/pubmed/2350982
https://www.ncbi.nlm.nih.gov/pubmed/3679816 https://www.ncbi.nlm.nih.gov/pubmed/29797344

Combination of Q-switched Nd: YAG and Fractional Carbon Dioxide Laser could be a promising therapy to pigmentation of Dowling-Degos diseaseÂ  https://www.ncbi.nlm.nih.gov/pubmed/28529428",selegiline+L-dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,lack of gross motor function,HP:0002194,,"https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.ncbi.nlm.nih.gov/pubmed/11241071,https://www.ncbi.nlm.nih.gov/pubmed/10753262,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1267,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,ECO:0000352,ECO:0000352,,(926T>C,metabolite replacement,,Decreased CSF homovanillic acid,HP:0003785,,"https://www.ncbi.nlm.nih.gov/pubmed/8817341,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1268,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/22815559,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1269,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,Myoclonus jerk,HP:0001336,,"https://www.ncbi.nlm.nih.gov/pubmed/22815559,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1270,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,"Abnormal epinephrine,norepinephrin ratio",NA,,"https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1271,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,Hypokinesia,HP:0002375,,"https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1272,605407,605407,Number Sign,605407,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE","PARKINSONISM, INFANTILE, AUTOSOMAL RECESSIVE;; DYSTONIA, DOPA-RESPONSIVE, AUTOSOMAL RECESSIVE;; DOPA-RESPONSIVE DYSTONIA, AUTOSOMAL RECESSIVE;; TYROSINE HYDROXYLASE DEFICIENCY",,"SEGAWA SYNDROME, AUTOSOMAL RECESSIVE",,TH,TH,Tyrosine hydroxylase,8754171abeacc3dfab3264073c9de7204ea55eea6f4423f469c8e7a1dc02bec0,1.14.16.2,1.14.16.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,L- dopa,DB01037+DB01235,DB01037 + DB01235,9ef7e492bfc07d2482de7fb26d057ff47d099f2188f5bb6f652fb49224364d04,,,,,"DB01037,DB01235","DB01037,DB01235",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10585338,https://www.ncbi.nlm.nih.gov/pubmed/10407773,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",7054,TH,,P07101,K00501,1.14.16.2,
1273,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,D-galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,ECO:0007121/ECO:0001565,"ECO:0007121,ECO:0001565",,,functional complementation of a genetically defective protein,B,"""abnormal alanine transaminase,""",HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5236,PGM1,600,P36871,K01835,5.4.2.2,
1274,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,D-galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,abnormal aspartate transaminase,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5236,PGM1,600,P36871,K01835,5.4.2.2,
1275,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,D-galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,abnormal activated partial thromboplastin time,HP:0003645,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5236,PGM1,600,P36871,K01835,5.4.2.2,
1276,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,D-galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,abnormal Antithrombin-III levels,HP:0001976,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5236,PGM1,600,P36871,K01835,5.4.2.2,
1277,614921,,Number Sign,614921,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T",CDG It; CDGIt;; PHOSPHOGLUCOMUTASE 1 DEFICIENCY;; PGM1 DEFICIENCY;; GLYCOGEN STORAGE DISEASE XIV; GSD14;; GSD XIV,,PGM1-CDG,,PGM1,PGM1,Phosphoglucomutase-1,f07cab4c490b2fe93feaa436f48a82bd4c277f46cee75f390e8f7f6e92822ec6,5.4.2.2,5.4.2.2,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,D-galactose,DB11735,DB11735,1f74e97fd235a447d80317e323eb6f46f11f6a21fb70732030e544ee44e1fb6c,DB11735,DB11735,,,,,,,,,,,,,abnormal nucleotide sugars,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://clinicaltrials.gov/ct2/show/NCT02955264,https://www.ncbi.nlm.nih.gov/pubmed/24499211/,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5236,PGM1,600,P36871,K01835,5.4.2.2,
1278,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,Fucose,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,ECO:0001565/ECO:0005542,"ECO:0001565,ECO:0005542",,,functional complementation of a genetically defective protein,B,defected phagocytic function,HP:0010977,,"https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",55343,SLC35C1,341,Q96A29,K15279,"""""",
1279,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,Fucose,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,,,,,,,low neutrophil count,HP:0001875,,"https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",55343,SLC35C1,341,Q96A29,K15279,"""""",
1280,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,Fucose,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,,,,,,,recurrent infection,HP:0002719,,"https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",55343,SLC35C1,341,Q96A29,K15279,"""""",
1281,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,Fucose,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,,,,,,,abnormal expression of E- and P-selectin ligands,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",55343,SLC35C1,341,Q96A29,K15279,"""""",
1282,266265,,Number Sign,266265,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE IIc; CDG2C","CDG IIc; CDGIIc;; LEUKOCYTE ADHESION DEFICIENCY, TYPE II; LAD2;; RAMBAM-HASHARON SYNDROME; RHS",,SLC35C1-CDG (CDG-IIc),,SLC35C1,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,75eda67f77806110cd38d0be0f56f1075955a28532e7b0ecb43cb99fa4186c77,Q96A29,,Q96A29,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,Fucose,DB03485,DB03485,44ef868db3e41e8089d51cc713bfaf6555cfe7d89e17a0581dd98b4b97eb1cb1,DB03485,DB03485,,,,,,,,,,,,,atypical psychomotor development,HP:0001263*,,"https://www.ncbi.nlm.nih.gov/pubmed/29702557,https://www.ncbi.nlm.nih.gov/pubmed/17276979,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",55343,SLC35C1,341,Q96A29,K15279,"""""",
1283,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,DOLK-CDG,,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,2.7.1.108,2.7.1.108,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,vigabatrin,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",22845,DOLK,342,Q9UPQ8,K00902,2.7.1.108,
1284,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,DOLK-CDG,,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,2.7.1.108,2.7.1.108,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,Carbamazepine,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Generalized tonicâclonic seizure,HP:0002069,,"https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",22845,DOLK,342,Q9UPQ8,K00902,2.7.1.108,
1285,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,DOLK-CDG,,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,2.7.1.108,2.7.1.108,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,Carbamazepine,DB01080,DB01080,f7a903b58407e908be2304aca45f2a6a325817759c863e9e5b0143a883b28f2b,DB01080,DB01080,,,,,,,,,,,,,Focal seizures,HP:0007359,,"https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",22845,DOLK,342,Q9UPQ8,K00902,2.7.1.108,
1286,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,DOLK-CDG,,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,2.7.1.108,2.7.1.108,,There is one case that didn't responed to l- dpa treatmet although of confirmed mutation in TH gene. https://www.ncbi.nlm.nih.gov/pubmed/11196107,clonazepam+vigabatrin,DB01068+DB01080,DB01068 + DB01080,8eef378a8660dc0af9d40175635094dbfa8cbe3a92f5ecea7d8fee292962f1d4,,,,,"DB01068,DB01080","DB01068,DB01080",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/10590041,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",22845,DOLK,342,Q9UPQ8,K00902,2.7.1.108,
1287,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,Dipsogenic diabetes insipidus,Behavioural therapy was a successful treatmemnt for primary polydipsia.https://www.ncbi.nlm.nih.gov/pubmed/2373769?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/12102585?dopt=Abstract https://www.ncbi.nlm.nih.gov/pubmed/3392224?dopt=Abstract,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,2.7.1.108,2.7.1.108,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",desmopressin,DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,polyuria,HP:0000103,,"https://www.ncbi.nlm.nih.gov/pubmed/16544179,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/16544179,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",22845,DOLK,342,Q9UPQ8,K00902,2.7.1.108,
1288,610768,,Number Sign,610768,"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Im; CDG1M",CDG Im; CDGIm;; DOLICHOL KINASE DEFICIENCY;; DK1 DEFICIENCY,,Dipsogenic diabetes insipidus,,DOLK,DOLK,dolichol kinase,b939fa5c82ed9cb7a78499f939b2226ab0495873deb99f7dfa7bd274972cf0ab,2.7.1.108,2.7.1.108,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",desmopressin,DB00035,DB00035,feb82d9987c103ae3b1243fcda6dc642f56545ca1dab9a1db2e75f54b3edb9ba,DB00035,DB00035,,,,,,,,,,,,,affected functional activity,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/16544179,https://www.ncbi.nlm.nih.gov/pubmed/23890587,https://www.ncbi.nlm.nih.gov/pubmed/16544179,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",22845,DOLK,342,Q9UPQ8,K00902,2.7.1.108,
1289,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,1.3.1.2,1.3.1.2,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",uridine triacetate,DB09144,DB09144,440fb1c050f1ba7bf4971a696a78852d6ee6bd1c41a83aae02605bb37880978d,DB09144,DB09144,,,,,,,ECO:0005542/ECO:0000305,"ECO:0005542,ECO:0000305",,,functional complementation of a defective protein by inhibition,B,mortality,HP:0040006,,"https://www.ncbi.nlm.nih.gov/pubmed/29908244,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://www.ncbi.nlm.nih.gov/pubmed/16544179,https://www.ncbi.nlm.nih.gov/pubmed/9732974,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",1806,DPYD,159,Q12882,K00207,1.3.1.2,
1290,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,1.3.1.2,1.3.1.2,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",uridine triacetate,DB09144,DB09144,440fb1c050f1ba7bf4971a696a78852d6ee6bd1c41a83aae02605bb37880978d,DB09144,DB09144,,,,,,,,,,,,,Weight loss,HP:0001824,,"https://www.ncbi.nlm.nih.gov/pubmed/29908244,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",1806,DPYD,159,Q12882,K00207,1.3.1.2,
1291,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,1.3.1.2,1.3.1.2,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Valproic acid,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Generalized muscular hypotonia,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pubmed/28275972,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",1806,DPYD,159,Q12882,K00207,1.3.1.2,
1292,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,1.3.1.2,1.3.1.2,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Valproic acid,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,,,,,,,EEG with parito-occipital spike waves,HP:0012011,,"https://www.ncbi.nlm.nih.gov/pubmed/28275972,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",1806,DPYD,159,Q12882,K00207,1.3.1.2,
1293,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,1.3.1.2,1.3.1.2,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Valproic acid,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,,,,,,,Developmental impairment,HP:0001270,,"https://www.ncbi.nlm.nih.gov/pubmed/28275972,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",1806,DPYD,159,Q12882,K00207,1.3.1.2,
1294,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,1.3.1.2,1.3.1.2,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Valproic acid,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,,,,,,,Speech and languague delay,,,"HP:0000750,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",1806,DPYD,159,Q12882,K00207,1.3.1.2,
1295,274270,,Number Sign,274270,DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY,"DPD DEFICIENCY;; DPYD DEFICIENCY;; THYMINE-URACILURIA, HEREDITARY;; PYRIMIDINEMIA, FAMILIAL","5-FLUOROURACIL TOXICITY, INCLUDED",Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,DPYD,dihydropyrimidine dehydrogenase,b3a1ac271f9b97332115ed9b6f93a913da4c4ccd8dac9ef3f0d828cbe00c82c9,1.3.1.2,1.3.1.2,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Valpric acid + carbamazepine,DB00313+DB00564,DB00313 + DB00564,c6e9b056eef426486b1fd24405f26f60b1ddc961400e456d079e3c602a7e0d8f,,,,,"DB00313,DB00564","DB00313,DB00564",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/30349988,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",1806,DPYD,159,Q12882,K00207,1.3.1.2,
1296,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",BH4+L-dopa/carbidopa +5-hydroxytryptophan+ folinic acid,DB00360+DB01235/DB00190+DB02959+DB00650,DB00360 + DB01235 / DB00190 + DB02959 + DB00650,29576ad8cd0445d4e64367ba9062b90f3558ef02a7e54a75d13c416f98fc6e43,DB00190,DB00190,,,"DB00360,DB01235,DB02959,DB00650","DB00360,DB01235,DB02959,DB00650",,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,High plasma phenylalanine level,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/30349988,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1297,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",BH4+L-dopa/carbidopa +5-hydroxytryptophan+ folinic acid,DB00360+DB01235/DB00190+DB02959+DB00650,DB00360 + DB01235 / DB00190 + DB02959 + DB00650,29576ad8cd0445d4e64367ba9062b90f3558ef02a7e54a75d13c416f98fc6e43,DB00190,DB00190,,,"DB00360,DB01235,DB02959,DB00650","DB00360,DB01235,DB02959,DB00650",,,,,,,,,developmental delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/30349988,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1298,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",BH4+L-dopa/carbidopa +5-hydroxytryptophan+ folinic acid,DB00360+DB01235/DB00190+DB02959+DB00650,DB00360 + DB01235 / DB00190 + DB02959 + DB00650,29576ad8cd0445d4e64367ba9062b90f3558ef02a7e54a75d13c416f98fc6e43,DB00190,DB00190,,,"DB00360,DB01235,DB02959,DB00650","DB00360,DB01235,DB02959,DB00650",,,,,,,,,unalertencess,HP:0002329*,,"https://www.ncbi.nlm.nih.gov/pubmed/30349988,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1299,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",BH4+L-dopa/carbidopa +5-hydroxytryptophan+ folinic acid,DB00360+DB01235/DB00190+DB02959+DB00650,DB00360 + DB01235 / DB00190 + DB02959 + DB00650,29576ad8cd0445d4e64367ba9062b90f3558ef02a7e54a75d13c416f98fc6e43,DB00190,DB00190,,,"DB00360,DB01235,DB02959,DB00650","DB00360,DB01235,DB02959,DB00650",,,,,,,,,Receptive language delay,HP:0010863,,"https://www.ncbi.nlm.nih.gov/pubmed/30349988,https://www.ncbi.nlm.nih.gov/pubmed/27622829,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1300,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phe-restricted diet +folinic acid+L-dopa+5-hydroxytryptophan,DB00650Â +DB01235+DB02959,DB00650 + DB01235 + DB02959,86c040d7868dcdc6489f6de80997a088405c40c3ed5c14490fe01ef702c7644d,,,,,"DB00650,DB01235,DB02959","DB00650,DB01235,DB02959",,,ECO:0000352,ECO:0000352,,,dietary exclusion+metabolite replacement,B,high plasma phenylalanine level,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1301,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phe-restricted diet +folinic acid+L-dopa+5-hydroxytryptophan,DB00650Â +DB01235+DB02959,DB00650 + DB01235 + DB02959,86c040d7868dcdc6489f6de80997a088405c40c3ed5c14490fe01ef702c7644d,,,,,"DB00650,DB01235,DB02959","DB00650,DB01235,DB02959",,,,,,,,,High serum  prolactin,HP:0040086,,"https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1302,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phe-restricted diet +folinic acid+L-dopa+5-hydroxytryptophan,DB00650Â +DB01235+DB02959,DB00650 + DB01235 + DB02959,86c040d7868dcdc6489f6de80997a088405c40c3ed5c14490fe01ef702c7644d,,,,,"DB00650,DB01235,DB02959","DB00650,DB01235,DB02959",,,,,,,,,Neurological abnormalities,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1303,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phe-restricted diet +folinic acid+L-dopa+5-hydroxytryptophan,DB00650Â +DB01235+DB02959,DB00650 + DB01235 + DB02959,86c040d7868dcdc6489f6de80997a088405c40c3ed5c14490fe01ef702c7644d,,,,,"DB00650,DB01235,DB02959","DB00650,DB01235,DB02959",,,,,,,,,abnormal blood Phe levels,HP:0010893,,"https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1304,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",lâdopa+5-hydroxytryptophan+BH4+entacapone,DB01235+DB02959+DB00360+DB00494,DB01235 + DB02959 + DB00360 + DB00494,8730bde4b23d9b4876637ff2cd6c2e341596f42e1436ed3a47738c52aad28ddc,,,,,"DB01235,DB02959,DB00360,DB00494","DB01235,DB02959,DB00360,DB00494",,,ECO:0000352,ECO:0000352,,,metabolite replacement+symptomatic treatment procedure,C,high plasma phenylalanine level,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/25667865,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1305,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/25667865,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1306,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phenobarbital + Valproate,DB01174+DB00313,DB01174 + DB00313,f3943775e79897639f46d338dc39d64a50d98f310366174caf16ade0529a0c51,,,,,"DB01174,DB00313","DB01174,DB00313",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Spastic tetraparesis,HP:0001285,,"https://www.ncbi.nlm.nih.gov/pubmed/18060820,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1307,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phenobarbital + Valproate,DB01174+DB00313,DB01174 + DB00313,f3943775e79897639f46d338dc39d64a50d98f310366174caf16ade0529a0c51,,,,,"DB01174,DB00313","DB01174,DB00313",,,,,,,,,Epilepsy,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/18060820,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1308,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phenobarbital + Valproate,DB01174+DB00313,DB01174 + DB00313,f3943775e79897639f46d338dc39d64a50d98f310366174caf16ade0529a0c51,,,,,"DB01174,DB00313","DB01174,DB00313",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/18060820,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1309,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",Phenobarbital + Valproate,DB01174+DB00313,DB01174 + DB00313,f3943775e79897639f46d338dc39d64a50d98f310366174caf16ade0529a0c51,,,,,"DB01174,DB00313","DB01174,DB00313",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/18060820,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1310,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",lâdopa+carbidop+5-hydroxytryptophan+selegiline,DB01235+DB00190+DB02959+DB01037,DB01235 + DB00190 + DB02959 + DB01037,eea62e63745c621fb4ae2eb82188ecbc61c87a6e208493f2151f170c54674bfd,,,,,"DB01235,DB00190,DB02959,DB01037","DB01235,DB00190,DB02959,DB01037",,,ECO:0000352,ECO:0000352,,,metabolite replacement+symptomatic treatment procedure,C,high plasma phenylalanine level,done,,"https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/7760062,https://www.ncbi.nlm.nih.gov/pubmed/18425437,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1311,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",pramipexole,DB00413,DB00413,290d325ba989b4fff91dd03ea4802da44c13419e775c00006b58d6a058ac79d4,DB00413,DB00413,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,dopamine deficiency,HP:0012656,,"https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1312,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",pramipexole,DB00413,DB00413,290d325ba989b4fff91dd03ea4802da44c13419e775c00006b58d6a058ac79d4,DB00413,DB00413,,,,,,,,,,,,,movement disability,HP:0100022,,"https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1313,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",pramipexole,DB00413,DB00413,290d325ba989b4fff91dd03ea4802da44c13419e775c00006b58d6a058ac79d4,DB00413,DB00413,,,,,,,,,,,,,behavioral disability,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1314,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Alhough therapy with desmopressin cannot be recommended based on the results of a single case, the outcome presented here is intriguing and suggests that larger studies in such patients is warranted to assess the broader application of such an intervention.",pramipexole,DB00413,DB00413,290d325ba989b4fff91dd03ea4802da44c13419e775c00006b58d6a058ac79d4,DB00413,DB00413,,,,,,,,,,,,,hyperprolactinemia,HP:0000870,,"https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1315,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,DB05271 + DB01235 + DB00190,1d815ccf058af50d2569cdf29a328ea01195a1ba97dafa1186c05bfec87f119b,,,,,"DB05271,DB01235,DB00190","DB05271,DB01235,DB00190",,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by stimulation,B,parkinsonian symptoms,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1316,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,DB05271 + DB01235 + DB00190,1d815ccf058af50d2569cdf29a328ea01195a1ba97dafa1186c05bfec87f119b,,,,,"DB05271,DB01235,DB00190","DB05271,DB01235,DB00190",,,,,,,,,Postural tremor,HP:0002174,,"https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1317,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,DB05271 + DB01235 + DB00190,1d815ccf058af50d2569cdf29a328ea01195a1ba97dafa1186c05bfec87f119b,,,,,"DB05271,DB01235,DB00190","DB05271,DB01235,DB00190",,,,,,,,,Kinetic tremor,HP:0030186,,"https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1318,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,DB05271 + DB01235 + DB00190,1d815ccf058af50d2569cdf29a328ea01195a1ba97dafa1186c05bfec87f119b,,,,,"DB05271,DB01235,DB00190","DB05271,DB01235,DB00190",,,,,,,,,Bradykinesia,HP:0002067,,"https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1319,261630,,Number Sign,261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO DHPR DEFICIENCY;; DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; DHPR DEFICIENCY;; QUINOID DIHYDROPTERIDINE REDUCTASE DEFICIENCY;; QDPR DEFICIENCY",,Dihydropteridine reductase deficiency,,QDPR,QDPR,quinoid dihydropteridine reductase,f66a689666513961f9f166502bbda6caa42c91d6a5a1965de0f3d872f4960c56,1.5.1.34,1.5.1.34,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Rotigotine+L-dopa+carbidopa,DB05271+DB01235+DB00190,DB05271 + DB01235 + DB00190,1d815ccf058af50d2569cdf29a328ea01195a1ba97dafa1186c05bfec87f119b,,,,,"DB05271,DB01235,DB00190","DB05271,DB01235,DB00190",,,,,,,,,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/25707872,https://www.ncbi.nlm.nih.gov/pubmed/27423595,https://www.ncbi.nlm.nih.gov/pubmed/26817292,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://www.ncbi.nlm.nih.gov/pubmed/8163996,https://www.ncbi.nlm.nih.gov/pubmed/1899474,https://www.ncbi.nlm.nih.gov/pubmed/12084887",5860,QDPR,5,P09417,K00357,1.5.1.34,
1320,222748,,Number Sign,222748,DIHYDROPYRIMIDINASE DEFICIENCY; DPYSD,DIHYDROPYRIMIDINURIA;; DPYS DEFICIENCY;; DPH DEFICIENCY,,Dihydropyrimidinase deficiency,,DPYS,DPYS,dihydropyrimidinase,37bc07b207a99262f09e5fa9bea99ca067b39876b3e11db1433a4471b1c9b598,3.5.2.2,3.5.2.2,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,dyskinesias,HP:0100660,,,1807,DPYS,268,Q14117,K01464,3.5.2.2,
1321,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352/ECO:0001565,"ECO:0000352,ECO:0001565",,,activity modification of a genetically defective protein,A,Exercise intolerance,HP:0003546,,"https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1322,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,Myopathy,HP:0003198,,"https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1323,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,Fatiguability,HP:0003750,,"https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1324,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",biotin+coenzyme Q+carnitine+Riboflavin,DB00121+DB09270+DB00148+DB00140,DB00121 + DB09270 + DB00148 + DB00140,1c722a390d858430bd6c9d60bb9a836cff1657dbec0d236538bb5a01efe2bfa9,,,,,"DB00121,DB09270,DB00148,DB00140","DB00121,DB09270,DB00148,DB00140",,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein+symptomatic treatment procedure,C,Repeated vomiting,HP:0002572,,"https://www.ncbi.nlm.nih.gov/pubmed/14765544,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1325,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",biotin+coenzyme Q+carnitine+Riboflavin,DB00121+DB09270+DB00148+DB00140,DB00121 + DB09270 + DB00148 + DB00140,1c722a390d858430bd6c9d60bb9a836cff1657dbec0d236538bb5a01efe2bfa9,,,,,"DB00121,DB09270,DB00148,DB00140","DB00121,DB09270,DB00148,DB00140",,,,,,,,C,Encephalopathy,HP:0001298,,"https://www.ncbi.nlm.nih.gov/pubmed/14765544,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1326,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",biotin+coenzyme Q+carnitine+Riboflavin,DB00121+DB09270+DB00148+DB00140,DB00121 + DB09270 + DB00148 + DB00140,1c722a390d858430bd6c9d60bb9a836cff1657dbec0d236538bb5a01efe2bfa9,,,,,"DB00121,DB09270,DB00148,DB00140","DB00121,DB09270,DB00148,DB00140",,,,,,,,C,Lactic acidosis,HP:0003128,,"https://www.ncbi.nlm.nih.gov/pubmed/14765544,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1327,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Sodium bicarbonate+Dichloroacetate+ Carnitine+ Thiamin+ Coenzyme Q+ Riboflavin,DB00121+DB09270+DB00148+DB00140,DB00121 + DB09270 + DB00148 + DB00140,1c722a390d858430bd6c9d60bb9a836cff1657dbec0d236538bb5a01efe2bfa9,,,,,"DB00121,DB09270,DB00148,DB00140","DB00121,DB09270,DB00148,DB00140",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+activity modification,,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/10448086,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1328,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Thiamine,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,ECO:0000352,ECO:0000352,p.I480M,,activity modification of a genetically defective protein,C,Recurrent vomiting,HP:0002572,,"https://www.ncbi.nlm.nih.gov/pubmed/10448086,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10448086,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1329,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Thiamine,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,,,,,,,Ptosis,HP:0000508,,"https://www.ncbi.nlm.nih.gov/pubmed/20652410,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10448086,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1330,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Beneficial effects were initially observed on parkinsonian symptoms. However, dyskinesia and dystonic features re-emerged after three months of treatment.",Thiamine,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,,,,,,,Increased muscle fatiguability,HP:0003750,,"https://www.ncbi.nlm.nih.gov/pubmed/20652410,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10448086,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1331,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",sodium dichloroacetate,DB08809,DB08809,71802b7b681b44ab3ed9d0b44efa6ba19246ead16dace1ff0c9770fb7d25a678,DB08809,DB08809,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,C,lactic acidemia,HP:0003128,,"https://www.ncbi.nlm.nih.gov/pubmed/8652022,https://www.ncbi.nlm.nih.gov/pubmed/11687750,https://www.ncbi.nlm.nih.gov/pubmed/23478190,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1332,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",Lipoic acid,DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,lactic acidemia,HP:0003128,,"https://www.ncbi.nlm.nih.gov/pubmed/6418873,https://www.ncbi.nlm.nih.gov/pubmed/11687750,https://www.ncbi.nlm.nih.gov/pubmed/23478190,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pubmed/10970889",1738,DLD,,P09622,K00382,1.8.1.4,
1333,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,Dihydrolipoamide dehydrogenase deficiency,,DLD,DLD,dihydrolipoamide dehydrogenase,2c1d2fb50d2b3e0cb6df05e2396a325e0cd83000e89f2b6f6f3b60a49ab49cfb,1.8.1.4,1.8.1.4,,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",Lipoic acid,DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,,,,,,,pyruvic acidemia,HP:0001941,,"https://www.ncbi.nlm.nih.gov/pubmed/6418873,https://www.ncbi.nlm.nih.gov/pubmed/11687750,https://www.ncbi.nlm.nih.gov/pubmed/23478190,https://www.ncbi.nlm.nih.gov/pubmed/25032271,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/",1738,DLD,,P09622,K00382,1.8.1.4,
1334,222730,,Number Sign,222730,DICARBOXYLIC AMINOACIDURIA; DCBXA,GLUTAMATE-ASPARTATE TRANSPORT DEFECT,,Dicarboxylic aminoaciduria,,SLC1A1,SLC1A1,Excitatory amino acid transporter 3,388765f2186b8e11bef3bfc40dcc4ab58b4aa6da4435048f90b5c68c4eec2fc5,P43005,,P43005,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,6505,SLC1A1,49,P43005,K05612,"""""",
1335,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Tonic-clonic seizures,HP:0002069,,"https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1336,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,,,,,,,Myoclonus,HP:0001336,,"https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1337,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,,,,,,,EEG abnormality,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1338,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,,,,,,,Poor appetite,HP:0004396,,"https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1339,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,,,,,,,Low quality of life,HP:0025142,,"https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1340,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"Use of dichloroacetate to activate the pyruvate dehydrogenase complex led to a significant decline in lactate levels, but this was also transient.https://www.ncbi.nlm.nih.gov/pubmed/8652022",levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,,,,,,,Epileptic seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1341,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"""A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA."" https://www.ncbi.nlm.nih.gov/pubmed/29739138",olanzapine,DB00334,DB00334,a177eb9898442efb8c5f5551b203d444eb5da39e37f430bbde66470ff016e333,DB00334,DB00334,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Psychosis,HP:0000709,,"https://www.ncbi.nlm.nih.gov/pubmed/29739138,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1342,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"""A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA."" https://www.ncbi.nlm.nih.gov/pubmed/29739138",olanzapine,DB00334,DB00334,a177eb9898442efb8c5f5551b203d444eb5da39e37f430bbde66470ff016e333,DB00334,DB00334,,,,,,,,,,,,,Hallucinatory-paranoid state,HP:0011999*,,"https://www.ncbi.nlm.nih.gov/pubmed/29739138,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1343,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,"""A limitation of this study is that we did not use quantative measures, such as the Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale, to evaluate severity of psychosis. This issue warrants further investigations for the benefit of SGAs to treat psychosis with DRPLA."" https://www.ncbi.nlm.nih.gov/pubmed/29739138",olanzapine,DB00334,DB00334,a177eb9898442efb8c5f5551b203d444eb5da39e37f430bbde66470ff016e333,DB00334,DB00334,,,,,,,,,,,,,Auditory hallucinations,HP:0008765,,"https://www.ncbi.nlm.nih.gov/pubmed/29739138,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1344,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,The treatment regimen resulted in neuroleptic malignant syndrome.,HaloperidolÂ +Levomepromazine,DB00502+DB01403,DB00502 + DB01403,547a3d253d72ab9407a98be4ebf722f2a979b4da95a69fa66e255759c945b8ad,,,,,"DB00502,DB01403","DB00502,DB01403",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Psychosis,HP:0000709,,"https://www.ncbi.nlm.nih.gov/pubmed/11449034/,https://www.ncbi.nlm.nih.gov/pubmed/29739138,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1345,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,The treatment regimen resulted in neuroleptic malignant syndrome.,Perampanel,DB08883,DB08883,fe228167ceb5a8d853ece56c0579ab7adf47ab79df2efc63d820119756651f6b,DB08883,DB08883,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Diminished intellectual abilities,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/28856097,https://www.ncbi.nlm.nih.gov/pubmed/29739138,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1346,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,The treatment regimen resulted in neuroleptic malignant syndrome.,Perampanel,DB08883,DB08883,fe228167ceb5a8d853ece56c0579ab7adf47ab79df2efc63d820119756651f6b,DB08883,DB08883,,,,,,,,,,,,,myoclonic seizures,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pubmed/28856097,https://www.ncbi.nlm.nih.gov/pubmed/29739138,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1347,125370,,Number Sign,125370,DENTATORUBRAL-PALLIDOLUYSIAN ATROPHY; DRPLA,"MYOCLONIC EPILEPSY WITH CHOREOATHETOSIS;; NAITO-OYANAGI DISEASE; NOD;; HAW RIVER SYNDROME; HRS;; ATAXIA, CHOREA, SEIZURES, AND DEMENTIA",,Dentatorubral-pallidoluysian atrophy,,ATN1,ATN1,atrophin 1,9397d8d8822049e9c35edbb75eb2bb39364f753ba7400616a9a4d504d566249b,P54259,,P54259,The treatment regimen resulted in neuroleptic malignant syndrome.,Perampanel,DB08883,DB08883,fe228167ceb5a8d853ece56c0579ab7adf47ab79df2efc63d820119756651f6b,DB08883,DB08883,,,,,,,,,,,,,inability to walk,HP:0002540,,"https://www.ncbi.nlm.nih.gov/pubmed/28856097,https://www.ncbi.nlm.nih.gov/pubmed/29739138,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1822,ATN1,,P54259,K05626,"""""",
1348,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,1.3.1.72,1.3.1.72,,The treatment regimen resulted in neuroleptic malignant syndrome.,Riboflavin+Nicotinamide+Thiamine,DB00140+DB02701+DB00152,DB00140 + DB02701 + DB00152,6cd9aa5c9e1c7e910b160594f3cfd879967ee0713cb7ed55f63046bdd608726b,,,,,"DB00140,DB02701,DB00152","DB00140,DB02701,DB00152",,,ECO:0007764/ECO:0007121,"ECO:0007764,ECO:0007121",,,activity modification of a genetically defective protein,B,High desmosterol levelsÂ (Abnormality of cholesterol metabolism)*,HP:0003107*,The change was not statistically significant.,"https://www.ncbi.nlm.nih.gov/pubmed/28856097,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1718,DHCR24,195,Q15392,K09828,1.3.1.72,
1349,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,1.3.1.72,1.3.1.72,,The treatment regimen resulted in neuroleptic malignant syndrome.,Riboflavin+Nicotinamide+Thiamine,DB00140+DB02701+DB00152,DB00140 + DB02701 + DB00152,6cd9aa5c9e1c7e910b160594f3cfd879967ee0713cb7ed55f63046bdd608726b,,,,,"DB00140,DB02701,DB00152","DB00140,DB02701,DB00152",,,,,,,,,"High desmosterol,cholesterol ratio",HP:0003107*,The change was not statistically significant.,"https://www.ncbi.nlm.nih.gov/pubmed/28856097,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1718,DHCR24,195,Q15392,K09828,1.3.1.72,
1350,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,1.3.1.72,1.3.1.72,,The treatment regimen resulted in neuroleptic malignant syndrome.,Riboflavin+Nicotinamide+Thiamine,DB00140+DB02701+DB00152,DB00140 + DB02701 + DB00152,6cd9aa5c9e1c7e910b160594f3cfd879967ee0713cb7ed55f63046bdd608726b,,,,,"DB00140,DB02701,DB00152","DB00140,DB02701,DB00152",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28856097,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1718,DHCR24,195,Q15392,K09828,1.3.1.72,
1351,602398,602398,Number Sign,602398,DESMOSTEROLOSIS,,,Desmosterolosis,,DHCR24,DHCR24,3-beta-hydroxysterol delta-24-reductase,32bbfd8a0635e6d6d217b3720536b4b40f8d79c794f4c5fa18d70feb59ef2b85,1.3.1.72,1.3.1.72,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",cholesterol,DB04540,DB04540,35d8d2e536310c7ee95cf58f43abb43574e00c3fcc4be87e1443448125e7a2e7,DB04540,DB04540,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,High desmosterol levelsÂ (Abnormality of cholesterol metabolism)*,HP:0003107*,,"https://www.ncbi.nlm.nih.gov/pubmed/10959439,https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6,https://www.ncbi.nlm.nih.gov/pubmed/24816443",1718,DHCR24,195,Q15392,K09828,1.3.1.72,
1352,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",L-leucine,DB00149,DB00149,0ab0e4635f785428b642513a35aa1de824a96f5a9002b3ceec83ccc40aa51fe9,DB00149,DB00149,,,,,,,ECO:0007121/ECO:0005542/ECO:0000352,"ECO:0007121,ECO:0005542,ECO:0000352",,,activity modification of a genetically defective protein by transcriptional or translational modification,B,low heamoglobin leval,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/10959439,https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1353,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",L-leucine,DB00149,DB00149,0ab0e4635f785428b642513a35aa1de824a96f5a9002b3ceec83ccc40aa51fe9,DB00149,DB00149,,,,,,,,,,,,,Defect in protein synthesis (Abnormality of circulating protein level)*,HP:0010876*,,"https://www.ncbi.nlm.nih.gov/pubmed/10959439,https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1354,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",L-leucine,DB00149,DB00149,0ab0e4635f785428b642513a35aa1de824a96f5a9002b3ceec83ccc40aa51fe9,DB00149,DB00149,,,,,,,,,,,,,Decreased red blood cell production,HP:0012133*,,"https://www.ncbi.nlm.nih.gov/pubmed/10959439,https://clinicaltrials.gov/ct2/show/NCT01362595?cond=Diamond-Blackfan+anemia&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1355,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Antithymocyte globulin+Cyclosporine,DB00098+DB00091,DB00098 + DB00091,c344136a5c9639c06b73479b19bb5da9553e14e73b250de8a062479209afd68c,,,,,"DB00098,DB00091","DB00098,DB00091",,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Pure red bllod cell aplasia,HP:0012410,,"https://www.ncbi.nlm.nih.gov/pubmed/15813920,https://clinicaltrials.gov/ct2/show/NCT00001749,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1356,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Rituximab,DB00073,DB00073,b6ad43e0794f0e25752143cc390b9c74dd387c0ab16f94cb2491cb43a2c010a8,DB00073,DB00073,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,symptomatic treatment procedure,C,low RBC count,HP:0001877,,"https://www.ncbi.nlm.nih.gov/pubmed/15813920,https://clinicaltrials.gov/ct2/show/study/NCT00229619?cond=Diamond-Blackfan+anemia&rank=7&sect=X70156,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1357,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Daclizumab,DB00111,DB00111,3a119e9c3f78fcad08e0c4a20a4f2b46d086c4c17746dcf9afed38af04dfa75c,DB00111,DB00111,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,low RBC count,HP:0001877,,"https://www.ncbi.nlm.nih.gov/pubmed/15813920,https://clinicaltrials.gov/ct2/show/results/NCT00001962?cond=Diamond-Blackfan+anemia&rank=8&sect=X70156#outcome1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1358,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",lenalidomide,DB00480,DB00480,4c9822a75b067e7e9b548521f4c40a7aa62f6b12e480199afc343541eaf4c8f6,DB00480,DB00480,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,low RBC count,HP:0001877,,"https://www.ncbi.nlm.nih.gov/pubmed/15813920,https://clinicaltrials.gov/ct2/show/NCT01034592?cond=Diamond-Blackfan+anemia&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1359,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",prednisolone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,low hb level,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1360,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",prednisolone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,low quality of ife,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1361,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",prednisolone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,Pathological apoptosis,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1362,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",prednisolone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,erythroid progenitor depletion,HP:0025034*,,"https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1363,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",prednisolone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,premature differentiation of erythroid cells,HP:0012130*,,"https://www.ncbi.nlm.nih.gov/pubmed/27329125,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26305041,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1364,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Prednisone +Cyclosporine,DB00635+DB00091,DB00635 + DB00091,cff51f590b9aab5047fe4ecad59b94f622e16f1ea2615a4a8fd063f05a7c91a2,,,,,"DB00635,DB00091","DB00635,DB00091",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a defective protein by inhibition,B,low Hb level,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/27329125,https://www.ncbi.nlm.nih.gov/pubmed/3389144?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2503027?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/1546717?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1365,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Prednisone +Cyclosporine,DB00635+DB00091,DB00635 + DB00091,cff51f590b9aab5047fe4ecad59b94f622e16f1ea2615a4a8fd063f05a7c91a2,,,,,"DB00635,DB00091","DB00635,DB00091",,,,,,,,,Reticulocytopenia,HP:0001896,,"https://www.ncbi.nlm.nih.gov/pubmed/27329125,https://www.ncbi.nlm.nih.gov/pubmed/3389144?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2503027?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/1546717?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1366,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Metoclopramide,DB01233,DB01233,8f4199ed3e9676670d7de1d9828519772dc66334e1bc8d3e042d2a8244732536,DB01233,DB01233,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by stimulation,,low Hb level,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/15795909,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1367,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Metoclopramide,DB01233,DB01233,8f4199ed3e9676670d7de1d9828519772dc66334e1bc8d3e042d2a8244732536,DB01233,DB01233,,,,,,,,,,,,,Reduced hematocrit,HP:0031851,,"https://www.ncbi.nlm.nih.gov/pubmed/15795909,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1368,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Metoclopramide+prednisolone,DB01233+DB00635,DB01233 + DB00635,0996df2ba4f7c62ba3b541137288ab6cc941cc6d98ad430389e16780689c904c,,,,,"DB01233,DB00635","DB01233,DB00635",,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by stimulation+functional complementation of a genetically defective protein,,low Hb level,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/24744655,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1369,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Eltrombopag,DB06210,DB06210,3b49c8d5051311812e28f412a50f7faf6bbdaef12a2d953de7528a2716de4042,DB06210,DB06210,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",(c.356+3>C),,functional complementation of a defective protein by stimulation,,low Hb level,HP:0001903,,"http://www.bloodjournal.org/content/128/22/2682,https://clinicaltrials.gov/ct2/show/NCT01328587,https://www.ncbi.nlm.nih.gov/pubmed/29684566,https://www.ncbi.nlm.nih.gov/pubmed/24744655,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1370,105650,,Number Sign,105650,DIAMOND-BLACKFAN ANEMIA 1; DBA1,"DBA;; BLACKFAN-DIAMOND SYNDROME; BDS;; ANEMIA, CONGENITAL HYPOPLASTIC, OF BLACKFAN AND DIAMOND;; ANEMIA, CONGENITAL ERYTHROID HYPOPLASTIC;; RED CELL APLASIA, PURE, HEREDITARY;; AREGENERATIVE ANEMIA, CHRONIC CONGENITAL;; ERYTHROGENESIS IMPERFECTA;; AASE-SMITH SYNDROME II;; AASE SYNDROME",,Diamond-Blackfan anemia,,"RPS19,Â RPL5, Â RPS10,Â RPL11,Â RPL35A,Â RPS7,Â Â RPS17,Â RPS24, Â RPS26Â andÂ GATA1","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,and,GATA1",40S ribosomal protein S19,33ddf34bb8063b65a93a3ab96bd6dc178aa68e0b91eddb946532a60964f8bbfb,P39019,,P39019,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Eltrombopag,DB06210,DB06210,3b49c8d5051311812e28f412a50f7faf6bbdaef12a2d953de7528a2716de4042,DB06210,DB06210,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,"http://www.bloodjournal.org/content/128/22/2682,https://clinicaltrials.gov/ct2/show/NCT01328587,https://www.ncbi.nlm.nih.gov/pubmed/29684566,https://www.ncbi.nlm.nih.gov/pubmed/24744655,https://www.ncbi.nlm.nih.gov/pubmed/10779036?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294","6223,6125,6204,6135,6165,6201,6218,6229,6231,,2623","RPS19,RPL5,RPS10,RPL11,RPL35A,RPS7,RPS17,RPS24,RPS26,,GATA1",,"P39019,P46777,P46783,P62913,P18077,P62081,P08708,P62847,P62854,,P15976","K02966,K02932,K02947,K02868,K02917,K02993,K02962,K02974,K02976,,K09182",",,,,,,,,,,",
1371,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",vitamin B6,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,high ornithine level,HP:0012026,,"https://www.ncbi.nlm.nih.gov/pubmed/29757052,https://www.ncbi.nlm.nih.gov/pubmed/17565677/,https://www.ncbi.nlm.nih.gov/pubmed/7028650/,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1372,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",lysine supplementation,DB00123,DB00123,ddfbdace28c1f9f81f233925d671c7da70607547088b3a060bd544b81ef7e66d,DB00123,DB00123,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,high ornithine level		HP:0012026,,,"https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf,https://www.ncbi.nlm.nih.gov/pubmed/11486915,https://www.ncbi.nlm.nih.gov/pubmed/10896280,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1373,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Low protein intake(arginine-restricted diet) + pyridoxine,NA+DB00165,NA + DB00165,efd0250fbb1646fcd8fa463817628cb7e29b0735b7a6d66484f159fb51fd180f,,,,,"NA,DB00165",DB00165,,NA,ECO:0000352,ECO:0000352,,,dietary exclusion+activity modification of a genetically defective protein,,cystoid macular edema,HP:0011505,,"https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11486915,https://www.ncbi.nlm.nih.gov/pubmed/10896280,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1374,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Low protein intake(arginine-restricted diet) + pyridoxine,NA+DB00165,NA + DB00165,efd0250fbb1646fcd8fa463817628cb7e29b0735b7a6d66484f159fb51fd180f,,,,,"NA,DB00165",DB00165,,NA,,,,,,,low visual acuity,HP:0007663,,"https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11486915,https://www.ncbi.nlm.nih.gov/pubmed/10896280,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1375,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Arginine-restricted diet,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary exclusion,,Disease progresssion,HP:0003676,,"https://www.ncbi.nlm.nih.gov/pubmed/16601905,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1376,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Arginine-restricted diet,NA,,,,,,,,,,,,,,,,,High ornithine plasma level,HP:0012026,,"https://www.ncbi.nlm.nih.gov/pubmed/16601905,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1377,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Arginine-restricted diet,NA,,,,,,,,,,,,,,,,,low visual acuity,HP:0007663,,"https://www.ncbi.nlm.nih.gov/pubmed/16601905,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1378,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",topical NSAIDs +systemic CAI,DB00586+DB00311,DB00586 + DB00311,b29ba3c629450dee9b9853db863f2c46f369146adf1469a2847cc23dc0851c9f,,,,,"DB00586,DB00311","DB00586,DB00311",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,cystoid macular edema,HP:0011505,,"https://www.ncbi.nlm.nih.gov/pubmed/28708224?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1379,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Intravitreal bevacizumab,DB00112,DB00112,d19137cecbc7955778ca2c83c3c0dafe91fa290e6003d7722e34c59412b184e5,DB00112,DB00112,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,choroidal neovascularization,HP:0011506,,"https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1380,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Intravitreal bevacizumab,DB00112,DB00112,d19137cecbc7955778ca2c83c3c0dafe91fa290e6003d7722e34c59412b184e5,DB00112,DB00112,,,,,,,,,,,,,decreased visual acuity,HP:0007663,,"https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1381,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Intravitreal bevacizumab,DB00112,DB00112,d19137cecbc7955778ca2c83c3c0dafe91fa290e6003d7722e34c59412b184e5,DB00112,DB00112,,,,,,,,,,,,,abnormal central vision,HP:0000504,,"https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/15159649,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1382,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Alpha-aminoisobutyric acid,DB02952,DB02952,acda85a38d430bb2519f3833703186a33f52d02ab15b2fcca6d2c05f23facad9,DB02952,DB02952,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,High ornithine plasma level,HP:0012026,,"https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/1755734,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1383,258870,,Number Sign,258870,GYRATE ATROPHY OF CHOROID AND RETINA; GACR,HYPERORNITHINEMIA WITH GYRATE ATROPHY OF CHOROID AND RETINA; HOGA;; GYRATE ATROPHY;; ORNITHINE AMINOTRANSFERASE DEFICIENCY;; OAT DEFICIENCY;; ORNITHINE KETO ACID AMINOTRANSFERASE DEFICIENCY;; OKT DEFICIENCY;; ORNITHINE-DELTA-AMINOTRANSFERASE DEFICIENCY,,Gyrate atrophy of the choroid and retina,,OAT,OAT,ornithine aminotransferase,685069d34dbe34491c73897b0fbc7d0e546500b27c7359df3e2a812c866b0f61,2.6.1.13,2.6.1.13,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",Gene therapy *,NA,,,,,,,,,,,ECO:0007121/ECO:0001565,"ECO:0007121,ECO:0001565",,,direct complementation of a genetically defective protein by gene therapy,A,"Abnormal enzyme,coenzyme activity",HP:0012379,,"https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/9414260,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/7356686,https://www.ncbi.nlm.nih.gov/pubmed/7254778/,https://www.ncbi.nlm.nih.gov/pubmed/28883274,https://www.ncbi.nlm.nih.gov/pubmed/22791294",4942,OAT,562,P04181,K00819,2.6.1.13,
1384,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,"There was no clinical effect, but amild reduction in the plasma level of desmosterol was observed.",creatine-monohydrate,DB00148,DB00148,ca6ae4a8ad76e426ecc26363a6d502ab7a26604d4642cf9e63dd1aa11d40af8d,DB00148,DB00148,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Extrapyramidal movement disorders,HP:0002071,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/18652077,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1385,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation,l-ornithine+Arginine restriction,DB00129,DB00129,c1d52e31c66fc159a26d79a88cb74151502b862d82633d79fe195678b2837322,DB00129,DB00129,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition+dietary exclusion,B,Epileptic seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/11749046,https://www.ncbi.nlm.nih.gov/pubmed/9686828,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1386,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation,l-ornithine+Arginine restriction,DB00129,DB00129,c1d52e31c66fc159a26d79a88cb74151502b862d82633d79fe195678b2837322,DB00129,DB00129,,,,,,,,,,,,,Slow background activity in the EEG(EEG abnormality)*,HP:0002353*,,"https://www.ncbi.nlm.nih.gov/pubmed/11749046,https://www.ncbi.nlm.nih.gov/pubmed/9686828,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1387,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,A competitive inhibition of AGAT activity via high-dose l-ornithine supplementation,l-ornithine+Arginine restriction,DB00129,DB00129,c1d52e31c66fc159a26d79a88cb74151502b862d82633d79fe195678b2837322,DB00129,DB00129,,,,,,,,,,,,,Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*,HP:0002453*,,"https://www.ncbi.nlm.nih.gov/pubmed/11749046,https://www.ncbi.nlm.nih.gov/pubmed/9686828,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1388,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,"The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoateÂ did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys",Sodium benzoate+ornithin +carnitine,DB03793+DB00129+DB00148,DB03793 + DB00129 + DB00148,d32d0bdcb9bff07135cf6cb9556c0e5872054e92c7e0ada00e1dbb468e222fc3,,,,,"DB03793,DB00129,DB00148","DB03793,DB00129,DB00148",,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,High CSF guanidinoacetate levels,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24071436,https://www.ncbi.nlm.nih.gov/pubmed/12557293,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1389,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,"The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoateÂ did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785
Sodium benzoate has been proposed as an additional approach to reduce the production of GAA via conjugation with glycine to form hippuric acid which is rapidly excreted by the kidneys",Sodium benzoate+ornithin +carnitine,DB03793+DB00129+DB00148,DB03793 + DB00129 + DB00148,d32d0bdcb9bff07135cf6cb9556c0e5872054e92c7e0ada00e1dbb468e222fc3,,,,,"DB03793,DB00129,DB00148","DB03793,DB00129,DB00148",,,,,,,,,High plasma guanidinoacetate levels,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24071436,https://www.ncbi.nlm.nih.gov/pubmed/12557293,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1390,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,DB00148 + DB00129,915ee2d7075e259ed6fa5909fa87d2723487a4f01160f460b9e7443e456aacec,,,,,"DB00148,DB00129","DB00148,DB00129",,,ECO:0000352,ECO:0000352,,,metabolite replacement+functional complementation of a defective protein by inhibition+dietary exclusion,,Epilepsy,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/12557293,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1391,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,DB00148 + DB00129,915ee2d7075e259ed6fa5909fa87d2723487a4f01160f460b9e7443e456aacec,,,,,"DB00148,DB00129","DB00148,DB00129",,,,,,,,,low urinary creatine excretion,HP:0012113,,"https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1392,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,DB00148 + DB00129,915ee2d7075e259ed6fa5909fa87d2723487a4f01160f460b9e7443e456aacec,,,,,"DB00148,DB00129","DB00148,DB00129",,,,,,,,,low brain creatine phosphate,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1393,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,DB00148 + DB00129,915ee2d7075e259ed6fa5909fa87d2723487a4f01160f460b9e7443e456aacec,,,,,"DB00148,DB00129","DB00148,DB00129",,,,,,,,,low cerebral creatine,HP:0025051,,"https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1394,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,DB00148 + DB00129,915ee2d7075e259ed6fa5909fa87d2723487a4f01160f460b9e7443e456aacec,,,,,"DB00148,DB00129","DB00148,DB00129",,,,,,,,,High plasma guanidinoacetate levels,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://www.ncbi.nlm.nih.gov/pubmed/12557293,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1395,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,DB00148 + DB00129,915ee2d7075e259ed6fa5909fa87d2723487a4f01160f460b9e7443e456aacec,,,,,"DB00148,DB00129","DB00148,DB00129",,,,,,,,,abnormal coordination of movements,HP:0011443,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1396,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,Creatine+l-ornithine+Arginine restriction,DB00148+DB00129,DB00148 + DB00129,915ee2d7075e259ed6fa5909fa87d2723487a4f01160f460b9e7443e456aacec,,,,,"DB00148,DB00129","DB00148,DB00129",,,,,,,,,behavioralÂ abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1397,612736,,Number Sign,612736,CEREBRAL CREATINE DEFICIENCY SYNDROME 2; CCDS2,GUANIDINOACETATE METHYLTRANSFERASE DEFICIENCY;; GAMT DEFICIENCY;; CREATINE DEFICIENCY SYNDROME DUE TO GAMT DEFICIENCY,,Guanidinoacetate methyltransferase deficiency,,GAMT,GAMT,guanidinoacetate methyltransferase,31387ee14a63c5d67f4f832b9311d27ccb0f15361d1362ad9949e1954136b19b,2.1.1.2,2.1.1.2,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,sodium phenylbutyrate+l-ornithine+Arginine restriction,DB06819+DB00129,DB06819 + DB00129,89e3391995e64dc51c3256218a8c131d3b4ef86e5c5f3cbd2d910856d0ab66be,,,,,"DB06819,DB00129","DB06819,DB00129",,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition+dietary exclusion,,High plasma guanidinoacetate levels,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2593,GAMT,104,Q14353,K00542,2.1.1.2,
1398,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,Tetrahydrobiopterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,metabolite replacement,B,high serum phenylalanine,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/9667588,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES,https://www.sciencedirect.com/science/article/pii/S1096719205003057?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,https://www.ncbi.nlm.nih.gov/pubmed/8813986",2643,GCH1,3,P30793,K01495,3.5.4.16,
1399,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,L-dopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/12391354,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1400,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,benserazide,DB12783,DB12783,af40e9d2d42c7675f2e5e0fe71508a5758ad995404ebb5fc6f0e7cad71a0a976,DB12783,DB12783,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,oromandibular dystonia,HP:0012048,,"https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1401,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,5-hydroxytryptophane,DB04159,DB04159,e704b6192e65cfb3fe694c24098aeada3ff2985e19be31fe1ea973a3ed522e03,DB04159,DB04159,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,spasticity,HP:0001257,,"https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1402,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,5-hydroxytryptophane,DB04159,DB04159,e704b6192e65cfb3fe694c24098aeada3ff2985e19be31fe1ea973a3ed522e03,DB04159,DB04159,,,,,,,,,,,,,abnormal motor development,HP:0001270,,"https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1403,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,5-hydroxytryptophane,DB04159,DB04159,e704b6192e65cfb3fe694c24098aeada3ff2985e19be31fe1ea973a3ed522e03,DB04159,DB04159,,,,,,,,,,,,,Sleep disturbance,HP:0002360,,"https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1404,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,5-hydroxytryptophane,DB04159,DB04159,e704b6192e65cfb3fe694c24098aeada3ff2985e19be31fe1ea973a3ed522e03,DB04159,DB04159,,,,,,,,,,,,,Defected neurotransmitter homeostasis in the CNS,HP:0012535,,"https://www.ncbi.nlm.nih.gov/pubmed/22729819,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1405,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,depletion of cerebral folate,HP:0012446,,"https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1406,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,Sodium phenylbutyrate lowers the resynthesis of arginine from ornithine via the urea cycle.https://www.ncbi.nlm.nih.gov/pubmed/24268530,folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,abnormal folate homeostasis in the CNS,HP:0012335,,"https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1407,233910,,Number Sign,233910,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, B; HPABH4B","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO GTP CYCLOHYDROLASE I DEFICIENCY;; GTP CYCLOHYDROLASE I DEFICIENCY","DYSTONIA, DOPA-RESPONSIVE, WITH OR WITHOUT HYPERPHENYLALANINEMIA, AUTOSOMAL RECESSIVE, INCLUDED",GTP cyclohydrolase I deficiency,,GCH1,GCH1,GTP cyclohydrolase 1,d5fe0cd28314fd8d4fc76e99c619d117f606de54abac1c5fb871aaef09840aa6,3.5.4.16,3.5.4.16,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Amantadine,DB00915,DB00915,20a06e9c70955f962a379c58cd1083f8a64e47e4e58c850cbe9ca05656efd7d5,DB00915,DB00915,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,levodopaâinduced choreic dyskinesia(Dyskinesia)*,HP:0100660*,,"https://www.ncbi.nlm.nih.gov/pubmed/15389992,https://www.ncbi.nlm.nih.gov/pubmed/18276179,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749",2643,GCH1,3,P30793,K01495,3.5.4.16,
1408,215140,,Number Sign,215140,GREENBERG DYSPLASIA; GRBGD,"HYDROPS-ECTOPIC CALCIFICATION-MOTH-EATEN SKELETAL DYSPLASIA;; HEM SKELETAL DYSPLASIA;; MOTH-EATEN SKELETAL DYSPLASIA;; CHONDRODYSTROPHY, HYDROPIC AND PRENATALLY LETHAL TYPE",,Greenberg dysplasia,,LBR,LBR,lamin B receptor,da519e2dbaa197f50ee710f838bd1a41ba2a87fc480c1ab0c9ccb5e7a5a5107e,Q14739,,Q14739,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,3930,LBR,197,Q14739,K19532,1.3.1.70,
1409,603358,603358,Number Sign,603358,GRACILE SYNDROME,"GROWTH RETARDATION, AMINO ACIDURIA, CHOLESTASIS, IRON OVERLOAD, LACTIC ACIDOSIS, AND EARLY DEATH;; FINNISH LETHAL NEONATAL METABOLIC SYNDROME; FLNMS;; LACTIC ACIDOSIS, FINNISH, WITH HEPATIC HEMOSIDEROSIS;; FELLMAN SYNDROME",,GRACILE syndrome,,BCS1L,BCS1L,ubiquinol-cytochrome c reductase complex chaperone,e24029ff6960f0803aa1392f17b9bba8a081111c7c22640b4ee18f5c60df23c8,Q9Y276,,Q9Y276,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Sodium bicarbonate,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,lactic acidosis,HP:0003128,,"https://www.ncbi.nlm.nih.gov/pubmed/22970607,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",617,BCS1L,208,Q9Y276,K08900,"""""",
1410,609056,,Number Sign,609056,SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS,"AMISH INFANTILE EPILEPSY SYNDROME;; EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC;; GM3 SYNTHASE DEFICIENCY;; SALT AND PEPPER MENTAL RETARDATION SYNDROME",,GM3 synthase deficiency,,ST3GAL5,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",40a0837b8496040de66966a525baa2d9f81e53eb7af7fb004686ee319282612f,2.4.99.9,2.4.99.9,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Gangliosides,DB12351,DB12351,1a0df9fbdd70d2ef2fed47efad22dbadd5103a65c8c794dbdf28311e4a6cd5ef,DB12351,DB12351,,,,,,,EC0:0007121,EC0:0007121,,,metabolite replacement,A,Delayed Develoment,HP:0001263,,"https://clinicaltrials.gov/ct2/show/NCT02234024?cond=GM3+synthase+deficiency&rank=1,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",8869,ST3GAL5,360,Q9UNP4,K03370,2.4.99.9,
1411,609056,,Number Sign,609056,SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS,"AMISH INFANTILE EPILEPSY SYNDROME;; EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC;; GM3 SYNTHASE DEFICIENCY;; SALT AND PEPPER MENTAL RETARDATION SYNDROME",,GM3 synthase deficiency,,ST3GAL5,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",40a0837b8496040de66966a525baa2d9f81e53eb7af7fb004686ee319282612f,2.4.99.9,2.4.99.9,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",CoQ10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Poor eye contect,HP:0000817,,"https://www.ncbi.nlm.nih.gov/pubmed/22990144,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",8869,ST3GAL5,360,Q9UNP4,K03370,2.4.99.9,
1412,609056,,Number Sign,609056,SALT AND PEPPER DEVELOPMENTAL REGRESSION SYNDROME; SPDRS,"AMISH INFANTILE EPILEPSY SYNDROME;; EPILEPSY SYNDROME, INFANTILE-ONSET SYMPTOMATIC;; GM3 SYNTHASE DEFICIENCY;; SALT AND PEPPER MENTAL RETARDATION SYNDROME",,GM3 synthase deficiency,,ST3GAL5,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",40a0837b8496040de66966a525baa2d9f81e53eb7af7fb004686ee319282612f,2.4.99.9,2.4.99.9,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",CoQ10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,abnormal interactivity,HP:0012433,,"https://www.ncbi.nlm.nih.gov/pubmed/22990144,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",8869,ST3GAL5,360,Q9UNP4,K03370,2.4.99.9,
1413,230500,,Number Sign,230500,"GM1-GANGLIOSIDOSIS, TYPE I","GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I;; GANGLIOSIDOSIS, GENERALIZED GM1, INFANTILE FORM;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 1;; BETA-GALACTOSIDASE-1 DEFICIENCY;; GLB1 DEFICIENCY","GM1-GANGLIOSIDOSIS, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED",GM1 gangliosidosis type 1,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",(5aR)-5a-C-Pentyl-4-epi-isofagomine,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,activity modification of a genetically defective protein,A,Neurologic abnormalities,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/27750150,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,284,P16278,K12309,3.2.1.23,
1414,230500,,Number Sign,230500,"GM1-GANGLIOSIDOSIS, TYPE I","GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I;; GANGLIOSIDOSIS, GENERALIZED GM1, INFANTILE FORM;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 1;; BETA-GALACTOSIDASE-1 DEFICIENCY;; GLB1 DEFICIENCY","GM1-GANGLIOSIDOSIS, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE I, WITH CARDIAC INVOLVEMENT, INCLUDED",GM1 gangliosidosis type 1,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Î²-galactosidase:RTB lectin fusion,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,direct complementation of a genetically defective protein,,Decreased beta-galactosidase activity,HP:0008166,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.ncbi.nlm.nih.gov/pubmed/27750150,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,284,P16278,K12309,3.2.1.23,
1415,230600,,Number Sign,230600,"GM1-GANGLIOSIDOSIS, TYPE II","GANGLIOSIDOSIS, GENERALIZED GM1, JUVENILE TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE II;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 2","GANGLIOSIDOSIS, GENERALIZED GM1, LATE-INFANTILE TYPE, INCLUDED",GM1 gangliosidosis type 2,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",6S-NBI-DGJ,PubChem:CID 76070514,PubChem:CID 76070514,33a6428b19e237bda98927c09285f2b77fc4c8c52f476e81c2e742a85838d698,,,,,,,,,ECO:0001565,ECO:0001565,,,activity modification of a genetically defective protein,A,Brain pathology,HP:0001298,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.ncbi.nlm.nih.gov/pubmed/23337983?dopt=Abstract,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,,P16278,K12309,3.2.1.23,
1416,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Cyclodextrin,CHEBI:23456,CHEBI:23456,95dc19d336b67ebbedde65739b789b6000d753c2aa04b9051341d71902d71543,CHEBI:23456,,CHEBI_23456,,,,,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,C,CD failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,,P16278,K12309,3.2.1.23,
1417,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",Cyclodextrin,CHEBI:23456,CHEBI:23456,95dc19d336b67ebbedde65739b789b6000d753c2aa04b9051341d71902d71543,CHEBI:23456,,CHEBI_23456,,,,,,,,,,,,elevated intraneuronal cholesterol,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,,P16278,K12309,3.2.1.23,
1418,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",AAV-treatedÂ Î²gal,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein,A,Abnormally decreased rate of beta-galactosidase activity,HP:0008166,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.ncbi.nlm.nih.gov/pubmed/17164772?dopt=Abstract,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,,P16278,K12309,3.2.1.23,
1419,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",miglustat,DB00419,DB00419,a47e10902853c2689213c0aa7da671fa33498cddf871edae57b1524b9caabad1,DB00419,DB00419,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a defective protein by inhibition,B,High ganglioside accumulation,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,,P16278,K12309,3.2.1.23,
1420,230650,,Number Sign,230650,"GM1-GANGLIOSIDOSIS, TYPE III","GANGLIOSIDOSIS, GENERALIZED GM1, ADULT TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, CHRONIC TYPE;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE III;; GANGLIOSIDOSIS, GENERALIZED GM1, TYPE 3",,GM1 gangliosidosis type 3,,GLB1,GLB1,beta-galactosidase,0b4152254d16b4b619bea4fae1728fd4523858464049014e0b0ccd55e52e9ffc,3.2.1.23,3.2.1.23,,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",miglustat,DB00419,DB00419,a47e10902853c2689213c0aa7da671fa33498cddf871edae57b1524b9caabad1,DB00419,DB00419,,,,,,,,,,,,,ataxic gait,HP:0002066,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",2720,GLB1,,P16278,K12309,3.2.1.23,
1421,607625,,Number Sign,607625,"NIEMANN-PICK DISEASE, TYPE C2; NPC2",,,Niemann-Pick disease type C2,,NPC2,NPC2,NPC intracellular cholesterol transporter 2,2ed64da7df8632596ae4994d325f85cd870e2bb1441f6923a7f4157453f407de,P61916,,P61916,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",2-hydroxypropyl-beta-cyclodextrin,DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,B,Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*,HP:0003107*,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",10577,NPC2,304,"""""","""""","""""",
1422,607625,,Number Sign,607625,"NIEMANN-PICK DISEASE, TYPE C2; NPC2",,,Niemann-Pick disease type C2,,NPC2,NPC2,NPC intracellular cholesterol transporter 2,2ed64da7df8632596ae4994d325f85cd870e2bb1441f6923a7f4157453f407de,P61916,,P61916,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",2-hydroxypropyl-beta-cyclodextrin,DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,High intraneuronal GSL storage,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",10577,NPC2,304,"""""","""""","""""",
1423,607625,,Number Sign,607625,"NIEMANN-PICK DISEASE, TYPE C2; NPC2",,,Niemann-Pick disease type C2,,NPC2,NPC2,NPC intracellular cholesterol transporter 2,2ed64da7df8632596ae4994d325f85cd870e2bb1441f6923a7f4157453f407de,P61916,,P61916,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",2-hydroxypropyl-beta-cyclodextrin,DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/26766614,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422",10577,NPC2,304,"""""","""""","""""",
1424,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,"The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake.",N-butyldeoxynojirimycin +allopregnanolone,DB00419Â +DB11859,DB00419 + DB11859,37bfa20d42e4aa5dbb8e6e37858970f92f897390e572fa1e6c2744b971feb8e2,,,,,"DB00419,DB11859","DB00419,DB11859",,,ECO:0005542,ECO:0005542,,,functional complementation of a defective protein by inhibition+metabolite replacement,B,elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*,HP:0003107*,,"https://www.ncbi.nlm.nih.gov/pubmed/11227045/,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract",4864,NPC1,303,O15118,K12385,"""""",
1425,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,ECO:0007121/ECO:0000352/ECO:0005542,"ECO:0007121,ECO:0000352,ECO:0005542",,,functional complementation of a defective protein by inhibition,B,High intraneuronal GSL storage,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1426,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1427,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Neurodegeneration,HP:0002180,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1428,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Poor swallowing,HP:0002015,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1429,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Cognitive impairment,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1430,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Fine motor impairment,HP:0007010,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1431,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Liver injury,HP:0001392,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1432,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Cholesterol sequestration (Abnormality of cholesterol metabolism)*,HP:0003107*,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1433,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Reduced life span (Mortality)*,HP:0040006*,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1434,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),DB15146,DB15146,5c19e0e62675bf44461516fba737c435296dbdf5fb000cf67735909e21654076,DB15146,DB15146,,,,,,,,,,,,,Rapid progression,HP:0003678,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/26027824,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1435,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Miglustat + Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,DB00419 + DB11859 + CHEBI:23456,dcd762463733bc404df3e37a24823317cb02d7eb19a0360dbea9637b53949d0b,,,,,"DB00419,DB11859,CHEBI:23456","DB00419,DB11859",CHEBI_23456,,ECO:0005542,ECO:0005542,,,functional complementation of a defective protein by inhibition+metabolite replacement,B,Motor function impairment,HP:0002275,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/23948640,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1436,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Miglustat + Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,DB00419 + DB11859 + CHEBI:23456,dcd762463733bc404df3e37a24823317cb02d7eb19a0360dbea9637b53949d0b,,,,,"DB00419,DB11859,CHEBI:23456","DB00419,DB11859",CHEBI_23456,,,,,,,,Cerebeller neurodegeneration( neurodegeneration)*,HP:0002180*,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/25400034,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1437,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Miglustat + Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,DB00419 + DB11859 + CHEBI:23456,dcd762463733bc404df3e37a24823317cb02d7eb19a0360dbea9637b53949d0b,,,,,"DB00419,DB11859,CHEBI:23456","DB00419,DB11859",CHEBI_23456,,,,,,,,Abnormality of lipid metabolism,HP:0003119,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/31248418,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1438,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Miglustat + Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,DB00419 + DB11859 + CHEBI:23456,dcd762463733bc404df3e37a24823317cb02d7eb19a0360dbea9637b53949d0b,,,,,"DB00419,DB11859,CHEBI:23456","DB00419,DB11859",CHEBI_23456,,,,,,,,Splenomegaly,HP:0001744,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/31248418,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1439,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Miglustat + Allopregnanolone+Cyclodextrin,DB00419+DB11859+CHEBI:23456,DB00419 + DB11859 + CHEBI:23456,dcd762463733bc404df3e37a24823317cb02d7eb19a0360dbea9637b53949d0b,,,,,"DB00419,DB11859,CHEBI:23456","DB00419,DB11859",CHEBI_23456,,,,,,,,Increased number of splenic myeloid cells,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/31248418,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1440,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Allopregnanolone,DB11859,DB11859,2bc0d12654c89591c52732a7b0b547a2e99b4655b7c3d8c5b930b755803b857a,DB11859,DB11859,,,,,,,ECO:0005542,ECO:0005542,,,metabolite replacement,,Mortality,HP:0040006,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1441,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Allopregnanolone,DB11859,DB11859,2bc0d12654c89591c52732a7b0b547a2e99b4655b7c3d8c5b930b755803b857a,DB11859,DB11859,,,,,,,,,,,,,Disease progression,HP:0003678,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1442,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Allopregnanolone,DB11859,DB11859,2bc0d12654c89591c52732a7b0b547a2e99b4655b7c3d8c5b930b755803b857a,DB11859,DB11859,,,,,,,,,,,,,cortical GM2 ganglioside accumulation,HP:0003495,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1443,257220,,Number Sign,257220,"NIEMANN-PICK DISEASE, TYPE C1; NPC1","NIEMANN-PICK DISEASE, TYPE C; NPC;; NIEMANN-PICK DISEASE WITH CHOLESTEROL ESTERIFICATION BLOCK;; NIEMANN-PICK DISEASE, SUBACUTE JUVENILE FORM;; NIEMANN-PICK DISEASE, CHRONIC NEURONOPATHIC FORM;; NIEMANN-PICK DISEASE WITHOUT SPHINGOMYELINASE DEFICIENCY;; NEUROVISCERAL STORAGE DISEASE WITH VERTICAL SUPRANUCLEAR OPHTHALMOPLEGIA","NIEMANN-PICK DISEASE, TYPE D, INCLUDED;; NIEMANN-PICK DISEASE, NOVA SCOTIAN TYPE, INCLUDED",Niemann-Pick disease type C1,,NPC1,NPC1,NPC intracellular cholesterol transporter 1,a781946ae62eac4e42dd2a9a7efe58bfa5c126c13e8818899eef11467d6c06dc,O15118,,O15118,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Allopregnanolone,DB11859,DB11859,2bc0d12654c89591c52732a7b0b547a2e99b4655b7c3d8c5b930b755803b857a,DB11859,DB11859,,,,,,,,,,,,,GM3 ganglioside accumulation (Ganglioside accumulation )*,HP:0004345,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/15208706/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",4864,NPC1,303,O15118,K12385,"""""",
1444,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,Dipeptidyl peptidase 1,a0a30d2f1916fa69f6d2836cd9db4e9681f1d224e17501869e14d616ff0e496e,3.4.14.1,3.4.14.1,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,(Trimethoprim+Sulfamethoxazole)+Acitretin,(DB00440+DB01015)+DB00459,(DB00440 + DB01015) + DB00459,23a0f4b029f47fa8586e2131cd2e014fe159b4ac93aeaa0c302f9e6fb3065ba2,,,,,"(DB00440,DB01015),DB00459",DB00459,,"(DB00440,DB01015)",ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Palmoplantar keratoderma,HP:0000982,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",1075,CTSC,1110,"""""","""""","""""",
1445,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,Dipeptidyl peptidase 1,a0a30d2f1916fa69f6d2836cd9db4e9681f1d224e17501869e14d616ff0e496e,3.4.14.1,3.4.14.1,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,(Trimethoprim+Sulfamethoxazole)+Acitretin,(DB00440+DB01015)+DB00459,(DB00440 + DB01015) + DB00459,23a0f4b029f47fa8586e2131cd2e014fe159b4ac93aeaa0c302f9e6fb3065ba2,,,,,"(DB00440,DB01015),DB00459",DB00459,,"(DB00440,DB01015)",,,,,,,Periodontitis,HP:0000704,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",1075,CTSC,1110,"""""","""""","""""",
1446,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,Dipeptidyl peptidase 1,a0a30d2f1916fa69f6d2836cd9db4e9681f1d224e17501869e14d616ff0e496e,3.4.14.1,3.4.14.1,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Periodontitis,HP:0000704,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",1075,CTSC,1110,"""""","""""","""""",
1447,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,Dipeptidyl peptidase 1,a0a30d2f1916fa69f6d2836cd9db4e9681f1d224e17501869e14d616ff0e496e,3.4.14.1,3.4.14.1,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,etretinate,DB00926,DB00926,21280346c8f4a95b457ffe02a7287c89f735cbcb08c492ddf69859485cf2a463,DB00926,DB00926,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Keratoderma,HP:0000982,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/10738634/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",1075,CTSC,1110,"""""","""""","""""",
1448,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,Dipeptidyl peptidase 1,a0a30d2f1916fa69f6d2836cd9db4e9681f1d224e17501869e14d616ff0e496e,3.4.14.1,3.4.14.1,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,etretinate,DB00926,DB00926,21280346c8f4a95b457ffe02a7287c89f735cbcb08c492ddf69859485cf2a463,DB00926,DB00926,,,,,,,,,,,,,Aggressive periodontitis(Sever periodontitis),HP:0000166,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/10738634/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",1075,CTSC,1110,"""""","""""","""""",
1449,245010,,Number Sign,245010,HAIM-MUNK SYNDROME; HMS,KERATOSIS PALMOPLANTARIS WITH PERIODONTOPATHIA AND ONYCHOGRYPOSIS;; COCHIN JEWISH DISORDER,,Haim-MunkÂ syndrome,,CTSC,CTSC,Dipeptidyl peptidase 1,a0a30d2f1916fa69f6d2836cd9db4e9681f1d224e17501869e14d616ff0e496e,3.4.14.1,3.4.14.1,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,salicylic acid+urea,DB00936+DB03904,DB00936 + DB03904,f56178fcba0fd1fb795da6da8773fec2be6bf2b5e1aae45c7f81a2fd898996b2,,,,,"DB00936,DB03904","DB00936,DB03904",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Palmoplantar hyperkeratosis,HP:0000972,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",1075,CTSC,1110,"""""","""""","""""",
1450,234500,,Number Sign,234500,HARTNUP DISORDER; HND,HARTNUP DISEASE,,Hartnup disease,,SLC6A19,SLC6A19,Sodium-dependent neutral amino acid transporter B(0)AT1,16310fa01d81495368c94c5a04758af36cdc0adc2eaeb7442906deeeb6603f0f,Q695T7,,Q695T7,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Chronic diarrhea,HP:0002028,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",340024,SLC6A19,50,Q695T7,K05334,"""""",
1451,234500,,Number Sign,234500,HARTNUP DISORDER; HND,HARTNUP DISEASE,,Hartnup disease,,SLC6A19,SLC6A19,Sodium-dependent neutral amino acid transporter B(0)AT1,16310fa01d81495368c94c5a04758af36cdc0adc2eaeb7442906deeeb6603f0f,Q695T7,,Q695T7,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,Hypoalbuminemia,HP:0003073,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",340024,SLC6A19,50,Q695T7,K05334,"""""",
1452,234500,,Number Sign,234500,HARTNUP DISORDER; HND,HARTNUP DISEASE,,Hartnup disease,,SLC6A19,SLC6A19,Sodium-dependent neutral amino acid transporter B(0)AT1,16310fa01d81495368c94c5a04758af36cdc0adc2eaeb7442906deeeb6603f0f,Q695T7,,Q695T7,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,Exfoliative erythema,HP:0001019,,"https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11787939/,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT02534844,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",340024,SLC6A19,50,Q695T7,K05334,"""""",
1453,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Ascorbic acid,DB00126,DB00126,46bcc3e9e8ea90f00063eb3e8afb136fcd18f75979e54917b7e77e08b5216eb3,DB00126,DB00126,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,Low activity of the immature 4-HPPD enzyme,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/26226126,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/14206878,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1454,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,N-acetyl-L-cysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,"secondary glutathione deficiency(Abnormality of metabolism,homeostasis)*",HP:0001939*,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1455,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,N-acetyl-L-cysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,pyroglutamic aciduria(Organic aciduria)*,HP:0001992*,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1456,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,N-acetyl-L-cysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1457,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,N-acetyl-L-cysteine,DB06151,DB06151,d65ac032d96128bab1cdc6a780555ee6dff7f9032f20182e0b2b251b4d42d81d,DB06151,DB06151,,,,,,,,,,,,,decreased appetite,HP:0004396,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1458,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Medium-chain triglyceride oil,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1459,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Medium-chain triglyceride oil,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,growth delay,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1460,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Medium-chain triglyceride oil,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,hemolytic anemia,HP:0001878,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1461,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Medium-chain triglyceride oil,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,"low Î²2 microglobulin,creatinine ratio",NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1462,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,phosphate,DB14573,DB14573,e3e6683b28e33eaa8e55b0e6a51e3c0059dca7a04015fd40fbb890b95a1a55e7,DB14573,DB14573,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hypophosphatemia,HP:0002148,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1463,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,sodium bicarbonate,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/27488560,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1464,140350,140350,Number Sign,140350,HAWKINSINURIA,,,Hawkinsinuria,,HPD,HPD,4-hydroxyphenylpyruvate dioxygenase,0ef090dd84e1d6ee8e4a9df15761129668a72f37b5ca403409cd28999c0e7d32,1.13.11.27,1.13.11.27,,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Nitisinone (NTBC),DB00348,DB00348,7c4b6db2c231de3544f887bbcf87476369137c671b51bdd2b20726e7f9d81df4,DB00348,DB00348,,,,,,,ECO:0005542,ECO:0005542,,,procedure to mitigate dominant effects of a genetically abnormal protein,A,Extreme frailty (Fatigue)*,HP:0012378*,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/20677779,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3242,HPD,22,P32754,K00457,1.13.11.27,
1465,235200,235200,Number Sign,235200,"HEMOCHROMATOSIS, TYPE 1; HFE1","HEMOCHROMATOSIS; HFE;; HEMOCHROMATOSIS, HEREDITARY; HH",,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Pantoprazole,DB00213,DB00213,324b88440d34dee63a069bd2b9f08e92a5a95b726cf3b1ab7475f0c16718df80,DB00213,DB00213,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,High serum ferritin,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3077,HFE,203,Q30201,"""""","""""",
1466,235200,235200,Number Sign,235200,"HEMOCHROMATOSIS, TYPE 1; HFE1","HEMOCHROMATOSIS; HFE;; HEMOCHROMATOSIS, HEREDITARY; HH",,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Pantoprazole,DB00213,DB00213,324b88440d34dee63a069bd2b9f08e92a5a95b726cf3b1ab7475f0c16718df80,DB00213,DB00213,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3077,HFE,203,Q30201,"""""","""""",
1467,235200,235200,Number Sign,235200,"HEMOCHROMATOSIS, TYPE 1; HFE1","HEMOCHROMATOSIS; HFE;; HEMOCHROMATOSIS, HEREDITARY; HH",,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,HFE,Hereditary hemochromatosis protein,319cc711cf1affb337665fc57bc1dfde2ed68b1e890d3ee8beb48511bccae248,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Pantoprazole,DB00213,DB00213,324b88440d34dee63a069bd2b9f08e92a5a95b726cf3b1ab7475f0c16718df80,DB00213,DB00213,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24683506?dopt=Abstract,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3077,HFE,203,Q30201,"""""","""""",
1468,602390,,Number Sign,602390,"HEMOCHROMATOSIS, TYPE 2A; HFE2A",,"HEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED;; HEMOCHROMATOSIS, JUVENILE, INCLUDED; JH, INCLUDED",Hemochromatosis type 2,,HJV/HAMP,"HJV,HAMP",hemojuvelin/hepcidin,b4315f8b7b3872ab484f7d04e94430a6e7f353baaab498692c917c88fc44bbef,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Deferoxamine,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/17124037,https://www.ncbi.nlm.nih.gov/pubmed/28624580,https://www.ncbi.nlm.nih.gov/pubmed/28803710/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","148738,57817","HJV,HAMP",581,"Q6ZVN8,P81172","K23100,K23106",",",
1469,602390,,Number Sign,602390,"HEMOCHROMATOSIS, TYPE 2A; HFE2A",,"HEMOCHROMATOSIS, TYPE 2, INCLUDED; HFE2, INCLUDED;; HEMOCHROMATOSIS, JUVENILE, INCLUDED; JH, INCLUDED",Hemochromatosis type 2,,HJV/HAMP,"HJV,HAMP",hemojuvelin/hepcidin,b4315f8b7b3872ab484f7d04e94430a6e7f353baaab498692c917c88fc44bbef,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,hepcidin,NA,,,,,,,,,,,ECO:0007764,ECO:0007764,,,metabolite replacement,A,Increased plasma iron concentration(Increased serum iron),HP:0003452,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives,http://www.bloodjournal.org/content/107/7/2952.abstract?ijkey=8710a861648a7799043d81f5a481aa922c2bd6df&keytype2=tf_ipsecsha&sso-checked=true,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","148738,57817","HJV,HAMP",581,"Q6ZVN8,P81172","K23100,K23106",",",
1470,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Deferoxamine,DB00746,DB00746,3cc274eb4905f5e9a35757845cb925848f8d6bc9f76d0a8172c20ba227afd169,DB00746,DB00746,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pubmed/29134618,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",7036,TFR2,582,Q9UP52,"""""","""""",
1471,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,hepcidin,NA,,,,,,,,,,,ECO:0007764,ECO:0007764,,,metabolite replacement,B,Increased plasma iron concentration(Increased serum iron),HP:0003452,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",7036,TFR2,582,Q9UP52,"""""","""""",
1472,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,LJPC-401(Synthetic human hepcidin),NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,metabolite replacement,B,High serum iron,HP:0003452,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://clinicaltrials.gov/ct2/show/NCT03395704?cond=Hemochromatosis+type+3&draw=2&rank=13,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",7036,TFR2,582,Q9UP52,"""""","""""",
1473,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Deferiprone (L1),DB08826,DB08826,ecac33e809e84cbd68c4ad875f2d52e72c6fc8367bdeabc70a344a6582d0858a,DB08826,DB08826,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,elevated liver iron concentration,HP:0040134,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://clinicaltrials.gov/ct2/show/NCT00350662?cond=Hemochromatosis+type+3&draw=4&rank=23,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",7036,TFR2,582,Q9UP52,"""""","""""",
1474,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,Nifedipine,DB01115,DB01115,2a3c3d72dc2507fe9bee48e2502b8ef0f3f4f1ad00867294ea36c87c0822ed7f,DB01115,DB01115,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://clinicaltrials.gov/ct2/show/NCT00712738?cond=Hemochromatosis+type+3&draw=4&rank=30,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",7036,TFR2,582,Q9UP52,"""""","""""",
1475,604250,,Number Sign,604250,"HEMOCHROMATOSIS, TYPE 3; HFE3",HEMOCHROMATOSIS DUE TO DEFECT IN TRANSFERRIN RECEPTOR 2,,Hemochromatosis type 3,,TFR2,TFR2,transferrin receptor 2,eed5c9beb5141f6f475ae7ab73d89b4110302b42015d23eb184cc747986eb0f3,Q30201,,Q30201,"Quercetin which is one of the polyphenols can reduce hepatic iron deposition in mice that were exposed to either ethanol or excess iron. They found that quercetin increased BMP6, intranuclear SMAD4, SMAD4 binding to the HAMP promoter, and hepcidin expression, which led to decreased hepatic iron levels and reduced iron-related damage. https://www.ncbi.nlm.nih.gov/pubmed/27393927",flavanols,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,iron overload(Abnormality of iron homeostasis)*,HP:0011031*,,"https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.semanticscholar.org/paper/The-Incidence-of-Transient-Neonatal-Tyrosinemia-a-Zea-Rey-Cruz-Camino/b66304a0a56304f686380af915a92b2b860e9305,https://clinicaltrials.gov/ct2/show/NCT03453918?cond=Hemochromatosis+type+3&draw=5&rank=34,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",7036,TFR2,582,Q9UP52,"""""","""""",
1476,151670,614025,Asterisk,151670,"LIPASE, HEPATIC; LIPC",LIPH;; HEPATIC TRIGLYCERIDE LIPASE; HTGL;; HEPATIC LIPASE; HL,,Hepatic lipase deficiency,,LIPC,LIPC,hepatic lipase,cf4fc3acf0ac1ee4385782abcce6c3dcb46bfa84ce5595b6e62d9eff980d95e5,3.1.1.3,3.1.1.3,,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,High atherogenic lipoprotein(Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/22798447,https://www.ncbi.nlm.nih.gov/pubmed/26194979,https://www.ncbi.nlm.nih.gov/pubmed/12547874,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3990,LIPC,,P11150,K22283,3.1.1.3,
1477,151670,614025,Asterisk,151670,"LIPASE, HEPATIC; LIPC",LIPH;; HEPATIC TRIGLYCERIDE LIPASE; HTGL;; HEPATIC LIPASE; HL,,Hepatic lipase deficiency,,LIPC,LIPC,hepatic lipase,cf4fc3acf0ac1ee4385782abcce6c3dcb46bfa84ce5595b6e62d9eff980d95e5,3.1.1.3,3.1.1.3,,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,,,,,,,High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/22798447,https://www.ncbi.nlm.nih.gov/pubmed/26194979,https://www.ncbi.nlm.nih.gov/pubmed/12547874,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3990,LIPC,,P11150,K22283,3.1.1.3,
1478,151670,614025,Asterisk,151670,"LIPASE, HEPATIC; LIPC",LIPH;; HEPATIC TRIGLYCERIDE LIPASE; HTGL;; HEPATIC LIPASE; HL,,Hepatic lipase deficiency,,LIPC,LIPC,hepatic lipase,cf4fc3acf0ac1ee4385782abcce6c3dcb46bfa84ce5595b6e62d9eff980d95e5,3.1.1.3,3.1.1.3,,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,,,,,,,High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/22798447,https://www.ncbi.nlm.nih.gov/pubmed/26194979,https://www.ncbi.nlm.nih.gov/pubmed/12547874,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",3990,LIPC,,P11150,K22283,3.1.1.3,
1479,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Hemin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,ECO:0005542/ECO:0001565,"ECO:0005542,ECO:0001565",,,metabolite replacement,B,Acute episodic abdominal pain,HP:0002574,,"https://www.ncbi.nlm.nih.gov/pubmed/24652768,https://www.ncbi.nlm.nih.gov/pubmed/24175354,https://www.ncbi.nlm.nih.gov/pubmed/12547874,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1480,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Hemin,DB03404,DB03404,0d22c2531eee5f7423c2fbd33ee7070224e0915a091f7b04e0153a6731d489a0,DB03404,DB03404,,,,,,,,,,,,,Low pancreatic zymogens,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24652768,https://www.ncbi.nlm.nih.gov/pubmed/24175354,https://www.ncbi.nlm.nih.gov/pubmed/12547874,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1481,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,ECO:0000352,ECO:0000352,,C282Y/H63D  heterozygosity or compound heterozygosity /C282Y(Homozygous mutation),symptomatic treatment procedure,,Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*,HP:0010472*,,"https://www.ncbi.nlm.nih.gov/pubmed/12622622,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.ncbi.nlm.nih.gov/pubmed/7324107,https://www.ncbi.nlm.nih.gov/pubmed/22985607,https://www.ncbi.nlm.nih.gov/pubmed/14632789,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1482,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,,,,,,,Increased liver iron level,HP:0012465,,"https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/6173993/,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1483,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,,,,,,,Abnormal liver function,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1484,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,,,,,,,Increased serum ferritin,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1485,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,,,,,,,Elevated transferrin saturation,HP:0012463,,"https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1486,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,,,,,,,Increased serum iron,HP:0003452,,"https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1487,176100,176100,Number Sign,176100,PORPHYRIA CUTANEA TARDA,"PCT;; PORPHYRIA CUTANEA TARDA, TYPE II;; PCT, TYPE II;; PCT, 'FAMILIAL' TYPE;; PORPHYRIA, HEPATOCUTANEOUS TYPE;; UROPORPHYRINOGEN DECARBOXYLASE DEFICIENCY;; UROD DEFICIENCY","PORPHYRIA, HEPATOERYTHROPOIETIC, INCLUDED; HEP, INCLUDED",PORPHYRIA CUTANEA TARDA,,UROD/HEF,"UROD,HEF",uroporphyrinogen decarboxylase/Hereditary hemochromatosis protein,bc6ccbfffc6c446f172f85a1b408a9d42386c2359e0d1fd3be5aeed6781f4b9d,Q30201,4.1.1.37,Q30201,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",Chloroquine,DB00608,DB00608,5b5b3f8275a75503fbeb528127d8b72c14023b2eb9785247f9fa42a11b051ed7,DB00608,DB00608,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/4739135,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,https://www.ncbi.nlm.nih.gov/pubmed/4811840/,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/","7389,","UROD,",114,"P06132,","K01599,","4.1.1.37,",
1488,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Defect of bone mineralisation,HP:0004348,,"https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1489,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,growth delay,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1490,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,poor skeletal mineralization,HP:0006462,,"https://www.ncbi.nlm.nih.gov/pubmed/30083035,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1491,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,respiratory insufficiency,HP:0002093,,"https://www.ncbi.nlm.nih.gov/pubmed/30083035,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1492,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,rickets,HP:0002748,,"https://cdn.intechopen.com/pdfs/56869.pdf,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1493,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,gross motor dysfunction,HP:0007015,,"https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1494,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,fine motor dysfunction,HP:0007010,,"https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1495,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,cognitive impairment,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1496,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1497,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,fatigue,HP:0012378,,"https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1498,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"The rationale and mechanism of action of chloroquine /hydroxychloroquine are not established, their use for this indication is off-label, suitable dosage forms are not available, tablets are not scored for division, and it is not established how treatment should be monitored and when it should be stopped. Potential hepatotoxicity and retinal damage with prolonged use and hemolysis particularly in patients with glucose-6- phosphate dehydrogenase (G6PD) deficiency are also concerns.",asfotase alfa,DB09105,DB09105,964cff8fd2243a799a204b9376d8097b86875d244b8ab03cd0ecfbded99c5d0b,DB09105,DB09105,,,,,,,,,,,,,delayed growth(stature),HP:0000002,,"https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1499,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,Vitamin D,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,,,,,activity modification of a genetically defective protein,A,secondary hyperparathyrodism,HP:0000867,,"https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,https://www.semanticscholar.org/paper/Hypophosphatasia%3A-A-Systemic-Skeletal-Disorder-by-Orimo/5d135fbc68735a3e95d3b313fc0636f10215b300,https://www.ncbi.nlm.nih.gov/pubmed/30811537,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1500,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,NSAID,S01BC,S01BC,3129336cd3c8009c8b0be3d1638c4949bcbb1b6961b378d017bcdc303ae04f71,S01BC,,,S01BC,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Lower limb pain,HP:0012514,,"https://www.ncbi.nlm.nih.gov/pubmed/16803637,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1501,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,NSAID,S01BC,S01BC,3129336cd3c8009c8b0be3d1638c4949bcbb1b6961b378d017bcdc303ae04f71,S01BC,,,S01BC,,,,,,,,,,,Abnormal prostaglandin level,HP:0011023,,"https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1502,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,NSAID,S01BC,S01BC,3129336cd3c8009c8b0be3d1638c4949bcbb1b6961b378d017bcdc303ae04f71,S01BC,,,S01BC,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1503,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,NSAID,S01BC,S01BC,3129336cd3c8009c8b0be3d1638c4949bcbb1b6961b378d017bcdc303ae04f71,S01BC,,,S01BC,,,,,,,,,,,Muscle weakness,,,"https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1504,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,NSAID,S01BC,S01BC,3129336cd3c8009c8b0be3d1638c4949bcbb1b6961b378d017bcdc303ae04f71,S01BC,,,S01BC,,,,,,,,,,,Abnormal walking distance,,,"https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1505,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,NSAID,S01BC,S01BC,3129336cd3c8009c8b0be3d1638c4949bcbb1b6961b378d017bcdc303ae04f71,S01BC,,,S01BC,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1506,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,D378V /G339R/E191K/A176T/V423A,N461L,activity modification of a genetically defective protein,B,stress fractures(Pathologic fracture)*,HP:0002756*,,"https://www.ncbi.nlm.nih.gov/pubmed/26245849,https://www.ncbi.nlm.nih.gov/pubmed/27042741,https://www.ncbi.nlm.nih.gov/pubmed/22218563,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1507,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,Ala176Thr/Val423Ala/Val522Ala,,,,metatarsal stress fractures,HP:0001832,,"https://www.ncbi.nlm.nih.gov/pubmed/20089612,https://www.ncbi.nlm.nih.gov/pubmed/17213282?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1508,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,compound heterozygotes for a p.G339R and p.E191KÂ ALPLÂ mutation,,,,proximal femur pseudofractures,HP:0100036,,"https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1509,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,,,,,High bone turnover markers,HP:0003260*,,"https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1510,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,,,,,defect in skeletal mineralization,HP:0006462,,"https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1511,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,,,,,Pain,HP:0012531,,"https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1512,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,,,,,mobility problems,HP:0001376,,"https://www.ncbi.nlm.nih.gov/pubmed/20739387,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1513,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,,,,,High urine phosphoethanolamine,HP:0003239,,"https://www.ncbi.nlm.nih.gov/pubmed/20089612,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1514,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Teriparatide,DB06285,DB06285,2509f3b9e67f8b44e711ebd9bd1fe72e8877701d20b35d533ff4e15706040b11,DB06285,DB06285,,,,,,,,,,,,,High serum pyridoxal 5'-phosphate,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/20089612,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1515,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin B6,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,Seizure,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/17395561?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/20739387?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1516,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",BPS804 (setrusumab),DB14778,DB14778,d97d983858dc6a85a79c82a3f439fcdf6ee671db03598832193c3cd74bde365a,DB14778,DB14778,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a defective protein by inhibition,B,bone weakness,HP:0002749,,"https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1517,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",BPS804 (setrusumab),DB14778,DB14778,d97d983858dc6a85a79c82a3f439fcdf6ee671db03598832193c3cd74bde365a,DB14778,DB14778,,,,,,,,,,,,,bone fructure,HP:0002757,,"https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1518,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",BPS804 (setrusumab),DB14778,DB14778,d97d983858dc6a85a79c82a3f439fcdf6ee671db03598832193c3cd74bde365a,DB14778,DB14778,,,,,,,,,,,,,low bone formation biomarkers,HP:0031429,,"https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1519,241500,241500,Number Sign,241500,"HYPOPHOSPHATASIA, INFANTILE",HOPS;; PHOSPHOETHANOLAMINURIA,"HYPOPHOSPHATASIA, PERINATAL LETHAL, INCLUDED","Hypophosphatasia, INFANTILE",,ALPL,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3ec7afef63a6cf20e9a727f715326de70039f3d8f63ea8feba87a9db2f6d526e,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",BPS804 (setrusumab),DB14778,DB14778,d97d983858dc6a85a79c82a3f439fcdf6ee671db03598832193c3cd74bde365a,DB14778,DB14778,,,,,,,,,,,,,low bone mineral density,HP:0004349,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",249,ALPL,561,P05186,K01077,3.1.3.1,
1520,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin A,DB00162,DB00162,415cee31ccc3e18e2a91e5fd40cbc64272408f601562756c6b3a48f5e0a5b46d,DB00162,DB00162,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Fat soluble vitamin  Malabsorption,HP:0002630,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1521,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin A,DB00162,DB00162,415cee31ccc3e18e2a91e5fd40cbc64272408f601562756c6b3a48f5e0a5b46d,DB00162,DB00162,,,,,,,,,,,,,Progressive ataxic retinopathy,HP:0000488,,"https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1522,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Central nervous degeneration,HP:0007009,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1523,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Retinal degeneration,HP:0000546,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1524,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Neuromuscular degeneration,HP:0002180,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1525,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1526,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Progressive ataxic neuropathy,HP:0003434,,"https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1527,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin A,DB00162,DB00162,415cee31ccc3e18e2a91e5fd40cbc64272408f601562756c6b3a48f5e0a5b46d,DB00162,DB00162,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Fat soluble vitamin  Malabsorption (Fat malabsorption)*,HP:0002630,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1528,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin A,DB00162,DB00162,415cee31ccc3e18e2a91e5fd40cbc64272408f601562756c6b3a48f5e0a5b46d,DB00162,DB00162,,,,,,,,,,,,,Progressive ataxic retinopathy,HP:0000488,,"https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1529,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Central nervous degeneration,HP:0007009,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1530,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Retinal degeneration,HP:0000546,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1531,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Neuromuscular degeneration,HP:0002180,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1532,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1533,615558,,Number Sign,615558,"HYPOBETALIPOPROTEINEMIA, FAMILIAL, 1; FHBL1","HYPOBETALIPOPROTEINEMIA, FAMILIAL; FHBL;; ACANTHOCYTOSIS WITH HYPOBETALIPOPROTEINEMIA;; HYPOBETALIPOPROTEINEMIA, NORMOTRIGLYCERIDEMIC","LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 4, INCLUDED; LDLCQ4, INCLUDED",Homozygous Hypolipoproteinemia,,APOB,APOB,apolipoprotein B-48Â + apolipoprotein B-100,bb128a3a534ee1461944ce7591a71aa469997407d5263ee069e23eb7807251f7,3.1.3.1,3.1.3.1,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin E,DB00163,DB00163,9fe753da7d63584900e76f4106bdd13cf4275a62b3337235d0b55e231a1a725a,DB00163,DB00163,,,,,,,,,,,,,Progressive ataxic neuropathy,HP:0003434,,"https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/24288038,https://www.ncbi.nlm.nih.gov/pubmed/18308659?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/9110486?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/4744026/,https://www.ncbi.nlm.nih.gov/pubmed/19415691/,https://www.ncbi.nlm.nih.gov/pubmed/25717099/",338,APOB,,P04114,K14462,"""""",
1534,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,Hypertryptophanemia should be regarded as a benign condition,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,1.13.11.11,1.13.11.11,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/22081291,https://www.ncbi.nlm.nih.gov/pubmed/28285122",6999,TDO2,618,P48775,K00453,1.13.11.11,
1535,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,1.13.11.11,1.13.11.11,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12822831,https://www.ncbi.nlm.nih.gov/pubmed/28285122",6999,TDO2,618,P48775,K00453,1.13.11.11,
1536,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,1.13.11.11,1.13.11.11,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15036384,https://www.ncbi.nlm.nih.gov/pubmed/28285122",6999,TDO2,618,P48775,K00453,1.13.11.11,
1537,600627,,Number Sign,600627,HYPERTRYPTOPHANEMIA; HYPTRP,"HYPERTRYPTOPHANEMIA, FAMILIAL",,Hypertryptophanemia,,TDO2,TDO2,"tryptophan 2,3-dioxygenase",69394423d20c15206b06ce6f23183f83c97d1db947bbfe5e8d0b6752e575124b,1.13.11.11,1.13.11.11,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15036384,https://www.ncbi.nlm.nih.gov/pubmed/28285122",6999,TDO2,618,P48775,K00453,1.13.11.11,
1538,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamen B6,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/24173411,https://www.ncbi.nlm.nih.gov/pubmed/28285122",5625,PRODH,40,O43272,K00318,1.5.5.2,
1539,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Pyridoxine phosphate,DB02209,DB02209,cb21ff1e3834345abf422c955689bf96a485c83a86e138f945a6d20a59935ab1,DB02209,DB02209,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/24173411,https://www.ncbi.nlm.nih.gov/pubmed/28285122",5625,PRODH,40,O43272,K00318,1.5.5.2,
1540,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",olanzapine,DB00334,DB00334,a177eb9898442efb8c5f5551b203d444eb5da39e37f430bbde66470ff016e333,DB00334,DB00334,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,behavioural disturbance,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/28202261,https://www.ncbi.nlm.nih.gov/pubmed/28285122",5625,PRODH,40,O43272,K00318,1.5.5.2,
1541,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",lithium,DB14507,DB14507,0952a37ef98709b89910d807b9944108664d234d76b1822b18096068328ab59a,DB14507,DB14507,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,psychotic  disorder,HP:0000725,,"https://www.ncbi.nlm.nih.gov/pubmed/28202261,https://www.ncbi.nlm.nih.gov/pubmed/28285122",5625,PRODH,40,O43272,K00318,1.5.5.2,
1542,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",green tea extract,DB14307,DB14307,a3f42d09b866035b6717e4b96d6039ab415cc23e3d7a5d6167b7957b7c8de639,DB14307,DB14307,,,,,,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,C,Oxidative Stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/27589827,https://www.ncbi.nlm.nih.gov/pubmed/24980685",5625,PRODH,40,O43272,K00318,1.5.5.2,
1543,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,"These inconsistent results have suggested that the response might depend on the specific gene mutations
 As the response was not sustained and serum ALP and PLP and urine PEA returned to baseline between 8 and 13 months of treatment 
In N461L mutation which led to complete disappearance of the bone isoenzyme, disease was not modified by PTH treatment.  

https://www.ncbi.nlm.nih.gov/pubmed/22218563?dopt=Abstract
https://www.ncbi.nlm.nih.gov/pubmed/20089612?dopt=Abstract (Lack of sustained response to teriparatide in a patient with adult hypophosphatasia_",Vitamin D,DB11094,DB11094,b1b699134b0a3d8bd00a5d4ffcea053fc10ea5b984622aa06238b8d15b7881a8,DB11094,DB11094,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein by transcriptional or translational modification,A,schizophrenia,HP:0100753,"The findings reported here support the possibility that supplementation might reduce symptoms or augment recovery of patients with schizophrenia, particularly targeting those with elevated proline, who may represent over one quarter of the schizophrenia population.","https://www.ncbi.nlm.nih.gov/pubmed/24787057,https://www.ncbi.nlm.nih.gov/pubmed/24980685",5625,PRODH,40,O43272,K00318,1.5.5.2,
1544,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Î±-Tocopherol+ascorbic acid,DB14476+DB00126,DB14476 + DB00126,73004c97c8adb40019f5442a216a37a9bdf0f7f1527e1d133720d46047c36941,,,,,"DB14476,DB00126","DB14476,DB00126",,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,C,impairment of reference,,,"https://www.ncbi.nlm.nih.gov/pubmed/16214240,https://www.ncbi.nlm.nih.gov/pubmed/24980685",5625,PRODH,40,O43272,K00318,1.5.5.2,
1545,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Î±-Tocopherol+ascorbic acid,DB14476+DB00126,DB14476 + DB00126,73004c97c8adb40019f5442a216a37a9bdf0f7f1527e1d133720d46047c36941,,,,,"DB14476,DB00126","DB14476,DB00126",,,,,,,,C,working spatial memoryÂ impairment*,HP:0002354,,"https://www.ncbi.nlm.nih.gov/pubmed/16214240,https://www.ncbi.nlm.nih.gov/pubmed/24980685",5625,PRODH,40,O43272,K00318,1.5.5.2,
1546,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Î±-Tocopherol+ascorbic acid,DB14476+DB00126,DB14476 + DB00126,73004c97c8adb40019f5442a216a37a9bdf0f7f1527e1d133720d46047c36941,,,,,"DB14476,DB00126","DB14476,DB00126",,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/16214240,https://www.ncbi.nlm.nih.gov/pubmed/24980685",5625,PRODH,40,O43272,K00318,1.5.5.2,
1547,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Î±-Tocopherol+ascorbic acid,DB14476+DB00126,DB14476 + DB00126,73004c97c8adb40019f5442a216a37a9bdf0f7f1527e1d133720d46047c36941,,,,,"DB14476,DB00126","DB14476,DB00126",,,,,,,,,cerebral cortex acetylcholinesterase inhibition,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16214240,https://www.ncbi.nlm.nih.gov/pubmed/24980685",5625,PRODH,40,O43272,K00318,1.5.5.2,
1548,239500,,Number Sign,239500,"HYPERPROLINEMIA, TYPE I; HYRPRO1",HPI;; PROLINE OXIDASE DEFICIENCY,,Hyperprolinemia,,PRODH,PRODH,proline dehydrogenase 1,e3cfbb8c84576b2a313cb54529a6cdebe8422ece661064eaa0ca7291bc18434e,1.5.5.2,1.5.5.2,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Î±-Tocopherol+ascorbic acid,DB14476+DB00126,DB14476 + DB00126,73004c97c8adb40019f5442a216a37a9bdf0f7f1527e1d133720d46047c36941,,,,,"DB14476,DB00126","DB14476,DB00126",,,,,,,,,"""hippocampal Na+, K+-ATPaseÂ reduced activity""",NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16214240,https://www.ncbi.nlm.nih.gov/pubmed/24980685",5625,PRODH,40,O43272,K00318,1.5.5.2,
1549,239510,,Number Sign,239510,"HYPERPROLINEMIA, TYPE II; HYRPRO2",HPII;; 1-PYRROLINE-5-CARBOXYLATE DEHYDROGENASE DEFICIENCY,,Hyperprolinemia type 2,,ALDH4A1,ALDH4A1,Î1-pyrroline 5-carboxylate dehydrogenase,16130b49e5865728dc21dcfcd547498a5468317685ff2d6a59c2b95efb363cc2,1.2.1.88,1.2.1.88,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,8659,ALDH4A1,38,P30038,K00294,1.2.1.88,
1550,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,Protein and phenylalanine restriction should be maintained in order to avoid disease progression.,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,4.2.1.96,4.2.1.96,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Tetrahydrobiopterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Muscular hypotonia,HP:0001252,,https://www.ncbi.nlm.nih.gov/pubmed/22729819,5092,PCBD1,6,P61457,K01724,4.2.1.96,
1551,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,4.2.1.96,4.2.1.96,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Tetrahydrobiopterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,Dystonia,HP:0001332,,https://www.ncbi.nlm.nih.gov/pubmed/22729819,5092,PCBD1,6,P61457,K01724,4.2.1.96,
1552,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,4.2.1.96,4.2.1.96,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Tetrahydrobiopterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/9585615,https://www.ncbi.nlm.nih.gov/pubmed/24204001",5092,PCBD1,6,P61457,K01724,4.2.1.96,
1553,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,4.2.1.96,4.2.1.96,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Tetrahydrobiopterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,Growth failure,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/9760199,https://www.ncbi.nlm.nih.gov/pubmed/24204001",5092,PCBD1,6,P61457,K01724,4.2.1.96,
1554,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,4.2.1.96,4.2.1.96,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Tetrahydrobiopterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,,,,,,,High urinary levels of primapterin (7-biopterin),NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24204001,https://www.ncbi.nlm.nih.gov/pubmed/24204001",5092,PCBD1,6,P61457,K01724,4.2.1.96,
1555,264070,,Number Sign,264070,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, D; HPABH4D","HYPERPHENYLALANINEMIA, TETRAHYDROBIOPTERIN-DEFICIENT, DUE TO PTERIN-4-ALPHA-CARBINOLAMINE DEHYDRATASE DEFICIENCY;; HYPERPHENYLALANINEMIA WITH PRIMAPTERINURIA;; CADH DEFICIENCY;; PCBD DEFICIENCY",,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,PCBD1,pterin-4 alpha-carbinolamine dehydratase,e535c3d808679fa1147d45f61b974cf861f73cc2f597014f45ca86c8bd4b832b,4.2.1.96,4.2.1.96,,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,Salfonylureas,DB01124,DB01124,0ad4ddcac409ec127b2a4a30aee705c2cd5bb1f4541bf111d75e4d2171488665,DB01124,DB01124,,,,,,,ECO:0005542,ECO:0005542,,,symptomatic treatment procedure,,PCBD1-diabetes (Noninsulin-dependent diabetes)*,HP:0005978*,,"https://www.ncbi.nlm.nih.gov/pubmed/24848070,https://www.ncbi.nlm.nih.gov/pubmed/24204001",5092,PCBD1,6,P61457,K01724,4.2.1.96,
1556,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in the patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,botulinum toxin,DB00083,DB00083,b9dc52dcd224285b94e12b074de67c2ffce6653f6761323b5a1e290921e09b72,DB00083,DB00083,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Delayed motor development,HP:0001270,,"https://www.ncbi.nlm.nih.gov/pubmed/23570448,https://www.ncbi.nlm.nih.gov/pubmed/24204001",10157,AASS,,"""""","""""","""""",
1557,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,valproate+carbamazepine,DB00313+DB00564,DB00313 + DB00564,c6e9b056eef426486b1fd24405f26f60b1ddc961400e456d079e3c602a7e0d8f,,,,,"DB00313,DB00564","DB00313,DB00564",,,,,,,symptomatic treatment procedure,C,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/23570448,https://www.ncbi.nlm.nih.gov/pubmed/24204001",10157,AASS,,"""""","""""","""""",
1558,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,Î±-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,valproate+carbamazepine,DB00313+DB00564,DB00313 + DB00564,c6e9b056eef426486b1fd24405f26f60b1ddc961400e456d079e3c602a7e0d8f,,,,,"DB00313,DB00564","DB00313,DB00564",,,,,,,,C,Generalized tonic convulsions,HP:0010818,,"https://www.ncbi.nlm.nih.gov/pubmed/23570448,https://www.ncbi.nlm.nih.gov/pubmed/24204001",10157,AASS,,"""""","""""","""""",
1559,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,The drug was accompanied with lysin restricted diet,Valproic acid+Lysin restricted diet,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+dietary exclusion,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/23570448,https://www.ncbi.nlm.nih.gov/pubmed/24204001",10157,AASS,,"""""","""""","""""",
1560,238700,,Number Sign,238700,"HYPERLYSINEMIA, TYPE I",LYSINE:ALPHA-KETOGLUTARATE REDUCTASE DEFICIENCY;; ALPHA-AMINOADIPIC SEMIALDEHYDE SYNTHASE DEFICIENCY;; LYSINE INTOLERANCE;; L-LYSINE:NAD-OXIDO-REDUCTASE DEFICIENCY,,Hyperlysinemia,,AASS,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",86e6ce17972a629d4dcf6aae3a214137690dfbc68981f110361bf603b0d734d4,1.5.1.9,"1.5.1.8,1.5.1.9",,The drug was accompanied with lysin restricted diet,pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+dietary exclusion,C,"""No remarkable clinical improvement was observed and therefore, treatment was discontinued""",,,"https://www.ncbi.nlm.nih.gov/pubmed/23890588,https://www.ncbi.nlm.nih.gov/pubmed/24204001",10157,AASS,,"""""","""""","""""",
1561,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:00007121,ECO:00007121,,,symptomatic treatment procedure+dietary exclusion,C,hypertriglyceridemia,HP:0002155,,"https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24204001",116519,APOA5,1086,Q6Q788,K09025,"""""",
1562,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,,,,,,,High LDL level,HP:0003141,,"https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24204001",116519,APOA5,1086,Q6Q788,K09025,"""""",
1563,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,,,,,,,High total cholesterol,HP:0003124,,"https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24204001",116519,APOA5,1086,Q6Q788,K09025,"""""",
1564,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,,,,,,,High Apoliporprotein B level(Abnormal abpolipoprotein level)*,HP:0025201*,,"https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24204001",116519,APOA5,1086,Q6Q788,K09025,"""""",
1565,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,fenofibrates,DB13873,DB13873,40dffefe9636445252bfe1faf8784881a90ce8af9f40e94156edbc6ce4638766,DB13873,DB13873,,,,,,,ECO:00007121,ECO:00007121,,,activity modification of a genetically defective protein by transcriptional or translational modification,B,hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496",116519,APOA5,1086,Q6Q788,K09025,"""""",
1566,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,fenofibrates,DB13873,DB13873,40dffefe9636445252bfe1faf8784881a90ce8af9f40e94156edbc6ce4638766,DB13873,DB13873,,,,,,,,,,,,,High level of very low-density lipoprotein,HP:0003362,,"https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496",116519,APOA5,1086,Q6Q788,K09025,"""""",
1567,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,fenofibrates,DB13873,DB13873,40dffefe9636445252bfe1faf8784881a90ce8af9f40e94156edbc6ce4638766,DB13873,DB13873,,,,,,,,,,,,,High total cholesterol,HP:0003124,,"https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496",116519,APOA5,1086,Q6Q788,K09025,"""""",
1568,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,The drug was accompanied with lysin restricted diet,fenofibrates,DB13873,DB13873,40dffefe9636445252bfe1faf8784881a90ce8af9f40e94156edbc6ce4638766,DB13873,DB13873,,,,,,,,,,,,,Low HDL-cholesterol,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,https://www.ncbi.nlm.nih.gov/pubmed/12709436,https://www.ncbi.nlm.nih.gov/pubmed/23633496",116519,APOA5,1086,Q6Q788,K09025,"""""",
1569,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",nicotinic acid,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1570,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",nicotinic acid,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,High total plasma cholesterol,HP:0003124,,"https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1571,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",nicotinic acid,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,Elevated LDL-C level,HP:0003141,,"https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1572,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",nicotinic acid,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,High VLDL-triglycerides,HP:0003362,,"https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1573,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",nicotinic acid,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,Low HDL-C,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/1894760,https://www.ncbi.nlm.nih.gov/pubmed/18001312,https://www.ncbi.nlm.nih.gov/pubmed/5679950,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1574,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,"strong statins (atorvastatin, pitavastatin, and rosuvastatin",DB01076Â or DB08860 or DB01098,DB01076 or DB08860 or DB01098,905041f8cb092cda36593dff4630e0452efe1622eb2276a924c4b81bfdb72cdf,"DB01076,DB08860,DB01098","DB01076,DB08860,DB01098",,,,,,,ECO:0000352,ECO:0000352,TT-1131,C-1131,functional complementation of a genetically defective protein,C,hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/19530961/,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1575,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,Gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,ECO:0000352/ ECO:0007121,"ECO:0000352,ECO:0007121",,,activity modification of a genetically defective protein by transcriptional or translational modification,B,Tuberoeruptive xanthomas,HP:0001013*,"The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860","https://www.ncbi.nlm.nih.gov/pubmed/2702860,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1576,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,Gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,,,,,,,Hyperchylomicronemia,HP:0012238,,"https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1577,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,Gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,,,,,,,High total plasma cholesterol leve,,,"https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1578,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,Gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,,,,,,,Elevated LDL-C level,HP:0003141,,"https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1579,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,Gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,,,,,,,High VLDL-triglycerides,HP:0003362,,"https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1580,144650,,Number Sign,144650,"HYPERLIPOPROTEINEMIA, TYPE V","HYPERLIPIDEMIA, TYPE V;; HYPERCHYLOMICRONEMIA, LATE-ONSET;; HYPERCHYLOMICRONEMIA WITH HYPERPREBETALIPOPROTEINEMIA, FAMILIAL;; HYPERLIPEMIA, MIXED;; HYPERLIPEMIA, COMBINED FAT AND CARBOHYDRATE-INDUCED",,Hyperlipoproteinemia type V,,APOA5,APOA5,apolipoprotein A5,e73ccf77a9d8dd2d28120788c41be54fd1c1370c09b136d5c0cac05c43854c64,Q6Q788,,Q6Q788,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,Gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,,,,,,,Low HDL-C,HP:0003233,,"https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",116519,APOA5,1086,Q6Q788,K09025,"""""",
1581,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,Hubacek et al. 2009 's results suggest that the APOA5 gene variants may play an important role in the pharmacogenetics of statin treatment. https://www.ncbi.nlm.nih.gov/pubmed/19530961/. https://www.ncbi.nlm.nih.gov/pubmed/25900265,Rosuvastatin+Pravastatin,DB01098Â +DB00175,DB01098 + DB00175,47be8dbad4d21c7f7abd5a8da79a0b39c5af2b2f3e8f617c547d527d0fec83e2,,,,,"DB01098,DB00175","DB01098,DB00175",,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,hypertriglycernemia,HP:0002155,,"https://clinicaltrials.gov/ct2/show/NCT00214604?cond=Hyperlipidemia+type+3&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",348,APOE,507,P02649,K04524,"""""",
1582,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,Study was terminated due to safety issues.,torcetrapib/atorvastatin,DB06281+ DB01076,DB06281 + DB01076,be90b560d5db4ed9c4bdd8fe031bc8d0321f607a9c68e3cb80a81ea407df90ba,,,,,"DB06281,DB01076","DB06281,DB01076",,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Study was terminated due to lack of safety,,,"https://clinicaltrials.gov/ct2/show/NCT00145431?cond=Hyperlipidemia+type+3&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/2681858,https://www.ncbi.nlm.nih.gov/pubmed/29695967,https://www.ncbi.nlm.nih.gov/pubmed/4883477",348,APOE,507,P02649,K04524,"""""",
1583,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1584,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,,,,,,,High VLDL triglycerides,,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1585,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1586,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",gemfibrozil,DB01241,DB01241,af60e43bd50d553e6982f10cacda754fa7c191d369c7e4ba3cd5b62916d31c17,DB01241,DB01241,,,,,,,,,,,,,High VLDL triglycerides,NA,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1587,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",lovastatin,DB00227,DB00227,2bf6e81837c66b9d3d2529f6ca9259051175f485b65557813573606670c9106d,DB00227,DB00227,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1588,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",clofibrate,DB00636,DB00636,4f4a0caa17de4a7c7581c0cd32e83b6af5948953cf19f3d8f3d787f30c592aa9,DB00636,DB00636,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,high non-HDL-C (Abnormality of lipid metabolism)*,HP:0003119*,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1589,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,lovastatin and clofibrate,DB00227+DB00636,DB00227 + DB00636,ebe11f6032da4ec7cd62232ee034ce4a0429c7f10f18081a76b28a34b32dbce2,,,,,"DB00227,DB00636","DB00227,DB00636",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+activity modification of a genetically defective protein,B,hypercholesterolemia,HP:0003124,,"https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1590,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Fenofibrate,DB13873,DB13873,40dffefe9636445252bfe1faf8784881a90ce8af9f40e94156edbc6ce4638766,DB13873,DB13873,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,Hypertriglyceridemia,HP:0002155,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1591,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,,B,Hypertriglyceridemia,HP:0002156,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1592,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Fish oil,DB13961,DB13961,a1f114161df905ead8073e35b571aebc7d01d63c91b1461750961e3e35a3e669,DB13961,DB13961,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+,C,Hypertriglyceridemia,HP:0002157,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1593,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,fenofibrate + atorvastatin,DB13873+ DB01076,DB13873 + DB01076,ab3545e1ccbf433d4356f659d0d8279f75fb2a01e2e5a3a85eae219e87482e29,,,,,"DB13873,DB01076","DB13873,DB01076",,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein+symptomatic treatment procedure,B,xanthomas,HP:0000991,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1594,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,fenofibrate + atorvastatin,DB13873+ DB01076,DB13873 + DB01076,ab3545e1ccbf433d4356f659d0d8279f75fb2a01e2e5a3a85eae219e87482e29,,,,,"DB13873,DB01076","DB13873,DB01076",,,,,,,,,stenotic coronary atherosclerosis,HP:0001677,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1595,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,fenofibrate + atorvastatin,DB13873+ DB01076,DB13873 + DB01076,ab3545e1ccbf433d4356f659d0d8279f75fb2a01e2e5a3a85eae219e87482e29,,,,,"DB13873,DB01076","DB13873,DB01076",,,,,,,,,angina pectoris,HP:0001681,,"https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1596,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Atrovastatin,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,High serum total cholesterol,HP:0003124,,"https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1597,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Atrovastatin,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,,,,,,,High serum triglyceride,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1598,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Atrovastatin,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,,,,,,,High remnant-like particle (RLP)-cholesterol,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1599,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Atrovastatin,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,,,,,,,High remnant-like particle (RLP)-TG,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1600,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Atrovastatin,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,,,,,,,"Elevated VLDL-cholesterol,serum TG ratio",HP:0003362,,"https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1601,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,Atrovastatin,DB01076,DB01076,f5f45e048b2f079c38865c62f353508890331d1cef484b1908c71c66310aa54a,DB01076,DB01076,,,,,,,,,,,,,Elevated apolipoprotein B level,HP:0031798,,"https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1602,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,Probucol is a non-Statin cholesterol-lowering drug and a potent inducer of apolipoprotein E (apoE) production in peripheral circulation. https://www.ncbi.nlm.nih.gov/pubmed/12946703,probucol,DB01599,DB01599,05376f8286d603d41a72cb424df20acf941f34da18505574bfdb7f7e3b796d96,DB01599,DB01599,,,,,,,ECO:0005542,ECO:0005542,,,activity modification of a genetically defective protein,,Atherosclerosis,HP:0002621,,"https://www.ncbi.nlm.nih.gov/pubmed/9185508,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1603,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",Bezafibrate/ atorvastatin,DB01393/DB01076,DB01393 / DB01076,fefc87183c114df83fad9fc94b40dbb5592ec54bcab3071c80b69696d34b9dbc,"DB01393,DB01076","DB01393,DB01076",,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein+symptomatic treatment procedure,,Atherogenic dyslipidemia(Dyslipidemia)*,HP:0003119*,,"https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1604,617347,617347,Number Sign,617347,"HYPERLIPOPROTEINEMIA, TYPE III","APOLIPOPROTEIN E, DEFICIENCY OR DEFECT OF;; DYSBETALIPOPROTEINEMIA DUE TO DEFECT IN APOLIPOPROTEIN E-d;; FAMILIAL HYPERBETA- AND PREBETALIPOPROTEINEMIA;; FAMILIAL HYPERCHOLESTEROLEMIA WITH HYPERLIPEMIA;; HYPERLIPEMIA WITH FAMILIAL HYPERCHOLESTEROLEMIC XANTHOMATOSIS;; BROAD-BETALIPOPROTEINEMIA;; FLOATING-BETALIPOPROTEINEMIA","CORONARY ARTERY DISEASE, SEVERE, SUSCEPTIBILITY TO, INCLUDED;; LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 5, INCLUDED; LDLCQ5, INCLUDED","HYPERLIPOPROTEINEMIA, TYPE III",,APOE,APOE,apolipoprotein E,a7b7727ec3eeab9f7f22edebd5dcb3e0afe800afb2356f2bdef8027f1914c388,P02649,,P02649,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",Recombinant apolipoprotein A-I,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a defective protein by stimulation,,Atherosclerosis,HP:0002621,,"https://www.ncbi.nlm.nih.gov/pubmed/11425766/,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract",348,APOE,507,P02649,K04524,"""""",
1605,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,"Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/",GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,ECO:0000352,ECO:0000352,,,procedure to mitigate dominant effects of a genetically abnormal protein,B,hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/23295286,https://www.ncbi.nlm.nih.gov/pubmed/20936362,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2746,GLUD1,567,P00367,K00261,1.4.1.3,
1606,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,,,,,epileptic seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481/,https://www.ncbi.nlm.nih.gov/pubmed/28621098,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2746,GLUD1,567,P00367,K00261,1.4.1.3,
1607,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,,,,,Hyperinsulinism,HP:0000842,,"https://www.ncbi.nlm.nih.gov/pubmed/10969108,https://www.ncbi.nlm.nih.gov/pubmed/10453735/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2746,GLUD1,567,P00367,K00261,1.4.1.3,
1608,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",Carglumic acid + diazoxide+ Glucose,DB06775+DB01119+DB01914,DB06775 + DB01119 + DB01914,3a11d0c7d259945cc14c3c834cddf696a2f316788d86bbd276a0cf1797968562,,,,,"DB06775,DB01119,DB01914","DB06775,DB01119,DB01914",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+procedure to mitigate dominant effects of a genetically abnormal protein,,hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/26962538,https://www.ncbi.nlm.nih.gov/pubmed/10453735/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2746,GLUD1,567,P00367,K00261,1.4.1.3,
1609,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",Levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/26962538,https://www.ncbi.nlm.nih.gov/pubmed/10453735/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2746,GLUD1,567,P00367,K00261,1.4.1.3,
1610,606762,,Number Sign,606762,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 6; HHF6",HYPERINSULINISM-HYPERAMMONEMIA SYNDROME,,Hyperinsulinism-hyperammonemiaÂ syndrome,,GLUD1,GLUD1,"Glutamate dehydrogenase, mitochondrial",3c61a7e8e428741f686daf4ca1f0ef27b509091203a810ab364e2ec54ea769bf,1.4.1.3,1.4.1.3,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",Levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,,,,,,,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/10969108,https://www.ncbi.nlm.nih.gov/pubmed/10453735/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2746,GLUD1,567,P00367,K00261,1.4.1.3,
1611,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,ECO:0000352,ECO:0000352,T65I,GK-Y214C(De novo muttation),procedure to mitigate dominant effects of a genetically abnormal protein,B,hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/15277402,https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1612,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,(Val455Met) at codon 455,,,,"https:,www.ncbi.nlm.nih.gov,pubmed,19336674",HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1613,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,M197I,Y214C,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1614,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,A456V,ins454A,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1615,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,W99R,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1616,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,S64Y,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1617,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,V452L,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1618,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,M197I,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/19336674,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1619,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Octreotide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,ECO:0007121,ECO:0007121,G68V,,procedure to mitigate dominant effects of a genetically abnormal protein,B,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/8410522/,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1620,602485,,Number Sign,602485,"HYPERINSULINEMIC HYPOGLYCEMIA, FAMILIAL, 3; HHF3",,,Hyperinsulinism due to glucokinase deficiency,,GCK,GCK,glucokinase-4,36256df462687b4d3f0643a536604e5d36daa065761a97292d0d49b7ae1c87be,2.7.1.1,2.7.1.1,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Dextrose +Diazoxide,DB09341+DB01119,DB09341 + DB01119,9bb504c3a2d85188e2c90bd8d7a0edb612d953ce46e42623454969e68f560268,,,,,"DB09341,DB01119","DB09341,DB01119",,,ECO:0000352,ECO:0000352,W99L,,symptomatic treatment procedure+procedure to mitigate dominant effects of a genetically abnormal protein,B,Hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/8410522/,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2645,GCK,1289,P35557,K12407,2.7.1.1,
1621,307030,,Number Sign,307030,GLYCEROL KINASE DEFICIENCY; GKD,GK DEFICIENCY;; GK1 DEFICIENCY;; HYPERGLYCEROLEMIA,,Hyperglycerolemia (Isolated glycerol kinase deficiency),,GK,GK,Glycerol kinase,c3e7e4cc9b8354aed11ae511c8456b4a16e9f085a19cc04075cf8df2e20ecc0a,2.7.1.30,2.7.1.30,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",2710,GK,542,P32189,K00864,2.7.1.30,
1622,307030,,Number Sign,307030,GLYCEROL KINASE DEFICIENCY; GKD,GK DEFICIENCY;; GK1 DEFICIENCY;; HYPERGLYCEROLEMIA,,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,PIGM,GPI mannosyltransferase 1,aa60de0635c3629d8d6cbef7740f8ae3da8edc011cd2d2436954d8d62a90b113,2.4.1.-,2.4.1.-,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Antithrombotic agents,B01,B01,83aa02054b48cae0a7a624c2800c41da465f3514b70a09550457ecd74267ff0b,B01,,,B01,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Thrombosis,HP:0001977,,"https://www.ncbi.nlm.nih.gov/pubmed/16767100,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",93183,PIGM,542,Q9H3S5,K05284,2.4.1.-,
1623,307030,,Number Sign,307030,GLYCEROL KINASE DEFICIENCY; GKD,GK DEFICIENCY;; GK1 DEFICIENCY;; HYPERGLYCEROLEMIA,,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,PIGM,GPI mannosyltransferase 1,aa60de0635c3629d8d6cbef7740f8ae3da8edc011cd2d2436954d8d62a90b113,2.4.1.-,2.4.1.-,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Sodium phenylbutyrate,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein by transcriptional or translational modification,B,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/17442906,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/26962538",93183,PIGM,542,Q9H3S5,K05284,2.4.1.-,
1624,237400,237400,NULL,237400,HYPER-BETA-ALANINEMIA,HYPERALANINEMIA,,HYPER-BETA-ALANINEMIA,,PIGM,PIGM,beta-alanine-alpha-ketoglutarate transaminase.,9c2691219129cb521a77f947dd1308b3cec62ffd1f6480dc4fffe00401a56d12,2.4.1.-,2.4.1.-,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Taurine,DB01956,DB01956,e2c35ccb93ffade0cbb9686ed721b0a3a2b9e0bc72b4e19db7c29c4ec1dba1b0,DB01956,DB01956,,,,,,,ECO:0001565,ECO:0001565,,,symptomatic treatment procedure,,mitochondrial toxicity*,HP:0012103,,"https://www.ncbi.nlm.nih.gov/pubmed/27023909,https://link.springer.com/article/10.1007%2Fs00726-017-2462-x,https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/26962538",93183,PIGM,161,Q9H3S5,K05284,2.4.1.-,
1625,237400,237400,NULL,237400,HYPER-BETA-ALANINEMIA,HYPERALANINEMIA,,HYPER-BETA-ALANINEMIA,,PIGM,PIGM,beta-alanine-alpha-ketoglutarate transaminase.,9c2691219129cb521a77f947dd1308b3cec62ffd1f6480dc4fffe00401a56d12,2.4.1.-,2.4.1.-,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/6198500,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",93183,PIGM,161,Q9H3S5,K05284,2.4.1.-,
1626,237400,237400,NULL,237400,HYPER-BETA-ALANINEMIA,HYPERALANINEMIA,,HYPER-BETA-ALANINEMIA,,PIGM,PIGM,beta-alanine-alpha-ketoglutarate transaminase.,9c2691219129cb521a77f947dd1308b3cec62ffd1f6480dc4fffe00401a56d12,2.4.1.-,2.4.1.-,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,somnolence,HP:0002360,,"https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/6198500,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",93183,PIGM,161,Q9H3S5,K05284,2.4.1.-,
1627,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,anti-TNF-alpha (Adalimumab)+Etanercept,DB00051+DB00005,DB00051 + DB00005,079a8c32a567d5da45511c5462944d43b3daeea685a701ac87ef56bd8ae63e46,,,,,"DB00051,DB00005","DB00051,DB00005",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,periodic fever,HP:0001954,,"https://www.ncbi.nlm.nih.gov/pubmed/24935455,https://www.ncbi.nlm.nih.gov/pubmed/6198500,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1628,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,anti-TNF-alpha (Adalimumab)+Etanercept,DB00051+DB00005,DB00051 + DB00005,079a8c32a567d5da45511c5462944d43b3daeea685a701ac87ef56bd8ae63e46,,,,,"DB00051,DB00005","DB00051,DB00005",,,,,,,,C,Abnormality of immune system physiology,HP:0010978,,"https://www.ncbi.nlm.nih.gov/pubmed/24935455,https://www.ncbi.nlm.nih.gov/pubmed/6198500,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1629,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Anakinra,DB00026,DB00026,5e71f801220feda13941c6cb41b2f9d50b040b99a73461c19aa223396944edaf,DB00026,DB00026,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Arthralgia,HP:0002829,,"https://www.ncbi.nlm.nih.gov/pubmed/20712835,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1630,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Anakinra,DB00026,DB00026,5e71f801220feda13941c6cb41b2f9d50b040b99a73461c19aa223396944edaf,DB00026,DB00026,,,,,,,,,,,,,joint swelling,HP:0001386,,"https://www.ncbi.nlm.nih.gov/pubmed/20712835,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1631,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Canakinumab,DB06168,DB06168,beb9e5b81bcf66f6d85baf3cbba13cd41cb6a815a35bfea4b8e1b7ff0511dbdb,DB06168,DB06168,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Fever,HP:0001945,,"https://www.ncbi.nlm.nih.gov/pubmed/25758134/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1632,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Canakinumab,DB06168,DB06168,beb9e5b81bcf66f6d85baf3cbba13cd41cb6a815a35bfea4b8e1b7ff0511dbdb,DB06168,DB06168,,,,,,,,,,,,,High serum amyloid A protein,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1633,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Canakinumab,DB06168,DB06168,beb9e5b81bcf66f6d85baf3cbba13cd41cb6a815a35bfea4b8e1b7ff0511dbdb,DB06168,DB06168,,,,,,,,,,,,,Elevated C-reactive protein,HP:0011227,,"https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1634,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,prednisolone + azathioprine + immunoglobulins,DB00860+DB00993+DB00028,DB00860 + DB00993 + DB00028,8b58b6d1d67c7792a60e3f5f365cdd6038769fe7683b3b5d20c4215925880692,,,,,"DB00860,DB00993,DB00028","DB00860,DB00993,DB00028",,,ECO:0000352,ECO:0000352,compound V377I and I126T mutations,,symptomatic treatment procedure,C,periodic fever,HP:0001954,,"https://www.ncbi.nlm.nih.gov/pubmed/18839211?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1635,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Thalidomide,DB01041,DB01041,95fdada91a05dc6af4aead5ec1a49f066392d411cfc9abb67523dc647c5ba069,DB01041,DB01041,,,,,,,ECO:0007121,ECO:0007121,,,,C,Limited Efficacy of the drug.,,,"https://www.ncbi.nlm.nih.gov/pubmed/11504824?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1636,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,steroids + simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Periodic fever,HP:0001954,,"https://www.ncbi.nlm.nih.gov/pubmed/19011501?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1637,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Infliximab,DB00065,DB00065,7765e08cdc99e4767116cc9af1c36b2de6865467f2f4486b8e5b04dc12637e85,DB00065,DB00065,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Nummular keratitis(keratitis)*,HP:0000491,,"https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1638,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Infliximab,DB00065,DB00065,7765e08cdc99e4767116cc9af1c36b2de6865467f2f4486b8e5b04dc12637e85,DB00065,DB00065,,,,,,,,,,,,,Corneal scar,HP:0000559,,"https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1639,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Infliximab,DB00065,DB00065,7765e08cdc99e4767116cc9af1c36b2de6865467f2f4486b8e5b04dc12637e85,DB00065,DB00065,,,,,,,,,,,,,Decreased visual acuity,HP:0007663,,"https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_199,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1640,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,tocilizumab,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Fever,HP:0001945,,"https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1641,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,tocilizumab,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,,,,,,,Fatigue,HP:0012378,,"https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1642,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,tocilizumab,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,,,,,,,Pain,HP:0012531,,"https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1643,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,tocilizumab,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,,,,,,,Oral ulceration,HP:0000155,,"https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1644,260920,,Number Sign,260920,HYPER-IgD SYNDROME; HIDS,"HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME;; PERIODIC FEVER, DUTCH TYPE",,Hyperimmunoglobulinemia D,,MVK,MVK,mevalonate kinase,550495318ca8338a28d809410aba1d1c253a5fa7677b33b2da8d821cfcc0a2f8,2.7.1.36,2.7.1.36,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Anakinra+ tocilizumab,DB06273,DB06273,9682b121eef6114981a5fce4e71d70f1971b7cd923c36808f10aa203fc332b94,DB06273,DB06273,,,,,,,ECO:0001565/ECO:0000352,"ECO:0001565,ECO:0000352",,,symptomatic treatment procedure,,Abnormal inflammatory response,HP:0012647,,"https://www.ncbi.nlm.nih.gov/pubmed/25173351,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",4598,MVK,191,Q03426,K00869,2.7.1.36,
1645,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,dermatitis,HP:0011123,,"https://www.ncbi.nlm.nih.gov/pubmed/14169454,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",8942,KYNU,,Q16719,K01556,3.7.1.3,
1646,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,diarrhoea,HP:0002014,,"https://www.ncbi.nlm.nih.gov/pubmed/14169454,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",8942,KYNU,,Q16719,K01556,3.7.1.3,
1647,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,dementia,HP:0000726,,"https://www.ncbi.nlm.nih.gov/pubmed/17334708,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",8942,KYNU,,Q16719,K01556,3.7.1.3,
1648,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Niacin,DB00627,DB00627,26b2f61833341e68c047d379982646d903e76c0777c5602b2e4bcc21c27e8209,DB00627,DB00627,,,,,,,,,,,,,sensitivity to sunlight,HP:0000992,,"https://www.ncbi.nlm.nih.gov/pubmed/10540864,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",8942,KYNU,,Q16719,K01556,3.7.1.3,
1649,236800,236800,Number Sign,236800,HYDROXYKYNURENINURIA,"XANTHURENIC ACIDURIA;; KYNURENINASE DEFICIENCY, PARTIAL",,hydroxykynureninuria,,KYNU,KYNU,kynureninase,103c04474ad11b3fc71ca6284ac2600ffad4810ee7aae88936baa331c7e6ea7d,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Pyridoxal phosphate,DB00114,DB00114,8aa8f0a051e57b66fec0638a7c38161ad76887734ba9bd3111cd00f3841f9b13,DB00114,DB00114,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,,Low enzyme activity,HP:0012379,,"https://www.ncbi.nlm.nih.gov/pubmed/5586569,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,https://www.ncbi.nlm.nih.gov/pubmed/26962538",8942,KYNU,,Q16719,K01556,3.7.1.3,
1650,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Laronidase,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein,A,Low Forced Vital Capacity,HP:0002111,,"https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1651,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Laronidase,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,"High Apnea,Hypopnea Index(sleep apnea)*",HP:0010535*,,"https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1652,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Laronidase,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Decreased pulmonary function,HP:0005952,,"https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1653,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Laronidase,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Hepatomegaly,HP:0002240,,"https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1654,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Laronidase,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Limitation of the Joint range of motion,HP:0001376,,"https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1655,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Laronidase,DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Six Minute Walk Test,NA,,"https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1656,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Nanotechnology-based gene therapy,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,direct complementation of a genetically defective protein by gene therapy,A,Low IDUA activity(Abnormal enzyme activity)*,HP:0012379,,"https://www.ncbi.nlm.nih.gov/pubmed/29122734,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1657,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,Nanotechnology-based gene therapy,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/29122734,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1658,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",GNeo-IDUA,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein,A,neurodegenerative astrogliosis,HP:0002180*,,"https://www.ncbi.nlm.nih.gov/pubmed/28958576,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1659,607015,,Number Sign,607015,HURLER-SCHEIE SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH/S; MPS1-HS,,Hurler-ScheieÂ syndrome,,IDUA,IDUA,alpha-L-iduronidase,09c644340c09af53e5b5bfefc70ddb5324d393af34357be3e80ce508a701ad15,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",GNeo-IDUA,NA,,,,,,,,,,,,,,,,,glycosaminoglycan accumulation,HP:0004371,,"https://www.ncbi.nlm.nih.gov/pubmed/28958576,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797",3425,IDUA,241,P35475,K01217,3.2.1.76,
1660,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,ECO:0000352,ECO:0000352,,,direct complementation of a genetically defective protein,A,Hepatosplenomegaly,HP:0001433,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1661,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Abnormality of joint mobility,HP:0011729,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1662,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Sleep apnea,HP:0010535,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1663,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Nocturnal hypopnea,HP:0002877,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1664,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Abnormal apneaâhypopnea index,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1665,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Urinary glycosaminoglycan excretion,HP:0003541,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1666,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,photophobia,HP:0000613,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1667,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,conjunctival irritation,HP:0030953,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1668,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,impaired Visual acuity,HP:0007663,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1669,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,low exercise endurance,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1670,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,tricuspid regurgitation,HP:0005180,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1671,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,pulmonary regurgitation,HP:0010444,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1672,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,dyspnea at rest,HP:0012763,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1673,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,pitting edema,HP:0000969,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1674,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,low quality of sleep,HP:0002360,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1675,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,Daytime somnolence,HP:0002189,,"https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1676,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,white matter abnormalities,HP:0002500,,"https://www.ncbi.nlm.nih.gov/pubmed/19748810,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1677,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,brain ventricular dilatation,HP:0002119,,"https://www.ncbi.nlm.nih.gov/pubmed/19748810,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1678,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",Laronidase (IRT),DB00090,DB00090,98a31d55f529805c37ab401b5e74b89ba45b73a0a19f52d3eb3be4bfb3111ab0,DB00090,DB00090,,,,,,,,,,,,,brain MRI abnormalities,HP:0002500,,"https://www.ncbi.nlm.nih.gov/pubmed/19748810,https://www.ncbi.nlm.nih.gov/pubmed/31630958,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1679,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Gene therapy,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,direct complementation of a genetically defective protein by gene therapy,A,Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*,HP:0004356,,"https://www.ncbi.nlm.nih.gov/pubmed/8700879,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1680,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Gene therapy,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,activity modification of a genetically defective protein by genome editing,A,ventricular hypertrophy,HP:0001714,,"https://www.ncbi.nlm.nih.gov/pubmed/30170069,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1681,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Gene therapy,NA,,,,,,,,,,,,,,,,,"cardiac dilation, Heart enlargment, cardimegaly",HP:0001640,,"https://www.ncbi.nlm.nih.gov/pubmed/30170069,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1682,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Gene therapy,NA,,,,,,,,,,,,,,,,,left ventricularc contractility abnormalities,HP:0006670*,,"https://www.ncbi.nlm.nih.gov/pubmed/30170069,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1683,607014,607014,Number Sign,607014,HURLER SYNDROME,MUCOPOLYSACCHARIDOSIS TYPE IH; MPS1-H,,Hurler syndrome,,IDUA,IDUA,"iduronidase, alpha-L",c1b83544d833c454b8c10cc67f12002b83a21a95e58da9340caa9ea2a98f4a7d,3.7.1.3,3.7.1.3,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Gene therapy,NA,,,,,,,,,,,,,,,,,Left ventricle dysfunction,HP:0030872,,"https://www.ncbi.nlm.nih.gov/pubmed/30170069,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",3425,IDUA,241,P35475,K01217,3.2.1.76,
1684,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine,DB04789 + DB00200 +DB00165+ DB06756,DB04789 + DB00200 + DB00165 + DB06756,cc0685b76815ebe5c1c8f1867b59541c328b34ba15aa2454e2656e71531a6439,,,,,"DB04789,DB00200,DB00165,DB06756","DB04789,DB00200,DB00165,DB06756",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Abnormal Folate level,HP:0040087,,"https://www.ncbi.nlm.nih.gov/pubmed/11916316,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",4524,MTHFR,,P42898,K00297,1.5.1.20,
1685,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine,DB04789 + DB00200 +DB00165+ DB06756,DB04789 + DB00200 + DB00165 + DB06756,cc0685b76815ebe5c1c8f1867b59541c328b34ba15aa2454e2656e71531a6439,,,,,"DB04789,DB00200,DB00165,DB06756","DB04789,DB00200,DB00165,DB06756",,,,,,,,,Abnormal serum Methylfolate Level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/11916316,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",4524,MTHFR,,P42898,K00297,1.5.1.20,
1686,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract",Betaine+Folinic acid,DB06756+DB00650,DB06756 + DB00650,f6abbfdcd45773b2171439108039d119470dc004c99e5d1a724d91296b8e3b31,,,,,"DB06756,DB00650","DB06756,DB00650",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+metabolite replacement,B+B,Abnormality of homocysteine metabolism,HP:0010919,,"https://www.ncbi.nlm.nih.gov/pubmed/25024447,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",4524,MTHFR,,P42898,K00297,1.5.1.20,
1687,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract",Betaine+Folinic acid,DB06756+DB00650,DB06756 + DB00650,f6abbfdcd45773b2171439108039d119470dc004c99e5d1a724d91296b8e3b31,,,,,"DB06756,DB00650","DB06756,DB00650",,,,,,,,,low muscle tone,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pubmed/25024447,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",4524,MTHFR,,P42898,K00297,1.5.1.20,
1688,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract",Topiramate,DB00273,DB00273,46d06fb3beec9e56fac672d0347e5531cd01d3fdc69d2741b9289b4fe642bf70,DB00273,DB00273,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/25024447,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",4524,MTHFR,,P42898,K00297,1.5.1.20,
1689,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract","Betaine, Folic acid, Vitamin B6 , Vitamin B12",DB06756+DB00158+DB00165+DB00115,DB06756 + DB00158 + DB00165 + DB00115,a3270ee06456b40d51341486b949645237dc5be36e9bb6feb6b0dfdb63ad152c,,,,,"DB06756,DB00158,DB00165,DB00115","DB06756,DB00158,DB00165,DB00115",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,High plasma homocysteine level(Abnormal homocysteine level)*,HP:0010919,,"https://www.ncbi.nlm.nih.gov/pubmed/29246599,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",4524,MTHFR,,P42898,K00297,1.5.1.20,
1690,603174,,NULL,603174,HOMOCYSTEINEMIA,HYPERHOMOCYSTEINEMIA,,Homocystinuria due to MTHFR deficiency,,MTHFR,MTHFR,methylenetetrahydrofolate reductase,791fe2c7939b20bd17cc0d478711104b6d5a95b6b518b397049e66546769dda3,1.5.1.20,1.5.1.20,,"Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773",Vitamin B+Betaine,DB00165+DB6756,DB00165 + DB6756,8ac2f1c39c49a46e4b2abc975de8ccc1bfdef496ff29ea2aa9649775f3053d4a,,,,,"DB00165,DB6756","DB00165,DB6756",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,B+B,Developmental abnormality,HP:0012759,,"https://www.ncbi.nlm.nih.gov/pubmed/20356773,https://www.ncbi.nlm.nih.gov/pubmed/30081189,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/31434105,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",4524,MTHFR,,P42898,K00297,1.5.1.20,
1691,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352/ECO:0005542,"ECO:0000352,ECO:0005542","""P49L, A114V, I278T, R266K, or R336H""","""R125Q, E176K, T191M, T262M, or G307S""",activity modification of a genetically defective protein,B,Misfolding of cystathionine Î²-synthase(Abnormal enzyme activity)*,HP:0012379*,,"https://www.ncbi.nlm.nih.gov/pubmed/29119254,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1692,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).,Î´-aminolevulinate,DB00855,DB00855,bdc657f560d06262a8ba1a8cbc5799dc5b23348226409d565ee1035925d19702,DB00855,DB00855,,,,,,,ECO:0001565,ECO:0001565,R125Q,,,C,Misfolding of cystathionine Î²-synthase(Abnormal enzyme activity)*,HP:0012379*,,"https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1693,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).,Î´-aminolevulinate,DB00855,DB00855,bdc657f560d06262a8ba1a8cbc5799dc5b23348226409d565ee1035925d19702,DB00855,DB00855,,,,,,,,,R266K,,,,Homocystinuria,HP:0002156,,"https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1694,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).,Î´-aminolevulinate,DB00855,DB00855,bdc657f560d06262a8ba1a8cbc5799dc5b23348226409d565ee1035925d19702,DB00855,DB00855,,,,,,,,,,H65R,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1695,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1â9%) or in plasma (typically 4â22%) (Fowler et al. 1978; Alcaide et al. 2015).,S-Adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0001565,ECO:0001565,,,activity modification of a genetically defective protein,A,"""The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM.""",,,"https://www.ncbi.nlm.nih.gov/pubmed/20506325?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1696,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU",bortezomib,DB00188,DB00188,a6a2133e216ab026d57f139fdb094f539926e74a46fd747087dc4a70e1f3b1a4,DB00188,DB00188,,,,,,,ECO:0005542,ECO:0005542,I278T,,activity modification of a genetically defective protein,A,Misfolding of cystathionine Î²-synthase(Abnormal enzyme activity)*,,,"https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1697,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU",ONX-0912,DB11991,DB11991,7a784d5ae86f72e3f18cfc49482833ce59550dba75ce45e72ce6c78b913d90d3,DB11991,DB11991,,,,,,,ECO:0005542,ECO:0005542,S466L /I278T,,activity modification of a genetically defective protein,A,Abnormal Hcy level,HP:0010919*,,"https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1698,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU",ONX-0912,DB11991,DB11991,7a784d5ae86f72e3f18cfc49482833ce59550dba75ce45e72ce6c78b913d90d3,DB11991,DB11991,,,,,,,,,,,,,Homocystinuria,HP:0002156,,"https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1699,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",pyridoxine/betaine,DB00165/DB06756,DB00165 / DB06756,0755377e352df328bfbf19894aa97ea4dd57f75ac4104c6e52efaac6bc623d0f,"DB00165,DB06756","DB00165,DB06756",,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,B,High total homocysteine levels,HP:0002160,,"https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1700,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",pyridoxine/betaine,DB00165/DB06756,DB00165 / DB06756,0755377e352df328bfbf19894aa97ea4dd57f75ac4104c6e52efaac6bc623d0f,"DB00165,DB06756","DB00165,DB06756",,,,,,,,,,,,,High total cysteine levels,HP:0010918,,"https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1701,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",pyridoxine/betaine,DB00165/DB06756,DB00165 / DB06756,0755377e352df328bfbf19894aa97ea4dd57f75ac4104c6e52efaac6bc623d0f,"DB00165,DB06756","DB00165,DB06756",,,,,,,,,,,,,Low plasma serine levels,HP:0012279,,"https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1702,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",pyridoxine/betaine,DB00165/DB06756,DB00165 / DB06756,0755377e352df328bfbf19894aa97ea4dd57f75ac4104c6e52efaac6bc623d0f,"DB00165,DB06756","DB00165,DB06756",,,,,,,,,,,,,high blood S -adenosylhomocysteine level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1703,236200,,Number Sign,236200,HOMOCYSTINURIA DUE TO CYSTATHIONINE BETA-SYNTHASE DEFICIENCY,HOMOCYSTINURIA WITH OR WITHOUT RESPONSE TO PYRIDOXINE;; CYSTATHIONINE BETA-SYNTHASE DEFICIENCY;; CBS DEFICIENCY,"HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED, INCLUDED",Homocystinuria due to CBS deficiency,,CBS,CBS,cystathionine beta-synthase,899b2fa405ec00e911e00571793543e954dc7887a05d0e40847b91b5afeae369,4.2.1.22,4.2.1.22,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",serine,DB00133,DB00133,c0d23226e9582983714d35d6d56065440bea047ae90f95c6635aae942f700144,DB00133,DB00133,,,,,,,ECO:0007764,ECO:0007764,,,symptomatic treatment procedure,C,,,,"https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",875,CBS,27,P35520,K01697,4.2.1.22,
1704,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1705,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,Low cerebral creatine content,HP:0012113*,,"https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1706,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,Low developmental score,HP:0012759*,,"https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1707,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,neurodevelopmental delay,HP:0012758,,"https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1708,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,cognitive dysfunction,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/20682460,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1709,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,Low IQ score,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/20682460,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1710,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,language impairment,HP:0002463,,"https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1711,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,behavior al abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1712,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,communicative skills abnormalities,HP:0002474*,,"https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1713,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,psychomotor retardation,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/23770102,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1714,602360,,Asterisk,602360,L-ARGININE:GLYCINE AMIDINOTRANSFERASE; GATM,AGAT,,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,GATM,arginine:glycine amidinotransferase,a2a99f3f3c590c7a9f319204233d07ab5868451ac1cfd8e5137d0ac0a345b87c,2.1.4.1,2.1.4.1,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",creatine/Creatine phosphate,DB00148/DB13191,DB00148 / DB13191,dc05f69ec8a2465419afda726ccaf0c558c087c2a9cfe77a6c95acdceb1e3c47,"DB00148,DB13191","DB00148,DB13191",,,,,,,,,,,,,METABOLIC ENCEPHALOMYOPATHY,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/20625172,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,https://www.ncbi.nlm.nih.gov/pubmed/31211405,https://www.ncbi.nlm.nih.gov/pubmed/31196723,https://www.ncbi.nlm.nih.gov/pubmed/31082797,https://www.ncbi.nlm.nih.gov/pubmed/30755342",2628,GATM,,P50440,K00613,2.1.4.1,
1715,612933,,Number Sign,612933,GLYCOGEN STORAGE DISEASE XI; GSD11,GSD XI;; LACTATE DEHYDROGENASE A DEFICIENCY,,Lactate dehydrogenase A deficiency,,LDHA,LDHA,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1efb27da4b03aac4145900c1daa0fb13afba88954e2134a8ee522b9df451639e,1.1.1.27,1.1.1.27,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,3939,LDHA,499,P00338,K00016,1.1.1.27,
1716,614128,,Number Sign,614128,LACTATE DEHYDROGENASE B DEFICIENCY; LDHBD,,,Lactate dehydrogenase B deficiency,,LDHB,LDHB,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1efb27da4b03aac4145900c1daa0fb13afba88954e2134a8ee522b9df451639e,1.1.1.27,1.1.1.27,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,3945,LDHB,916,P07195,K00016,1.1.1.27,
1717,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",cholesterol+Simvastatin,DB04540+DB00641,DB04540 + DB00641,9a8d43f9cb10bdfa9f1e668552f8dc1e464446314faea1126b8e401fc1b7de81,,,,,"DB04540,DB00641","DB04540,DB00641",,,ECO:0000352,ECO:0000352,,,metabolite replacement+functional complementation of a defective protein by inhibition,B,Abnormal blood lathosterol level,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pubmed/30097991,6309,SC5D,196,O75845,K00227,1.14.19.20,
1718,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991,Simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,ECO:0000352,ECO:0000352,p.K148E and p.D210E,,functional complementation of a defective protein by inhibition,B,Abnormal neurodevelopmental profile,HP:0012759,,https://www.ncbi.nlm.nih.gov/pubmed/24142275,6309,SC5D,196,O75845,K00227,1.14.19.20,
1719,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991,Simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,,,,,,,Developmental delay,HP:0001263,,https://www.ncbi.nlm.nih.gov/pubmed/24142275,6309,SC5D,196,O75845,K00227,1.14.19.20,
1720,607330,607330,Number Sign,607330,LATHOSTEROLOSIS,STEROL C5-DESATURASE DEFICIENCY;; SC5D DEFICIENCY,,Lathosterolosis,,SC5D,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,8c519a6f36efb374ae931d1b9a964edd6b2c479931bd817c784cac8fe0f69e66,1.1.1.27,1.1.1.27,,The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991,Simvastatin,DB00641,DB00641,571b9ad2e319ddb979754051530ee428e58d73f9bdc15e22c3a3db979966b578,DB00641,DB00641,,,,,,,,,,c.479C>G p.(Pro160Arg) and c.630C>A p.(Asp210Glu),,,Abnormal blood lathosterol level,HP:0001939*,,https://www.ncbi.nlm.nih.gov/pubmed/24142275,6309,SC5D,196,O75845,K00227,1.14.19.20,
1721,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991,heptanoate,CHEBI:32362,CHEBI:32362,4b49a1cef723433bb858ec2f03322aeba381e458cea8fb8e7d6ccbdaff2a4076,CHEBI:32362,,CHEBI_32362,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,C,Elevation of creatine kinase,HP:0003236,,https://www.ncbi.nlm.nih.gov/pubmed/24997711/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1722,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,The drug has been reported to be unbeneficial in one patient . https://www.ncbi.nlm.nih.gov/pubmed/30097991,heptanoate,CHEBI:32362,CHEBI:32362,4b49a1cef723433bb858ec2f03322aeba381e458cea8fb8e7d6ccbdaff2a4076,CHEBI:32362,,CHEBI_32362,,,,,,,,,,,,Exercise-induced muscle cramps,HP:0003710,,https://www.ncbi.nlm.nih.gov/pubmed/24997711/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1723,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,Docosahexaenoic acid (DHA),DB03756,DB03756,16c5d8e3c2f1478a5f7643170003668626f452b44f7243f41dc742daab8d153f,DB03756,DB03756,,,,,,,ECO:0007121,ECO:0007121,,,dietary supplementation,C,Metabolic acidosis,HP:0001942,,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1724,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,Docosahexaenoic acid (DHA),DB03756,DB03756,16c5d8e3c2f1478a5f7643170003668626f452b44f7243f41dc742daab8d153f,DB03756,DB03756,,,,,,,,,,,,,Disease progression(Retinopathy),HP:0003676,,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1725,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,Docosahexaenoic acid (DHA),DB03756,DB03756,16c5d8e3c2f1478a5f7643170003668626f452b44f7243f41dc742daab8d153f,DB03756,DB03756,,,,,,,,,,,,,Reduced visual acuity,HP:0007663,,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1726,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,ECO:0000352,ECO:0000352,,,dietary supplementation,C,Cardiomyopathy,HP:0001638,,https://www.ncbi.nlm.nih.gov/pubmed/12122118/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1727,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Rhabdomyolysis,HP:0003201,,https://www.ncbi.nlm.nih.gov/pubmed/12122118/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1728,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Muscle weakness,HP:0001324,,https://www.ncbi.nlm.nih.gov/pubmed/12122118/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1729,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,Triheptanoin,DB11677,DB11677,115f88e792ac4c1f77dd94eaa4397c6786548cf7579b5261b32e39aba75c2e5d,DB11677,DB11677,,,,,,,,,,,,,Low quality of life,HP:0025142,,https://www.ncbi.nlm.nih.gov/pubmed/16763896/,3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1730,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,ECO:0001565,ECO:0001565,c.1528Gâ>âC,c.1528Gâ>âC,activity modification of a genetically defective protein,A,Abnormal Fatty acid oxidation,HP:0004359*,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1731,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,C2129-2Aâ>âC,,,,Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity,NA,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1732,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,c. 1393_1479del-Del exon,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1733,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,c.180â+â3Aâ>âG,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1734,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,c.914Â Tâ>âA,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1735,600890,,Asterisk,600890,"HYDROXYACYL-CoA DEHYDROGENASE/3-KETOACYL-CoA THIOLASE/ENOYL-CoA HYDRATASE, ALPHA SUBUNIT; HADHA","TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT;; MITOCHONDRIAL TRIFUNCTIONAL PROTEIN, ALPHA SUBUNIT; MTPA;; LONG-CHAIN HYDROXYACYL-CoA DEHYDROGENASE; LCHAD;; ECHA",,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,07e83efd57d770459e1e008ca1fc6ffda21a0698515595aed4c09ed788992cc6,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,c.982Gâ>âA and c.1072Câ>âA,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),3030,HADHA,178,P40939,K07515,2.3.1.-; 4.2.1.17; 1.1.1.211,
1736,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND1/MT-ND4L/MT-ND6,"MT-ND1,MT-ND4L,MT-ND6",mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6,3ad59e352a3baec4679dd9ff354f7fc1a087b007a7d559238b3a0657ec010276,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,",,",",,",402,",,",",,",",,",
1737,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene),NA,,,,,,,,,,,ECO:0001565,ECO:0001565,G11778A,,functional complementation of a genetically defective protein,B,Optic nerve damage,HP:0001138,,"https://www.ncbi.nlm.nih.gov/pubmed/17296905,https://www.ncbi.nlm.nih.gov/pubmed/30107658","""""","""""",402,"""""","""""","""""",
1738,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene),NA,,,,,,,,,,,,,,,,,Mitochondrial oxidative stress,HP:0012103,,"https://www.ncbi.nlm.nih.gov/pubmed/17296905,https://www.ncbi.nlm.nih.gov/pubmed/30107658","""""","""""",402,"""""","""""","""""",
1739,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,"rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)ï¼rAAV2-ND4))",NA,,,,,,,,,,,ECO:0007121,ECO:0007121,G11778A,,direct complementation of a genetically defective protein,A,Abnormal visual acuity,HP:0030532,,"https://clinicaltrials.gov/ct2/show/results/NCT01267422?cond=Leber+Hereditary+Optic+Neuropathy&rank=2&sect=X970156#outcome3,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/30107658","""""","""""",402,"""""","""""","""""",
1740,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,,,,,,,,,,,ECO:0007121,ECO:0007121,G11778A,,direct complementation of a genetically defective protein by gene therapy,A,Low ATP synthesis,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/30208599,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/30107658","""""","""""",402,"""""","""""","""""",
1741,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,,,,,,,,,,,,,,,,,Optic atrophy,HP:0000648,,"https://www.ncbi.nlm.nih.gov/pubmed/30208599,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/30107658","""""","""""",402,"""""","""""","""""",
1742,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,,,,,,,,,,,,,,,,,Abnormal visual acuity,HP:0030534,,"https://www.ncbi.nlm.nih.gov/pubmed/30208599,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/30107658","""""","""""",402,"""""","""""","""""",
1743,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,Dietry treatment supplementation,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30208599,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/30107658","""""","""""",402,"""""","""""","""""",
1744,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0000352/ECO:0007121/ECO:0005542,"ECO:0000352,ECO:0007121,ECO:0005542","""m.3460G>A, m.11778G>A, and m.14484T>C""",,functional complementation of a genetically defective protein,C,Abnormal visual acuity,HP:0030532,,"https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://www.ncbi.nlm.nih.gov/pubmed/11001192,https://www.ncbi.nlm.nih.gov/pubmed/17573650,https://www.ncbi.nlm.nih.gov/pubmed/21788663,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1745,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Abnormal retinal ganglion cell function,HP:0001112,,"https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1746,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Retinal thickness,HP:0000630,,"https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1747,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Gliosis,HP:0002171,,"https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1748,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Functional loss of vision,HP:0000572,,"https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1749,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1750,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Idebenone+Vitamin C+Vitamin B12,DB09081+DB00126+DB00115,DB09081 + DB00126 + DB00115,212e4cce099decca0400320c49f275e248d9861dbc202e49f204147f7322e3bd,,,,,"DB09081,DB00126,DB00115","DB09081,DB00126,DB00115",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+symptomatic treatment procedure,B,Slow recovery,HP:0012823*,,"https://www.ncbi.nlm.nih.gov/pubmed/11001192/,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,https://www.ncbi.nlm.nih.gov/pubmed/21788663/,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1751,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",EPI-743(Vatiquinone),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Disease progression (Rapidly progressive)*,HP:0003678*,,"https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1752,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",EPI-743(Vatiquinone),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,Abnormal visual acuity,HP:0030534,,"https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1753,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",EPI-743(Vatiquinone),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,Visual loss,HP:0000572,,"https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1754,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",EPI-743(Vatiquinone),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,Retinal ganglion loss,HP:0000479,,"https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1755,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Estrogens,DB00783,DB00783,102bf3a48f5629450533d490b6f3cdafd4acafc04910d4d17440e7aa962a1c8d,DB00783,DB00783,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a genetically defective protein,B,Mitochondrial dysfunction,HP:0003287,,"https://www.ncbi.nlm.nih.gov/pubmed/20943885,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://www.ncbi.nlm.nih.gov/pubmed/26448041,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1756,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",elamipretide (MTP-131),DB11981,DB11981,93106ebba74b42431139bfb7235cd31d8452a8ca11f25d519d7a7e064b452ff8,DB11981,DB11981,,,,,,,ECO:0007121,ECO:0007121,,,activity modification of a genetically defective protein,A,Increased reactive oxygen species production,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1757,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",elamipretide (MTP-131),DB11981,DB11981,93106ebba74b42431139bfb7235cd31d8452a8ca11f25d519d7a7e064b452ff8,DB11981,DB11981,,,,,,,,,,,,,Low ATP synthesis,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1758,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",Curcumin,DB11672,DB11672,75495fe6add4f3e7ec689ed63fe192cec61e871e134d0fd3277a365ad0ad134d,DB11672,DB11672,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Oxidative stress,HP:0025464,,"https://clinicaltrials.gov/ct2/show/NCT00528151,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1759,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Cyclosporine,DB00091,DB00091,13d35d65cb3bb074f90d6868ed89c129d48145825aea20089025fd435a5bf52d,DB00091,DB00091,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Disease progression,HP:0003678*,,"https://www.ncbi.nlm.nih.gov/pubmed/24161764,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1760,535000,,Number Sign,535000,LEBER OPTIC ATROPHY,LEBER HEREDITARY OPTIC NEUROPATHY; LHON,,Leber hereditary optic neuropathy,,MT-ND4,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,eacb5cefd183b9cb102c3705d86568a83f4578dd6ad18f45a6fa349fd60f6e30,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Corticosteroid+Antiaggregates,H02+B01A,H02 + B01A,a5ec57e88cb5d66bd6b9dc17b3e7ac187083877fe4bfb29b97d51caf826c403e,,,,,"H02,B01A",,,"H02,B01A",ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Large central visual field defect,HP:0001129,,"https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/","""""","""""",402,"""""","""""","""""",
1761,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type","Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death. Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/",LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,methylene blue,DB09241,DB09241,cd6f137529c9886a5f82247ebaf4ca529fefa604daa656312db529260334cd8f,DB09241,DB09241,,,,,,,ECO:0001565,ECO:0001565,A354V,,metabolite replacement,B,Low COX content and activity,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22202226,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1762,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,methylene blue,DB09241,DB09241,cd6f137529c9886a5f82247ebaf4ca529fefa604daa656312db529260334cd8f,DB09241,DB09241,,,,,,,,,A354V and C12775STOP,,,,acidotic crises,HP:0001941*,,"https://www.ncbi.nlm.nih.gov/pubmed/22202226,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1763,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,propionate,DB03766,DB03766,429ffe8122c00772e3095dbc757b5ccb8f2447908143e18f816253bd8469bb21,DB03766,DB03766,,,,,,,ECO:0001565,ECO:0001565,,,symptomatic treatment procedure,C,Palmitate plus lactate-induced cell death,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25835550,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1764,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0001565,ECO:0001565,,,symptomatic treatment procedure,C,PL-induced cytotoxicity,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/25835550,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1765,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Trolox ornithylamide hydrochloride,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,symptomatic treatment procedure,,Increased ROS production,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/25620325/,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1766,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Trolox ornithylamide hydrochloride,NA,,,,,,,,,,,,,,,,,Decreased activity of mitochondrial complex I,HP:0011923,,"https://www.ncbi.nlm.nih.gov/pubmed/25620325/,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1767,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Trolox ornithylamide hydrochloride,NA,,,,,,,,,,,,,,,,,Decreased activity of mitochondrial complex IV,HP:0008347,,"https://www.ncbi.nlm.nih.gov/pubmed/25620325/,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1768,220111,,Number Sign,220111,"LEIGH SYNDROME, FRENCH CANADIAN TYPE; LSFC","CYTOCHROME c OXIDASE DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, FRENCH CANADIAN TYPE;; COX DEFICIENCY, SAGUENAY-LAC-SAINT-JEAN TYPE;; LEIGH SYNDROME, SAGUENAY-LAC-SAINT-JEAN TYPE",,"Leigh syndrome, French Canadian type",,LRPPRC,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,689f2d6e5ce57fc4b97429b809f669d1e8e027a1a11d150e193a29bfd24872f4,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Trolox ornithylamide hydrochloride,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/25620325/,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,https://clinicaltrials.gov/ct2/show/NCT02805790,https://www.ncbi.nlm.nih.gov/pubmed/21600768/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",10128,LRPPRC,425,"""""","""""","""""",
1769,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Ecopipam ((PSYRX 101),DB12273,DB12273,fc97ec403ea9c1721c4f7d10463041a1db67d448e4629ab43161b88137e33856,DB12273,DB12273,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Self-injurious Behavior,HP:0100716,,"https://clinicaltrials.gov/ct2/show/results/NCT01751802?cond=Lesch-Nyhan+Disease&rank=3&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1770,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,sapropterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Behaviour abnormalities,HP:0100851,,"https://clinicaltrials.gov/ct2/show/NCT00935753,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1771,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,aminomidazole carboxamide riboside,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,B,No result was added,,,"https://clinicaltrials.gov/ct2/show/NCT00004314?cond=Lesch-Nyhan+Disease&rank=4,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1772,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,Hypoxanthine+ tetrahydrobiopterin,DB04076+DB00360,DB04076 + DB00360,e10ffe12ea8f06f63494ac5b3af791d6c470f6133f6a081c1cada5ff932d1ca3,,,,,"DB04076,DB00360","DB04076,DB00360",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+symptomatic treatment procedure,B,No result was accessible,,,"https://www.ncbi.nlm.nih.gov/pubmed/3728152,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1773,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,SAM (S-adenosyl methionine ),DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Self-injurious behaviour,HP:0100716,,"https://www.ncbi.nlm.nih.gov/pubmed/16906475/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1774,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,SAM (S-adenosyl methionine ),DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Aggressive behavior,HP:0000718,,"https://www.ncbi.nlm.nih.gov/pubmed/24055166/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1775,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,SAM (S-adenosyl methionine ),DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24055166/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1776,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hyperuricemia,HP:0002149,,"https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1777,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,gouty arthritis,HP:0001997,,"https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1778,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Allopurinol,DB00437,DB00437,9c64837868ead6fb87035a7174fcd5424dbe6691fe85e870c4d216fe8ff2ee96,DB00437,DB00437,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1779,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Baclofen,DB00181,DB00181,283d4a5ab576ae808a0995e16fe21d81a8a4de4f3d61614edd1975a48037e4c1,DB00181,DB00181,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Spasticity,HP:0001257,,"https://www.ncbi.nlm.nih.gov/pubmed/16549399,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1780,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",diazepam or alprazolam,DB00829 or DB00404,DB00829 or DB00404,d31535d9b1caed200979c1bd39915bd5c013123f2b9204c2b9348d8a4811bee9,"DB00829,DB00404","DB00829,DB00404",,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,anxiety,HP:0000739,,"https://www.ncbi.nlm.nih.gov/pubmed/21126241,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1781,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",diazepam or alprazolam,DB00829 or DB00404,DB00829 or DB00404,d31535d9b1caed200979c1bd39915bd5c013123f2b9204c2b9348d8a4811bee9,"DB00829,DB00404","DB00829,DB00404",,,,,,,,,Spa,,,,Abnormal muscle tone,HP:0003808,,"https://www.ncbi.nlm.nih.gov/pubmed/21126241,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1782,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Risperidone,DB00734,DB00734,3386dc330cfd8bc8e3e77c8209b4c33d8c91496c09c526e583f1be47c58819dc,DB00734,DB00734,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Self-mutilation,HP:0000742,,"https://www.ncbi.nlm.nih.gov/pubmed/8870064/,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1783,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Tetrabenazin,DB04844,DB04844,3c691bde691be0bb10887f2109ce799a1166619ac2503e0085a835f70baa14ae,DB04844,DB04844,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Chorea,HP:0002072,,"https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1784,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Tetrabenazin,DB04844,DB04844,3c691bde691be0bb10887f2109ce799a1166619ac2503e0085a835f70baa14ae,DB04844,DB04844,,,,,,,,,,,,,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1785,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Carbidopaâlevodopa,DB00190+DB01235,DB00190 + DB01235,a833b7564ae1ab0a9d22f26acf51f694431037621f537bac04993eae8f229885,,,,,"DB00190,DB01235","DB00190,DB01235",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1786,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Carbidopaâlevodopa,DB00190+DB01235,DB00190 + DB01235,a833b7564ae1ab0a9d22f26acf51f694431037621f537bac04993eae8f229885,,,,,"DB00190,DB01235","DB00190,DB01235",,,,,,,,,Chorea,HP:0002072,,"https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1787,300322,,Number Sign,300322,LESCH-NYHAN SYNDROME; LNS,"HYPOXANTHINE GUANINE PHOSPHORIBOSYLTRANSFERASE 1 DEFICIENCY;; HPRT1 DEFICIENCY;; HPRT DEFICIENCY;; HPRT DEFICIENCY, COMPLETE","HPRT DEFICIENCY, NEUROLOGIC VARIANT, INCLUDED;; LESCH-NYHAN SYNDROME, NEUROLOGIC VARIANT, INCLUDED",Lesch Nyhan syndrom,,HPRT1,HPRT1,hypoxanthine phosphoribosyltransferase 1,3234a49c0c9bdfac6bdabd721d8f5d5c43477aa9cd6ac1ac382126553c8e53bc,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",Carbidopaâlevodopa,DB00190+DB01235,DB00190 + DB01235,a833b7564ae1ab0a9d22f26acf51f694431037621f537bac04993eae8f229885,,,,,"DB00190,DB01235","DB00190,DB01235",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",3251,HPRT1,145,P00492,K00760,2.4.2.8,
1788,240800,,Number Sign,240800,"HYPOGLYCEMIA, LEUCINE-INDUCED; LIH",LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY,,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ABCC8,ATP binding cassette subfamily C member 8,01ff38107ea9c258db49fbe3e65c6d6d04da8c08c01482bc1d1ce8dfd0331c4d,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,ECO:0000352,ECO:0000352,E1506K,,functional complementation of a genetically defective protein,B,hypoglycemia,HP:0001943,,"https://www.ncbi.nlm.nih.gov/pubmed/15356046,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",6833,ABCC8,,Q09428,K05032,"""""",
1789,240800,,Number Sign,240800,"HYPOGLYCEMIA, LEUCINE-INDUCED; LIH",LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY,,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ABCC8,ATP binding cassette subfamily C member 8,01ff38107ea9c258db49fbe3e65c6d6d04da8c08c01482bc1d1ce8dfd0331c4d,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,R1353H,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15356046,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",6833,ABCC8,,Q09428,K05032,"""""",
1790,240800,,Number Sign,240800,"HYPOGLYCEMIA, LEUCINE-INDUCED; LIH",LEUCINE-SENSITIVE HYPOGLYCEMIA OF INFANCY,,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ABCC8,ATP binding cassette subfamily C member 8,01ff38107ea9c258db49fbe3e65c6d6d04da8c08c01482bc1d1ce8dfd0331c4d,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",diazoxide,DB01119,DB01119,6af21bd45766235b23da706ad24fd400a590205df9bddfd6b49e174b92f9087a,DB01119,DB01119,,,,,,,,,delSer1387,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15356046,https://www.ncbi.nlm.nih.gov/pubmed/12593632,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,https://www.ncbi.nlm.nih.gov/pubmed/24093206/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/",6833,ABCC8,,Q09428,K05032,"""""",
1791,613724,,Number Sign,613724,LEUKOENCEPHALOPATHY WITH DYSTONIA AND MOTOR NEUROPATHY; LKDMN,STEROL CARRIER PROTEIN 2 DEFICIENCY,,Leukoencephalopathy-dystonia-motor neuropathy syndrome(STEROL CARRIER PROTEIN 2 DEFICIENCY),,SCP2,SCP2,sterol carrier protein 2,170522625b29ee7a1ef0982e1c33fd140870d731fbdb6b7e262ccc6dcd07a0b6,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16685654,6342,SCP2,1114,P22307,K08764,2.3.1.176,
1792,611105,,Number Sign,611105,LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL,MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY,,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,DARS2,mitochondrial aspartyl-tRNA synthetase,f8ba6cb37bd1ac95d2d09b924400cc0cd155df7c4cd1de7c2df6a4cb8a4c4952,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",acetazolamide,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia ),HP:0002066*,,https://www.ncbi.nlm.nih.gov/pubmed/21749991,55157,DARS2,446,Q6PI48,K01876,6.1.1.12,
1793,611105,,Number Sign,611105,LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL,MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY,,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,DARS2,mitochondrial aspartyl-tRNA synthetase,f8ba6cb37bd1ac95d2d09b924400cc0cd155df7c4cd1de7c2df6a4cb8a4c4952,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",acetazolamide,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,,,,,,,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/21749991,55157,DARS2,446,Q6PI48,K01876,6.1.1.12,
1794,611105,,Number Sign,611105,LEUKOENCEPHALOPATHY WITH BRAINSTEM AND SPINAL CORD INVOLVEMENT AND LACTATE ELEVATION; LBSL,MITOCHONDRIAL ASPARTYL-tRNA SYNTHETASE DEFICIENCY,,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,DARS2,mitochondrial aspartyl-tRNA synthetase,f8ba6cb37bd1ac95d2d09b924400cc0cd155df7c4cd1de7c2df6a4cb8a4c4952,4.2.1.17,"1.1.1.211,4.2.1.17",,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",glucocorticosteroid,DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,spastic bladder,HP:0005340,,https://www.ncbi.nlm.nih.gov/pubmed/23644316,55157,DARS2,446,Q6PI48,K01876,6.1.1.12,
1795,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,Prednisolone,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,ECO:0000352/ECO:0007764,"ECO:0000352,ECO:0007764",,,symptomatic treatment procedure,C,Myositis,HP:0100614,,"https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099",79147,FKRP,,Q9H9S5,K19873,2.4.2.-,
1796,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,Prednisolone,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,,,,,,,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099",79147,FKRP,,Q9H9S5,K19873,2.4.2.-,
1797,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,Prednisolone,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,,,,,,,Difficulty walking,HP:0002355,,"https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099",79147,FKRP,,Q9H9S5,K19873,2.4.2.-,
1798,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,Prednisolone,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,,,,,,,Rapid progression,HP:0003678,,"https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099",79147,FKRP,,Q9H9S5,K19873,2.4.2.-,
1799,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,rAAV-Fkrp,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Abnormal serum creatine kinase,HP:0040081,,"https://www.ncbi.nlm.nih.gov/pubmed/25048216,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302",79147,FKRP,,Q9H9S5,K19873,2.4.2.-,
1800,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,rAAV-Fkrp,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,,,,,,,Muscle dystrophy,HP:0006785,,"https://www.ncbi.nlm.nih.gov/pubmed/28107841,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302",79147,FKRP,,Q9H9S5,K19873,2.4.2.-,
1801,607155,,Number Sign,607155,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 5; MDDGC5","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 9; LGMDR9;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I;; MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, FRKP-RELATED",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,FKRP,fukutin-related protein (FKRP),a1f0a63d49c0b5bf78fa214aab2bddf5fad3abde399c484b16bb23c8e7a66bfd,4.2.1.17,"1.1.1.211,4.2.1.17",,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,rAAV-Fkrp,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,,,,,,,Abnormal muscle function,HP:0011804,,"https://www.ncbi.nlm.nih.gov/pubmed/28107841,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302",79147,FKRP,,Q9H9S5,K19873,2.4.2.-,
1802,609308,,Number Sign,609308,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 1; MDDGC1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 11; LGMDR11;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2K; LGMD2K",,LGMD2K,,POMT1,POMT1,protein O-mannosyltransferase 1,c7f8ff87033b272860227f552819241c016e0fca894341285c3e08c74a60a022,2.4.1.109,2.4.1.109,,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17339125,10585,POMT1,352,"""""","""""","""""",
1803,611307,,Number Sign,611307,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 12; LGMDR12","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2L; LGMD2L",,Limb-girdle muscular dystrophy type 2I (LGMD2I),,ANO5,ANO5,anoctamin 5,edacd0e23a519c1071120a82bd17a5efb3583aba8c0d520c1ba3f297e773bf0f,Q75V66,,Q75V66,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,203859,ANO5,,Q75V66,K19480,"""""",
1804,253601,,Number Sign,253601,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 2; LGMDR2","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 3; LGMD3",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B",,DYSF,DYSF,dysferlin,1805ac6983333359231feb5ac6a1abc39a425f5fcd774cefdd24cc6462b1e9b1,O75923,,O75923,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,Resolaris (ATYR1940),NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Abnormal muscle function,HP:0011804,,"https://clinicaltrials.gov/ct2/show/NCT02579239,https://musculardystrophynews.com/resolaris-atyr1940/,https://www.ncbi.nlm.nih.gov/pubmed/17339125",8291,DYSF,,O75923,K18261,"""""",
1805,253600,,Number Sign,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2;; MUSCULAR DYSTROPHY, PELVOFEMORAL;; LEYDEN-MOEBIUS MUSCULAR DYSTROPHY;; CALPAINOPATHY","MYOSITIS, EOSINOPHILIC, INCLUDED","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,CAPN3,calpain 3,9f57413f2bcf5f1092500e07fadf843a176e9629dcd8e6b31cdfdc927e6d020b,3.4.22.17,3.4.22.17,,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,AAV2 /1-mSeAP-propmyoD76A,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,B,Muscle atrophy,HP:0003797,,"https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/17339125",825,CAPN3,,P20807,K08573,3.4.22.54,
1806,253600,,Number Sign,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2;; MUSCULAR DYSTROPHY, PELVOFEMORAL;; LEYDEN-MOEBIUS MUSCULAR DYSTROPHY;; CALPAINOPATHY","MYOSITIS, EOSINOPHILIC, INCLUDED","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,CAPN3,calpain 3,9f57413f2bcf5f1092500e07fadf843a176e9629dcd8e6b31cdfdc927e6d020b,3.4.22.17,3.4.22.17,,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,AAV2 /1-mSeAP-propmyoD76A,NA,,,,,,,,,,,,,,,,,abnormal muscle strenght,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",825,CAPN3,,P20807,K08573,3.4.22.54,
1807,253600,,Number Sign,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 1; LGMDR1","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A; LGMD2A;; MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2; LGMD2;; MUSCULAR DYSTROPHY, PELVOFEMORAL;; LEYDEN-MOEBIUS MUSCULAR DYSTROPHY;; CALPAINOPATHY","MYOSITIS, EOSINOPHILIC, INCLUDED","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,CAPN3,calpain 3,9f57413f2bcf5f1092500e07fadf843a176e9629dcd8e6b31cdfdc927e6d020b,3.4.22.17,3.4.22.17,,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,(r) AAV2/1-mediated calpain 3,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,Low muscle mass,,,"https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",825,CAPN3,,P20807,K08573,3.4.22.54,
1808,608099,,Number Sign,608099,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 3; LGMDR3","MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D;; DUCHENNE-LIKE AUTOSOMAL RECESSIVE MUSCULAR DYSTROPHY, TYPE 2; DMDA2;; ADHALINOPATHY, PRIMARY",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D",,SGCA,SGCA,sarcoglycan alpha,842cd54aa7005064468652bc60f277a58b791db371ea81bba4c5fd0e90bdfcfa,Q16586,,Q16586,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,AAV2/1-MCK-Sgca,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,A,Decreased muscle mass,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=AAV-mediated+delivery+of+a+mutated+myostatin+propeptide+ameliorates+calpain+3+but+not+Î±-sarcoglycan+deficiency,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",6442,SGCA,,Q16586,K12565,"""""",
1809,608896,,Asterisk,608896,"SARCOGLYCAN, GAMMA; SGCG","DYSTROPHIN-ASSOCIATED GLYCOPROTEIN, 35-KD",,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C",,SGCG,SGCG,sarcoglycan gamma,eb776936c6a52d632a7fb1ead88eda8815e2f5f90251fefd3f7a8ed6b86bb29d,Q16586,,Q16586,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,AAV2/1-MCK-Sgca,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/15252120,https://www.ncbi.nlm.nih.gov/pubmed/16635485,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",6445,SGCG,,Q13326,K12564,"""""",
1810,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,Poor compliance to the treatment was noticed,Fenofibrate+Ï-3 fatty acids+EPA+DHA,DB01039+DB11133+DB00159 +DB03756,DB01039 + DB11133 + DB00159 + DB03756,72b61c38d6e676cffe014e9afb89ce70e0cccfe4f486b35c127c5d344c23313e,,,,,"DB01039,DB11133,DB00159,DB03756","DB01039,DB11133,DB00159,DB03756",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,C,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/19820022,https://www.ncbi.nlm.nih.gov/pubmed/16635485,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",64788,LMF1,1085,Q96S06,K23555,"""""",
1811,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,"Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil",gemfibrozil+Ï-3 fatty acids,DB01241+DB11133,DB01241 + DB11133,8f5884bac439787a67097c69c67edfcd5d928a572e2bd2a37b3a1b2ce810a82e,,,,,"DB01241,DB11133","DB01241,DB11133",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,C,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/19820022,https://www.ncbi.nlm.nih.gov/pubmed/16635485,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",64788,LMF1,1085,Q96S06,K23555,"""""",
1812,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,"Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil",Insulin aspart+Fibrate(gemfibrozil)+ Ï-3 fatty acids,DB01306+DB01241+DB11133,DB01306 + DB01241 + DB11133,678375cc4026977112d122e2dc7f43de1b5f4447b15fca0eb9e681f398c4f073,,,,,"DB01306,DB01241,DB11133","DB01306,DB01241,DB11133",,,ECO:0000352,ECO:0000352,W464X,,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,C,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/19820022,https://www.ncbi.nlm.nih.gov/pubmed/16635485,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",64788,LMF1,1085,Q96S06,K23555,"""""",
1813,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,"Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil",Insulin aspart+Fibrate(gemfibrozil)+ Ï-3 fatty acids,DB01306+DB01241+DB11133,DB01306 + DB01241 + DB11133,678375cc4026977112d122e2dc7f43de1b5f4447b15fca0eb9e681f398c4f073,,,,,"DB01306,DB01241,DB11133","DB01306,DB01241,DB11133",,,,,,,,,Hyperglycemia,HP:0003074,,"https://www.ncbi.nlm.nih.gov/pubmed/19820022,https://www.ncbi.nlm.nih.gov/pubmed/16635485,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",64788,LMF1,1085,Q96S06,K23555,"""""",
1814,246650,,Number Sign,246650,"LIPASE DEFICIENCY, COMBINED",LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY;; LPL AND HTGL DEFICIENCY;; LPL AND HL DEFICIENCY,,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,LMF1,lipase maturation factor 1,c194b68024b44905d05a261bcc72f4359fe731dfc155bab00486a72ebc8951b7,Q96S06,,Q96S06,A low fat regimen was added to metformin while treating the patient.,Metformin,DB00331,DB00331,d056ae45d37c6e46046e3261b7b1c388af8a39d409eaa6caf8955e1f26e8277c,DB00331,DB00331,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hypertriglyceridemia,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/17994020/,https://www.ncbi.nlm.nih.gov/pubmed/16635485,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",64788,LMF1,1085,Q96S06,K23555,"""""",
1815,614462,,Number Sign,614462,"HYPERGLYCINEMIA, LACTIC ACIDOSIS, AND SEIZURES; HGCLAS",PYRUVATE DEHYDROGENASE LIPOIC ACID SYNTHETASE DEFICIENCY; PDHLD,,Lipoic acid synthetase deficiency,,LIAS,LIAS,lipoic acid synthetase,336baf56ca1cf9884a870e108ed4d86e41b121aecab300950098b617e853a008,2.8.1.8,2.8.1.8,,A low fat regimen was added to metformin while treating the patient.,Topiramate+lamotrigine,DB00273+DB00555,DB00273 + DB00555,b9a56afd3455e636c1ea14454da0a47ef94ff78d7dced696f889989c09267458,,,,,"DB00273,DB00555","DB00273,DB00555",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/24777537,https://www.ncbi.nlm.nih.gov/pubmed/16635485,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",11019,LIAS,836,O43766,K03644,2.8.1.8,
1816,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,A low fat regimen was added to metformin while treating the patient.,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Skin lesion,HP:0011122,,"https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",1893,ECM1,,Q16610,"""""","""""",
1817,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,A low fat regimen was added to metformin while treating the patient.,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,,,,,,,Skin papules,HP:0200034,,"https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",1893,ECM1,,Q16610,"""""","""""",
1818,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,A low fat regimen was added to metformin while treating the patient.,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,,,,,,,Mucosal lesions,,,"https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",1893,ECM1,,Q16610,"""""","""""",
1819,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,A low fat regimen was added to metformin while treating the patient.,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,,,,,,,Hoarseness,HP:0001609,,"https://www.ncbi.nlm.nih.gov/pubmed/23259080/,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",1893,ECM1,,Q16610,"""""","""""",
1820,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,A low fat regimen was added to metformin while treating the patient.,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,,,,,,,Elbow skin thickening,HP:0001072,,"https://www.ncbi.nlm.nih.gov/pubmed/28681064,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",1893,ECM1,,Q16610,"""""","""""",
1821,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,A low fat regimen was added to metformin while treating the patient.,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,,,,,,,hyperkeratosis,HP:0000962,,"https://www.ncbi.nlm.nih.gov/pubmed/28681064,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",1893,ECM1,,Q16610,"""""","""""",
1822,247100,247100,Number Sign,247100,LIPOID PROTEINOSIS OF URBACH AND WIETHE,LIPOID PROTEINOSIS;; URBACH-WIETHE DISEASE;; HYALINOSIS CUTIS ET MUCOSAE,,Lipoid proteinosis of Urbach and Wiethe,,ECM1,ECM1,extracellular matrix protein 1,a6f95e4be5c2afc8f1ce5a1bf8e365578cc786a11f79966e3b631091c4fe4369,Q16610,,Q16610,A low fat regimen was added to metformin while treating the patient.,Acitretin,DB00459,DB00459,0aaa38c28875aaa37b8328faf720670e786550db77bcc9953c111f2e53aa0d8b,DB00459,DB00459,,,,,,,,,,,,,verrucous lesions,HP:0012500,,"https://www.ncbi.nlm.nih.gov/pubmed/28681064,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",1893,ECM1,,Q16610,"""""","""""",
1823,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",sodium bicarbonate,DB01390,DB01390,e12c53e6369e9c574ad9dc881999d7c5a618fd7ddc3a1149ebd431905726baf6,DB01390,DB01390,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Proximal tubular dysfunction,HP:0000114,,"https://www.ncbi.nlm.nih.gov/pubmed/12937245,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1824,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",potassium bicarbonate,DB11098,DB11098,99c93e7455a78824d81499f20c391ff8aa6048be5c1e071b2a842aff08583fc5,DB11098,DB11098,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1825,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",Potassium citrate,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Metabolic acidosis (Hyperchloremic metabolic acidosis),HP:0004918,,"https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1826,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",Potassium citrate,DB09125,DB09125,2675de608f438c601c1b73a0de680dc36af0c6e026f47eaee69b7ddd736c0b19,DB09125,DB09125,,,,,,,,,,,,,Hypokalemia,HP:0002900,,"https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1827,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",phosphate+calcitriol,DB14573+DB00136,DB14573 + DB00136,97a3e9d877bccd9c942df123da571dc27ac9f8f93a241833174e40e2f124e28c,,,,,"DB14573,DB00136","DB14573,DB00136",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Renal rickets,HP:0002748,,"https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1828,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",phosphate+calcitriol,DB14573+DB00136,DB14573 + DB00136,97a3e9d877bccd9c942df123da571dc27ac9f8f93a241833174e40e2f124e28c,,,,,"DB14573,DB00136","DB14573,DB00136",,,,,,,,C,Hypophosphatemia,HP:0002148,,"https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1829,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",1-OH vitamin D,DB14573+DB00136,DB14573 + DB00136,97a3e9d877bccd9c942df123da571dc27ac9f8f93a241833174e40e2f124e28c,,,,,"DB14573,DB00136","DB14573,DB00136",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hyperparathyrodism,HP:0000867,,"https://www.ncbi.nlm.nih.gov/pubmed/2017228,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1830,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",pamidronate +growth hormone,DB00282+DB00052,DB00282 + DB00052,23e8fee8c911ae066de3ac1d6590ba9e86e318f401a7c3a7127663b65e849e51,,,,,"DB00282,DB00052","DB00282,DB00052",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Hypophosphatasia,HP:0002148,,"https://www.ncbi.nlm.nih.gov/pubmed/19773212/,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1831,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",pamidronate +growth hormone,DB00282+DB00052,DB00282 + DB00052,23e8fee8c911ae066de3ac1d6590ba9e86e318f401a7c3a7127663b65e849e51,,,,,"DB00282,DB00052","DB00282,DB00052",,,,,,,,,Osteoporosis,HP:0000939,,"https://www.ncbi.nlm.nih.gov/pubmed/19773212/,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1832,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",Thiazide,DB01325,DB01325,218140bfb4aa9cf2acfbdbf3cf994ecb7422df77aedc77f45b82c7ed496f941f,DB01325,DB01325,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,High calcium excretion,HP:0002150,,"https://www.ncbi.nlm.nih.gov/pubmed/26251718,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1833,309000,,Number Sign,309000,LOWE OCULOCEREBRORENAL SYNDROME; OCRL,"OCRL1;; LOWE SYNDROME;; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 5-PHOSPHATASE DEFICIENCY",,Lowe oculocerebrorenal,,OCRL,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,ef0949fba73f766899805e1c93e04649d41b5b6b980eae75aeea549afb16f66f,3.1.3.86,"3.1.3.36,3.1.3.56,3.1.3.86",,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,secondary carnitine deficiency (Carnitine deficiency)*,HP:0003234,,"https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf,https://www.ncbi.nlm.nih.gov/books/NBK1480/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A",4952,OCRL,1061,Q01968,K01099,3.1.3.36; 3.1.3.56; 3.1.3.86,
1834,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,"General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/",SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Citrulline should be given in ""Low-dose"" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650",Citrulline,DB00155,DB00155,f220a4f6ebbf26d38e30093b27cfa690c0d7ecacdd94dc8fd4976db62b0aed4b,DB00155,DB00155,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1835,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",corticosteroids(Amcinonide),DB00288,DB00288,43f2ff812575fee5fecc0d3cac01be897524bb6a94e576dac5aefe7d62fcd5ec,DB00288,DB00288,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*,HP:0010978,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1836,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",cyclosporin,DB00091,DB00091,13d35d65cb3bb074f90d6868ed89c129d48145825aea20089025fd435a5bf52d,DB00091,DB00091,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1837,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",Alendronate,DB00091,DB00091,13d35d65cb3bb074f90d6868ed89c129d48145825aea20089025fd435a5bf52d,DB00091,DB00091,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Osteopenia,HP:0000938,,"https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1838,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",ACEI (Benazepril),DB00542,DB00542,319fb70aaaefde71913ae194827adc63b4824662d899ec62d1d9351723e1d9b6,DB00542,DB00542,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Kidney failure,HP:0000083,,"https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1839,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",ACEI (Benazepril),DB00542,DB00542,319fb70aaaefde71913ae194827adc63b4824662d899ec62d1d9351723e1d9b6,DB00542,DB00542,,,,,,,,,,,,,proteinuria,HP:0000093,,"https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1840,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",ACEI (Benazepril),DB00542,DB00542,319fb70aaaefde71913ae194827adc63b4824662d899ec62d1d9351723e1d9b6,DB00542,DB00542,,,,,,,,,,,,,hypertension,HP:0000822,,"https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1841,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Drug has no difference in terms of prognosis.,sodium phenylbutyrate,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/26865117,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1842,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Drug has no difference in terms of prognosis.,sodium benzoate,DB03793,DB03793,6fac18cc5e193e26705b1cafd1139dbfac2e66ab9c2727b72d3a14280ac4dfd7,DB03793,DB03793,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1843,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,Drug has no difference in terms of prognosis.,Lysine,DB00123,DB00123,ddfbdace28c1f9f81f233925d671c7da70607547088b3a060bd544b81ef7e66d,DB00123,DB00123,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,,hypolysinemia,,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1844,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583,DB00123 / DB00125 / DB00583,155110350052021a097a15d4af37febf5999d53f44f0ed8a09b4a20b42cc8fca,"DB00123,DB00125,DB00583","DB00123,DB00125,DB00583",,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,C,orotic aciduria,HP:0003218,The drug works through preventing the aciduria and the hyperammonemia rather than treating it.,"https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1845,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583,DB00123 / DB00125 / DB00583,155110350052021a097a15d4af37febf5999d53f44f0ed8a09b4a20b42cc8fca,"DB00123,DB00125,DB00583","DB00123,DB00125,DB00583",,,,,,,,,,,,C,hypolysinemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1846,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583,DB00123 / DB00125 / DB00583,155110350052021a097a15d4af37febf5999d53f44f0ed8a09b4a20b42cc8fca,"DB00123,DB00125,DB00583","DB00123,DB00125,DB00583",,,,,,,,,,,,,intracellular defect of arginine,HP:0005961,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1847,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Lysine/Arginine/carnitine/Citrulline,DB00123/DB00125/DB00583,DB00123 / DB00125 / DB00583,155110350052021a097a15d4af37febf5999d53f44f0ed8a09b4a20b42cc8fca,"DB00123,DB00125,DB00583","DB00123,DB00125,DB00583",,,,,,,,,,,,,hyperproteinemia,HP:0002152,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1848,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Growth hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,growth impairment,HP:0001510,,"https://www.ncbi.nlm.nih.gov/pubmed/16775724/,https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1849,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",Growth hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,,,,,,,Short stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/16775724/,https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1850,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1851,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,DB03793 + DB00583 + DB00155,fa475ebf9e681771186325a2d773598150d24979e78ed2913c0157d73e1db6e2,,,,,"DB03793,DB00583,DB00155","DB03793,DB00583,DB00155",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,C,episodic behavioral abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1852,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,DB03793 + DB00583 + DB00155,fa475ebf9e681771186325a2d773598150d24979e78ed2913c0157d73e1db6e2,,,,,"DB03793,DB00583,DB00155","DB03793,DB00583,DB00155",,,,,,,,,social interaction defect,HP:0000735,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1853,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,DB03793 + DB00583 + DB00155,fa475ebf9e681771186325a2d773598150d24979e78ed2913c0157d73e1db6e2,,,,,"DB03793,DB00583,DB00155","DB03793,DB00583,DB00155",,,,,,,,,lack eye-eye contact,HP:0000817,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1854,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sodium benzoate+ L-carnitine+ low dose citrulline,DB03793+DB00583+DB00155,DB03793 + DB00583 + DB00155,fa475ebf9e681771186325a2d773598150d24979e78ed2913c0157d73e1db6e2,,,,,"DB03793,DB00583,DB00155","DB03793,DB00583,DB00155",,,,,,,,,Hepatosplenomegaly,HP:0001433,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1855,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Azathioprine,DB00993,DB00993,9cc88629a863a5b4624dcdb4e9555f1f32829311a490b2c7dd7ab7b0cdd88e06,DB00993,DB00993,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1856,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Azathioprine,DB00993,DB00993,9cc88629a863a5b4624dcdb4e9555f1f32829311a490b2c7dd7ab7b0cdd88e06,DB00993,DB00993,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1857,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Azathioprine,DB00993,DB00993,9cc88629a863a5b4624dcdb4e9555f1f32829311a490b2c7dd7ab7b0cdd88e06,DB00993,DB00993,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,https://www.ncbi.nlm.nih.gov/pubmed/20301535,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1858,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sargramostim,DB00020,DB00020,b30e8917a9527780729c37174f10d6b3473ada85a8039e302e35ce90cd12fc78,DB00020,DB00020,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,C,Pulmonary Alveolar Proteinosis,HP:0006517,,"https://www.ncbi.nlm.nih.gov/pubmed/27783330,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1859,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Sargramostim,DB00020,DB00020,b30e8917a9527780729c37174f10d6b3473ada85a8039e302e35ce90cd12fc78,DB00020,DB00020,,,,,,,,,,,,,Low pulmonary function,HP:0005952,,"https://www.ncbi.nlm.nih.gov/pubmed/27783330,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/25859380",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1860,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Regramostim,DB05386,DB05386,cbe58720e48c0726a5bfcdce15a5c5b83399fad147b650d68ad6779adde0706b,DB05386,DB05386,,,,,,,ECO:0007121,ECO:0007121,,,activity modification of a genetically defective protein,C,Pulmonary Alveolar Proteinosis,HP:0006517,,"https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1861,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Regramostim,DB05386,DB05386,cbe58720e48c0726a5bfcdce15a5c5b83399fad147b650d68ad6779adde0706b,DB05386,DB05386,,,,,,,,,,,,,Low pulmonary function,HP:0005952,,"https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1862,222700,,Number Sign,222700,LYSINURIC PROTEIN INTOLERANCE; LPI,DIBASIC AMINO ACIDURIA II,,Lysinuric protein intolerance,,SLC7A7,SLC7A7,Y+L amino acid transporter 1,4248f05c34ee32d51c99243e367f3dd5a023a0c76729a1a9be9c9bc53396453c,Q9UM01,,Q9UM01,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,prednisolone+mycophenolate mofetil,DB00860+DB00688,DB00860 + DB00688,ad0d467cd315ed5394c57672960e4f25f158361bd7f052555203dfe6ed5e58a8,,,,,"DB00860,DB00688","DB00860,DB00688",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,C,membranoproliferative glomerulonephritis,HP:0000793,,"https://www.ncbi.nlm.nih.gov/pubmed/28087478,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",9056,SLC7A7,51,Q9UM01,K13867,"""""",
1863,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,Carnitine+Fat-limited diet+High carbohydrate diet,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+dietary regime modification,B,High urinary malonic acid,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",23417,MLYCD,177,O95822,K01578,4.1.1.9,
1864,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Mediumâchain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,ECO:0000352,ECO:0000352,,,dietary regime modification,B,High blood malonylcarnitine level,HP:0031544,,"https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",23417,MLYCD,177,O95822,K01578,4.1.1.9,
1865,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Mediumâchain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Low endurance,HP:0025142,,"https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",23417,MLYCD,177,O95822,K01578,4.1.1.9,
1866,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Mediumâchain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Failurre to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",23417,MLYCD,177,O95822,K01578,4.1.1.9,
1867,248360,248360,Number Sign,248360,MALONYL-CoA DECARBOXYLASE DEFICIENCY,,,Malonyl-CoA decarboxylase Deficiency,,MLYCD,MLYCD,malonyl-CoA decarboxylase,1ff5b89cd5a9c94fa9fa5c21755ce0f4361a77eaf50854c0313d8b251a722bcf,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Mediumâchain triglycerides,DB13959,DB13959,a2b2582becf37b240e7781ba0ddd6155cc0d9f89917782a4346b282558cd736e,DB13959,DB13959,,,,,,,,,,,,,Cardiomyopathy progrssion,HP:0003679,,"https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,https://www.ncbi.nlm.nih.gov/pubmed/28649527,https://www.ncbi.nlm.nih.gov/pubmed/25859380,https://www.ncbi.nlm.nih.gov/pubmed/24886114",23417,MLYCD,177,O95822,K01578,4.1.1.9,
1868,614202,,Number Sign,614202,"MENTAL RETARDATION, AUTOSOMAL RECESSIVE 15; MRT15",,,MAN1B1-CDG,,MAN1B1,MAN1B1,mannosidase alpha class 1B member 1,8684d28c786ecaaee0c6ae544c9292c71eaecada039a8188bee8575ed73e1097,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29908352,11253,MAN1B1,611,Q9UKM7,K01230,3.2.1.113,
1869,611722,,Number Sign,611722,"KRABBE DISEASE, ATYPICAL, DUE TO SAPOSIN A DEFICIENCY",SAPOSIN A DEFICIENCY,,Krabbe disease atypical due to Saposin A deficiency,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,5660,PSAP,292,P07602,K12382,"""""",
1870,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,C,Low 5âMTHF level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733",5660,PSAP,398,P07602,K12382,"""""",
1871,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,White matter alteration,HP:0002500,,"https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733",5660,PSAP,398,P07602,K12382,"""""",
1872,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,deambulation,HP:0100022,,"https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733",5660,PSAP,398,P07602,K12382,"""""",
1873,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Growth Hormone,DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Short Stature,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/27718492,https://www.ncbi.nlm.nih.gov/pubmed/28318733",5660,PSAP,398,P07602,K12382,"""""",
1874,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,Corneal Oedema,HP:0012040,,"https://www.ncbi.nlm.nih.gov/pubmed/27442316,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1875,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/26118651,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1876,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,l-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,C,Mitochondrial respiratory chain defects,HP:0200125,,"https://www.ncbi.nlm.nih.gov/pubmed/19891905,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1877,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,l-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Myopathy,HP:0003198,,"https://www.ncbi.nlm.nih.gov/pubmed/26884075,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1878,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,"dopamine, dobutamine, thiazide and milrinone",DB00988+DB0084+DB00232+DB00235,DB00988 + DB0084 + DB00232 + DB00235,ff4de40c92295359317d4460c5368d43666b6d88865ca66fd94ef71a229b18e2,,,,,"DB00988,DB0084,DB00232,DB00235","DB00988,DB0084,DB00232,DB00235",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,acute congestive heart failure,HP:0001635,,"https://www.ncbi.nlm.nih.gov/pubmed/26884075,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1879,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,mitochonic acid 5,NA,,,,,,,,,,,ECO:0001565,ECO:0001565,,,functional complementation of a defective protein by stimulation,C,Mitochondrial dysfunction,HP:0003287,,"https://www.ncbi.nlm.nih.gov/pubmed/26118651,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1880,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,mitochonic acid 5,NA,,,,,,,,,,,,,,,,,Decreased cellular ATP level,HP:0011925*,,"https://www.ncbi.nlm.nih.gov/pubmed/26118651,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1881,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,mitochonic acid 5,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/26118651,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1882,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Insulin,DB00030,DB00030,cf26fce19e07aebb15d6d50e81eac479c8ce3fbd496c7010461f41ac5f463a3e,DB00030,DB00030,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Diabetes mellitus,HP:0000819,,"https://www.ncbi.nlm.nih.gov/pubmed/25092642,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1883,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,cysteamine bitartrate,DB00847,DB00847,5c2de8576fd1b1bd087d0e03d76d3ce754f80497b74bfef4f55ed523641b98e7,DB00847,DB00847,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001,,,"https://clinicaltrials.gov/ct2/show/NCT02023866?cond=Kearns-Sayre+Syndrome&rank=4,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1884,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Elevated serum lactate level,HP:0002151,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1885,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,,,,,,,"High lactate ,pyruvate ratio(Mitochondrial respiratory chain defects)*",HP:0200125,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1886,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,,,,,,,Increased lateral ventricular lactate level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1887,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,,,,,,,High serum GDF15 level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1888,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Phenobarbital+phenytoin,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,Generalized tonic-clonic seizures,HP:0002069,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1889,530000,,Number Sign,530000,KEARNS-SAYRE SYNDROME; KSS,"OPHTHALMOPLEGIA, PIGMENTARY DEGENERATION OF RETINA, AND CARDIOMYOPATHY;; OCULOCRANIOSOMATIC SYNDROME;; OPHTHALMOPLEGIA-PLUS SYNDROME;; MITOCHONDRIAL CYTOPATHY;; OPHTHALMOPLEGIA, PROGRESSIVE EXTERNAL, WITH RAGGED-RED FIBERS;; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MYOPATHY;; CPEO WITH MYOPATHY;; CPEO WITH RAGGED-RED FIBERS",,Kearns-Sayre syndrome,,PSAP,PSAP,prosaposin,0f36e7131d62492d4dd4109a460cacc4f7b4caeb4393373eebee08cba7993116,4.1.1.9,4.1.1.9,,MCT should be at least 70% of the total fat content of the diet.,Phenobarbital+phenytoin,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",5660,PSAP,398,P07602,K12382,"""""",
1890,609242,,Number Sign,609242,KANZAKI DISEASE,"ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE II;; ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, ADULT-ONSET;; NAGA DEFICIENCY, TYPE II;; SCHINDLER DISEASE, TYPE II",,Kanzaki disease/schindler Disease type 2,,NAGA,NAGA,alpha-N-acetylgalactosaminidase,e1bc66017ff77da9dff9bfd69363bbb79ee406e7d2b958ca8632639009921c6e,4.1.1.9,4.1.1.9,,"A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to Î±-GAL A and GLB1, so it has improved selectivity for Î±-NAGAL and makes it superior to DGJ.","iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)",NA,,,,,,,,,,,EC0:0005542/ECO:0001565,"EC0:0005542,ECO:0001565",,,activity modification of a genetically defective protein,A,Abnormal enzyme activity,,,"https://www.ncbi.nlm.nih.gov/pubmed/23045655,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",4668,NAGA,263,P17050,K01204,3.2.1.49,
1891,609242,,Number Sign,609242,KANZAKI DISEASE,"ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, TYPE II;; ALPHA-N-ACETYLGALACTOSAMINIDASE DEFICIENCY, ADULT-ONSET;; NAGA DEFICIENCY, TYPE II;; SCHINDLER DISEASE, TYPE II",,Kanzaki disease/schindler Disease type 2,,NAGA,NAGA,alpha-N-acetylgalactosaminidase,e1bc66017ff77da9dff9bfd69363bbb79ee406e7d2b958ca8632639009921c6e,4.1.1.9,4.1.1.9,,"A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to Î±-GAL A and GLB1, so it has improved selectivity for Î±-NAGAL and makes it superior to DGJ.",1-deoxygalactonojirimycin (DGJ,DB05018,DB05018,26263afdee071b23830adcf1925dfad451b65fba8859d901c4a85d66dd2edd33,DB05018,DB05018,,,,,,,EC0:0005542/ECO:0001565,"EC0:0005542,ECO:0001565",,,activity modification of a genetically defective protein,A,,,,"https://www.ncbi.nlm.nih.gov/pubmed/23045655,https://clinicaltrials.gov/ct2/show/NCT02473445,https://www.ncbi.nlm.nih.gov/pubmed/26884075",4668,NAGA,263,P17050,K01204,3.2.1.49,
1892,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,"A clinical candidate for drug repuropsing. DGJNAc contains an N-acetyl group that sterically precludes it from binding to Î±-GAL A and GLB1, so it has improved selectivity for Î±-NAGAL and makes it superior to DGJ.",carglumic acid,DB06775,DB06775,4232311e92dd47c3fa1cd15c2af2c63ef49708a80c82e3cc943e86fc4cfdfaf2,DB06775,DB06775,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by stimulation,C,acute hyperammonemia,HP:0008281,,"https://www.ncbi.nlm.nih.gov/pubmed/21207059,https://www.ncbi.nlm.nih.gov/pubmed/21403788,https://www.ncbi.nlm.nih.gov/pubmed/26884075",3712,IVD,56,P26440,K00253,1.3.8.4,
1893,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,DB00583 + DB00145,e7bdf8ca6658cfab50f85450e190827e89275102cdae9ec2b09e0232e439e81e,,,,,"DB00583,DB00145","DB00583,DB00145",,,ECO:0000352,ECO:0000352,,,functional complementation of a defective protein by inhibition,C,High toxic acyl-CoA level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/21290185,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",3712,IVD,56,P26440,K00253,1.3.8.4,
1894,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,DB00583 + DB00145,e7bdf8ca6658cfab50f85450e190827e89275102cdae9ec2b09e0232e439e81e,,,,,"DB00583,DB00145","DB00583,DB00145",,,,,,,,,"""abnormal Na+,K+-ATPase activity""",NA,,"https://www.ncbi.nlm.nih.gov/pubmed/15624372,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",3712,IVD,56,P26440,K00253,1.3.8.4,
1895,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,DB00583 + DB00145,e7bdf8ca6658cfab50f85450e190827e89275102cdae9ec2b09e0232e439e81e,,,,,"DB00583,DB00145","DB00583,DB00145",,,,,,,,,Metabolic acidosis,HP:0001942,,"https://www.ncbi.nlm.nih.gov/pubmed/16602101,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",3712,IVD,56,P26440,K00253,1.3.8.4,
1896,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,DB00583 + DB00145,e7bdf8ca6658cfab50f85450e190827e89275102cdae9ec2b09e0232e439e81e,,,,,"DB00583,DB00145","DB00583,DB00145",,,,,,,,,High 3-hydroxyisovaleric acid level (C5),NA,,"https://www.ncbi.nlm.nih.gov/pubmed/17299485,https://www.ncbi.nlm.nih.gov/pubmed/16602101/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",3712,IVD,56,P26440,K00253,1.3.8.4,
1897,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,DB00583 + DB00145,e7bdf8ca6658cfab50f85450e190827e89275102cdae9ec2b09e0232e439e81e,,,,,"DB00583,DB00145","DB00583,DB00145",,,,,,,,,Metabolic stress,HP:0001942,The regimen maximally increases isovaleryl conjugate excretion during metabolic stress rather than under stable conditions.,"https://www.ncbi.nlm.nih.gov/pubmed/8804338,https://www.ncbi.nlm.nih.gov/pubmed/16602101/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",3712,IVD,56,P26440,K00253,1.3.8.4,
1898,243500,,Number Sign,243500,ISOVALERIC ACIDEMIA; IVA,ISOVALERIC ACID CoA DEHYDROGENASE DEFICIENCY;; IVD DEFICIENCY,,Isovaleric acidemia,,IVD,IVD,isovaleryl-CoA dehydrogenase,2e6a6a9425d001dede96880249e2143d705c3547097e8570fe490dcb0f8281ac,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine +L- glycine,DB00583+DB00145,DB00583 + DB00145,e7bdf8ca6658cfab50f85450e190827e89275102cdae9ec2b09e0232e439e81e,,,,,"DB00583,DB00145","DB00583,DB00145",,,,,,,,,Developmental delay,,,"https://www.ncbi.nlm.nih.gov/pubmed/8804338,https://www.ncbi.nlm.nih.gov/pubmed/16602101/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957",3712,IVD,56,P26440,K00253,1.3.8.4,
1899,611283,,Number Sign,611283,ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD,"IBD DEFICIENCY;; ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8, DEFICIENCY OF;; ACAD8 DEFICIENCY",,Isobutyryl-CoA dehydrogenase deficiency,"It is as yet uncertain whether IBD deficiency may cause significant morbidity in affected children and whether treatment is necessary. In view of the limited experience worldwide, careful monitoring of the children is recommended. https://www.ncbi.nlm.nih.gov/pubmed/15505379",ACAD8,ACAD8,isobutyryl-CoA dehydrogenase,3635f69daf4aed89522045025cdbe0f13d5dd67ad828da07a18615b21fa50b06,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,C,Carnitine deficiency,HP:0003234,,"https://www.ncbi.nlm.nih.gov/pubmed/28053874,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/9889013/,https://www.ncbi.nlm.nih.gov/pubmed/19210957",27034,ACAD8,135,Q9UKU7,K11538,1.3.8.-,
1900,611283,,Number Sign,611283,ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD,"IBD DEFICIENCY;; ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8, DEFICIENCY OF;; ACAD8 DEFICIENCY",,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,ACAD8,isobutyryl-CoA dehydrogenase,3635f69daf4aed89522045025cdbe0f13d5dd67ad828da07a18615b21fa50b06,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Failure to thrive,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/9889013/,https://www.ncbi.nlm.nih.gov/pubmed/19210957",27034,ACAD8,135,Q9UKU7,K11538,1.3.8.-,
1901,611283,,Number Sign,611283,ISOBUTYRYL-CoA DEHYDROGENASE DEFICIENCY; IBDD,"IBD DEFICIENCY;; ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 8, DEFICIENCY OF;; ACAD8 DEFICIENCY",,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,ACAD8,isobutyryl-CoA dehydrogenase,3635f69daf4aed89522045025cdbe0f13d5dd67ad828da07a18615b21fa50b06,4.1.1.9,4.1.1.9,,"1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies. 2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate. (https://www.ncbi.nlm.nih.gov/pubmed/16602101) 3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions. https://www.ncbi.nlm.nih.gov/pubmed/8804338",L- carnitine+valine-restricted diet+riboflavin,DB00583+DB00140,DB00583 + DB00140,650f11b7e6f4777f00adca00b7917adc93c6bc3fa59a316e4ef42c82577b9fdc,,,,,"DB00583,DB00140","DB00583,DB00140",,,ECO:0000352,ECO:0000352,,,metabolite replacement+dietary exclusion+symptomatic treatment procedure,,Growth abnormality,HP:0001507,,"https://www.ncbi.nlm.nih.gov/pubmed/16857760?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/12359132?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/9889013/,https://www.ncbi.nlm.nih.gov/pubmed/19210957",27034,ACAD8,135,Q9UKU7,K11538,1.3.8.-,
1902,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/",Vitamin B12,DB00115,DB00115,09d1640c1033b1c7e861047a863362e2af2b6bc5ebb67876b539c3c7e3ffa46a,DB00115,DB00115,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,B,Low levels of serum vitamin B12,HP:0100502,,"https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707","""""","""""",80,"""""","""""","""""",
1903,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/",Vitamin B12,DB00115,DB00115,09d1640c1033b1c7e861047a863362e2af2b6bc5ebb67876b539c3c7e3ffa46a,DB00115,DB00115,,,,,,,,,,,,,High RBC's mean corpuscular volume,HP:0025548,,"https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707","""""","""""",80,"""""","""""","""""",
1904,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/",Vitamin B12,DB00115,DB00115,09d1640c1033b1c7e861047a863362e2af2b6bc5ebb67876b539c3c7e3ffa46a,DB00115,DB00115,,,,,,,,,,,,,Low Hemoglobin concentration,HP:0020062,,"https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707","""""","""""",80,"""""","""""","""""",
1905,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/",Vitamin B12,DB00115,DB00115,09d1640c1033b1c7e861047a863362e2af2b6bc5ebb67876b539c3c7e3ffa46a,DB00115,DB00115,,,,,,,,,,,,,Abnormal reticulocyte count,HP:0004312,,"https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/25308559,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707","""""","""""",80,"""""","""""","""""",
1906,261000,,Number Sign,261000,INTRINSIC FACTOR DEFICIENCY; IFD,"PERNICIOUS ANEMIA, CONGENITAL, DUE TO DEFECT OF INTRINSIC FACTOR",,Intrinsic factor deficiency,,GIF,GIF,gastric intrinsic factor,7ef003b0e5a2177708d0a142214102e89451592b5a2fd3e4a260971af896bf19,4.1.1.9,4.1.1.9,,"The standardized treatment consists of weekly to monthly intramuscular injections of vitamin B12. Hydroxocobalamin injections are preferred over cyanocobalamin as the latter may cause muscular pain and have ophthalmo-neurological side effects. Oral vitamin B12 supplementation may be ineffective and not recommended.

https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=332

Cyanocobalamin, a pharmacologic preparation requiring conversion to metabolically active cobalamins, is the form commonly available in the United States, whereas hydroxocobalamin, which requires less frequent injections,1,15 is preferred in parts of Europe. Methylcobalamin, a light-sensitive form, is rarely used.
https://www.ncbi.nlm.nih.gov/pubmed/6019807/",Corticosteroid,DB00860,DB00860,9e7baffa0f7233d9ca3e2723ead6e2c9b793c85dc17f66c041aa683d397aedc7,DB00860,DB00860,,,,,,,,,,,symptomatic treatment procedure,C,Gastric mucosal atrophy(Abnormality of gastric mucosa)*,HP:0004295,,"https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://www.ncbi.nlm.nih.gov/pubmed/921733,https://www.ncbi.nlm.nih.gov/pubmed/6823973,https://www.ncbi.nlm.nih.gov/pubmed/9694707","""""","""""",80,"""""","""""","""""",
1907,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,direct complementation of a genetically defective protein,A,Low height velocity,HP:0004322,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1908,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,Low lean body mass,HP:0045082,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1909,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,"Abnormal linear growth (Decreased linear growth ,Abnormal body height)*",HP:0000002,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1910,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,low insulin senstivity,HP:0008189,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1911,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,Abnormal circulating GH level,HP:0032367,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1912,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,Abnormal circulating IGFBP level,HP:0031034,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1913,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,Abnormal circulating insulin level,HP:0040215,,"https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1914,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,Decreased body mass index,HP:0045082,,"https://www.ncbi.nlm.nih.gov/pubmed/10770174,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1915,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,Abnormal Body fat composition,HP:0025521,,"https://www.ncbi.nlm.nih.gov/pubmed/10770174,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1916,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"The drug has been tested in many clinical trials. However Two studies have been terminated, one is for unacceptable hypoglycemic attacks as a side effect of the treatment and the other time is due to shortage of ""increlex "" supply.",Recombinant human IGF1(Mecasermin),DB01277,DB01277,f1d089b45e2146c1d98e48bdd6b54f3d32f0d7a1415e34cb8ef4b9f569d45599,DB01277,DB01277,,,,,,,,,,,,,Insulin resistance,HP:0000855,,"https://www.ncbi.nlm.nih.gov/pubmed/10770174,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1917,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,The study is terminated (The study was prematurely terminated due to strategic reasons.),NutropinAqÂ® (Somatropin [rDNA origin],DB00052,DB00052,962dc4a43a184e79a884e7d7a5680b43d45ffdfdd54221d80445f80323d352c2,DB00052,DB00052,,,,,,,ECO:0007121,ECO:0007121,,,functional complementation of a genetically defective protein,,Short stature,HP:0004322,,"https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1918,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,The study is terminated (The study was prematurely terminated due to strategic reasons.),IncrelexÂ® (Mecasermin [rDNA origin] injection) + NutropinAqÂ® (Somatropin [rDNA origin]),DB01277+DB00052,DB01277 + DB00052,cdd06774e2eb8190f89bab536b2d4cc5c21a12daa7fa5015ac6466ea05847297,,,,,"DB01277,DB00052","DB01277,DB00052",,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein+Functional complementation of a genetically defective protein,,Short stature,HP:0004322,,"https://clinicaltrials.gov/ct2/show/study/NCT00572156?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1919,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement",Mecasermin rinfabate,DB14751,DB14751,a7d057ff847ce97784ab5b4d87757d5aa4d6e8ccbdb96f8b83d050b7905b6be5,DB14751,DB14751,,,,,,,ECO:0000352,ECO:0000352,,,direct complementation of a genetically defective protein,A,hypoglycemia,HP:0001943,"The hypoglycemia is not a disesae phenotype, rather its a side effect of Mecasermin medication.The new combination in Mecasermin rinfabate has over come this side effect.","https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1920,608747,608747,Number Sign,608747,INSULIN-LIKE GROWTH FACTOR I DEFICIENCY,IGF1 DEFICIENCY;; GROWTH RETARDATION WITH SENSORINEURAL DEAFNESS AND MENTAL RETARDATION,,insulin-like growth factor I deficiency,,IGF1,IGF1,insulin like growth factor 1,a6602f68e7878d17c83221eb0aea597d644b0b65a41cdb8fec98a091f1f4020a,P05019,,P05019,"Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement",Mecasermin rinfabate,DB14751,DB14751,a7d057ff847ce97784ab5b4d87757d5aa4d6e8ccbdb96f8b83d050b7905b6be5,DB14751,DB14751,,,,,,,,,,,,,Low serum ICFBP level,,,"https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",3479,IGF1,,P05019,K05459,"""""",
1921,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,Conventional antiepileptic drugs (phenytoin and phenobarbital) are ineffective in most affected individuals.,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,The drug is occasionally effective especially when started early in status epilepticus.,Benzodiazepines,DB00252,DB00252,7355ede4950f929c039e58163d1daf16e75b5ea0f0e2193086b6c3e613e23110,DB00252,DB00252,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/20301746,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1922,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,The drug has some effects but hyponatremia is a troublesome side effect.,Oxcarbazepine,DB00776,DB00776,6a44b1d0bede25feaed15b1c595afe0b465e2e906bd91165d2306e1d9da650cf,DB00776,DB00776,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Short nocturnal tonic seizures,HP:0031951,,"https://www.ncbi.nlm.nih.gov/pubmed/19304794,https://www.ncbi.nlm.nih.gov/pubmed/20301746,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1923,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",valproate,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/27551684,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1924,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",Selective serotonin reuptake inhibitors+Antipsychotics,N06AB +N05A,N06AB + N05A,d6bc2556cc2e1a4c6be6507b80eff36469add8387a07fb04ca5ca09625ce7c08,,,,,"N06AB,N05A",,,"N06AB,N05A",ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,Agitation,HP:0000713,,"https://www.ncbi.nlm.nih.gov/pubmed/19304794,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1925,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",Selective serotonin reuptake inhibitors+Antipsychotics,N06AB +N05A,N06AB + N05A,d6bc2556cc2e1a4c6be6507b80eff36469add8387a07fb04ca5ca09625ce7c08,,,,,"N06AB,N05A",,,"N06AB,N05A",,,,,,,Aggressive behavior,HP:0000718,,"https://www.ncbi.nlm.nih.gov/pubmed/19304794,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1926,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",Carbamazepine,N06AB +N05A,N06AB + N05A,d6bc2556cc2e1a4c6be6507b80eff36469add8387a07fb04ca5ca09625ce7c08,,,,,"N06AB,N05A",,,"N06AB,N05A",ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Complex partial seizure,,,"https://www.ncbi.nlm.nih.gov/pubmed/19304794,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1927,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",Carbamazepine,N06AB +N05A,N06AB + N05A,d6bc2556cc2e1a4c6be6507b80eff36469add8387a07fb04ca5ca09625ce7c08,,,,,"N06AB,N05A",,,"N06AB,N05A",,,,,,,Generalized convulsion,,,"https://www.ncbi.nlm.nih.gov/pubmed/19304794,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1928,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Valporate has been used in two patients, but it had to be discontinued because of a severe elevation of liver enzymes. since then it hasn't been used in IOSCA. VAlporic acid Should be avoided in those patients.",Topiramate + pyridoxine,DB00273+DB00165,DB00273 + DB00165,1cfeb12bf19316636d650695e7a4f8df6caf6f6ae8e2a1af8457c6c2c67b3ca2,,,,,"DB00273,DB00165","DB00273,DB00165",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/27551684,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1929,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"The increased creatine/creatinine ratio in adult IOSCA patients, as well as in the IOSCA child patient who is motorically as active as her ageâmates, suggests an important role of creatine metabolism in the disease pathogenesis. Creatine synthesis is a major methyl group user, utilizing the same 1C/methyl pool as transsulfuration cycle, and thus, the creatine supplementation in IOSCA and IBM should be studied thus creatine is considered as a potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373890",creatine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0007764,ECO:0007764,,,functional complementation of a defective protein by stimulation,C,Abnormal circulating creatinine level,HP:0012100,,"https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1930,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891",Glutathione [Nâacetylâcysteine],DB00143,DB00143,47128d69a6436e8bc030c60539ca77b0da944edbbd6b971074ad7717b1db1b54,DB00143,DB00143,,,,,,,ECO:0007764,ECO:0007764,,,functional complementation of a defective protein by stimulation,C,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1931,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,"Glutathione depletion indicates decreased potential for antioxidant capacity in IOSCA. Additionally, we analysed a blood sample of an IOSCA child patient who showed high creatine/creatinine ratio and low taurine and kynurenate. The significant depletion of kynurenate and the significant depletion of niacinamide are both consistent with depletion of NAD+thus both Clutathione and Nicotinamide riboside are considered as potential drugs for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373891",Glutathione [Nâacetylâcysteine],DB00143,DB00143,47128d69a6436e8bc030c60539ca77b0da944edbbd6b971074ad7717b1db1b54,DB00143,DB00143,,,,,,,,,,,,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1932,271245,,Number Sign,271245,MITOCHONDRIAL DNA DEPLETION SYNDROME 7 (HEPATOCEREBRAL TYPE); MTDPS7,"SPINOCEREBELLAR ATAXIA, INFANTILE-ONSET; IOSCA;; OPHTHALMOPLEGIA, HYPOTONIA, ATAXIA, HYPOACUSIS, AND ATHETOSIS;; OHAHA SYNDROME;; SPINOCEREBELLAR ATAXIA, INFANTILE, WITH SENSORY NEUROPATHY;; SPINOCEREBELLAR ATAXIA 8, FORMERLY; SCA8, FORMERLY",,Infantile-onset spinocerebellar ataxia,,TWNK,TWNK,twinkle mtDNA helicase,a0224d6917b3b9258c06bc8e1d4cac1fa72fdce0b1cf7399c494e8b25862d448,Q96RR1,,Q96RR1,A potential drug for treatment of IOSCA.https://www.ncbi.nlm.nih.gov/pubmed/30373892,NAD+ [nicotinamide riboside],DB14933,DB14933,eac71e7eb319c2e3868d8a86f694a284411193fa9e33a2609b5f95d3737597e5,DB14933,DB14933,,,,,,,ECO:0007764,ECO:0007764,,,functional complementation of a defective protein by stimulation,C,Decreased niacinamide level,,,"https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",56652,TWNK,944,Q96RR1,K17680,3.6.4.12,
1933,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,metabolite replacement,B,Chronic constipation,HP:0012450,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1934,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,,,,,,,,Bulbar dysfunction,HP:0001283,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1935,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,,,,,,,,Functional motoe deficit,HP:0004302,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1936,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,,,,,,,,Defective eye motor function,HP:0000496,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1937,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,,,,,,,,Poor head control,HP:0002421,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1938,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"The clinicl trial status is active and not recruiting and no results have been yet posted.

The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (âfireproofâ) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/","RT001 (11,11-di-deutero-linoleic acid ethyl ester)",NA,,,,,,,,,,,,,,,,,,,,"https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1939,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Desipramine,DB01151,DB01151,36798a080dc39909ba7a44f76f4ae4b38a64630581bea5a22cadc4f8bb511b8f,DB01151,DB01151,,,,,,,ECO:0007121/ECO:0005542,"ECO:0007121,ECO:0005542",,,functional complementation of a defective protein by inhibition,C,Lysosomal stress (Abnormality of lysosomal metabolism)*,HP:0004356,In the mouse model syudy,"https://clinicaltrials.gov/ct2/show/NCT03726996,https://www.ncbi.nlm.nih.gov/pubmed/29909971,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1940,256600,,Number Sign,256600,NEURODEGENERATION WITH BRAIN IRON ACCUMULATION 2A; NBIA2A,"NEURODEGENERATION, PLA2G6-ASSOCIATED; PLAN;; NEUROAXONAL DYSTROPHY, INFANTILE; INAD; INAD1;; SEITELBERGER DISEASE",,Infantile neuroaxonal dystrophy,,PLA2G6,PLA2G6,85/88 kDa calcium-independent phospholipase A2,0851676142976572871f254769686ef6653aec142f6727ac913a262642e8a07a,3.1.1.4,3.1.1.4,,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Desipramine,DB01151,DB01151,36798a080dc39909ba7a44f76f4ae4b38a64630581bea5a22cadc4f8bb511b8f,DB01151,DB01151,,,,,,,,,,,,,Neurodegeneration,HP:0002180,In the mouse model syudy,"https://clinicaltrials.gov/ct2/show/NCT03726996,https://www.ncbi.nlm.nih.gov/pubmed/29909971,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",8398,PLA2G6,760,O60733,K16343,3.1.1.4,
1941,269920,,Number Sign,269920,INFANTILE SIALIC ACID STORAGE DISEASE; ISSD,"SIALURIA, INFANTILE FORM;; N-ACETYLNEURAMINIC ACID STORAGE DISEASE;; NANA STORAGE DISEASE; NSD",,Free sialic acid storage disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Treatment of manifestations:Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions.,DB01151,DB01151,36798a080dc39909ba7a44f76f4ae4b38a64630581bea5a22cadc4f8bb511b8f,DB01151,DB01151,,,,,,,,,,,,C,,,,"https://clinicaltrials.gov/ct2/show/NCT03726996,https://www.ncbi.nlm.nih.gov/pubmed/20301643,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",26503,SLC17A5,267,Q9NRA2,K12301,"""""",
1942,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,generalized tonic-clonic seizure,HP:0002069,,"https://www.ncbi.nlm.nih.gov/pubmed/28662915,https://www.ncbi.nlm.nih.gov/pubmed/20301643,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",26503,SLC17A5,1369,Q9NRA2,K12301,"""""",
1943,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Phenobarbital,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Seizures,,,"https://www.ncbi.nlm.nih.gov/pubmed/12794688,https://www.ncbi.nlm.nih.gov/pubmed/20301643,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",26503,SLC17A5,1369,Q9NRA2,K12301,"""""",
1944,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Phenobarbital,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12794688,https://www.ncbi.nlm.nih.gov/pubmed/20301643,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",26503,SLC17A5,1369,Q9NRA2,K12301,"""""",
1945,604369,,Number Sign,604369,SALLA DISEASE; SD,"SIALURIA, FINNISH TYPE",,Salla Disease,,SLC17A5,SLC17A5,solute carrier family 17 member 5,c1411b0480386347636cbf48852a42f184361e6a687d4d11a9116b39d7fa7568,Q9NRA2,,Q9NRA2,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Phenobarbital,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12794688,https://www.ncbi.nlm.nih.gov/pubmed/20301643,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",26503,SLC17A5,1369,Q9NRA2,K12301,"""""",
1946,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",ManNac (N-acetylmannosamine),DB12536,DB12536,19405aa93bb2bbf18ee9664f0d2836ed598d9bf87edfebbbf2ebf6c0bfcbe702,DB12536,DB12536,,,,,,,ECO:0007121,ECO:0007121,,,metabolite replacement,B,Decreased sialylation of muscle glycans,HP:0012350,,"https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1947,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",ManNac (N-acetylmannosamine),DB12536,DB12536,19405aa93bb2bbf18ee9664f0d2836ed598d9bf87edfebbbf2ebf6c0bfcbe702,DB12536,DB12536,,,,,,,,,,,,,Low circulating levels of free sialic acids,HP:0012363,,"https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1948,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",ManNac (N-acetylmannosamine),DB12536,DB12536,19405aa93bb2bbf18ee9664f0d2836ed598d9bf87edfebbbf2ebf6c0bfcbe702,DB12536,DB12536,,,,,,,,,,,,,Rimmed vacuoles,HP:0003805,,"https://www.ncbi.nlm.nih.gov/pubmed/21517694,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1949,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",ManNac (N-acetylmannosamine),DB12536,DB12536,19405aa93bb2bbf18ee9664f0d2836ed598d9bf87edfebbbf2ebf6c0bfcbe702,DB12536,DB12536,,,,,,,,,,,,,Amyloid deposition,HP:0003216*,,"https://www.ncbi.nlm.nih.gov/pubmed/21517694,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1950,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine),CHEBI:17012+DB12536,CHEBI:17012 + DB12536,1ee4ce78419fbf47e9341c2013d9573879a1cbb3218ad8db3174804bae6d0b1c,,,,,"CHEBI:17012,DB12536",DB12536,CHEBI_17012,,ECO:0007121,ECO:0007121,,,metabolite replacement+metabolite replacment,B,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1951,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine),CHEBI:17012+DB12536,CHEBI:17012 + DB12536,1ee4ce78419fbf47e9341c2013d9573879a1cbb3218ad8db3174804bae6d0b1c,,,,,"CHEBI:17012,DB12536",DB12536,CHEBI_17012,,,,,,,,Decreased sialylation of muscle glycans,HP:0012350,,"https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1952,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",GNE gene lipoplex,NA,,,,,,,,,,,ECO:0007121,ECO:0007121,,,direct complementation of a genetically defective protein by gene therapy,A,Decline of muscle strength (Muscle weakness),HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/21517694,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1953,605820,,Number Sign,605820,NONAKA MYOPATHY; NM,"NONAKA DISTAL MYOPATHY;; MYOPATHY, DISTAL, WITH OR WITHOUT RIMMED VACUOLES;; INCLUSION BODY MYOPATHY, HEREDITARY, AUTOSOMAL RECESSIVE; HIBM;; INCLUSION BODY MYOPATHY, QUADRICEPS-SPARING; QSM;; GNE MYOPATHY;; INCLUSION BODY MYOPATHY 2, AUTOSOMAL RECESSIVE, FORMERLY; IBM2, FORMERLY",,Inclusion body myopathy 2,,GNE,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,ae08dfaaa2bca2c49b3c532be0bb5c2f22ede606381b474216c812d47810df5f,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Sialic acid,CHEBI:17012,CHEBI:17012,d0e14b7fc3e352405716c3695a24532140cd82532f1ea97fefce1cff7857daa7,CHEBI:17012,,CHEBI_17012,,,,,,,,,,metabolite replacement,B,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/21517694,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,https://clinicaltrials.gov/ct2/show/NCT00125190?cond=Insulin-Like+Growth+Factor+I+Deficiency&rank=1",10020,GNE,1299,"""""","""""","""""",
1954,252500,,Number Sign,252500,MUCOLIPIDOSIS II ALPHA/BETA,MUCOLIPIDOSIS II; ML II;; ML II ALPHA/BETA;; I-CELL DISEASE; ICD,,I cell disease,,GNPTAB,GNPTAB,(Î±) &(Î²)GlcNAc-1-phosphotransferas,c006250556b586a6a83267fa1c76f3af62b033b1ecb685bb54d495655c2b65f9,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,79158,GNPTAB,299,Q3T906,K08239,2.7.8.17,
1955,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,B,Megalobalstic anaemia,HP:0001889,,"https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1956,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,,,,,,,Low level of serum B12,HP:0040126,,"https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1957,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,,,,,,,Neurological abnormalities,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1958,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,,,,,,,Normocytic anemia,HP:0001897,,"https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1959,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,,,,,,,Hyperammonemia,HP:0001987,,"https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1960,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,,,,,,,Increased liver enzyme activities,HP:0002910,,"https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1961,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,,,,,,,Abnormal methylmalonic acid level.,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1962,261100,,Number Sign,261100,MEGALOBLASTIC ANEMIA 1,"MGA1;; IMERSLUND-GRASBECK SYNDROME; IGS;; PERNICIOUS ANEMIA, JUVENILE, DUE TO SELECTIVE INTESTINAL MALABSORPTION OF VITAMIN B12, WITH PROTEINURIA;; ENTEROCYTE COBALAMIN MALABSORPTION;; ENTEROCYTE INTRINSIC FACTOR RECEPTOR, DEFECT OF",,Imerslund-Grasbeck syndrome,,CUBN/AMN,"CUBN,AMN",cubilin/amnion associated transmembrane protein,4231d28a1e58b77eafa4cb60196c77cadf2c5632eec1d1a39d5d46401fe28041,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",methylcobalamin,DB03614,DB03614,eaea0e67daa023ee1d8ad2b37edb71e0b851425b7081673512e3e741af253f05,DB03614,DB03614,,,,,,,,,,,,,Hyperpigmentation,HP:0000953,,"https://www.ncbi.nlm.nih.gov/pubmed/24222293,https://www.ncbi.nlm.nih.gov/pubmed/18768530,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566","8029,81693","CUBN,AMN",83,"O60494,Q9BXJ7","K14616,K18259",",",
1963,242600,242600,Number Sign,242600,IMINOGLYCINURIA,,,Iminoglycinuria,,SLC36A2 /SLC6A20/SLC6A19,"SLC36A2,SLC6A20,SLC6A19",solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19,32edfb4290a5c7f37848c48e31c682f40441ef9a6d1fc9b559674d8947a6be44,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,"153201,54716,340024","SLC36A2,SLC6A20,SLC6A19",798,"Q495M3,Q9NP91,Q695T7","K14209,K05048,K05334",",,",
1964,605637,,Number Sign,605637,"MYOPATHY, PROXIMAL, AND OPHTHALMOPLEGIA","MYPOP;; MYOPATHY WITH CONGENITAL JOINT CONTRACTURES, OPHTHALMOPLEGIA, AND RIMMED VACUOLES;; INCLUSION BODY MYOPATHY 3, AUTOSOMAL DOMINANT, FORMERLY; IBM3, FORMERLY",,Inclusion body myopathy type 3,,MYH2,MYH2,myosin heavy chain 2,2091f9744d556c7e160085f9df23d3066594e864b405f4ce8e866628c5d7e411,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,4620,MYH2,,Q9UKX2,K10352,"""""",
1965,246450,246450,Number Sign,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA,,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMGCL,HMG-CoA lyase,ba2a6771a4da37dd9401caee75cb6a90c287071eebc775f4b5d006f76db88208,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Carnitine+high-carbohydrate+low-protein and low-fat diet,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+dietary regime modification,,Disease progression,HP:0003678,,"https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/29565174,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",3155,HMGCL,62,P35914,K01640,4.1.3.4,
1966,246450,246450,Number Sign,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA,,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMGCL,HMG-CoA lyase,ba2a6771a4da37dd9401caee75cb6a90c287071eebc775f4b5d006f76db88208,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",Carnitine+high-carbohydrate+low-protein and low-fat diet,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,,,,,,,Decreased plasma carnitine,HP:0003234,,"https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/29565174,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",3155,HMGCL,62,P35914,K01640,4.1.3.4,
1967,246450,246450,Number Sign,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA,,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMGCL,HMG-CoA lyase,ba2a6771a4da37dd9401caee75cb6a90c287071eebc775f4b5d006f76db88208,2.7.1.60,"3.2.1.183,2.7.1.60",,"In the clinical trial: The trial is not enrolling by invitation, no results have been posted yet. update by Oct.7th 2019
Authors have stated that ""The data indicate that the retromer and sphingolipid metabolism play a critical role in PLA2G6-associated diseases. These observations may be relevant to Parkinson disease (PD) given that loss of vps35 or gain of Î±-Syn also affects retromer function and causes ceramide accumulation."" https://www.ncbi.nlm.nih.gov/pubmed/29909971",leucine-restricted diet,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,dietary exclusion,,White matter changes,HP:0007103,,"https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/29565174,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",3155,HMGCL,62,P35914,K01640,4.1.3.4,
1968,246450,246450,Number Sign,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA,,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMGCL,HMG-CoA lyase,ba2a6771a4da37dd9401caee75cb6a90c287071eebc775f4b5d006f76db88208,2.7.1.60,"3.2.1.183,2.7.1.60",,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Glucose+leucine-restricted diet,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+dietary exclusion,,Nonketotic hypoglycemia,HP:0001958,,"https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",3155,HMGCL,62,P35914,K01640,4.1.3.4,
1969,246450,246450,Number Sign,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA,,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMGCL,HMG-CoA lyase,ba2a6771a4da37dd9401caee75cb6a90c287071eebc775f4b5d006f76db88208,2.7.1.60,"3.2.1.183,2.7.1.60",,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Glucose+leucine-restricted diet,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,,,,,,,Acute decompensation,,,"https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",3155,HMGCL,62,P35914,K01640,4.1.3.4,
1970,246450,246450,Number Sign,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,HMG-CoA LYASE DEFICIENCY;; HMGCL DEFICIENCY;; HL DEFICIENCY;; HYDROXYMETHYLGLUTARIC ACIDURIA,,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMGCL,HMG-CoA lyase,ba2a6771a4da37dd9401caee75cb6a90c287071eebc775f4b5d006f76db88208,2.7.1.60,"3.2.1.183,2.7.1.60",,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Glucose+leucine-restricted diet,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/17628222/,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",3155,HMGCL,62,P35914,K01640,4.1.3.4,
1971,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Tauroursodeoxycholic acid,DB08834,DB08834,21a431c60b3527945cb2c8797188e4496fdf35037b7454503d027df62bdc0d04,DB08834,DB08834,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,,ER (endoplasmic reticulum) stress,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1972,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Tauroursodeoxycholic acid,DB08834,DB08834,21a431c60b3527945cb2c8797188e4496fdf35037b7454503d027df62bdc0d04,DB08834,DB08834,,,,,,,,,,,,,High triglyceride levels,HP:0002155,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1973,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",Tauroursodeoxycholic acid,DB08834,DB08834,21a431c60b3527945cb2c8797188e4496fdf35037b7454503d027df62bdc0d04,DB08834,DB08834,,,,,,,,,,,,,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1974,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,,Increased muscle lipid droplets,HP:0012240,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1975,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,,,,,ER (endoplasmic reticulum) stress,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1976,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,,,,,muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1977,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,,,,,fiber necrosis,HP:0003713,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1978,268200,268200,Number Sign,268200,"MYOGLOBINURIA, ACUTE RECURRENT, AUTOSOMAL RECESSIVE","MYOGLOBINURIA, FAMILIAL PAROXYSMAL PARALYTIC;; RHABDOMYOLYSIS, ACUTE RECURRENT",,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,LPIN1,Phosphatidate phosphatase,a8813eb66867b0be81bdf77741232092954c56f5e245e120275acccf2d253ae0,3.1.3.4,3.1.3.4,,"The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",bezafibrate,DB01393,DB01393,dc9dd37e8fdb62f390ae20a599a295f88aedb1b00e4a975ae78d8daf9eb9ea66,DB01393,DB01393,,,,,,,,,,,,,Myopathy,HP:0003198,,"https://www.ncbi.nlm.nih.gov/pubmed/30420558,https://www.ncbi.nlm.nih.gov/pubmed/28220407,https://www.ncbi.nlm.nih.gov/pubmed/26997609/,https://www.ncbi.nlm.nih.gov/pubmed/2443756,https://www.ncbi.nlm.nih.gov/pubmed/1886403,https://www.ncbi.nlm.nih.gov/pubmed/28220407",23175,LPIN1,750,Q14693,K15728,3.1.3.4,
1979,550500,,Number Sign,550500,"MYOGLOBINURIA, RECURRENT",,,Myoglobinuria recurrent,,MT-CO1/MT-CYB/MT-CO3,"MT-CO1,MT-CYB,MT-CO3",Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3,efc819ecfc95950874b24fb75047360709d4ee1c7af8f39542687bc6ecea0a0e,P00414,1.9.3.1,"P00403,P00414","The mainstays of treatment are moderate protein (leucine) restriction and avoidance of prolonged fasting and of excessive dietary fat intake, both of which increase fatty acid oxidation; these measures are generally effective in preventing acute decompensations.https://www.ncbi.nlm.nih.gov/pubmed/3128690",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,",,",",,",,",,",",,",",,",
1980,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,"Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.",MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414","Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Levetiracetam/Clonazepam/Zonisamide,DB01202/DB01068/DB00909,DB01202 / DB01068 / DB00909,5b37759a7630bfde9d160fdfc1e1079649a4825a4e435a81aa3567126adf4be1,"DB01202,DB01068,DB00909","DB01202,DB01068,DB00909",,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Myoclonic epliepsy,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pubmed/14981187,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",400,"""""","""""","""""",
1981,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414","Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Coenzyme Q10+L-carnitine+ lipoic acid,DB09270+DB00583+ DB00166,DB09270 + DB00583 + DB00166,a82a7a6847c1cab2c36814ff22f93cfd415d5b654ca2891596ceca5fdeec25fb,,,,,"DB09270,DB00583,DB00166","DB09270,DB00583,DB00166",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Ankle weakness progression(Disease progression)*,HP:0003287,,"https://www.ncbi.nlm.nih.gov/pubmed/17080429,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",400,"""""","""""","""""",
1982,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414","Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Coenzyme Q10+L-carnitine+ lipoic acid,DB09270+DB00583+ DB00166,DB09270 + DB00583 + DB00166,a82a7a6847c1cab2c36814ff22f93cfd415d5b654ca2891596ceca5fdeec25fb,,,,,"DB09270,DB00583,DB00166","DB09270,DB00583,DB00166",,,,,,,,,High resting plasma lactate concentration,HP:0003288,,"https://www.ncbi.nlm.nih.gov/pubmed/17275787,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",400,"""""","""""","""""",
1983,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414","Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Levetiracetam+ l-carnitine +CoQ10,DB01202+DB00583+DB09270,DB01202 + DB00583 + DB09270,42ca91327c1669921d53dd0e207dd08ca4dceb72e32c238ca1a70bcf9faa0870,,,,,"DB01202,DB00583,DB09270","DB01202,DB00583,DB09270",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Myoclonus,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pubmed/17275787,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",400,"""""","""""","""""",
1984,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414","Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Levetiracetam+ l-carnitine +CoQ10,DB01202+DB00583+DB09270,DB01202 + DB00583 + DB09270,42ca91327c1669921d53dd0e207dd08ca4dceb72e32c238ca1a70bcf9faa0870,,,,,"DB01202,DB00583,DB09270","DB01202,DB00583,DB09270",,,,,,,,,Low quality of life (Constitutional symptoms)*,,,"https://www.ncbi.nlm.nih.gov/pubmed/28686997,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",400,"""""","""""","""""",
1985,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414","Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",piracetam,DB09210,DB09210,8ee096a00f28ec447d107f6d69a991017c968be0f92012a5f7dac48d685da58a,DB09210,DB09210,,,,,,,ECO:0000352,ECO:0000352,m.8344A > G,,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Myoclonic seizures,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pubmed/28717435,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",400,"""""","""""","""""",
1986,545000,,Number Sign,545000,MYOCLONIC EPILEPSY ASSOCIATED WITH RAGGED-RED FIBERS; MERRF,MERRF SYNDROME,,Myoclonic epilepsy with ragged red fibers,,MT-TK,MT-TK,Mitochondrially encoded tRNA lysine,740fcd2ba1cfd962db79fc60fbe8c1504d141617aa42e49f98d09079b2a6630e,P00414,1.9.3.1,"P00403,P00414","Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Clonazepam,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Asterixis-like movement(Abnormality of movement),HP:0100022,,"https://www.ncbi.nlm.nih.gov/pubmed/1490314,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",400,"""""","""""","""""",
1987,601776,601776,Number Sign,601776,"EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1","EDSMC;; ADDUCTED THUMB, CLUBFOOT, AND PROGRESSIVE JOINT AND SKIN LAXITY SYNDROME;; EHLERS-DANLOS SYNDROME, TYPE VIB, FORMERLY; EDS6B, FORMERLY;; ADDUCTED THUMB-CLUBFOOT SYNDROME; ATCS;; DUNDAR SYNDROME;; ARTHROGRYPOSIS, DISTAL, WITH PECULIAR FACIES AND HYDRONEPHROSIS",,"EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1",,CHST14,CHST14,Dermatan-4-sulfotransferase-1,c10dbc3bc5764b00c110988af2c0900102f8990181b09add53a96440529463a3,2.8.2.35,2.8.2.35,,"Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",Magnesium,DB14513,DB14513,116742a5189aa98a20a72c182521d21a502ab3bce11ea855b99d4697f7a573bc,DB14513,DB14513,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,constipation,HP:0002019,,"https://www.ncbi.nlm.nih.gov/pubmed/21744491,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",113189,CHST14,1130,Q8NCH0,K08105,2.8.2.35,
1988,300559,,Number Sign,300559,"GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D","GSD IXd;; MUSCLE PHOSPHORYLASE KINASE DEFICIENCY;; MUSCLE GLYCOGENOSIS, X-LINKED",,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,PHKA1,alpha subunit of muscle phosphorylase kinase,c11d5221b35a2e83c0f0a80e0e927f1a871844354ae56562aae92002447577ed,2.7.11.19,2.7.11.19,,"Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigineâs myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",cortisone,DB14681,DB14681,6aaa696df62f8f21055a8e74cdbb67bc3cefa6271fd55579c3ae70046fcacd45,DB14681,DB14681,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Muscular hypotonia,HP:0001252,,"https://www.ncbi.nlm.nih.gov/pubmed/15637709,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",5255,PHKA1,563,P46020,K07190,"""""",
1989,300559,,Number Sign,300559,"GLYCOGEN STORAGE DISEASE, TYPE IXd; GSD9D","GSD IXd;; MUSCLE PHOSPHORYLASE KINASE DEFICIENCY;; MUSCLE GLYCOGENOSIS, X-LINKED",,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,PHKA1,alpha subunit of muscle phosphorylase kinase,c11d5221b35a2e83c0f0a80e0e927f1a871844354ae56562aae92002447577ed,2.7.11.19,2.7.11.19,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Glucose,DB01914,DB01914,5ec49cef8ee40bee4f80609968f272296a71d673c1be1232583b7dc93dbd7923,DB01914,DB01914,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,,Exercise intolerance,HP:0009020,,"https://www.ncbi.nlm.nih.gov/pubmed/18401027,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",5255,PHKA1,563,P46020,K07190,"""""",
1990,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,L-carnitine,DB00583,DB00583,27d90b3e5086b28f1ce01c78aa839daa030188da8d95b7366f1e3667fbd11291,DB00583,DB00583,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,HP:0003287*,,"https://www.ncbi.nlm.nih.gov/pubmed/26006750,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",1120,CHKB,1047,Q9Y259,K14156,2.7.1.32; 2.7.1.82,
1991,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,HP:0003287*,,"https://www.ncbi.nlm.nih.gov/pubmed/26006750,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",1120,CHKB,1047,Q9Y259,K14156,2.7.1.32; 2.7.1.82,
1992,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Thiamine,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,HP:0003287*,,"https://www.ncbi.nlm.nih.gov/pubmed/26006750,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",1120,CHKB,1047,Q9Y259,K14156,2.7.1.32; 2.7.1.82,
1993,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Corticosteroid,D07A,D07A,2cb015d1511207ad26a4d38b5c32d88029cf77233411add4a47ca8e56421499b,D07A,,,D07A,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Nummular eczema (Eczema)*,HP:0000964*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701/,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",1120,CHKB,1047,Q9Y259,K14156,2.7.1.32; 2.7.1.82,
1994,602541,,Number Sign,602541,"MUSCULAR DYSTROPHY, CONGENITAL, MEGACONIAL TYPE; MDCMC","MUSCULAR DYSTROPHY, CONGENITAL, WITH MITOCHONDRIAL STRUCTURAL ABNORMALITIES",,Congenital megaconial myopathy,,CHKB,CHKB,Choline/ethanolamine kinase,977ad4afe223442ad032ee62069834f8e2642980daf4dcb4410f0683078cfc99,2.7.1.82,"2.7.1.32,2.7.1.82",,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,B-Blockers+Angiotensin-converting enzyme inhibitors,C07+C09,C07 + C09,0dd6fd179ec7c4bd311f3450dcb680839eb067e81ce9c4a617e00808de939e4d,,,,,"C07,C09",,,"C07,C09",ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Cardiomyopathy,HP:0001638,,"https://www.ncbi.nlm.nih.gov/pubmed/26067811,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",1120,CHKB,1047,Q9Y259,K14156,2.7.1.32; 2.7.1.82,
1995,253280,,Number Sign,253280,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED",,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",d70b03a3a40b1a1168f3f51e29029b6ac3423494f653f41506929964fb774634,Q8WZA1,,Q8WZA1,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,botulinum toxin,DB00083,DB00083,b9dc52dcd224285b94e12b074de67c2ffce6653f6761323b5a1e290921e09b72,DB00083,DB00083,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,strabismus,HP:0000486,,"https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",55624,POMGNT1,354,Q8WZA1,K09666,2.4.1.-,
1996,253280,,Number Sign,253280,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED",,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",d70b03a3a40b1a1168f3f51e29029b6ac3423494f653f41506929964fb774634,Q8WZA1,,Q8WZA1,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,botulinum toxin,DB00083,DB00083,b9dc52dcd224285b94e12b074de67c2ffce6653f6761323b5a1e290921e09b72,DB00083,DB00083,,,,,,,,,,,,,esotropia,HP:0000565,,"https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",55624,POMGNT1,354,Q8WZA1,K09666,2.4.1.-,
1997,253280,,Number Sign,253280,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 3; MDDGA3","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMGNT1-RELATED",,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",d70b03a3a40b1a1168f3f51e29029b6ac3423494f653f41506929964fb774634,Q8WZA1,,Q8WZA1,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Ad5-LARGE-eGFP,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,,Muscle dystrophy,HP:0003560,,"https://www.ncbi.nlm.nih.gov/pubmed/15184894,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",55624,POMGNT1,354,Q8WZA1,K09666,2.4.1.-,
1998,236670,236670,Number Sign,236670,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT1-RELATED;; HYDROCEPHALUS, AGYRIA, AND RETINAL DYSPLASIA;; HARD SYNDROME;; CEREBROOCULAR DYSPLASIA-MUSCULAR DYSTROPHY SYNDROME;; COD-MD SYNDROME",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1",,POMT1,POMT1,protein O-mannosyltransferase 1,c7f8ff87033b272860227f552819241c016e0fca894341285c3e08c74a60a022,2.4.1.109,2.4.1.109,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Ad5-LARGE-eGFP,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,,Muscle dystrophy,HP:0003560,,"https://www.nature.com/articles/nm1059,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",10585,POMT1,352,"""""","""""","""""",
1999,613150,613150,Number Sign,613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,POMT2,Protein O-mannosyl-transferase 2,097ad49f5521518b32c2cca0cdf2be4bdbd4d20603044715ba88dbb9616ef8ab,2.4.1.109,2.4.1.109,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Diuretics,C03,C03,0dfab5acbae0000ecfc55bf78f6be90842878115c5802d14dd7312bebc9e627a,C03,,,C03,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,congestive cardiac failure,HP:0001635,,"https://www.ncbi.nlm.nih.gov/pubmed/28980384,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",29954,POMT2,353,Q9UKY4,K00728,2.4.1.109,
2000,613150,613150,Number Sign,613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMT2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,POMT2,Protein O-mannosyl-transferase 2,097ad49f5521518b32c2cca0cdf2be4bdbd4d20603044715ba88dbb9616ef8ab,2.4.1.109,2.4.1.109,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Diuretics,C03,C03,0dfab5acbae0000ecfc55bf78f6be90842878115c5802d14dd7312bebc9e627a,C03,,,C03,,,,,,,,,,,tachypnea,HP:0002789,,"https://www.ncbi.nlm.nih.gov/pubmed/28980384,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",29954,POMT2,353,Q9UKY4,K00728,2.4.1.109,
2001,253800,253800,Number Sign,253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4","FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FCMD;; WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKTN-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4",,FKTN,FKTN,Fukutin,e2280cceba60a485896d6ee0ae5b4ef7286ded3d8716ea4b928b8c1a5a33c6a9,O75072,,O75072,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Antisense oligonucleotide,C03,C03,0dfab5acbae0000ecfc55bf78f6be90842878115c5802d14dd7312bebc9e627a,C03,,,C03,,,,,ECO:0001565/ECO:0005542,"ECO:0001565,ECO:0005542",,,activity modification of a genetically defective protein by transcriptional or translational modification,A,Abnormal Fukutin function,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/21979053,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",2218,FKTN,642,O75072,K19872,2.4.2.-,
2002,613153,613153,Number Sign,613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKRP-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,FKRP,Fukutin-related protein,8edd0c7b5b360f8dd25b7ceb32c870632438ef7f2899a90fd27fc4e8d271d442,Q9H9S5,,Q9H9S5,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Adeno-associated Virus 9 Mediated FKRP Gene Therapy,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,abnormal muscle function,HP:0011804,,"https://www.sciencedirect.com/science/article/pii/S152500161632250X,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",79147,FKRP,645,Q9H9S5,K19873,2.4.2.-,
2003,613153,613153,Number Sign,613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, FKRP-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,FKRP,Fukutin-related protein,8edd0c7b5b360f8dd25b7ceb32c870632438ef7f2899a90fd27fc4e8d271d442,Q9H9S5,,Q9H9S5,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Ad5-LARGE-eGFP,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,,Muscle dystrophy,HP:0003560,,"https://www.nature.com/articles/nm1059,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z",79147,FKRP,645,Q9H9S5,K19873,2.4.2.-,
2004,613154,613154,Number Sign,613154,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, LARGE-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6",,LARGE,LARGE,LARGE xylosyl- and glucuronyltransferase 1,4a75624094bb9c5b27b81c2ab5d84c7ce85379a40721abd66a3edc89426197ea,O95461,,O95461,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Ad5-LARGE-eGFP,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,Muscle dystrophy,HP:0003560,,"https://www.nature.com/articles/nm1059,https://link.springer.com/article/10.1007/s11940-011-0131-z,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z","""""","""""",1125,"""""","""""","""""",
2005,614643,614643,Number Sign,614643,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, ISPD-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7",,ISPD,ISPD,D-ribitol-5-phosphate cytidylyltransferase,10bdf4c4f285c1ce6ee17dd5ee486693dfa59931fa716040f6879d4c1b29ca5c,2.7.7.40,2.7.7.40,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,"""""","""""",641,"""""","""""","""""",
2006,614830,614830,Number Sign,614830,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, GTDC2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8",,POMGNT2,POMGNT2,"Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2",d3af412b529d4c6d7f8bb5d14ba7576a6b23a1b3b47d909368684a75f49a6727,2.4.1.312,2.4.1.312,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,84892,POMGNT2,1120,Q8NAT1,K18207,2.4.1.312,
2007,616538,616538,Number Sign,616538,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9","WALKER-WARBURG SYNDROME OR MUSCLE-EYE BRAIN DISEASE, DAG1-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9",,DAG1,DAG1,Dystroglycan,454bf13807a5c0a75636fd2014216e1277b482a1171ab578c58150092787fea9,Q14118,,Q14118,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,1605,DAG1,,Q14118,K06265,"""""",
2008,615041,615041,Number Sign,615041,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, TMEM5-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10",,RXYLT1,RXYLT1,Ribitol-5-phosphate xylosyltransferase 1,d8d34cc8b62f435e85d09444b024d6f5fcce046c880d2ef74a2f8f841e0725ec,Q9Y2B1,,Q9Y2B1,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,10329,RXYLT1,640,"""""","""""","""""",
2009,615181,615181,Number Sign,615181,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GALNT2-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11",,B3GALNT2,B3GALNT2,"UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2",f34c269281f61dc12a835c76d8f23c0b5bcb8b3f2f1e305d0de0d363a022e55e,2.4.1.313,2.4.1.313,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Phenobarbital,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Seizures,HP:0001250,,https://www.ncbi.nlm.nih.gov/pubmed/29273094,148789,B3GALNT2,1121,Q8NCR0,K09654,2.4.1.313,
2010,615249,615249,Number Sign,615249,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, POMK-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12",,POMK,POMK,Protein O-mannose kinase,dc1d24f7d7689be2947236a17fb249c84137b1f67a5d8dbc9725544beca83ae8,2.7.1.183,2.7.1.183,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,84197,POMK,1122,Q9H5K3,K17547,2.7.1.183,
2011,615287,615287,Number Sign,615287,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13","WALKER-WARBURG SYNDROME OR MUSCLE-EYE-BRAIN DISEASE, B3GNT1-RELATED",,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13",,B4GAT1,B4GAT1,"Beta-1,4-glucuronyltransferase 1",d8250f2948c4766858a55379a932da1d0debf8ae4db042ab3d7cc2f6c2a34f4e,O43505,,O43505,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,11041,B4GAT1,1124,O43505,K21032,2.4.1.-,
2012,151800,,NULL,151800,"LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL","LIPOMATOSIS, FAMILIAL BENIGN CERVICAL;; LIPODYSTROPHY, CEPHALOTHORACIC",,Multiple symmetric lipomatosis,The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/,MT-TK,MT-TK,"Beta-1,4-glucuronyltransferase 1",d8250f2948c4766858a55379a932da1d0debf8ae4db042ab3d7cc2f6c2a34f4e,O43505,,O43505,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,salbutamol,DB01001,DB01001,3b6e397cc9094d0d3a05544365c79995d6a8a88352fa9f8d370c63a52b3ac3a2,DB01001,DB01001,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,C,Rapid progression in body fat mass( Abnormality of adipose tissue* ),HP:0009124*,,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,"""""","""""",,"""""","""""","""""",
2013,151800,,NULL,151800,"LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL","LIPOMATOSIS, FAMILIAL BENIGN CERVICAL;; LIPODYSTROPHY, CEPHALOTHORACIC",,Multiple symmetric lipomatosis,,MT-TK,MT-TK,"Beta-1,4-glucuronyltransferase 1",d8250f2948c4766858a55379a932da1d0debf8ae4db042ab3d7cc2f6c2a34f4e,O43505,,O43505,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Fenofibrates,DB01001,DB01001,3b6e397cc9094d0d3a05544365c79995d6a8a88352fa9f8d370c63a52b3ac3a2,DB01001,DB01001,,,,,,,,,,,,,Disease progression,,,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,"""""","""""",,"""""","""""","""""",
2014,151800,,NULL,151800,"LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL","LIPOMATOSIS, FAMILIAL BENIGN CERVICAL;; LIPODYSTROPHY, CEPHALOTHORACIC",,Multiple symmetric lipomatosis,,MT-TK,MT-TK,"Beta-1,4-glucuronyltransferase 1",d8250f2948c4766858a55379a932da1d0debf8ae4db042ab3d7cc2f6c2a34f4e,O43505,,O43505,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Fenofibrates,DB01001,DB01001,3b6e397cc9094d0d3a05544365c79995d6a8a88352fa9f8d370c63a52b3ac3a2,DB01001,DB01001,,,,,,,,,,,,,Increased intraabdominal fat,HP:0008993,,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,"""""","""""",,"""""","""""","""""",
2015,151800,,NULL,151800,"LIPOMATOSIS, MULTIPLE SYMMETRIC; MSL","LIPOMATOSIS, FAMILIAL BENIGN CERVICAL;; LIPODYSTROPHY, CEPHALOTHORACIC",,Multiple symmetric lipomatosis,,MT-TK,MT-TK,"Beta-1,4-glucuronyltransferase 1",d8250f2948c4766858a55379a932da1d0debf8ae4db042ab3d7cc2f6c2a34f4e,O43505,,O43505,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Fenofibrates,DB01001,DB01001,3b6e397cc9094d0d3a05544365c79995d6a8a88352fa9f8d370c63a52b3ac3a2,DB01001,DB01001,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,"""""","""""",,"""""","""""","""""",
2016,272200,,Number Sign,272200,MULTIPLE SULFATASE DEFICIENCY; MSD,"MUCOSULFATIDOSIS;; SULFATIDOSIS, JUVENILE, AUSTIN TYPE",,Multiple sulfatase deficiency,,SUMF1,SUMF1,Formylglycine-generating enzyme,ddad1534997c2598bdbd497a3952e451b5f9f63e985e1642291441b812ad246b,1.8.3.7,1.8.3.7,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,Low metabolic rate ( Abnormality of fatty acid metabolism)*,HP:0004359*,,,285362,SUMF1,301,Q8NBK3,K13444,1.8.3.7,
2017,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,Dexamethasone,DB01234,DB01234,3f1b1f0b3a5b0c71023f1bfae7c65b77356cb16d76709a21997bc073d1c4f125,DB01234,DB01234,,,,,,,ECO:0001565,ECO:0001565,,,procedure to mitigate dominant effects of a genetically abnormal protein,A,Abnormal cellular proliferation,HP:0031377,,"https://www.ncbi.nlm.nih.gov/pubmed/10947080,https://www.ncbi.nlm.nih.gov/pubmed/3491070/",5979,RET,,P07949,K05126,2.7.10.1,
2018,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,ECO:0007121,ECO:0007121,M918T,,procedure to mitigate dominant effects of a genetically abnormal protein,A,low quality of life ( Constitutional symptom)*,HP:0025142*,,"https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://www.ncbi.nlm.nih.gov/pubmed/3491070/",5979,RET,,P07949,K05126,2.7.10.1,
2019,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Pain,HP:0012531,,"https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://www.ncbi.nlm.nih.gov/pubmed/3491070/",5979,RET,,P07949,K05126,2.7.10.1,
2020,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Objective response rate (ORR),NA,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,https://www.ncbi.nlm.nih.gov/pubmed/3491070/",5979,RET,,P07949,K05126,2.7.10.1,
2021,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,disease control rate(  Rapid disease progression),HP:0003678,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,https://www.ncbi.nlm.nih.gov/pubmed/3491070/",5979,RET,,P07949,K05126,2.7.10.1,
2022,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Short Progression-free survival,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/22025146/,https://www.ncbi.nlm.nih.gov/pubmed/20371662/,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2023,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Elevated calcitonin,HP:0003528,,"https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2024,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Increased plasma CEA,HP:0031029,,"https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2025,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Bone pain,HP:0002653,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225/,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2026,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Low skeletal muscle mass,HP:0003199,,"https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2027,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Weight loss,HP:0001824,,"https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2028,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,Decreased adipose tissue,HP:0040063,,"https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2029,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",vandetanib,DB05294,DB05294,3c81e12b39086777419be896dce087e6f39b50841e3cd4391da15485d761b94e,DB05294,DB05294,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT00514046,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",5979,RET,,P07949,K05126,2.7.10.1,
2030,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",bortezomib + vandetanib,DB00188+DB05294,DB00188 + DB05294,22f83ab11572b99f4651a2f912c9d37c16f8cfeccc93bc6a827a7ecf7282ccf7,,,,,"DB00188,DB05294","DB00188,DB05294",,,ECO:0007121,ECO:0007121,,,procedure to mitigate dominant effects of a genetically abnormal protein+procedure to mitigate dominant effects of a genetically abnormal protein,,neoplastic growth,HP:0002664,,"https://www.ncbi.nlm.nih.gov/pubmed/18381602/,https://www.ncbi.nlm.nih.gov/pubmed/26170630,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2031,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,ECO:0007121,ECO:0007121,,,procedure to mitigate dominant effects of a genetically abnormal protein,,phospholylation of RET,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/21606412/,https://clinicaltrials.gov/ct2/show/NCT00215605,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2032,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,Elevated calcitonin,HP:0003528,,"https://www.ncbi.nlm.nih.gov/pubmed/21606412/,https://clinicaltrials.gov/ct2/show/NCT00215605,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2033,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,Short Progression-free survival,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2034,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,Low tumor response rate,NA,"The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501","https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2035,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,overall survival( premature death),MP:    ....,"Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/","https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2036,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2037,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2038,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2039,162300,,Number Sign,162300,"MULTIPLE ENDOCRINE NEOPLASIA, TYPE IIB; MEN2B","MEN IIB;; NEUROMATA, MUCOSAL, WITH ENDOCRINE TUMORS;; WAGENMANN-FROBOESE SYNDROME;; MULTIPLE ENDOCRINE NEOPLASIA, TYPE III, FORMERLY; MEN3, FORMERLY","MUCOSAL NEUROMA SYNDROME, INCLUDED",Multiple endocrine neoplasia type 2B,,RET,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,e3a991b788e9c54ce3aed1aacafb03644632edf1eba05b5f269bb07b756c4c51,2.7.10.1,2.7.10.1,,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",cabozantinib ( XL184),DB08875,DB08875,238ef1b2004014ff03f8ef56d83dcbadd824738d96fc282a132961cad2fab74f,DB08875,DB08875,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",5979,RET,,P07949,K05126,2.7.10.1,
2040,614080,,Number Sign,614080,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 3; GPIBD3,,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,PIGN,GPI ethanolamine phosphate transferase 1,0b43ef9a0233a8839aabca8bf8e219041ebb968f70a27d1e8c88ac3486cdb1e0,O95427,,O95427,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",levetiracetam,DB01202,DB01202,de7620bd4f3a13052a75ed96377f33788ecbcde95a22a64fbb454cddb84dd13b,DB01202,DB01202,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",23556,PIGN,1145,O95427,K05285,2.-.-.-,
2041,614080,,Number Sign,614080,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 3; GPIBD3,,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,PIGN,GPI ethanolamine phosphate transferase 1,0b43ef9a0233a8839aabca8bf8e219041ebb968f70a27d1e8c88ac3486cdb1e0,O95427,,O95427,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",topiramate,DB00273,DB00273,46d06fb3beec9e56fac672d0347e5531cd01d3fdc69d2741b9289b4fe642bf70,DB00273,DB00273,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",23556,PIGN,1145,O95427,K05285,2.-.-.-,
2042,614080,,Number Sign,614080,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 1; MCAHS1,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 3; GPIBD3,,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,PIGN,GPI ethanolamine phosphate transferase 1,0b43ef9a0233a8839aabca8bf8e219041ebb968f70a27d1e8c88ac3486cdb1e0,O95427,,O95427,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",oxcarbazepine,DB00776,DB00776,6a44b1d0bede25feaed15b1c595afe0b465e2e906bd91165d2306e1d9da650cf,DB00776,DB00776,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/,https://clinicaltrials.gov/ct2/show/NCT00704730,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/",23556,PIGN,1145,O95427,K05285,2.-.-.-,
2043,300868,,Number Sign,300868,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 2; MCAHS2,"EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 20; EIEE20;; GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 4; GPIBD4",,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 2,Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216,PIGA,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,22da0bb2fd3a94ca0f43e9aeeb0619bf5c68b6b0496b3b0e04a36197b3c55c48,2.4.1.198,2.4.1.198,,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,5277,PIGA,1141,P37287,K03857,2.4.1.198,
2044,300818,,Number Sign,300818,PAROXYSMAL NOCTURNAL HEMOGLOBINURIA 1; PNH1,,,Paroxysmal nocturnal hemoglobinuria,PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949,PIGA,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,22da0bb2fd3a94ca0f43e9aeeb0619bf5c68b6b0496b3b0e04a36197b3c55c48,2.4.1.199,2.4.1.199,,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",Eculizumab,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,Paroxysmal nocturnal hemoglobinuria,HP:0004818,,https://www.ncbi.nlm.nih.gov/pubmed/28516949,5277,PIGA,1141,P37287,K03857,2.4.1.198,
2045,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,Drugs has decreased rhe frequency of the tonic seizuress,Phenobarbital,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,tonic seizures ( Focal tonic seizures),HP:0011167*,,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,51604,PIGT,1147,Q969N2,K05292,"""""",
2046,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,Drugs has decreased rhe frequency of the tonic seizuress,Clonzepam,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,tonic seizures ( Focal tonic seizures),HP:0011167*,,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,51604,PIGT,1147,Q969N2,K05292,"""""",
2047,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,Drugs has decreased rhe frequency of the tonic seizuress,Potassium bromide,CHEBI:32030,CHEBI:32030,d48d05e725d73ea326f70f870fab57c6eb2a2947e5367197e9bd5486d5614ccf,CHEBI:32030,,CHEBI_32030,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,tonic seizures ( Focal tonic seizures),HP:0011167*,,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,51604,PIGT,1147,Q969N2,K05292,"""""",
2048,615398,,Number Sign,615398,MULTIPLE CONGENITAL ANOMALIES-HYPOTONIA-SEIZURES SYNDROME 3; MCAHS3,GLYCOSYLPHOSPHATIDYLINOSITOL BIOSYNTHESIS DEFECT 7; GPIBD7,,Multiple congenital anomalies-hypotonia-seizures syndromeÂ type 3,,PIGT,PIGT,GPI transamidase component PIG-T,c2e07e6ac9e17fdad602da250028f78170a5326fbbeb0f32e0178b3e422557b6,Q969N2,,Q969N2,Drugs has decreased rhe frequency of the tonic seizuress,acetazolamide,DB00819,DB00819,12d947586c80f83a0d8dc71e808f47ac01d4fa210a8b7c7d7dcdeb91f64764b5,DB00819,DB00819,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,C,"""Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)""",HP:0002872*,,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,51604,PIGT,1147,Q969N2,K05292,"""""",
2049,248510,248510,Number Sign,248510,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",BETA-MANNOSIDOSIS;; LYSOSOMAL BETA-MANNOSIDASE DEFICIENCY;; BETA-MANNOSIDASE DEFICIENCY,,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",,MANBA,MANBA,Beta-mannosidase,94644c41f9880dc9478e8f8fc63d2bdc0175246a57a0d31c0c7867a5c87de1e2,3.2.1.25,3.2.1.25,,Drugs has decreased rhe frequency of the tonic seizuress,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,4126,MANBA,261,O00462,K01192,3.2.1.25,
2050,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,"In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.",BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Drugs has decreased rhe frequency of the tonic seizuress,Natural osmolyte trimethylamine N-oxide (TMAO),CHEBI:15724,CHEBI:15724,44eb303a64e5b597de9983ee80a31523772fc8e9c1ccc10fcbeec2b6d310e57c,CHEBI:15724,,CHEBI_15724,,,,,,ECO:0000352,ECO:0000352,F364C- alpha,A209D-alpha,activity modification of a genetically defective protein,A,No phenotypes were mentioned in the study. In vitro Study.,,,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,593,BCKDHA,1252,P12694,K00166,1.2.4.4,
2051,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Drugs has decreased rhe frequency of the tonic seizuress,Natural osmolyte trimethylamine N-oxide (TMAO),CHEBI:15724,CHEBI:15724,44eb303a64e5b597de9983ee80a31523772fc8e9c1ccc10fcbeec2b6d310e57c,CHEBI:15724,,CHEBI_15724,,,,,,,,Y368C- alpha,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,593,BCKDHA,1252,P12694,K00166,1.2.4.4,
2052,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Drugs has decreased rhe frequency of the tonic seizuress,Natural osmolyte trimethylamine N-oxide (TMAO),CHEBI:15724,CHEBI:15724,44eb303a64e5b597de9983ee80a31523772fc8e9c1ccc10fcbeec2b6d310e57c,CHEBI:15724,,CHEBI_15724,,,,,,,,Y393N- alpha,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,593,BCKDHA,1252,P12694,K00166,1.2.4.4,
2053,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Drugs has decreased rhe frequency of the tonic seizuress,Norleucine,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,functional complementatin of a genetically defective protein,,Branched-chain amino acid accumulation,HP:0008344,Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,593,BCKDHA,1252,P12694,K00166,1.2.4.4,
2054,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Drugs has decreased rhe frequency of the tonic seizuress,Norleucine,NA,,,,,,,,,,,,,,,,,Encephalopathy,HP:0001298,"The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,593,BCKDHA,1252,P12694,K00166,1.2.4.4,
2055,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ia,,BCKDHA,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",aa904e78d0c8547b426a48b3269cdffd688ace0a7b94d4bd23fdfe771231b668,1.2.4.4,1.2.4.4,,Drugs has decreased rhe frequency of the tonic seizuress,Norleucine,NA,,,,,,,,,,,,,,,,,High Î±-ketoisocaproate level,NA,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,593,BCKDHA,1252,P12694,K00166,1.2.4.4,
2056,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ib,,BCKDHB,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",34bb8a3f0cdff01269838ceecbbf1a5135f8c33bf6b636c5eaf0e64b0af8107b,1.2.4.4,1.2.4.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Sodium phenylbutyrate,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,High plasma branched chain keto acids,NA,,"https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799",594,BCKDHB,1252,P21953,K00167,1.2.4.4,
2057,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type Ib,,BCKDHB,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",34bb8a3f0cdff01269838ceecbbf1a5135f8c33bf6b636c5eaf0e64b0af8107b,1.2.4.4,1.2.4.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Sodium phenylbutyrate,DB06819,DB06819,f2049a3365c837ee8ed31133f1444469f1bdb41042f0754c7659de0278a32bcf,DB06819,DB06819,,,,,,,,,,,,,High plasma branched chain amino acids,HP:0008344,,"https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799",594,BCKDHB,1252,P21953,K00167,1.2.4.4,
2058,248600,,Number Sign,248600,MAPLE SYRUP URINE DISEASE; MSUD,BRANCHED-CHAIN KETOACIDURIA;; BRANCHED-CHAIN ALPHA-KETO ACID DEHYDROGENASE DEFICIENCY;; BCKD DEFICIENCY;; KETO ACID DECARBOXYLASE DEFICIENCY,"MAPLE SYRUP URINE DISEASE, CLASSIC, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMEDIATE, INCLUDED;; MAPLE SYRUP URINE DISEASE, INTERMITTENT, INCLUDED;; MAPLE SYRUP URINE DISEASE, THIAMINE-RESPONSIVE, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IA, INCLUDED; MSUD1A, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE IB, INCLUDED; MSUD1B, INCLUDED;; MAPLE SYRUP URINE DISEASE, TYPE II, INCLUDED; MSUD2, INCLUDED",Maple syrup urine disease type II,,DBT,DBT,"Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial",63b1c771f8947b9cd2157b2b8ea31efcc598ead581b2c0255da6899126199074,2.3.1.168,2.3.1.168,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Thiamine,DB00152,DB00152,4b49abbd544319dccb37f55e816228b43edd4d7988ec60a9415b9bcfdc8a16d6,DB00152,DB00152,,,,,,,ECO:0000352,ECO:0000352,,,functional complementatin of a genetically defective protein,B,High plasma branched chain amino acids,HP:0008344,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Thiamin-responsive+maple-syrup-urine+disease+chuang+2006,https://www.ncbi.nlm.nih.gov/pubmed/28919799",1629,DBT,1252,P11182,K09699,2.3.1.168,
2059,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",N-acetylcysteine +deferoxamine,DB06151+ DB00746,DB06151 + DB00746,764cb139d71f9fbf021cbcc86b977a64c126be2ea9e8d040ff1662efa6533282,,,,,"DB06151,DB00746","DB06151,DB00746",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,C,Memory impairment,HP:0002354,,"https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799",1738,DLD,,P09622,K00382,1.8.1.4,
2060,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",N-acetylcysteine +deferoxamine,DB06151+ DB00746,DB06151 + DB00746,764cb139d71f9fbf021cbcc86b977a64c126be2ea9e8d040ff1662efa6533282,,,,,"DB06151,DB00746","DB06151,DB00746",,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2061,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",N-acetylcysteine +deferoxamine,DB06151+ DB00746,DB06151 + DB00746,764cb139d71f9fbf021cbcc86b977a64c126be2ea9e8d040ff1662efa6533282,,,,,"DB06151,DB00746","DB06151,DB00746",,,,,,,,,Behavioural abnormalites,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2062,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",N-acetylcysteine +deferoxamine,DB06151+ DB00746,DB06151 + DB00746,764cb139d71f9fbf021cbcc86b977a64c126be2ea9e8d040ff1662efa6533282,,,,,"DB06151,DB00746","DB06151,DB00746",,,,,,,,,cognitive imapirment,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2063,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",N-acetylcysteine +deferoxamine,DB06151+ DB00746,DB06151 + DB00746,764cb139d71f9fbf021cbcc86b977a64c126be2ea9e8d040ff1662efa6533282,,,,,"DB06151,DB00746","DB06151,DB00746",,,,,,,,,Learning impairment,HP:0001328,,"https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2064,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,Exercise intolerance,HP:0003546,,"https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2065,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,Mitochondrial proliferation in the muscle,HP:0003200,,"https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2066,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,Myopathy,HP:0003198,,"https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2067,246900,,Number Sign,246900,DIHYDROLIPOAMIDE DEHYDROGENASE DEFICIENCY; DLDD,"DLD DEFICIENCY;; E3 DEFICIENCY;; LIPOAMIDE DEHYDROGENASE DEFICIENCY, LACTIC ACIDOSIS DUE TO;; MAPLE SYRUP URINE DISEASE, TYPE III",,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",218c59dd44adc09d64be258921a174856025e89e161b200650d1656c9bdc604a,1.8.1.4,1.8.1.4,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Riboflavin,DB00140,DB00140,20ff155eaf0154e7b459d6ba9ebe29f99655a84d8a0455b618fd05e9fa51b27f,DB00140,DB00140,,,,,,,,,,,,,Lactic acidosis,HP:0003128,,"https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/12927581",1738,DLD,,P09622,K00382,1.8.1.4,
2068,261600,,Number Sign,261600,PHENYLKETONURIA; PKU,PHENYLALANINE HYDROXYLASE DEFICIENCY;; PAH DEFICIENCY;; OLIGOPHRENIA PHENYLPYRUVICA;; FOLLING DISEASE,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED;; HPA, NON-PKU MILD, INCLUDED;; PHENYLKETONURIA, MATERNAL, INCLUDED",PHENYLKETONURIA,"Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub",PAH,PAH,PHENYLALANINE HYDROXYLASE,7704789f8f42a1e5b8586ba0ec8af599b87b1d785f974ba4f7f9486df359d951,1.14.16.1,1.14.16.1,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Tetrahydrobiopterin (sapropterin),DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0000352,ECO:0000352,"P407S,A373T,R241C","Homozygotes of R252W ,Homozygotes of IVS4-1GâA ,Homozygotes of R413P",activity modification of a genetically defective protein,A,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/20971365,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://clinicaltrials.gov/ct2/show/results/NCT01977820?cond=sapropterin&rank=1,https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub",5053,PAH,1,P00439,K00500,1.14.16.1,
2069,261600,,Number Sign,261600,PHENYLKETONURIA; PKU,PHENYLALANINE HYDROXYLASE DEFICIENCY;; PAH DEFICIENCY;; OLIGOPHRENIA PHENYLPYRUVICA;; FOLLING DISEASE,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED;; HPA, NON-PKU MILD, INCLUDED;; PHENYLKETONURIA, MATERNAL, INCLUDED","HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PAH,PHENYLALANINE HYDROXYLASE,7704789f8f42a1e5b8586ba0ec8af599b87b1d785f974ba4f7f9486df359d951,1.14.16.1,1.14.16.1,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Tetrahydrobiopterin,DB00360,DB00360,6917a883338d2ff6cd576fed5a92d86333d2b6d8b9ad944da82718ae636efcee,DB00360,DB00360,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,A,Hyperphenylalaninemia,HP:0004923,,"https://www.ncbi.nlm.nih.gov/pubmed/20971365,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://clinicaltrials.gov/ct2/show/results/NCT01977820?cond=sapropterin&rank=1,https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub",5053,PAH,1,P00439,K00500,1.14.16.1,
2070,261600,,Number Sign,261600,PHENYLKETONURIA; PKU,PHENYLALANINE HYDROXYLASE DEFICIENCY;; PAH DEFICIENCY;; OLIGOPHRENIA PHENYLPYRUVICA;; FOLLING DISEASE,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED;; HPA, NON-PKU MILD, INCLUDED;; PHENYLKETONURIA, MATERNAL, INCLUDED","HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PAH,PHENYLALANINE HYDROXYLASE,7704789f8f42a1e5b8586ba0ec8af599b87b1d785f974ba4f7f9486df359d951,1.14.16.1,1.14.16.1,,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Pegvaliase,DB12839,DB12839,bf68275714e8f1adc53ed49e332120b42a92d5b072866e0613ce5a74f6af3e54,DB12839,DB12839,,,,,,,ECO:0007121+ECO:0005542,"ECO:0007121,ECO:0005542",,,functional complementation of a genetically defective protein,B,Abnormal blood Phenylalanine levels,HP:0004923,,"https://www.sciencedirect.com/science/article/pii/S1096719218300210,https://www.sciencedirect.com/science/article/pii/S1525001605000845,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",5053,PAH,1,P00439,K00500,1.14.16.1,
2071,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",Coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Muscle weakness,HP:0001324,,"https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2072,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",Vitamin B12+imipramine,DB00115+DB00458,DB00115 + DB00458,a94f3e3f7ee031ae53fd86bab25c5b58f28ed0d7e3cf476fc361409ff5879926,,,,,"DB00115,DB00458","DB00115,DB00458",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,Diabetic polyneuropathy,HP:0001271,,"https://www.ncbi.nlm.nih.gov/pubmed/28766015,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2073,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",Prokinetic agents,NA,,,,,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Epigastric pain,HP:0410019,,"https://www.ncbi.nlm.nih.gov/pubmed/28766015,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2074,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",Prokinetic agents,NA,,,,,,,,,,,,,,,,,Acid regurgitation,HP:0002020,,"https://www.ncbi.nlm.nih.gov/pubmed/28766015,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2075,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",pregabalin,DB00230,DB00230,465268e6188d99fe04e7f35af0afce31725c036f584899a741f34203de7dc38d,DB00230,DB00230,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Neuropathic pain(Abnormality of pain sensation)*,HP:0010832*,,"https://www.ncbi.nlm.nih.gov/pubmed/28766015,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2076,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",insulin,DB00030,DB00030,cf26fce19e07aebb15d6d50e81eac479c8ce3fbd496c7010461f41ac5f463a3e,DB00030,DB00030,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Diabetes,HP:0000819,"Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802","https://www.ncbi.nlm.nih.gov/pubmed/28756474,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2077,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",clonazepam,DB01068,DB01068,7e588a5450b185e2c1d4925ebde4c410605ef07c78f041d6fdbe4870cc5e473b,DB01068,DB01068,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Involuntary movement,HP:0004305,,"https://www.ncbi.nlm.nih.gov/pubmed/28756475,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2078,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,"The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.",Immunosuppressent +Carbonic anhydrase inhibitors,L04+S01EC,L04 + S01EC,25cb721097bc18b8babbbb546737efd243e4b49c650cf59db78289e7701d108e,,,,,"L04,S01EC",,,"L04,S01EC",ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,Macular cystoid changes,HP:0008028,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2079,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Triamcinolone acetonide,DB00620,DB00620,aceb2282ca3dc2d9e48b9a62c6c2ebc5c9926d969a8541e72d631f13cc666e4a,DB00620,DB00620,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Macular cystoid changes,HP:0011505,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2080,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Triamcinolone acetonide,DB00620,DB00620,aceb2282ca3dc2d9e48b9a62c6c2ebc5c9926d969a8541e72d631f13cc666e4a,DB00620,DB00620,,,,,,,,,,,,,Abnormal visual acuity,HP:0030532,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2081,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Triamcinolone acetonide,DB00620,DB00620,aceb2282ca3dc2d9e48b9a62c6c2ebc5c9926d969a8541e72d631f13cc666e4a,DB00620,DB00620,,,,,,,,,,,,,Intraretinal cystoid spaces (Retinal disease)*,HP:0000479*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2082,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Non-steroidal anti-inflammatory agents,M02AA,M02AA,028aa0edadc8fb72bc2fa2825a3abb4fefecacbd19e2d18dd9e079ccaba6846c,M02AA,,,M02AA,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Intraretinal cystoid spaces (Retinal disease)*,HP:0000479*,,"https://www.ncbi.nlm.nih.gov/pubmed/23806424/,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2083,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Vitamins,A11,A11,37b5be61fefd1edea7761c41767c6c4e8bda09d7e7b73002b6ef98b481bb68a5,A11,,,A11,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Malnutrition,HP:0004395,,"https://www.ncbi.nlm.nih.gov/pubmed/23806424/,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2084,520000,,Number Sign,520000,"DIABETES AND DEAFNESS, MATERNALLY INHERITED; MIDD","DIABETES-DEAFNESS SYNDROME, MATERNALLY TRANSMITTED;; BALLINGER-WALLACE SYNDROME;; DIABETES MELLITUS, TYPE II, WITH DEAFNESS;; NONINSULIN-DEPENDENT DIABETES MELLITUS WITH DEAFNESS;; NIDDM WITH DEAFNESS",,Maternally inherited diabetes and deafness,,MT-TL1/MT-TE/MT-TK,"MT-TL1,MT-TE,MT-TK",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Coenzyme Q10+Vitamin C+Vitamin B+Vitamin K +Carnitine,DB09270+A11EB+B02BA+ DB00583,DB09270 + A11EB + B02BA + DB00583,596ffc1f4b7ee7738d579680464e03d84daf73f9d03f62b4eebdb86768f34a73,,,,,"DB09270,A11EB,B02BA,DB00583","DB09270,DB00583",,"A11EB,B02BA",ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Mitochondrial dysfunction,HP:0003287,,"https://www.ncbi.nlm.nih.gov/pubmed/23806424/,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,",",,",409,",,",",,",",,",
2085,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS","MELAS syndrome can be caused by mutation in several genes, including MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000",MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Myopathy,HP:0003198,,"https://www.ncbi.nlm.nih.gov/pubmed/26823911,https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29596118,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2086,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*,HP:0008972*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994/,https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29596118,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2087,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,arginine hydrochloride,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Stroke-like episodes,HP:0002401,,"https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2088,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,arginine hydrochloride,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,,,,,,,Painful neuropathy(neuropathy)*,HP:0009830*,,"https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2089,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,arginine hydrochloride,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,,,,,,,Congestive heart failure,HP:0001635,,"https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2090,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,arginine hydrochloride,DB00125,DB00125,afb1e16fcfda6c365591ed8f536b508f9717bf6d790a2323bc6d928fc980de28,DB00125,DB00125,,,,,,,,,,,,,Pancreatic beta-cell dysfunction,HP:0006279,,"https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2091,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Nicotinamide Riboside,DB03227,DB03227,82435dc28985eea848a447ae2ad7c0f00d4219d1bd246cb036ff994edeb18815,DB03227,DB03227,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,Muscle abnormality related to mitochondrial dysfunction,HP:0003800,,"https://clinicaltrials.gov/ct2/show/NCT03432871?cond=Chronic+progressive+external+ophthalmoplegia&rank=2,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2092,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,Elevated serum lactate level,HP:0002151,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2093,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,,,,,,,"High lactate ,pyruvate ratio",NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2094,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,,,,,,,Increased lateral ventricular lactate level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2095,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Sodium Pyruvate,DB00119,DB00119,e4e8f53c0dbeebd7bc0fe315371f25a6e351d496a54e4c2139c718fbfb7ac0c0,DB00119,DB00119,,,,,,,,,,,,,High serum GDF15 level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30738201,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2096,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Duloxetine,DB00476,DB00476,9e638cc22e8ada9b06b373ac7b1a0dd2f6e8b8a89ac7ea830119149470414ee9,DB00476,DB00476,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Depression,HP:0000716,,"https://www.ncbi.nlm.nih.gov/pubmed/29596118,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2097,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Taurine,DB01956,DB01956,e2c35ccb93ffade0cbb9686ed721b0a3a2b9e0bc72b4e19db7c29c4ec1dba1b0,DB01956,DB01956,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/29596118,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2098,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Taurine,DB01956,DB01956,e2c35ccb93ffade0cbb9686ed721b0a3a2b9e0bc72b4e19db7c29c4ec1dba1b0,DB01956,DB01956,,,,,,,,,,,,,Mitochondrial dysfunction,HP:0003287,,"https://www.ncbi.nlm.nih.gov/pubmed/29596118,http://ichgcp.net/clinical-trials-registry/NCT03432871,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2099,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,Decreased activity of mitochondrial ATP synthase complex,HP:0011925,,"https://clinicaltrials.gov/ct2/show/NCT00887562,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2100,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Idebenone+Riboflavin,DB09081+DB00140,DB09081 + DB00140,4972ea57eb644d98329ff8d20365dacd1e5daf6fe39faba1496cba9499b0e559,,,,,"DB09081,DB00140","DB09081,DB00140",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,Neurological abnormality,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/11382201,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2101,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Idebenone+Riboflavin,DB09081+DB00140,DB09081 + DB00140,4972ea57eb644d98329ff8d20365dacd1e5daf6fe39faba1496cba9499b0e559,,,,,"DB09081,DB00140","DB09081,DB00140",,,,,,,,,Abnormal EEG (focal epileptiform activity),HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/11382201,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2102,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Idebenone+Riboflavin,DB09081+DB00140,DB09081 + DB00140,4972ea57eb644d98329ff8d20365dacd1e5daf6fe39faba1496cba9499b0e559,,,,,"DB09081,DB00140","DB09081,DB00140",,,,,,,,,Hyperintensity of cerebral white matter on MRI,HP:0030890,,"https://www.ncbi.nlm.nih.gov/pubmed/11382201,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2103,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Idebenone+Riboflavin,DB09081+DB00140,DB09081 + DB00140,4972ea57eb644d98329ff8d20365dacd1e5daf6fe39faba1496cba9499b0e559,,,,,"DB09081,DB00140","DB09081,DB00140",,,,,,,,,Stroke-like attacks,HP:0002401,,"https://www.ncbi.nlm.nih.gov/pubmed/11382201,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2104,540000,540000,Number Sign,540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",MELAS SYNDROME,,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MT-TL1/ MT-TQ /MT-TH/MT-TK / MTTC/ MT-TS1/ MT-ND1/ MT-ND5/ MT-ND6/ MT-TS2,"MT-TL1,MT-TQ,MT-TH,MT-TK,MTTC,MT-TS1,MT-ND1,MT-ND5,MT-ND6,MT-TS2",tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,495ef41115352366ccaf852782fd9dee9b0057e87e695919790c41ba3ab7f193,NA,,NA,The drug was administered through intravitreal injection.,Idebenone+Coenzyme Q10,DB09081+DB09270,DB09081 + DB09270,3898f75122df4adcec19acb5eda5edc015a70f7e191cb483747a9431860ec796,,,,,"DB09081,DB09270","DB09081,DB09270",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,Abnormal EEG,HP:0002353,,"https://www.sciencedirect.com/science/article/pii/0022510X89901123,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",",,,,,,,,,",",,,,,,,,,",399,",,,,,,,,,",",,,,,,,,,",",,,,,,,,,",
2105,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,ECO:0000352,ECO:0000352,R229W,,functional complementatin of a genetically defective protein,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2106,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,Clonic contractions,,There was partial improvement then patients died,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2107,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,Lip-smacking automatisms(Epilepsy)*,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2108,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2109,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2110,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2111,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2112,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxine,DB00165,DB00165,f14e66804487e2409da77d6bfcfab2bd9c0a270113e55ef5ea6a0ff8187b9952,DB00165,DB00165,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2113,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxal phosphate,DB00114,DB00114,8aa8f0a051e57b66fec0638a7c38161ad76887734ba9bd3111cd00f3841f9b13,DB00114,DB00114,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/12747882,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2114,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxal phosphate,DB00114,DB00114,8aa8f0a051e57b66fec0638a7c38161ad76887734ba9bd3111cd00f3841f9b13,DB00114,DB00114,,,,,,,,,,,,,Developmental delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/12747882,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2115,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Pyridoxal phosphate,DB00114,DB00114,8aa8f0a051e57b66fec0638a7c38161ad76887734ba9bd3111cd00f3841f9b13,DB00114,DB00114,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12747882,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2116,610090,,Number Sign,610090,PYRIDOXAMINE 5-PRIME-PHOSPHATE OXIDASE DEFICIENCY; PNPOD,"PNPO DEFICIENCY;; SEIZURES, PYRIDOXINE-RESISTANT, PLP-SENSITIVE;; EPILEPTIC ENCEPHALOPATHY, NEONATAL, PNPO-RELATED",,PNPO deficiency,,PNPO,PNPO,Pyridoxamine 5'-phosphate oxidase,ec0903feef2b91b2ef84c55f5cb58e2c76f2af958c39d7edb17335e661adf9a2,1.4.3.5,1.4.3.5,,The drug was administered through intravitreal injection.,Phenobarbitone,DB01174,DB01174,cf19736875f02161254b61398049018a0bcd5f0608ca0ceb09e1e0c53483df66,DB01174,DB01174,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",55163,PNPO,76,Q9NVS9,K00275,1.4.3.5,
2117,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,,Low total RBC folate level,HP:0040087,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2118,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,Bone marrow megaloblastic changes,HP:0001980,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/8757046,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2119,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,Low 5-MTHF level,HP:0012446,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2120,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,Abscent 5-MTHF(Abnormal CSF metabolite level)*,HP:0025454*,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2121,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,Abnormal CSF folate level,HP:0012446,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2122,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,Megaloblastic anemia,HP:0001889,,"https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2123,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2124,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Folinic acid,DB00650,DB00650,ff44e875ecda22ed833e21236076fca0290d25715401c92ff482002ccffe01dd,DB00650,DB00650,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2125,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Hydroxycobalamin + Folic acid,DB00200+DB00158,DB00200 + DB00158,bc68f3adc5677a3e362d5e6039d3f3d63c1739de17bbe6d2508434f0a86176c0,,,,,"DB00200,DB00158","DB00200,DB00158",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Abnormal hemoglobin level,HP:0025546,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2126,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Hydroxycobalamin + Folic acid,DB00200+DB00158,DB00200 + DB00158,bc68f3adc5677a3e362d5e6039d3f3d63c1739de17bbe6d2508434f0a86176c0,,,,,"DB00200,DB00158","DB00200,DB00158",,,,,,,,,Abnormal MCV level,HP:0025065,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2127,613839,613839,Number Sign,613839,MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY,DHFR DEFICIENCY,,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,DHFR,Dihydrofolate reductase,4fafc06b63a8971c6235b088e59951867fe038808ac5b7814f79a095ef39f650,1.5.1.3,1.5.1.3,,The drug was administered through intravitreal injection.,Phenobarbitone+levetiracetam,DB01174+DB01202,DB01174 + DB01202,59709b84f52729770a9fd2d0a7bf0f754282c3510642d40ab5b7a0a043ccf628,,,,,"DB01174,DB01202","DB01174,DB01202",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,seizure,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/26095523,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",1719,DHFR,,P00374,K00287,1.5.1.3,
2128,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,ECO:0000352/ECO:0007121,"ECO:0000352,ECO:0007121",G666R,2757delAG,functional complementation of a genetically defective protein,,Abnormal brain electrical activity,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://clinicaltrials.gov/ct2/show/results/NCT00001262?cond=Menkes&rank=1,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2129,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,N1304S,Del ex20â23,,,Seizures,HP:0001250,,"https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2130,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,"""IVS9,DS,+6TâG""",Q1385X,,,Neurological abnormalities.,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2131,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Neurologic burden,HP:0002344,,"https://clinicaltrials.gov/ct2/show/results/NCT00001262,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2132,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Rapid disease progression,HP:0003678,,"https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2133,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Eplieptic discharge (Interictal EEG abnormality)*,HP:0025373,,"https://www.ncbi.nlm.nih.gov/pubmed/8223785,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2134,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Low muscular tone,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pubmed/8223785,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2135,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Appendicular hyoptonia,HP:0012389,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2136,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Socio-cognitive abnormality(Neurodevelopmental abnormality)*,HP:0012759*,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2137,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Poor weight gain,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2138,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Woolly hair,HP:0002224,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2139,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",Copper Histidine,NA,,,,,,,,,,,,,,,,,Hypopigmented skin,HP:0001010,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2140,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",Thiuram + Copper Dimethyldithiocarbamate (Cu-DMDTC ),DB13245+DB09130+CHEBI:84293,DB13245 + DB09130 + CHEBI:84293,d7c060bd822c9384dd782e524c06d917379bdc37ed2702caa0864cfcc59e2d7d,,,,,"DB13245,DB09130,CHEBI:84293","DB13245,DB09130",CHEBI_84293,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Low Brain Copper (Abnormal copper levels)*,HP:0010836*,,"https://www.ncbi.nlm.nih.gov/pubmed/22815746,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2141,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",Thiuram + Copper Dimethyldithiocarbamate (Cu-DMDTC ),DB13245+DB09130+CHEBI:84293,DB13245 + DB09130 + CHEBI:84293,d7c060bd822c9384dd782e524c06d917379bdc37ed2702caa0864cfcc59e2d7d,,,,,"DB13245,DB09130,CHEBI:84293","DB13245,DB09130",CHEBI_84293,,,,,,,,Copper accumulation in kidney(Abnormal copper levels)*,HP:0010836*,,"https://www.ncbi.nlm.nih.gov/pubmed/22815746,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2142,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",Copper nitrilotriacetate (Cu-NTA),DB09130+CHEBI:25548,DB09130 + CHEBI:25548,41ffb8f8da0dbf9a1c2c49cefe6943a600378afbfb3838d61eabd64235443da5,,,,,"DB09130,CHEBI:25548",DB09130,CHEBI_25548,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,,Low survival rate (Mortality)*,HP:0040006*,,"https://www.ncbi.nlm.nih.gov/pubmed/?term=Copper+nitrilotriacetate%3A+A+potent+therapeutic+agent+in+the+treatment+of+a+genetic+disorder+of+copper+metabolism,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2143,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,"Due to its strong copper chelation capability, a copper salt should be added simultaneously",Alpha-lipoic acid,DB00166,DB00166,cf1f0e710cc17ef27aeae00511718e9e41e45c3999e438d336be0a76b85951b7,DB00166,DB00166,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Copper storage abnormalities (Copper storage abnormalities)*,HP:0010836*,,"https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2144,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,functional complementation of a genetically defective protein,,Low life span (Mortality)*,HP:0040006*,,"https://www.ncbi.nlm.nih.gov/pubmed/30127521,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2145,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,,ECO:0005542,ECO:0005542,,,direct complementation of a genetically defective protein by gene therapy,,Low brain copper levels (Abnormal copper levels)*,HP:0010836*,,"https://www.ncbi.nlm.nih.gov/pubmed/30090842,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2146,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,,,,,,,,Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*,HP:0012535*,,"https://www.ncbi.nlm.nih.gov/pubmed/30090842,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2147,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,,,,,,,,Abnormal growth,HP:0001507,,"https://www.ncbi.nlm.nih.gov/pubmed/30090842,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2148,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,,,,,,,,Brain mitochondrial abnormalities (Mitochondrial dysfunction),HP:0003287*,,"https://www.ncbi.nlm.nih.gov/pubmed/30090842,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2149,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,,,,,,,,Behavioral abnormality,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/30090842,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2150,309400,309400,Number Sign,309400,MENKES DISEASE,MK; MNK;; MENKES SYNDROME;; KINKY HAIR DISEASE;; STEELY HAIR DISEASE;; COPPER TRANSPORT DISEASE,,Menkes disease,,ATP7A,ATP7A,Copper-transporting ATPase 1,22d5feba58ce34a766abc119b69195c927d1eae2ab58776bab11eaf2311c30a1,7.2.2.8,7.2.2.8,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,NA,,,,,,,,,,,,,,,,,Neurological abnormalties,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/30090842,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",538,ATP7A,199,Q04656,K17686,7.2.2.8,
2151,249900,249900,Number Sign,249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,METACHROMATIC LEUKODYSTROPHY DUE TO CEREBROSIDE SULFATASE ACTIVATOR DEFICIENCY;; SAPOSIN B DEFICIENCY,,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,,PSAP,PSAP,Prosaposin,e38e3a0b3942f1718f3ea65419b9a3dda09953bf21d3e6f6ce819d60b65baea0,P07602,,P07602,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,No medical treatment is available in DDIEM,NA,,,,,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/30090842,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",5660,PSAP,293,P07602,K12382,"""""",
2152,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,,Poor appetite,HP:0004396,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2153,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Low IQ,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2154,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Behavioural abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2155,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Abnormal Awake EEG,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2156,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Delayed mylination,HP:0012449,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2157,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2158,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Hyperreflexia,HP:0001347,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2159,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Irritability,HP:0000737,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2160,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Foot clouns,HP:0011448,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2161,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Poor traction response,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2162,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Poor weight gain,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2163,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Delayed motor milestone,HP:0001270,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2164,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Neurodevelopmental abnormalities,HP:0012759,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2165,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Brain demylination,HP:0007266,,"https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2166,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Valproic acid,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Myoclonic epilepsy,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2167,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,ECO:0000352,ECO:0000352,,,metabolite replacement,,Poor appetite,HP:0004396,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,"https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/014067369192373A,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2168,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Low IQ,HP:0001249,,"https://www.ncbi.nlm.nih.gov/pubmed/27671892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2169,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Behavioural abnormalities,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/27671893,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2170,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Abnormal Awake EEG,HP:0002353,,"https://www.ncbi.nlm.nih.gov/pubmed/27671894,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2171,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Delayed development,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/27671895,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2172,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/27671896,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2173,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Hyperreflexia,HP:0001347,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2174,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Irritability,HP:0000737,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2175,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Foot clouns,HP:0011448,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2176,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Poor traction response (Poor muscle tone)*,HP:0001290,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2177,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Poor weight gain,HP:0001508,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2178,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Delayed motor milestone,HP:0001270,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2179,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Neurodevelopmental abnormality,HP:0012759,,"https://www.ncbi.nlm.nih.gov/pubmed/30389272,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2180,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,S-adenosylmethionine,DB00118,DB00118,0d011a3350a5bff3d471af4781bf2b458a9a3cc12abb3fd9b73970b5617da03e,DB00118,DB00118,,,,,,,,,,,,,Brain demylination,HP:0007266,,"https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2181,250850,,Number Sign,250850,METHIONINE ADENOSYLTRANSFERASE I/III DEFICIENCY,"MAT DEFICIENCY;; MAT I/III DEFICIENCY;; HYPERMETHIONINEMIA, ISOLATED PERSISTENT",,Persistent Hypermethioninemia,,MAT1A,MAT1A,S-adenosylmethionine synthase isoform type-1,9f81e1726cdda2d94cdef4ae00ed56149e094c939d2deaf42bffa44a2333eedd,2.5.1.6,2.5.1.6,,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,Valproic acid,DB00313,DB00313,a1ad79c758fe57f69ab701a6881b5f61660173359ab5193d6bd648caaacb55be,DB00313,DB00313,,,,,,,ECO:0000352,ECO:0000352,,,,,Myoclonic epilepsy,HP:0002123,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",4143,MAT1A,1283,Q00266,K00789,2.5.1.6,
2182,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Haemolysis,HP:0001878,,"https://www.ncbi.nlm.nih.gov/pubmed/24210589,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://www.ncbi.nlm.nih.gov/pubmed/9511979,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2183,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,Elevated total plasma homocysteine,HP:0002160,,"https://www.ncbi.nlm.nih.gov/pubmed/24210590,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2184,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,High urine methylmalonic acid level,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2185,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,Impaired renal function,HP:0012211,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2186,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,decreased glomerular filtration rate,HP:0012213,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2187,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,Fatigue,HP:0012378,,"https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2188,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,Anorexia,HP:0002039,,"https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2189,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,Delirium,HP:0031258,,"https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2190,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,Spasticity,HP:0001257,,"https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2191,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",Hydroxicobalamin + betaine+ Folinic acid,DB00200+DB06756+DB00650,DB00200 + DB06756 + DB00650,4bc4e1981040909b2d7b9758077b86eb76bf83ee576fc6670c0368ca4018c41f,,,,,"DB00200,DB06756,DB00650","DB00200,DB06756,DB00650",,,,,,,,,Lower limb hyperreflexia,HP:0002395,,"https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2192,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,All patients received OHCbl (intramuscular injection; 0.5â1 mg/week) and betaine (oral administration; 1â3 g/day). Some patients also took oral administration of folic acid (10â30 mg/day) and compound vitamin B (20â60 mg/day),Hydroxicobalamin + betaine+ Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,DB00200 + DB06756 + DB00650 + A11EA,3766322ddf58151727f9422ea3f645c2fe9161a1ec9cb35cda516c862e63d905,,,,,"DB00200,DB06756,DB00650,A11EA","DB00200,DB06756,DB00650",,A11EA,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,Psychiatric disturbances,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2193,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,All patients received OHCbl (intramuscular injection; 0.5â1 mg/week) and betaine (oral administration; 1â3 g/day). Some patients also took oral administration of folic acid (10â30 mg/day) and compound vitamin B (20â60 mg/day),Hydroxicobalamin + betaine+ Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,DB00200 + DB06756 + DB00650 + A11EA,3766322ddf58151727f9422ea3f645c2fe9161a1ec9cb35cda516c862e63d905,,,,,"DB00200,DB06756,DB00650,A11EA","DB00200,DB06756,DB00650",,A11EA,,,,,,,Lower extremity weakness,HP:0007340,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2194,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,All patients received OHCbl (intramuscular injection; 0.5â1 mg/week) and betaine (oral administration; 1â3 g/day). Some patients also took oral administration of folic acid (10â30 mg/day) and compound vitamin B (20â60 mg/day),Hydroxicobalamin + betaine+ Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,DB00200 + DB06756 + DB00650 + A11EA,3766322ddf58151727f9422ea3f645c2fe9161a1ec9cb35cda516c862e63d905,,,,,"DB00200,DB06756,DB00650,A11EA","DB00200,DB06756,DB00650",,A11EA,,,,,,,Gait instability,HP:0002317,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2195,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,All patients received OHCbl (intramuscular injection; 0.5â1 mg/week) and betaine (oral administration; 1â3 g/day). Some patients also took oral administration of folic acid (10â30 mg/day) and compound vitamin B (20â60 mg/day),Hydroxicobalamin + betaine+ Folinic acid+Vitamin B complex,DB00200+DB06756+DB00650+A11EA,DB00200 + DB06756 + DB00650 + A11EA,3766322ddf58151727f9422ea3f645c2fe9161a1ec9cb35cda516c862e63d905,,,,,"DB00200,DB06756,DB00650,A11EA","DB00200,DB06756,DB00650",,A11EA,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2196,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High urine methylmalonic acid level,HP:0012120,,"https://link.springer.com/article/10.1023/A:1005353530303,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2197,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Elevated total plasma homocysteine,HP:0002160,,"https://link.springer.com/article/10.1023/A:1005353530304,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2198,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,High urine methylmalonic acid level,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2199,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Abnormal brain stem auditory evoked potentials,HP:0006958,,"https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2200,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Abnormal visual evoked potentials,HP:0000649,,"https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2201,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Mental impairment,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2202,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Emotional lability,HP:0000712,,"https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2203,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Psychiatric disturbances,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2204,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Difficulty walking,HP:0002355,,"https://www.ncbi.nlm.nih.gov/pubmed/2873525/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2205,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,Dementia,HP:0000726,,"https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2206,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin + betaine+ carnitine,DB00200+DB06756+DB00583,DB00200 + DB06756 + DB00583,07ae6e3040de55a09826d76fd6f0281f9e628b6d1afee7387c936e57b209659c,,,,,"DB00200,DB06756,DB00583","DB00200,DB06756,DB00583",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2207,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,Megaloblastic anemia,HP:0001889,,"https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2208,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Methylmalonic aciduria,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2209,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Elevated blood homocystine,HP:0002160,,"https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2210,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Dementia,HP:0000726,,"https://www.ncbi.nlm.nih.gov/pubmed/6749192/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2211,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Myelopathy,HP:0002196,,"https://www.ncbi.nlm.nih.gov/pubmed/6749192/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2212,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Gait instability,HP:0002317,,"https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2213,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Coumadin,DB00682,DB00682,62aa94367de86d58ee9af6efff9cc00a45b7c1a21a2ea4d1896ae452a1f89458,DB00682,DB00682,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Deep venous thrombosis,HP:0002625,,"https://www.ncbi.nlm.nih.gov/pubmed/11320193/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2214,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Fluoxetine,DB00472,DB00472,49364ceecbc7bb7f74d1a2853dec65abe9be41304aef496551b4f6652893cae5,DB00472,DB00472,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Emotional lability,HP:0000712,,"https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2215,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",Fluoxetine,DB00472,DB00472,49364ceecbc7bb7f74d1a2853dec65abe9be41304aef496551b4f6652893cae5,DB00472,DB00472,,,,,,,,,,,,,Poor eye contact,HP:0000817,,"https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2216,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",lorazepam,DB00186,DB00186,5b85ccbd9dcc0c2b679cb7769a095a9de2345c006c12195d688d24fb6fc0ec6f,DB00186,DB00186,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Abnormal mental status,HP:0100543,,"https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2217,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120,Zonisamide,DB00909,DB00909,18de586f793c8d7432d331c9afe6dfcf1fcb41f7152cad42ef308d101c3060c9,DB00909,DB00909,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,sleep cycle disturbance,HP:0002360,,"https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2218,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120","Methylprednisolone sodium succinate +
Immune Globulin",DB14644+DB00028,DB14644 + DB00028,b6b05e1366ceaa298aed959d7b3bfa931fd0d2471e75e86c01a8291a6420bb5a,,,,,"DB14644,DB00028","DB14644,DB00028",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure,,"Autoimmune encephalopathy(Encephalopathy)*,(Autoimmune disorder)*","HP:0001298*,HP:0002960*","Doctors prescribed these drugs combination""""Methylprednisolone sodium succinate +
Immune Globulin """" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120","https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2219,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Risperidone,DB00734,DB00734,3386dc330cfd8bc8e3e77c8209b4c33d8c91496c09c526e583f1be47c58819dc,DB00734,DB00734,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Psychiatric disturbance,HP:0000708,,"https://www.ncbi.nlm.nih.gov/pubmed/17431913,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2220,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin + betaine+Folinic acid+ carnitine,DB00200+DB06756+DB00650+DB00583,DB00200 + DB06756 + DB00650 + DB00583,564819e8fa6cdc7a662745b83daf152c552a7057a07562eb6cb61f9eec78f834,,,,,"DB00200,DB06756,DB00650,DB00583","DB00200,DB06756,DB00650,DB00583",,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein+functional complementation of a genetically defective protein,,High urine methylmalonic acid level,HP:0012120,,"https://www.ncbi.nlm.nih.gov/pubmed/18848477,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2221,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin + betaine+Folinic acid+ carnitine,DB00200+DB06756+DB00650+DB00583,DB00200 + DB06756 + DB00650 + DB00583,564819e8fa6cdc7a662745b83daf152c552a7057a07562eb6cb61f9eec78f834,,,,,"DB00200,DB06756,DB00650,DB00583","DB00200,DB06756,DB00650,DB00583",,,,,,,,,Elevated total plasma homocysteine,HP:0002160,,"https://www.ncbi.nlm.nih.gov/pubmed/18848477,https://www.ncbi.nlm.nih.gov/pubmed/25511120,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2222,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Vatiquinone (Epi-743),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2223,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Vatiquinone (Epi-743),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2224,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Vatiquinone (Epi-743),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2225,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Vatiquinone (Epi-743),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2226,277400,,Number Sign,277400,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE; MAHCC","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE;; METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, VITAMIN B12-RESPONSIVE;; VITAMIN B12 METABOLIC DEFECT WITH COMBINED DEFICIENCY OF METHYLMALONYL-CoA MUTASE AND HOMOCYSTEINE:METHYLTETRAHYDROFOLATE METHYLTRANSFERASE","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblC TYPE, DIGENIC, INCLUDED","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,7142bddef26722559ee37201c25249f8714aaa5248478d07e6d9813cf8ba4fac,Q9Y4U1,,Q9Y4U1,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Vatiquinone (Epi-743),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",25974,MMACHC,90,Q9Y4U1,K14618,1.16.1.-,
2227,277410,,Number Sign,277410,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE; MAHCD","METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblD TYPE;; METHYLMALONIC ACIDURIA, cblH TYPE, FORMERLY;; METHYLMALONIC ACIDEMIA, cblH TYPE, FORMERLY","HOMOCYSTINURIA, cblD TYPE, VARIANT 1, INCLUDED;; METHYLMALONIC ACIDURIA, cblD TYPE, VARIANT 2, INCLUDED","METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE;",,MMADHC,MMADHC,"Methylmalonic aciduria and homocystinuria type D protein, mitochondrial",c078e7f188ee3b4d848889488761fabcc897ce61727ec2a8cf6b017c2e354245,Q9H3L0,,Q9H3L0,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Vatiquinone (Epi-743),DB11917,DB11917,f453d463c7df8d54aeaeac7b287e204fb142630b4bbd6ca42b47c65e6ba50943,DB11917,DB11917,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",27249,MMADHC,316,Q9H3L0,"""""","""""",
2228,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Eculizumab,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Microhematuria,HP:0002907,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2229,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Eculizumab,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,,,,,,,Microalbuminura,HP:0012594,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2230,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Eculizumab,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,,,,,,,Anemia,HP:0001903,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2231,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Eculizumab,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2232,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Eculizumab,DB01257,DB01257,2bbd3c01c9e0e71f06a0b5483d362bf2a0e733b99e46241eb3d3217d443ea5ea,DB01257,DB01257,,,,,,,,,,,,,Thrombotic microangiopathy,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2233,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,ECO:0000352,ECO:0000352,,,activity modification of a genetically defective protein,,Elevated plasma homocysteine concentration,HP:0002160,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2234,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Megaloblastic anemia,HP:0001889,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2235,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Thrombocytopenia,HP:0001873,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2236,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Granulocytopenia,HP:0001913,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2237,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Microhematuria,HP:0002907,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2238,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Neurological abnormality,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2239,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,Developmental delay,HP:0001263,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2240,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2241,250940,,Number Sign,250940,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblG COMPLEMENTATION TYPE; HMAG","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblG COMPLEMENTATION TYPE;; METHYLCOBALAMIN DEFICIENCY, cblG TYPE;; METHIONINE SYNTHASE DEFICIENCY",,Methylcobalamin deficiency cbl G type,,MTR,MTR,Methionine synthase,8e873e74343202f9378005d75dc18a8acf62b494dfcf7461553878303849103b,2.1.1.13,2.1.1.13,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxicobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4548,MTR,30,Q99707,K00548,2.1.1.13,
2242,236270,236270,Number Sign,236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblE COMPLEMENTATION TYPE;; VITAMIN B12-RESPONSIVE HOMOCYSTINURIA, cblE TYPE;; METHYLCOBALAMIN DEFICIENCY, cblE TYPE",,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,MTRR,Methionine synthase reductase,353c4ad43857fb31edfd977b8de50fef0674cacb7598a896e79d78b4f9d736e3,1.16.1.8,1.16.1.8,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxycobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,ECO:0000352,ECO:0000352,,,functional complementation of a genetically defective protein,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4552,MTRR,31,Q9UBK8,K00597,1.16.1.8,
2243,236270,236270,Number Sign,236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE","HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA DUE TO DEFECT IN COBALAMIN METABOLISM, cblE COMPLEMENTATION TYPE;; VITAMIN B12-RESPONSIVE HOMOCYSTINURIA, cblE TYPE;; METHYLCOBALAMIN DEFICIENCY, cblE TYPE",,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,MTRR,Methionine synthase reductase,353c4ad43857fb31edfd977b8de50fef0674cacb7598a896e79d78b4f9d736e3,1.16.1.8,1.16.1.8,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",Hydroxycobalamin,DB00200,DB00200,d5020a645198b50c704b17f976a3357d37dc37de010655fd8f21ceeb3e28da1a,DB00200,DB00200,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/28210839,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",4552,MTRR,31,Q9UBK8,K00597,1.16.1.8,
2244,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Limb dystonia,HP:0001332,,"https://www.ncbi.nlm.nih.gov/pubmed/30838265,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2245,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Axial dystonia,HP:0002530,,"https://www.ncbi.nlm.nih.gov/pubmed/30838265,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2246,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Gait abnormality,HP:0001288,,"https://www.ncbi.nlm.nih.gov/pubmed/30838265,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2247,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/24943079,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2248,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Tremor,HP:0001337,,"https://www.ncbi.nlm.nih.gov/pubmed/30941926,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2249,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Rigidity,HP:0002063,,"https://www.ncbi.nlm.nih.gov/pubmed/30941926,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2250,157640,,Number Sign,157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 1; PEOA1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,POLG,DNA polymerase subunit gamma-1,5d599304ba13ac72cc4d9bf75d9b304f0f67ad84bece5eeeb9bb4c8b1a4dcc47,2.7.7.7,2.7.7.7,,"Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,Bradykinesia,HP:0002067,,"https://www.ncbi.nlm.nih.gov/pubmed/30941926,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2251,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",Phenytoin+oxcarbazepine+levetiracetam,DB00252+DB00776+ DB01202,DB00252 + DB00776 + DB01202,bf9b4958be979c4a6c5d145ce58a557c9836bf45156ad5f94ec054196f7ffe75,,,,,"DB00252,DB00776,DB01202","DB00252,DB00776,DB01202",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Mitochondrial epilepsy(Epilepsy)*,HP:0001250*,,"https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2252,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",Phenytoin+oxcarbazepine+levetiracetam,DB00252+DB00776+ DB01202,DB00252 + DB00776 + DB01202,bf9b4958be979c4a6c5d145ce58a557c9836bf45156ad5f94ec054196f7ffe75,,,,,"DB00252,DB00776,DB01202","DB00252,DB00776,DB01202",,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2253,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,symptomatic treatment procedure,C,Mitochondrial myopathy,HP:0003737,,"https://www.ncbi.nlm.nih.gov/pubmed/27442316,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2254,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",coenzyme Q10,DB09270,DB09270,ccb07838cfe28513966982b1c8683d31b5969a26e1703cc0b69062545a8ad009,DB09270,DB09270,,,,,,,,,,,,,Low energy level,HP:0003473,,"https://www.ncbi.nlm.nih.gov/pubmed/27442316,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2255,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,symptomatic treatment procedure,C,Inflammatory myopathy,HP:0009071,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2256,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,dysphagia,HP:0002015,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2257,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2258,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,neck muscle weakness,HP:0000467,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2259,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2260,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,dysarthria,HP:0001260,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2261,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2262,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2263,610131,,Number Sign,610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 4; PEOA4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",617f9b2d7b394860699db330520332d4831292d9864eb959a6adf3f1e0879e17,2.7.7.7,2.7.7.7,,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",prednisone,DB00635,DB00635,043baac45d888200eaf3bed073051fec986b55b3a7bcfeb4972235c2aa72c4b3,DB00635,DB00635,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/25674260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",11232,POLG2,942,Q9UHN1,K02333,"""""",
2264,258450,,Number Sign,258450,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 1; PEOB1","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1",,POLG,POLG,DNA polymerase subunit gamma-2,05ca22b9f15a9940d875945b3bbba14821ca93eecb651a7b2c8e9c2f553fe566,2.7.7.7,2.7.7.7,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260,levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/12872260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",5428,POLG,418,P54098,K02332,2.7.7.7,
2265,609283,,Number Sign,609283,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 2; PEOA2","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2",,SLC25A4,SLC25A4,ADP/ATP translocase 1,3ba299a94b1a380dd555b61a544a885b0a16565a455b3c8691e10fb862205c14,P12235,,P12235,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260,levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/12872260,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.ncbi.nlm.nih.gov/pubmed/19821145,https://www.pnas.org/content/96/5/2339.short",291,SLC25A4,1372,P12235,K05863,"""""",
2266,616479,,Number Sign,616479,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 2; PEOB2","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2",,RNASEH1,RNASEH1,Ribonuclease H1,91deb5452e18b29f70319e80bc6672fb58aab312e38daa894f9bb4a350dfb8f8,3.1.26.4,3.1.26.4,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,246243,RNASEH1,,O60930,K03469,3.1.26.4,
2267,609286,,Number Sign,609286,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 3; PEOA3","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3",,TWNK,TWNK,"Twinkle protein, mitochondrial",9134aee3c28e981e7960ed4c82017c85369bd5c2afcd3f00fc573f5c62739de1,3.6.4.12,3.6.4.12,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure,,Parkinsonism,HP:0001300,,"https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260",56652,TWNK,,Q96RR1,K17680,3.6.4.12,
2268,617069,,Number Sign,617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,TK2,"Thymidine kinase 2, mitochondrial",d9b49c2facb54007cc8c7f4bd7acf15b82512be76500ecd24a8de6a105ae3542,2.7.1.21,2.7.1.21,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260",7084,TK2,,O00142,K00857,2.7.1.21,
2269,617069,,Number Sign,617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,TK2,"Thymidine kinase 2, mitochondrial",d9b49c2facb54007cc8c7f4bd7acf15b82512be76500ecd24a8de6a105ae3542,2.7.1.21,2.7.1.21,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260",7084,TK2,,O00142,K00857,2.7.1.21,
2270,617070,,Number Sign,617070,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 4; PEOB4","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4",,DGUOK,DGUOK,"Deoxyguanosine kinase, mitochondrial",109fec707f195cc06764d1cb304ea423e4d8093988104a24242677bbdf0e1920,2.7.1.113,2.7.1.113,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260",1716,DGUOK,,Q16854,K00904,2.7.1.113,
2271,613077,,Number Sign,613077,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 5; PEOA5","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5",,RRM2B,RRM2B,Ribonucleoside-diphosphate reductase subunit M2 B,12060fb8d515e9d5e2fd2631cb7e308570657ff4261d704c49c49281e8ffced9,1.17.4.1,1.17.4.1,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260",50484,RRM2B,,Q7LG56,K10808,1.17.4.1,
2272,618098,,Number Sign,618098,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 5; PEOB5","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5",,TOP3A,TOP3A,DNA topoisomerase 3-alpha,5119b72ceb81745461fc50d5d947c7637e19f46c5e39c9412b6e334b3decd1be,5.6.2.2,5.6.2.2,,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Levodopa,DB01235,DB01235,253ac1ae40c946da52f37e12253d104135830e31bb3ab9532d0f572e9377b9bf,DB01235,DB01235,,,,,,,,,,,,,,,,"https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260",7156,TOP3A,1336,Q13472,K03165,5.6.2.1,
2273,615156,,Number Sign,615156,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL DOMINANT 6; PEOA6","PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6",,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6",,DNA2,DNA2,DNA replication ATP-dependent helicase/nuclease DNA2,49165101c2efa3057c537686188ad7851b54c79672860fd927688f32250cbb47,3.1.-.-,"3.6.4.12,3.1.-.-",,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,Vitamin E+L-carnitine+Dichloroacetate+Creatine,DB00163+DB00583+DB08809+DB00148,DB00163 + DB00583 + DB08809 + DB00148,903cace9e734a215ed260b48972258380ffa2d611967c0fcd32e3514eddc89c7,,,,,"DB00163,DB00583,DB08809,DB00148","DB00163,DB00583,DB08809,DB00148",,,ECO:0000352,ECO:0000352,,,symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure+symptomatic treatment procedure,,Difficulty walking,HP:0002355,,"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770/,https://www.ncbi.nlm.nih.gov/pubmed/12872260",1763,DNA2,946,P51530,K10742,3.1.-.-; 3.6.4.12,
2274,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,ECO:0007121/ECO:0000352,"ECO:0007121,ECO:0000352",,,symptomatic treatment procedure,,High left ventricular mass index ( Left ventricular hypertrophy)*,HP:0001712*,,"https://www.ncbi.nlm.nih.gov/pubmed/11907009,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2275,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Interventricular septal thickning (Ventricular septum abnormality)*,HP:0010438*,,"https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2276,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Neurological abnormality,"Another study has an opposing results https:,www.ncbi.nlm.nih.gov,pubmed,20697044",,"https://www.ncbi.nlm.nih.gov/pubmed/17826341,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2277,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Cerebellar dysfunction,HP:0001317,,"https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2278,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Saccadic ocular movement abnormality (Abnormality of saccadic eye movements),HP:0000570,,"https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2279,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Nystagmus,HP:0000639,,"https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2280,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Ataxia,HP:0001251,,"https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2281,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Idebenone,DB09081,DB09081,b21e8d8806b255ec826127dda010688bb9de83c83d4c0b0628f1654aea59efb3,DB09081,DB09081,,,,,,,,,,,,,Disease progression (Rapid progression)*,HP:0003678,,"https://www.ncbi.nlm.nih.gov/pubmed/18234531,https://www.ncbi.nlm.nih.gov/pubmed/12368988,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2282,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",recombinant human erythropoietin (rhuEPO),DB00016,DB00016,0178f9b956549d858f4477597c30a73e61af5dc69f0e42926a2145172927983e,DB00016,DB00016,,,,,,,ECO:0001565/ECO:0007121,"ECO:0001565,ECO:0007121",,,compensatory complementation of a genetically defective protein,,Low Frataxin expression level,NA,,"https://www.ncbi.nlm.nih.gov/pubmed/16269021?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2283,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",recombinant human erythropoietin (rhuEPO),DB00016,DB00016,0178f9b956549d858f4477597c30a73e61af5dc69f0e42926a2145172927983e,DB00016,DB00016,,,,,,,,,,,,,Oxidative stress,HP:0025464,,"https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2284,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",recombinant human erythropoietin (rhuEPO),DB00016,DB00016,0178f9b956549d858f4477597c30a73e61af5dc69f0e42926a2145172927983e,DB00016,DB00016,,,,,,,,,,,,,High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*,HP:0003254,,"https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2285,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",recombinant human erythropoietin (rhuEPO),DB00016,DB00016,0178f9b956549d858f4477597c30a73e61af5dc69f0e42926a2145172927983e,DB00016,DB00016,,,,,,,,,,,,,Neurological impairment,HP:0000707,,"https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2286,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",recombinant human erythropoietin (rhuEPO),DB00016,DB00016,0178f9b956549d858f4477597c30a73e61af5dc69f0e42926a2145172927983e,DB00016,DB00016,,,,,,,,,,,,,Tiredness,HP:0012378,,"https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2287,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",recombinant human erythropoietin (rhuEPO),DB00016,DB00016,0178f9b956549d858f4477597c30a73e61af5dc69f0e42926a2145172927983e,DB00016,DB00016,,,,,,,,,,,,,High ferritin level,HP:0003281,,"https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2288,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",recombinant human erythropoietin (rhuEPO),DB00016,DB00016,0178f9b956549d858f4477597c30a73e61af5dc69f0e42926a2145172927983e,DB00016,DB00016,,,,,,,,,,,,,"Low NADH,NAD ratio(Mitochondrial dysfunction)",HP:0003287,,"https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
2289,229300,,Number Sign,229300,FRIEDREICH ATAXIA 1; FRDA,FRDA1;; FA,"FRIEDREICH ATAXIA WITH RETAINED REFLEXES, INCLUDED; FARR, INCLUDED",Friedreich Ataxia,,FXN,FXN,"Frataxin, mitochondrial",20202b65f6e6ff05ff232ef1c21844eba7b198b7f8ad9cc21e39b5a2814a7dc5,1.16.3.1,1.16.3.1,,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",Rosuvastatin,DB01098,DB01098,56addcb958510d38f7524cfcb67525591f5e9ae3ebc3ff3867d2e6ec33bfc970,DB01098,DB01098,,,,,,,ECO:0007121,ECO:0007121,,,symptomatic treatment procedure,,,,,"https://clinicaltrials.gov/ct2/show/NCT02705547,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract",2395,FXN,1241,Q16595,K19054,1.16.3.1,
